Rank	NCT Number	Title	Acronym	Status	Study Results	Conditions	Interventions	Outcome Measures	Sponsor/Collaborators	Gender	Age	Phases	Enrollment	Funded Bys	Study Type	Study Designs	Other IDs	Start Date	Primary Completion Date	Completion Date	First Posted	Results First Posted	Last Update Posted	Locations	Study Documents	URL
1	NCT02279862	Safety and Efficacy Study of Ipilimumab 3 mg/kg Versus Ipilimumab 10 mg/kg in Subjects With Metastatic Castration Resistant Prostate Cancer Who Are Chemotherapy Naive		Terminated	Has Results	Prostate Cancer	Drug: Ipilimumab	Radiographic Progression-free Survival (rPFS)|Number of Participants Who Experienced Immune-related Adverse Events (irAEs)|Overall Survival (OS)|Prostate Specific Antigen Progression-free Survival (PSA PFS)|Time to Pain Progression|Prostate Specific Antigen Response Rate	Bristol-Myers Squibb	Male	18 Years and older   (Adult, Older Adult)	Phase 2	82	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA184-437|2014-002987-34	December 2, 2014	December 15, 2016	December 15, 2016	October 31, 2014	July 19, 2018	July 19, 2018	San Francisco Oncology Associates, San Francisco, California, United States|George Washington University Medical Center, Washington, District of Columbia, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|North Mississippi Med Center, Tupelo, Mississippi, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Providence Portland Medical Center, Portland, Oregon, United States|Northwest Cancer Specialists, Pc, Tualatin, Oregon, United States|University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh, Pennsylvania, United States|Texas Oncology, Houston, Texas, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Local Institution, St Leonards, New South Wales, Australia|Local Institution, Wahroonga, New South Wales, Australia|Local Institution, Parkville, Victoria, Australia|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Recoleta, Santiago DE Chile, Chile|Local Institution, Vina Del Mar, Valparaiso, Chile|Local Institution, Clermont Ferrand cedex 01, France|Local Institution, Marseille Cedex 9, France|Local Institution, Poitiers, France|Local Institution, Rennes Cedex, France|Local Institution, Saint Herblain, France|Local Institution, Villejuif, France|Universitaetsklinikum Aachen, Aachen, Germany|Uniklinik Heidelberg, Heidelberg, Germany|Universitaetsklinikum Jena, Jena, Germany|Universitaetsklinikum Magdeburg, Magdeburg, Germany|Universitaetsklinikum Mannheim, Mannheim, Germany|Local Institution, Marktredwitz, Germany|Klinikum Rechts Der Isar Der Tum, Muenchen, Germany|Urologische Praxis, Rostock, Germany|Urologische Gemeinschaftspraxis Dres Stammel U. Garcia, Wesel, Germany|Dgu Urologie, Wuppertal, Germany|Local Institution, Milano, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Local Institution, Amsterdam, Netherlands|Hospital General Universitari Vall D'Hebron, Barcelona, Spain|Hospital Duran I Reynals, Hospitalet de Llobregat - Barcelona, Spain|Hosp Univ Virgen Macarena, Sevilla, Spain|Instituto Valenciano De Oncologia, Valencia, Spain|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, Nottingham, Nottinghamshire, United Kingdom|Local Institution, Guildford, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT02279862
2	NCT02869789	An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers		Recruiting	No Results Available	Lung Cancer	Drug: Nivolumab in combination with Ipilimumab	Number of participants who experience high grade AEs (Adverse Events)|Percentage of participants who experience high grade AEs|Progression-free survival (PFS)|ORR|Duration of Response (DOR)|Functional Assessment of Cancer Therapy-Lung (FACT-L)|Overall Survival (OS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 4	1100	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-817|2016-002621-10	September 14, 2016	June 16, 2020	November 17, 2021	August 17, 2016	null	November 29, 2018	Alabama Oncology, Birmingham, Alabama, United States|Local Institution, Chandler, Arizona, United States|Arizona Oncology Assoc, Pc-Hal, Phoenix, Arizona, United States|Arizona Oncol Assoc Dba (Hem Onc Physicians&Extenders) Hope, Tucson, Arizona, United States|Local Institution, Hot Springs, Arkansas, United States|University Of Arkansas For Medical Sciences, Little Rock, Arkansas, United States|CBCC Global Research, Inc., Bakersfield, California, United States|Local Institution, Berkeley, California, United States|Marin Cancer Care, Inc, Greenbrae, California, United States|Local Institution, La Jolla, California, United States|Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States|Ucla, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Local Institution, San Diego, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Medical Oncology Corporation, Santa Maria, California, United States|Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California, United States|Innovative Clinical Research Institute, Whittier, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|St. Mary's Hospital Regional Cancer Center, Grand Junction, Colorado, United States|Memorial Cancer Institute, Hollywood, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Florida Cancer Affiliates - Ocala, Ocala, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Northside Hospital, Inc, Atlanta, Georgia, United States|Local Institution, Macon, Georgia, United States|Local Institution, Boise, Idaho, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Local Institution, Skokie, Illinois, United States|Local Institution, Indianapolis, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Kentucky One Health St. Joseph East Cancer Center, Lexington, Kentucky, United States|Maryland Oncology Hematology, P.A., Columbia, Maryland, United States|Minnesota Oncology Hematology, Pa, Edina, Minnesota, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|St. Francis Cancer Treatment Center, Grand Island, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Cancer Care Specialists, Reno, Nevada, United States|Essex Oncology Of North Jersey P.A., Belleville, New Jersey, United States|Saint Barnabas Medical Cancer Center, Livingston, New Jersey, United States|Local Institution, Morristown, New Jersey, United States|Local Institution, Bronx, New York, United States|Dumc, Durham, North Carolina, United States|Wake Forest Baptist Health, Winston-Salem, North Carolina, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|Local Institution, Corvallis, Oregon, United States|Local Institution, Portland, Oregon, United States|Willamette Valley Cancer Center, Springfield, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Local Institution, Langhorne, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Guthrie Medical Group, Pc, Sayre, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tennessee Oncology, Pc, Nashville, Tennessee, United States|Texas Oncology, PA - South Austin Cancer Center, Austin, Texas, United States|Texas Oncology, P.A., Dallas, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology-Fort Worth 12th Ave, Fort Worth, Texas, United States|Texas Oncology-Longview, Longview, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Texas Oncology Cancer Care And Research Center, Waco, Texas, United States|Virginia Cancer Specialists, Pc, Fairfax, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Providence Regional Cancer Partnership, Everett, Washington, United States|Local Institution, Renton, Washington, United States|Local Institution, Spokane, Washington, United States|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Hospital Italiano De Buenos Aires, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Centro Medico San Roque, Tucuman, Argentina|Local Institution, Gent, Belgium|Local Institution, Liege, Belgium|Local Institution, Sint-Niklaas, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Newmarket, Ontario, Canada|Local Institution, Greenfield Park, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Hopital Du Sacre-Coeur De Montreal, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du-Quebec, Trois-Rivieres, Quebec, Canada|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Fundacion Arturo Lopez Perez, Santiago, Chile|Komplexni onkologicke centrum, Novy Jicin, Czechia|Onkologicka klinika VFN a 1. LF UK, Praha 2, Czechia|Local Institution, Bordeaux, France|Local Institution, Dijon Cedex, France|Local Institution, Marseille Cedex 20, France|Local Institution, Nice, France|Local Institution, Paris, France|Local Institution, Pessac cedex, France|Local Institution, Rennes Cedex 9, France|Local Institution, Saint Herblain, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulon Cedex, France|Krankenhaus Nordwest Gmbh, Frankfurt, Frankfurt, Germany|SRH WALD KLINIKUM GERA gGmbH, Gera, Germany|Klinikum Kassel, Kassel, Germany|Klinik Loewenstein, Loewenstein, Germany|Hsk Dr.-Horst-Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany|Sotiria General Hospital, Athens, Greece|Metropolitan Hospital, Neo Faliro, Greece|Papageorgiou General Hospital, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Matrahaza, Hungary|Local Institution, Genova, Italy|Istituto Romagnolo Per Lo Studio E La Cura Dei Tumori, Meldola, Italy|Local Institution, Milan, Italy|Local Institution, Napoli, Italy|Ospedale Degli Infermi, Rimini, Italy|Local Institution, Siena, Italy|Azienda Ospedaliera S. Maria, Terni, Italy|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Cuernavaca, Morelos, Mexico|Local Institution, Mazatlan, Sinaloa, Mexico|Local Institution, Monterrey, NL, Mexico|Local Institution, Queretaro, Mexico|Local Institution, Groningen, Netherlands|Local Institution, Rotterdam, Netherlands|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Oddzial Wewnetrzny, Sucha Beskidzka, Poland|Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, Poland|Focus Lab Plus SRL, Bucuresti, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep, Romania, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, A Coru?a, Spain|Local Institution, Barcelona, Spain|Local Institution, Jaen, Spain|Local Institution, Madrid, Spain|Local Institution, Majadahonda - Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Zaragoza, Spain|University Hospital Basel, Basel, Switzerland|University Hospital Zurich, Zuerich, Switzerland|Local Institution, Adana, Turkey|Local Institution, Antalya, Turkey|Local Institution, Istanbul, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, Leicester, Leicestershire, United Kingdom|Local Institution, Edinburgh, Midlothian, United Kingdom|Local Institution, Newcastle Upon Tyne, United Kingdom|Local Institution, Wirral, United Kingdom		https://ClinicalTrials.gov/show/NCT02869789
3	NCT02985957	A Study to Evaluate Preliminary Safety and Efficacy of Nivolumab Plus Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer	CheckMate 650	Active, not recruiting	No Results Available	Prostate Cancer	Biological: Nivolumab|Biological: Ipilimumab	Objective Response Rate (ORR)|Radiographic Progression-Free Survival (rPFS)|Radiographic/Clinical Progression-Free Survival (rcPFS)|Overall Survival (OS)|Number of patients with adverse events|Number of patients with serious adverse events|Number of patients with adverse events leading to discontinuation|Number of patients with immune-mediated adverse events|Number of patients with deaths|Number of patients with laboratory abnormalities|Number of patients with changes in pain as measured by Brief Pain Inventory-Short Form (BPI-SF)|European Quality of Life- Five Dimensions (EQ-5D-3L) scores	Bristol-Myers Squibb	Male	18 Years and older   (Adult, Older Adult)	Phase 2	90	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-650|2016-001928-54	March 17, 2017	December 16, 2018	March 24, 2022	December 7, 2016	null	June 19, 2018	University of Chicago, Chicago, Illinois, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Icahn School Of Medicine At Mount Sinai, New York, New York, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|MD Anderson Cancer Center, Houston, Texas, United States|Local Institution, Clermont-ferrand, France|Local Institution, Lyon, France|Local Institution, Marseille Cedex 9, France|Local Institution, Villejuif, France		https://ClinicalTrials.gov/show/NCT02985957
4	NCT01611558	Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer		Active, not recruiting	Has Results	Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line	Biological: Ipilimumab	Number of Participants With Drug-related Adverse Events (AEs) of Grade 3 or Higher|Best Overall Response Rate (BORR)|Number of Participants Who Died and With Serious Adverse Events (SAEs), Drug-related SAEs, Drug-related AEs, AEs Leading to Discontinuation, and Drug-related AEs Leading to Discontinuation	Bristol-Myers Squibb	Female	18 Years and older   (Adult, Older Adult)	Phase 2	49	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-201	August 21, 2012	November 3, 2014	July 8, 2019	June 5, 2012	April 19, 2016	November 7, 2017	Yale University School Of Medicine, New Haven, Connecticut, United States|Florida Hospital Cancer Institute, Orlando, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Dr. Sudarshan K. Sharma, Ltd., Hinsdale, Illinois, United States|Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, Indiana, United States|Women'S Cancer Care, Covington, Louisiana, United States|Dana Faber Cancer Institute, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Montefiore Medical Center, The Bronx, New York, United States|The Charlotte-Mecklenburg Hospital Authority, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Magee-Womens Hospital Of Upmc, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT01611558
5	NCT02538666	An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy	CheckMate 451	Active, not recruiting	No Results Available	Lung Cancer	Biological: Nivolumab|Biological: Ipilimumab|Other: Placebo	Overall Survival (OS)|Progression Free Survival (PFS)|An OS descriptive analysis will be performed to evaluate nivolumab monotherapy versus nivolumab with Ipilimumab treatment regimen|A PFS descriptive analysis will be performed to evaluate nivolumab monotherapy versus nivolumab with Ipilimumab treatment regimen|Tumor mutation burden (TMB)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	1327	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA209-451|2015-002441-61	September 30, 2015	October 1, 2018	November 20, 2019	September 2, 2015	null	November 6, 2018	Sutter Cancer Center, Sacramento, California, United States|Yale University, New Haven, Connecticut, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Franciscan St. Francis Health, Indianapolis, Indiana, United States|University of Kansas Cancer Center - Clinical Research Center, Fairway, Kansas, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|Sanford Health, Fargo, North Dakota, United States|Oncology Hematology Care, Inc., Cincinnati, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Donald Guthrie Foundation, Sayre, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Sanford Health, Sioux Falls, South Dakota, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Local Institution, Berazategui, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Tucuman, Argentina|Local Institution, Kogarah, New South Wales, Australia|Local Institution, Wollongong, New South Wales, Australia|Local Institution, Birtinya, Queensland, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, East Melbourne, Victoria, Australia|Local Institution, Innsbruck, Austria|Local Institution, Salzburg, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Charleroi, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Itajai, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Salvador, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Oshawa, Ontario, Canada|Health Sciences North, Sudbury, Ontario, Canada|Local Institution, Windsor, Ontario, Canada|Local Institution, Hefei, Anhui, China|Local Institution, Hefei, Anhui, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Wuhang, Hubei, China|Local Institution, Changsha, Hunan, China|Local Institution, Nantong, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Kunming, Yunnan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Wenzhou, Zhejiang, China|Local Institution, Guangzhou, China|Local Institution, Monteria, Cordoba, Colombia|Local Institution, Bogota, Colombia|Local Institution, Medellin, Colombia|Local Institution, Oulu, Finland|Local Institution, Tampere, Finland|Local Institution, Turku, Finland|Local Institution, Vaasa, Finland|Local Institution, Avignon Cedes 9, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 20, France|Local Institution, Paris Cedex 20, France|Local Institution, Pierre Benite, France|Local Institution, Rennes Cedex 9, France|Local Institution, Saint Herblain, France|Local Institution, Strasbourg, France|Local Institution, Toulouse, France|Local Institution, Augsburg, Germany|Local Institution, Bad Berka, Germany|Local Institution, Berlin, Germany|Local Institution, Bochum, Germany|Local Institution, Gauting, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Immenhausen, Germany|Local Institution, Tuebingen, Germany|Agioi Anargyroi Cancer Center, Nea Kifissia, Greece|Interbalkan European Medical Center, Thessaloniki, Greece|Local Institution, Hong Kong, Hong Kong|Local Institution, Wilton, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Limerick, Ireland|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Zerifin, Israel|Local Institution, Avellino, Italy|Local Institution, Bologna, Italy|Local Institution, Messina, Italy|Local Institution, Milan, Italy|Local Institution, Perugia, Italy|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Gifu-shi, Gifu, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Takatsuki-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Wakayama-shi, Wakayama, Japan|Local Institution, Seongnam-si, Gyeonggi-do, Korea, Republic of|Local Institution, Suwon-si, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Leon de los Aldama, Guanajuato, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Santiago de Queretaro, Queretaro, Mexico|Local Institution, 's-Hertogenbosch, Netherlands|Local Institution, Eindhoven, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Miraflores, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Gdansk, Poland|Local Institution, Gdynia, Poland|Local Institution, Olsztyn, Poland|Local Institution, Warszawa, Poland|Local Institution, Bucharest, Romania|Local Institution, Bucharest, Romania|Local Institution, Craiova, Romania|Local Institution, Lasi, Romania|Local Institution, Romania, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, George, Western CAPE, South Africa|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Sevilla, Spain|Local Institution, Lund, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Aarau, Switzerland|Local Institution, Geneve, Switzerland|Local Institution, St. Gallen, Switzerland|Local Institution, Tainan, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Truro, Cornwall, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Sheffield, United Kingdom|Local Institution, Wirral, United Kingdom		https://ClinicalTrials.gov/show/NCT02538666
6	NCT03001882	An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)	CheckMate 592	Recruiting	No Results Available	Non-Small Cell Lung Cancer	Biological: Nivolumab|Biological: Ipilimumab	Objective Response Rate (ORR)|Objective Response Rate (ORR) of patient subgroups defined by baseline biomarkers|Disease Control Rate (DCR) of patient subgroups defined by baseline biomarkers|Duration of Response (DOR) of patient subgroups defined by baseline biomarkers|Time to Response (TTR) of patient subgroups defined by baseline biomarkers|Progression Free Survival (PFS) of patient subgroups defined by baseline biomarkers|Overall Survival (OS) of patient subgroups defined by baseline biomarkers|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	250	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-592|2018-000462-11	March 14, 2017	September 28, 2021	December 14, 2021	December 23, 2016	null	November 20, 2018	Highland Oncology Group, Fayetteville, Arkansas, United States|Yale University, New Haven, Connecticut, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Local Institution, Bronx, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Bon Secours-St Francis Hosp, Greenville, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Local Institution, Gent, Belgium|Local Institution, Gent, Belgium|Local Institution, Haine Saint Paul, Belgium|Local Institution, Liege, Belgium|Local Institution, Sint-Niklaas, Belgium|Local Institution, Pierre Benite, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulon, France|Klinik Essen-Mitte, Essen, Germany|Klinikverbund Kempten-Oberallgau, Immenstadt, Germany|Local Institution, Lowenstein, Germany|Klinikum Stuttgart, Stuttgart, Germany|ASST Papa Giovanni XXIII, Bergamo, Italy|Aou Policlinico V. Emanuele Di Catania, Catania, Italy|Azienda Ospedaliero Universitaria di Parma, Parma, Italy|Azienda Ospedaliera Di Perugia, Perugia, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Instituto Catalan De Oncologia, Barcelona, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hospital Universitario La Paz, Madrid, Spain|Hosp Univ Virgen Macarena, Sevilla, Spain		https://ClinicalTrials.gov/show/NCT03001882
7	NCT03048136	A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer	CheckMate 955	Withdrawn	No Results Available	Non-Small Cell Lung Cancer	Drug: Nivolumab|Drug: Ipilimumab	Incidence of high grade (Grade 3-4 and Grade 5) treatment-related select adverse events|Incidence of high grade (Grade 3-4 and Grade 5) immune-mediated adverse events|Progression-free survival (PFS) as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1)|Objective Response Rate (ORR) as assessed by the Investigator using tumor progression per Response Evaluation Criteria in Solid Tumors (RECIST v1.1)|Overall survival (OS) as defined as the time from first dosing to the date of death|Duration of Response (DOR) as assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST v1.1)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	0	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-955	March 9, 2018	September 29, 2019	September 29, 2019	February 9, 2017	null	April 17, 2018	Local Institution, San Francisco, California, United States|Local Institution, Lincoln, Nebraska, United States|Local Institution, Hackensack, New Jersey, United States|Local Institution, Columbus, Ohio, United States|Local Institution, Lancaster, Pennsylvania, United States|Local Institution, Langhorne, Pennsylvania, United States|Local Institution, Sayre, Pennsylvania, United States|Local Institution, Charleston, South Carolina, United States|Local Institution, Saint George, Utah, United States|Local Institution, Viedma, RIO Negro, Argentina|Local Institution, Montreal, Quebec, Canada|Local Institution, Dresden, Germany|Local Institution, Gauting, Germany|Local Institution, Gerlingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Lima, Peru|Local Institution, Lima, Peru		https://ClinicalTrials.gov/show/NCT03048136
8	NCT01471197	Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer		Terminated	Has Results	Lung Cancer - Non Small Cell	Biological: Ipilimumab|Biological: Pemetrexed	Overall Survival of Participants During the Study - All Treated Participants|Number of Participants Who Died Within 30 Days and 31 Days After Last Dose - All Treated Participants|Number of Participants With Deaths, Adverse Events (AEs), Serious AEs (SAEs) and AEs Leading to Discontinuation - All Treated Participants	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	9	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-124 ST|2011-000732-29	July 2012	February 2013	February 2013	November 15, 2011	May 12, 2014	May 12, 2014	Marin Specialty Care, Inc., Greenbrae, California, United States|Medical And Surgical Specialists, Llc, Galesburg, Illinois, United States|Quincy Medical Group, Quincy, Illinois, United States|Montgomery Cancer Center, Mount Sterling, Kentucky, United States|Meritus Center For Clinical Research, Hagerstown, Maryland, United States|Carolina Biooncology Institute, Huntersville, North Carolina, United States|Blue Ridge Cancer Care, Christiansburg, Virginia, United States|Local Institution, Brugge, Belgium|Local Institution, Sint Niklaas, Belgium|Local Institution, Paris, France|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Benidorm-Alicante, Spain		https://ClinicalTrials.gov/show/NCT01471197
9	NCT01057810	Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer		Completed	Has Results	Prostate Cancer	Drug: Ipilimumab|Drug: Placebo	Overall Survival (OS) Time|Progression-Free Survival (PFS) Time|Time to Subsequent Non-hormonal Cytotoxic Therapy|Time to Pain Progression|Number of Participants Who Died or Had Adverse Events (AEs), Serious Adverse Events (SAEs), Immune-related AEs (irAEs), or Immune-mediated Adverse Reactions (imARs)|Number of Treated Participants With Grade 3 or 4 Clinical Laboratory Abnormalities	Bristol-Myers Squibb	Male	18 Years and older   (Adult, Older Adult)	Phase 3	837	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA184-095|2009-016217-23	July 2010	April 2015	July 2015	January 27, 2010	August 18, 2016	August 18, 2016	Alaska Clinical Research Center, Llc, Anchorage, Alaska, United States|Pinnacle Oncology Hematology, Scottsdale, Arizona, United States|Arizona Cancer Center, Tucson, Arizona, United States|Desert Hematology Oncology, Rancho Mirage, California, United States|Southern California Permanente Medical Group, San Diego, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|George Washington University, Washington, District of Columbia, United States|Lynn Cancer Institute Center For Hematology-Oncology, Boca Raton, Florida, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Md Anderson Cancer Center Orlando, Orlando, Florida, United States|Hematology Oncology Associates Of The Treasure Coast, Port Saint Lucie, Florida, United States|Northside Hospital, Atlanta, Georgia, United States|Georgia Regents University, Augusta, Georgia, United States|Gwinnett Hospital System Inc., Lawrenceville, Georgia, United States|Straub Clinic And Hospital, Honolulu, Hawaii, United States|University Of Chicago, Chicago, Illinois, United States|Cancer Care Specialists Of Central Illinois, Decatur, Illinois, United States|Goshen Center For Cancer Care, Goshen, Indiana, United States|Hutchinson Clinic, Pa, Hutchinson, Kansas, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|University Of Maryland, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Mayo Clinic, Rochester, Minnesota, United States|Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada, United States|Montefiore Medical Center, Bronx, New York, United States|North Shore Hematology/Oncology Associates, P.C., East Setauket, New York, United States|Goshen Medical Associates, Goshen, New York, United States|Stony Brook University Medical Center, Stony Brook, New York, United States|Suny Upstate Medical University, Syracuse, New York, United States|Novant Health Oncology Specialists, Winston Salem, North Carolina, United States|Tulsa Cancer Institute, Tulsa, Oklahoma, United States|Kaiser Permanente Oncology/Hematology, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|St. Luke'S Hospital & Health Network Laboratory, Bethlehem, Pennsylvania, United States|Cancer Center Of The Carolinas, Greenville, South Carolina, United States|Carolina Urologic Research Center, Myrtle Beach, South Carolina, United States|Scott & White Memorial Hospital And Clinic, Temple, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, La Rioja, Argentina|Local Institution, Kogarah, New South Wales, Australia|Local Institution, Ashford, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, East Bentleigh, Victoria, Australia|Local Institution, Frankston, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Subiaco, Western Australia, Australia|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Belo Horizonte - Mg, Minas Gerais, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Kingston, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Temuco, Araucania, Chile|Local Institution, Vina Del Mar, Valparaiso, Chile|Local Institution, Santiago, Chile|Local Institution, Monteria, Cordoba, Colombia|Local Institution, Bogota, Colombia|Local Institution, Bucaramanga, Colombia|Local Institution, Medellin, Colombia|Local Institution, Hradec Kralove, Czech Republic|Local Institution, Liberec, Czech Republic|Local Institution, Praha 5, Czech Republic|Local Institution, Praha 8, Czech Republic|Local Institution, Herlev, Denmark|Local Institution, Kobenhavn O, Denmark|Local Institution, Bordeaux, France|Local Institution, Clermont-ferrand, France|Local Institution, Marseille Cedex 9, France|Local Institution, Pointe A Pitre, France|Local Institution, Poitiers, France|Local Institution, Villejuif Cedex, France|Local Institution, Aachen, Germany|Local Institution, Heidelberg, Germany|Local Institution, Marktredwitz, Germany|Local Institution, Munich, Germany|Local Institution, Wesel, Germany|Local Institution, Athens, Greece|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Gyula, Hungary|Local Institution, Szekesfehervar, Hungary|Local Institution, Meldola (FC), Italy|Local Institution, Milano, Italy|Local Institution, Siena, Italy|Local Institution, Terni, Italy|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Mexico, Queretaro, Mexico|Local Institution, San Luis Potosi, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Sittard-geleen, Netherlands|Local Institution, Kristiansand, Norway|Local Institution, Gdansk, Poland|Local Institution, Koscierzyna, Poland|Local Institution, Krakow, Poland|Local Institution, Kutno, Poland|Local Institution, Lublin, Poland|Local Institution, Poznan, Poland|Local Institution, Slupsk, Poland|Va Caribbean Healthcare System, San Juan, Puerto Rico|Local Institution, Bucuresti, Romania|Local Institution, Cluj-napoca, Cluj County, Romania|Local Institution, Timisoara,timis County, Romania|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Stockholm, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Vaxjo, Sweden|Local Institution, Adana, Turkey|Local Institution, Bornova, Izmir, Turkey|Local Institution, Gaziantep, Turkey|Local Institution, Kocaeli, Turkey|Local Institution, Kocaeli, Turkey|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, Guildford, Surrey, United Kingdom|Local Institution, Birmingham, West Midlands, United Kingdom		https://ClinicalTrials.gov/show/NCT01057810
10	NCT02659059	Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer	CheckMate 568	Active, not recruiting	No Results Available	Non-Small-Cell Lung Cancer	Biological: Nivolumab|Biological: Ipilimumab|Drug: Platinum Doublet Chemotherapy	Objective response rate (ORR)|ORR|Number of Patients with dose Limiting Toxicities (DLTs)|Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Number of Deaths|Number of Laboratory Abnormalities Graded by Common Terminology Criteria for Adverse Events (CTCAE)|Progression free survival (PFS)|Overall Response Rate (ORR)|Overall Survival (OS)|PFS|OS	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	507	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-568	February 10, 2016	November 6, 2018	April 20, 2022	January 20, 2016	null	September 19, 2018	Sharp Memorial Hospital, San Diego, California, United States|Cancer Center Of Central Connecticut, Plainville, Connecticut, United States|Cleveland Clinic Florida, Weston, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Summit Cancer Care, Savannah, Georgia, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|University Of Louisville Medical Center, Inc., Dba, Louisville, Kentucky, United States|Johns Hopkins Cancer Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center., Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Nebraska Hematology Oncology Pc, Lincoln, Nebraska, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|New Mexico Hematology Oncology Consultants, Albuquerque, New Mexico, United States|Lovelace Cancer Care, Albuquerque, New Mexico, United States|New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States|Presbyterian Rust Medical Center, Albuquerque, New Mexico, United States|The Cancer Center at Presbyterian, Albuquerque, New Mexico, United States|Winthrop University Hospital, Mineola, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University, Durham, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Kingston Regional Cancer Centre, Kingston, Ontario, Canada|Sault Area Hospital, Sault Ste Marie, Ontario, Canada|Csss De St-Jerome, St.Jerome, Quebec, Canada		https://ClinicalTrials.gov/show/NCT02659059
11	NCT01750580	Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor		Completed	No Results Available	CANCER, NOS	Drug: Lirilumab|Drug: Ipilimumab	Safety as measured by the rate of adverse events, and serious adverse events|Efficacy as measured by tumor assessment|The maximum observed serum concentration (Cmax) of BMS-986015 and Ipilimumab|The time of maximum observed serum concentration (Tmax) of BMS-986015 and Ipilimumab|Area under the serum concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986015 and Ipilimumab|Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986015 and Ipilimumab|Apparent total body clearance (CL) of BMS-986015 and Ipilimumab|Apparent volume of distribution at steady state (Vss) of BMS-986015 and Ipilimumab|Serum half-life (T-HALF) of BMS-986015 and Ipilimumab|Trough observed serum concentration (Cmin) of BMS-986015 and Ipilimumab|Immunogenicity as measured by the incidence of Ipilimumab and anti-Killer cell immunoglobulin-like receptor (KIR) (BMS-986015) anti-drug antibodies (ADA)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	22	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA223-002	December 2012	April 2015	April 2015	December 17, 2012	null	July 22, 2015	H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University Of Minnesota, Minneapolis, Minnesota, United States|Memorial Sloan Kettering Cancer Ctr, New York, New York, United States|The Ohio State University, Columbus, Ohio, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT01750580
12	NCT02872116	Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer	CheckMate649	Recruiting	No Results Available	Gastric Cancer|Gastroesophageal Junction Cancer	Drug: Nivolumab|Drug: Ipilimumab|Drug: Oxaliplatin|Drug: Capecitabine|Drug: Leucovorin|Drug: Fluorouracil	Overall survival (OS) of nivolumab in combination with oxaliplatin + fluoropyrimidine versus oxaliplatin + fluoropyrimidine in programmed cell death ligand 1 (PD-L1) positive participants|Progression-free survival (PFS), as assessed by Blinded Independent Central Review (BICR), of nivolumab in combination with oxaliplatin plus fluoropyrimidine versus oxaliplatin plus fluoropyrimidine in PD-L1 positive participants|OS in all randomized participants|PFS, as assessed by BICR, in all randomized participants|Objective Response Rate (ORR), as assessed by BICR, in all randomized participants|Time to symptom deterioration (TTSD) of nivolumab + ipilimumab vs oxaliplatin + fluoropyrimidine in all randomized participants	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	1649	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-649|2016-001018-76	October 4, 2016	March 28, 2021	October 6, 2022	August 19, 2016	null	November 6, 2018	Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|Georgetown University Med Ctr, Washington, District of Columbia, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Baptist Health Medical Group Oncology LLC, Miami, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Illinois Cancer Specialists, Arlington Heights, Illinois, United States|Northwestern University, Chicago, Illinois, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Willamette Valley Cancer Center, Eugene, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Allegheny Health Network, Pittsburgh, Pennsylvania, United States|Tennessee Oncology, Pc, Nashville, Tennessee, United States|Texas Oncology, Bedford, Texas, United States|Texas Oncology, Texas Cancer Center At Medical City, Dallas, Texas, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Texas Oncology-Plano East, Plano, Texas, United States|Virginia Oncology Associates, Newport News, Virginia, United States|Hospital Municipal De Gastroenterologia Dr.Udaondo, Capital Federal, Buenos Aires, Argentina|Hospital Britanico, Capital Federal, Buenos Aires, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Instituto Alexander Fleming, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, La Rioja, Argentina|Blacktown Hospital, Blacktown, New South Wales, Australia|Gosford Hospital, Gosford, New South Wales, Australia|Tasman Oncology Research Pty Ltd, Southport, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Ballarat Base Hospital, Ballarat, Victoria, Australia|Goulburn Valley Health, Shepparton, Victoria, Australia|Sunshine Hospital, St Albans, Victoria, Australia|St John of God Murdoch Hospital, Perth, Western Australia, Australia|Local Institution, Subiaco, Western Australia, Australia|Local Institution, Salvador, Bahia, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, London, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS, Sherbrooke, Quebec, Canada|Local Institution, Trois-Rivieres, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Pontificia Universidad Catolica de Chile, Santiago, Metropolitana, Chile|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Hospital Clinico de la Universidad De Chile, Independencia, Santiago, Chile|Instituto Oncologico Clinica Renaca, Vina Del Mar, Valparaiso, Chile|ICOS - Inmunomedica, Temuco, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Ha Erbin, Heilongjiang, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Changzhou, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Qingdao, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Hangzhou, China|Local Institution, Tianjin, China|Local Institution, Bogota, Cundinamarca, Colombia|Administradora Del Country S.A. - Clinica Del Country, Bogota, Colombia|Local Institution, Pasto, Colombia|Interni hematologicka a onkologicka klinika, Brno, Czechia|Klinika komplexni onkologicke pece, Brno, Czechia|Local Institution, Caen, France|Local Institution, Dijon, France|Local Institution, Lille, France|Local Institution, Montpellier, France|Local Institution, Nantes, France|Local Institution, Nice Cedex 2, France|Local Institution, Paris, France|Local Institution, Plerin, France|Charite Campus Virchow Klinikum, Berlin, Germany|University Hospital Of Cologne, Cologne, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, Germany|Universitatsklinikum Dusseldorf, Dusseldorf, Germany|Universitaetsklinikum Essen, Essen, Germany|Medizinische Universitaetsklinik Freiburg, Freiburg, Germany|Universitaets-Krankenhaus Eppendorf, Hamburg, Germany|Johannes -Gutenberg Universitat, Mainz, Germany|Klinikum Rechts Der Isar, Muenchen, Germany|Laiko General Hospital Of Athens, Athens, Greece|Ioannina University Hospital, Ioannina, Greece|Agioi Anargyroi Cancer Center, Nea Kifissia, Greece|University General Hospital of Patras, Patras, Greece|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Semmelweis Egyetem Onkologiai Kozpont, Budapest, Hungary|Orszagos Onkologiai Intezet, Budapest, Hungary|DE KK Onkologiai Intezet, Debrecen, Hungary|Local Institution, Gyula, Hungary|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Tel Aviv, Israel|ASST Papa Giovanni XXIII, Bergamo, Italy|Local Institution, Firenze, Italy|Azienda Ospedaliera Universitaria Di Modena, Modena, Italy|Aorn Dei Colli, Napoli, Italy|Azienda Ospedaliera Universitaria Pisana, Pisa, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Osp. Casa Sollievo Della Sofferenza, San Giovanni Rotondo, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Kita-gun, Japan|Local Institution, Tokyo, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Toluca, Estado DE Mexico, Mexico|Local Institution, Queretaro, Mexico|Clinica Anglo Americana, Lima, Peru|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Hospital Nacional Cayetano Heredia, Lima, Peru|Clinica Internacional sede San Borja, Lima, Peru|II Klinika Chirurgii Ogolnej, Gastroenterologicznej i Nowotworow Ukladu Pokarmowego, Lublin, Poland|Local Institution, Nowy Sacz, Poland|Centrum Onkologiczne: Oddzial Onkologii Klinicznej oraz Poradnia Onkologiczna, Tarnobrzeg, Poland|Klinika Gastroenterologii Onkologicznej, Warszawa, Poland|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Local Institution, Baia Mare, JUD Maramures, Romania|Local Institution, Bucharest, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Suceava, Romania|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Kazan, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Badajoz, Spain|Local Institution, Badalona-barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Pozuelo De Alarcon, Madrid, Spain|Local Institution, Valencia, Spain|Local Institution, Zaragoza, Spain|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Diyarbak?r, Turkey|Local Institution, Edrine, Turkey|Local Institution, Istanbul, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Nottingham, Nottinghamshire, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Southampton, United Kingdom		https://ClinicalTrials.gov/show/NCT02872116
13	NCT00323882	Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer		Completed	Has Results	Prostate Cancer|Neoplasm Metastasis	Drug: MDX-010	Number of Participants With Serious AEs (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Immune-related AEs - Treated Participants|Number of Participants With Best PSA Response at Day 85 by Category - PSA Evaluable Participants|Number of Participants With Best Overall PSA Response by Category - PSA Evaluable Participants|Number of Participants With Best Overall Tumor Response by Category - Tumor Evaluable Participants|Time to PSA Response at Day 85 in Participants With Complete Response (CR) or Confirmed Partial Response (PR) at Day 85|Overall Tumor Response Rate in 10 mg/kg Ipilimumab Monotherapy and Ipilimumab/XRT Combination Therapy|PSA Response Rate at Day 85 and Overall PSA Response Rate in 10 mg/kg Monotherapy and Combination Therapy|Number of Participants Who Died by Date of Primary Analysis and by Date of Completion of Follow Up - All Treated Participants|Overall Survival at Completion of Follow Up Period - Treated Participants|Number of Participants With On-Study Hematology Laboratory Tests Worst Common Terminology Criteria (CTC) Grade - Treated Participants|Number of Participants With On-Study Serum Chemistry Laboratory Tests Worst Common Terminology Criteria (CTC) Grade - Treated Participants|Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities at Baseline and During Treatment Period - Treated Participants|Number of Participants Positive for Human Anti-Human Antibodies (HAHA) - Treated Participants	Bristol-Myers Squibb	Male	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	75	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-017 ST|CA184-017	January 2006	September 2009	July 2013	May 10, 2006	August 28, 2014	August 28, 2014	The Angeles Clinic and Research Institute, Los Angeles, California, United States|The Angeles Clinic and Research Institute, Los Angeles, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|Josephine Ford Cancer Center-Downriver, Brownstown, Michigan, United States|Henry Ford Medical Center-Fairlane, Dearborn, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Henry Ford Medical Center-West Bloomfield, West Bloomfield, Michigan, United States|Washington University School of Medicine, St. Louis, Missouri, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Carolina BioOncology Institute, Huntersville, North Carolina, United States|Oregon Health and Science University, Portland, Oregon, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|University of Washington Medical Center, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00323882
14	NCT01165216	Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer		Completed	Has Results	Non-Small Cell Lung Cancer	Drug: Ipilimumab, 3 mg|Drug: Ipilimumab, 10 mg|Drug: Paclitaxel|Drug: Carboplatin	Number of Participants Experiencing a Dose-limiting Toxicity (DLT)|Number of Participants With Death As Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Drug-related Adverse Events (AEs), AEs Leading to Discontinuation, Drug-related AEs Leading to Discontinuation|Number of Participants With Best Overall Response (BOR) of Partial Response (PR) or Stable Disease|Maximum Serum Concentration (Cmax) of Ipilimumab|Trough Observed Serum Concentration (Cmin) of Ipilimumab|Area Under the Concentration Curve From Time 0 to Day 21 (in 1 Interval Dosing) (AUC[0-21d]) for Ipilimumab|Time of Maximum Observed Serum Concentration (Tmax)|Serum Half-life (T-HALF) of Ipilimumab	Bristol-Myers Squibb	All	20 Years and older   (Adult, Older Adult)	Phase 1	15	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-113	September 2010	June 2013	June 2013	July 19, 2010	July 22, 2014	July 22, 2014	Local Institution, Chuo-ku, Tokyo, Japan		https://ClinicalTrials.gov/show/NCT01165216
15	NCT02279732	Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin		Completed	No Results Available	Lung Cancer (NSCLC)	Biological: Paclitaxel|Biological: Carboplatin|Biological: Ipilimumab|Other: Placebo	Overall survival (OS) in the population of all randomized subjects who received at least one dose of blinded study therapy|Progression-free Survival Per mWHO among Subjects who Received Blinded Study Therapy|OS among All Randomized Subjects	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	344	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA184-153|2014-002604-25	October 13, 2014	May 3, 2018	May 3, 2018	October 31, 2014	null	June 20, 2018	Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Shantou, Guangdong, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Chang Chun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Changsha, China|Local Institution, Chongqing, China|Local Institution, Fuzhou, China|Local Institution, Kunming, China|Local Institution, Shanghai, China|Local Institution, Berlin, Germany|Local Institution, Halle, Germany|Local Institution, Hamburg, Germany|Local Institution, Leipzig, Germany|Local Institution, Loewenstein, Germany|Local Institution, Mainz, Germany|Pulmonologiai Klinika, Budapest, Hungary|Csongrad Megyei Onkormanyzat Mellkasi Betegsegek Szakkorhaza, Deszk, Hungary|Torokbalinti Tudogyogyintezet, Torokbalint, Hungary|Local Institution, Cheongju-si, Chungcheonbuk-do, Korea, Republic of|Local Institution, Suwon-si, Gyeonggi-do, Korea, Republic of|Local Institution, Hwasun-gun, Jeonnam, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Oddzial Onkologiczny, Elblag, Poland|Oddzial Chemioterapii, Poznan, Poland|Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, Poland|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore		https://ClinicalTrials.gov/show/NCT02279732
16	NCT00050596	Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer		Completed	No Results Available	Prostate Cancer	Drug: MDX-010 / MDX-010 + Docetaxel		Bristol-Myers Squibb	Male	18 Years and older   (Adult, Older Adult)	Phase 2	null	Industry	Interventional	Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MDX010-07|CA184-019	November 2002	November 2004	November 2004	December 17, 2002	null	June 27, 2011	Advanced Clinical Therapeutics, Tucson, Arizona, United States|Pacific Shores Medical Group, Long Beach, California, United States|San Diego Uro-Research, San Diego, California, United States|LSU Health Science Center/ Stanley S. Scott Cancer Center (uptown campus), New Orleans, Louisiana, United States|Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|University Urological Research Institute, Providence, Rhode Island, United States|Grand Strand Urology, Myrtle Beach, South Carolina, United States|Urology Associates of North Texas, Arlington, Texas, United States|Utah Cancer Specialists, Salt Lake City, Utah, United States|Salt Lake Research, Salt Lake City, Utah, United States|Seattle Cancer Center Alliance, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00050596
17	NCT01285609	Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin		Completed	Has Results	Lung Cancer - Non Small Cell Squamous	Drug: Ipilimumab|Drug: Placebo|Drug: Paclitaxel|Drug: Carboplatin	Overall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study Therapy at Primary Endpoint|Overall Survival (OS) in All Randomized Participants at Primary Endpoint|Median Number of Months With Progression Free Survival (PFS) Per mWHO in Participants Who Have Received at Least One Dose of Blinded Study Therapy at Primary Endpoint	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	1289	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA184-104|2009-017396-19	January 16, 2011	June 9, 2015	August 22, 2017	January 28, 2011	June 23, 2016	September 19, 2018	Sharp Memorial Hospital, San Diego, California, United States|Va Connecticut Healthcare System, West Haven, Connecticut, United States|Local Institution, Boca Raton, Florida, United States|Integrated Community Oncology Network, Jacksonville, Florida, United States|Quincy Medical Group, Quincy, Illinois, United States|Presence Medical Group Hematology Oncology, Skokie, Illinois, United States|Local Institution, Springfield, Illinois, United States|St. Francis Hospital & Health Centers, Indianapolis, Indiana, United States|Floyd Memorial Cancer Center Of Indiana, New Albany, Indiana, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Montgomery Cancer Center, Mount Sterling, Kentucky, United States|Local Institution, Ypsilanti, Michigan, United States|University Of Kansas Cancer Center, Kansas City, Missouri, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Clinical Research Alliance, Inc., Lake Success, New York, United States|Durham Va Medical Center (111g), Durham, North Carolina, United States|Carolina Biooncology Institute, Huntersville, North Carolina, United States|Novant Health Oncology Specialists, Lexington, North Carolina, United States|Gabrail Cancer Center Research, Canton, Ohio, United States|Oklahoma Oncology And Hematology, Pc Dba, Tulsa, Oklahoma, United States|Local Institution, Portland, Oregon, United States|Guthrie Medical Group, P.C., Sayre, Pennsylvania, United States|Wjb Dorn Va Medical Center, Columbia, South Carolina, United States|Cancer Center Of The Carolinas, Greenville, South Carolina, United States|Tennessee Cancer Specialists, Knoxville, Tennessee, United States|Thompson Oncology Group, Knoxville, Tennessee, United States|Texas Oncology, PA - South Austin Cancer Center, Austin, Texas, United States|Blue Ridge Cancer Care, Blacksburg, Virginia, United States|Local Institution, Quilmes, Buenos Aires, Argentina|Local Institution, Rosario, Santa FE, Argentina|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Santa Fe, Argentina|Local Institution, Bedford Park, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Frankston, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Wodonga, Victoria, Australia|Local Institution, Graz, Austria|Local Institution, Linz, Austria|Local Institution, Salzburg, Austria|Local Institution, Aalst, Belgium|Local Institution, Liege, Belgium|Local Institution, Sint Niklaas, Belgium|Local Institution, Yvoir, Belgium|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Passo Fundo, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose dos Campos, SAO Paulo, Brazil|Local Institution, Porto Alegre, Brazil|Local Institution, Ribeirao Preto, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Oshawa, Canada|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Vina Del Mar, Valparaiso, Chile|Local Institution, Santiago, Chile|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Shantou, Guangdong, China|Local Institution, Wuhan, Hubei, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Xi'an, Shaanxi, China|Local Institution, Xi'an, Shaanxi, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Santiago, China|Local Institution, Shanghai, China|Local Institution, Shanghai, China|Local Institution, Monteria, Cordoba, Colombia|Local Institution, Pereira, Risaralda, Colombia|Local Institution, Ostrava, Poruba, Czechia|Local Institution, Prague 2, Czechia|Local Institution, Praha 5, Czechia|Local Institution, Praha 8, Czechia|Local Institution, Pribram V-Zdabor, Czechia|Local Institution, Usti Nad Labem, Czechia|Local Institution, Znojmo, Czechia|Local Institution, Aalborg, Denmark|Local Institution, Herlev, Denmark|Local Institution, Hillerod, Denmark|Local Institution, Naestved, Denmark|Local Institution, Odense, Denmark|Local Institution, Caen Cedex 05, France|Local Institution, Marseille Cedex 20, France|Local Institution, Paris, France|Local Institution, Poitiers, France|Local Institution, Rennes Cedex 9, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Vandoeuvre-les-nancy, France|Local Institution, Bad Berka, Germany|Local Institution, Bochum, Germany|Local Institution, Darmstadt, Germany|Local Institution, Dresden, Germany|Local Institution, Frankfurt Am Main, Germany|Local Institution, Gauting, Germany|Local Institution, Grosshandsdorf, Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kassel, Germany|Local Institution, Lubeck, Germany|Local Institution, Mainz, Germany|Local Institution, Muenchen, Germany|Local Institution, Neumunster, Germany|Local Institution, Regensburg, Germany|Local Institution, Tuebingen, Germany|Local Institution, Ulm, Germany|Local Institution, Villingen-Schwenningen, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Local Institution, New Territories, Hong Kong|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Deszk, Hungary|Local Institution, Farkasgyepu, Hungary|Local Institution, Gyula, Hungary|Local Institution, Matrahaza, Hungary|Local Institution, Nyiregyhaza, Hungary|Local Institution, Pecs, Hungary|Local Institution, Sopron, Hungary|Local Institution, Szekesfehervar, Hungary|Local Institution, Szolnok, Hungary|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Beer Sheva, Israel|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Nahariya, Israel|Local Institution, Petah-Tikva, Israel|Local Institution, Rehovot, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Tel-aviv, Israel|Local Institution, Tel-hashomer, Israel|Local Institution, Zerifin, Israel|Local Institution, Benevento, Italy|Local Institution, Bologna, Italy|Local Institution, Lido Di Camaiore, Italy|Local Institution, Lucca, Italy|Local Institution, Monza, Italy|Local Institution, Padova, Italy|Local Institution, Perugia, Italy|Local Institution, Siena, Italy|Local Institution, Sondrio, Italy|Local Institution, Terni, Italy|Local Institution, Treviglio, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Yokohama-Shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Sendai, Miyagi, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Local Institution, Akashi, Hyogo, Japan|Local Institution, Fukuoka, Japan|Local Institution, Matsuyama, Ehime, Japan|Local Institution, Osakasayama-city, Japan|Local Institution, Sapporo Hokkaido, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Sendai, Miyagi, Japan|Local Institution, Takatsuki, Japan|Local Institution, Tokyo, Japan|Local Institution, Cheonju-si, Chungcheongbuk-do, Korea, Republic of|Local Institution, Goyang-si, Gyeonggi-do, Korea, Republic of|Local Institution, Suwon-si, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Kangnam-gu, Korea, Republic of|Local Institution, Seoul, Seodaemungu, Korea, Republic of|Local Institution, Busan, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Suwon, Korea, Republic of|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Breda, Netherlands|Local Institution, Harderwijk, Netherlands|Local Institution, Hertogenbosch, Netherlands|Local Institution, Nieuwegein, Netherlands|Local Institution, Trujillo, LA Libertad, Peru|Local Institution, Arequipa, Peru|Local Institution, Cercado, Peru|Local Institution, Lima, Peru|Local Institution, Elblag, Poland|Local Institution, Gdansk- Zaspa, Poland|Local Institution, Gdansk, Poland|Local Institution, Grudziadz, Poland|Local Institution, Olsztyn, Poland|Local Institution, Otwock, Poland|Local Institution, Poznan, Poland|Local Institution, Szczecin, Poland|Local Institution, Torun, Poland|Local Institution, Warsaw, Poland|Local Institution, Sao Martinho Do Bispo, Coimbra, Portugal|Local Institution, Lisboa, Portugal|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Local Institution, Santa Maria Da Feira, Portugal|Local Institution, Vila Nova De Gaia, Portugal|Local Institution, Bucharest, Romania|Local Institution, Bucuresti, Romania|Local Institution, Cluj Napoca, Romania|Local Institution, Sibiu, Romania|Local Institution, Suceava, Romania|Local Institution, Timisoara, Romania|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Kazan, Russian Federation|Local Institution, Kazan, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Pyatigorsk, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, St-Peterburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Tula, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Vereeniging, Gauteng, South Africa|Local Institution, Panorama,cape Town, Western CAPE, South Africa|Local Institution, Rondebosch, Western CAPE, South Africa|Local Institution, Cape Town, South Africa|Local Institution, Durban, South Africa|Local Institution, Barakaldo, Vizcaya, Spain|Local Institution, Benidorm-alicante, Spain|Local Institution, Castellon, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Manresa, Spain|Local Institution, Ourense, Spain|Local Institution, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Ávila, Spain|Local Institution, Gothenburg, Sweden|Local Institution, Lund, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Umea, Sweden|Local Institution, Basel, Switzerland|Local Institution, Winterthur, Switzerland|Local Institution, Changhua City, Taiwan|Local Institution, Chiayi, Taiwan|Local Institution, Kaohsiung County, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taipei City, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Bangkok, Tungpayathai, Thailand|Local Institution, Bangkok, Thailand|Local Institution, Bangkok, Thailand|Local Institution, Bangkok, Thailand|Local Institution, Chiang Mai, Thailand|Local Institution, Songkhla, Thailand|Local Institution, Dundee, Angus/forfarshire, United Kingdom|Local Institution, Truro, Cornwall, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Nottingham, United Kingdom|Local Institution, Sheffield, United Kingdom		https://ClinicalTrials.gov/show/NCT01285609
18	NCT00861614	Study of Immunotherapy to Treat Advanced Prostate Cancer		Completed	Has Results	Prostate Cancer	Drug: Ipilimumab|Drug: Placebo	Overall Survival (OS)|Overall Survival Rate|Progression Free Survival (PFS)|Pain Response|Duration of Pain Response|Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs, Immune-Related Adverse Events (irAE) and Immune-Mediated Adverse Reaction (imAR)|Time to Onset of Grade 3 or 4 Immune-Related Adverse Event (irAE)|Time to Resolution of Grade 3 or 4 Immune-Related Adverse Event (irAE)|Time to Onset of Grade 3 to 5 Immune-Mediated Adverse Reaction (imAR)|Time to Resolution of Grade 3 to 5 to Grade 0 Immune-Mediated Adverse Reactions (imARs) to Grade 0|Number of Participants With Worst On-Study Hematology Common Toxicity Criteria (CTC) Grade and Shift From Baseline|Number of Participants With Worst On-Study Liver Common Toxicity Criteria (CTC) Grade and Shift From Baseline|Number of Participants With Worst On-Study Serum Chemistry Common Toxicity Criteria (CTC) Grade and Shift From Baseline|Number of Participants With Worst On-Study Renal Function Common Toxicity Criteria (CTC) Grade and Shift From Baseline	Bristol-Myers Squibb	Male	18 Years and older   (Adult, Older Adult)	Phase 3	988	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA184-043|2008-003314-97	May 2009	November 2012	August 2015	March 13, 2009	March 16, 2016	September 30, 2016	Southern Cancer Center, Mobile, Alabama, United States|Alaska Clinical Research Center, Llc, Anchorage, Alaska, United States|Arizona Clinical Research Center, Inc., Tucson, Arizona, United States|Highlands Oncology Group, P.A., Fayetteville, Arkansas, United States|Marsha G. Fink, Md, Inc., Fountain Valley, California, United States|Loma Linda University Cancer Center, Loma Linda, California, United States|Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Prostate Oncology Specialists, Inc., Marina Del Rey, California, United States|Comprehensive Cancer Center, Palm Springs, California, United States|Va San Diego Healthcare System, San Diego, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|Suburban Hematology-Oncology Associates, Pc, Lawrenceville, Georgia, United States|University Of Chicago, Chicago, Illinois, United States|Cancer Care Specialists Of Central Illinois, Decatur, Illinois, United States|Edward Cancer Center, Naperville, Illinois, United States|Mid-Illinois Hematology & Oncology Associates, Ltd, Normal, Illinois, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Siouxland Hematology-Oncology Assoc., Llp, Sioux City, Iowa, United States|Hutchinson Clinic, Pa, Hutchinson, Kansas, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|The Bunting-Blaustein Cancer Research Building, Baltimore, Maryland, United States|Frederick Memorial Hospital Regional Cancer Therapy Center, Frederick, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Kansas City Veterans Affairs Medical Center, Kansas City, Missouri, United States|St Johns Medical Research Institute, Inc., Springfield, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|Raleigh Hematology Oncology Associates, Raleigh, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|University Of Cincinnati, Cincinnati, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|St. Luke'S Hospital & Health Network Laboratory, Bethlehem, Pennsylvania, United States|Va Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Associates In Hematology & Oncology, P.C., Upland, Pennsylvania, United States|Musc Hollings Cancer Center, Charleston, South Carolina, United States|Center For Oncology Research & Treatment, P.A., Dallas, Texas, United States|The Center For Cancer And Blood Disorders, Fort Worth, Texas, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|Northwest Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Edwards Comprehensive Cancer Center, Huntington, West Virginia, United States|Local Institution, Caba, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, Rosario, Santa Fe, Argentina|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, La Rioja, Argentina|Local Institution, Box Hill, Victoria, Australia|Local Institution, Frankston, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Subiaco, Western Australia, Australia|Local Institution, Salzburg, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Ijui, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Curitiba, Sao Paulo, Brazil|Local Institution, Divinopolis, Sao Paulo, Brazil|Local Institution, Mogi Das Cruzes, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Greenfield Park, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Temuco, Araucania, Chile|Local Institution, Santiago - Independencia, Metropolitana, Chile|Local Institution, Santiago De Chile, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Vi?a Del Mar, Valparaiso, Chile|Local Institution, Monteria, Cordoba, Colombia|Local Institution, Bogota, Colombia|Local Institution, Brno, Czech Republic|Local Institution, Hradec Kralove, Czech Republic|Local Institution, Liberec, Czech Republic|Local Institution, Aalborg, Denmark|Local Institution, Aarhus, Denmark|Local Institution, Herlev, Denmark|Local Institution, Kobenhavn O, Denmark|Local Institution, Odense C, Denmark|Local Institution, Besancon Cedex, France|Local Institution, Bordeaux, France|Local Institution, Clermont-ferrand, France|Local Institution, Marseille Cedex 20, France|Local Institution, Pointe A Pitre, France|Local Institution, Villejuif Cedex, France|Local Institution, Berlin, Germany|Local Institution, Bonn, Germany|Local Institution, Eschweiler, Germany|Local Institution, Mannheim, Germany|Local Institution, Wuppertal, Germany|Local Institution, Athens, Greece|Local Institution, Budapest, Hungary|Local Institution, Gyula, Hungary|Local Institution, Kaposvar, Hungary|Local Institution, Kecskemet, Hungary|Local Institution, Dublin 7, Dublin, Ireland|Local Institution, Tallaght, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Beer Jacob, Israel|Local Institution, Beer-sheva, Israel|Local Institution, Haifa, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Tel Hashomer, Israel|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Rimini, Italy|Local Institution, Siena, Italy|Local Institution, Sondrio, Italy|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Acapulco, Guerrero, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, Cuernavaca, Morelos, Mexico|Local Institution, Aguascalientes, Mexico|Local Institution, Puebla, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Mb Amsterdam, Netherlands|Local Institution, Arequipa, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Olsztyn, Poland|Ponce School Of Medicine, Ponce, Puerto Rico|Local Institution, Bucharest, Romania|Local Institution, Romania, Romania|Local Institution, Suceava, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Obninsk, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Benidorm-alicante, Spain|Local Institution, Madrid, Spain|Local Institution, Santiago De Compostela, Spain|Local Institution, Valencia, Spain|Local Institution, Chelmsford, Essex, United Kingdom|Local Institution, Cardiff, Glamorgan, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Scunthorpe, Lincolnshire, United Kingdom|Local Institution, Nottingham, Nottinghamshire, United Kingdom		https://ClinicalTrials.gov/show/NCT00861614
19	NCT02477826	An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)	CheckMate 227	Recruiting	No Results Available	Non-Small Cell Lung Cancer	Drug: Nivolumab|Drug: Ipilimumab|Drug: Carboplatin|Drug: Cisplatin|Drug: Gemcitabine|Drug: Pemetrexed|Drug: Paclitaxel	Overall survival (OS)|Progression-free Survival (PFS) as determined by blinded independent central review (BICR)|Objective response rate (ORR)|Disease related symptom improvement as measured by the Lung Cancer Symptom Score (LCSS) in all subjects	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	2220	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-227|2014-003630-23	August 5, 2015	January 31, 2019	December 31, 2020	June 23, 2015	null	November 29, 2018	Southern Cancer Center, Inc., Mobile, Alabama, United States|Local Institution, La Jolla, California, United States|California Pacific Medical Center, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|Emory University Hospital, Atlanta, Georgia, United States|Northwest Georgia Oncology Centers, P.C., Marietta, Georgia, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Southfield, Michigan, United States|Local Institution, Rochester, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|University Hospitals, Cleveland, Ohio, United States|The Ohio State University, Columbus, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Guthrie Medical Group, Pc, Sayre, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Greenville Health System, Greenville, South Carolina, United States|St Francis Hospital, Greenville, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|The University Of Texas, Dallas, Texas, United States|University Of Texas Southwestern Medical Center, Dallas, Texas, United States|University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States|Huntsman Cancer Institute At The Univ. Of Utah, Salt Lake City, Utah, United States|Kadlec Clinical Hematology and Oncology, Kennewick, Washington, United States|COIBA, Berazategui, Buenos Aires, Argentina|Instituto Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Fundacion Investigar, Ciudad de Buenos Aires, Buenos Aires, Argentina|Hospital Privado De Comunidad, Mar Del Plata, Buenos Aires, Argentina|Hospital Privado Centro Medico De Cordoba, Córdoba, Cordoba, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Tucuman, Argentina|Local Institution, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Clinica Privada Universitaria Reina Fabiola, Cordoba, Argentina|Local Institution, Garran, Australian Capital Territory, Australia|Blacktown Hospital, Blacktown, New South Wales, Australia|Local Institution, Gosford, New South Wales, Australia|Tamworth Hospital, Tamworth, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Clayton, Victoria, Australia|St Vincent's Hospital, Fitzroy, Victoria, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Murdoch, Australia|Medizinische Universitatsklinik, Graz, Austria|Akh Wien, Vienna, Austria|Klinikum Wels-Grieskirchen Gmbh, Wels, Austria|Local Institution, Charleroi, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Hasselt, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Sint Niklaas, Belgium|Local Institution, Salvador, Bahia, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Cross Cancer Institute, Edmonton, Alberta, Canada|Dr. H.Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada|London Regional Cancer Program, London, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS, Sherbrooke, Quebec, Canada|Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du-Quebec, Trois-Rivieres, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Institut Universitaire de Cardiologie et de Pneumologie de Quebec - Universite Laval, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Instituto Oncologico, Vina Del Mar, Valparaiso, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guanzhou, Guangdong, China|Local Institution, Haikou, Hainan, China|Local Institution, Haerbin, Heilongjiang, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Xi'an, Shaanxi, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Qingdao, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Hanghzou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Changsha, China|Local Institution, Chongqing, China|Local Institution, Chongqing, China|Local Institution, Hangzhou, China|Local Institution, Hangzhou, China|Local Institution, Kunming, China|Local Institution, Shanghai, China|Oncologos Del Occidente Sa, Pereira, Risaralda, Colombia|Administradora Del Country S.A. - Clinica Del Country, Bogota, Colombia|Hospital Universitario San Ignacio, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Plicni klinika, Hradec Kralove, Czechia|Klinika plicnich nemoci a tuberkulozy, Olomouc, Czechia|Pneumologicka klinika 1. LF a TN, Praha 4, Czechia|Oddeleni Onkologie, Pribram, Czechia|Local Institution, Oulu, Finland|Local Institution, Turku, Finland|Local Institution, ANGERS Cedex 2, France|Local Institution, Besançon Cedex, France|Local Institution, Bron Cedex, France|Local Institution, Caen, France|Local Institution, Creteil, France|Local Institution, Limoges cedex, France|Local Institution, Marseille Cedex 20, France|Local Institution, Paris, France|Local Institution, Pessac, France|Local Institution, Rennes Cedex 9, France|Local Institution, Rouen, France|Local Institution, Saint Herblain, France|Local Institution, Saint Priest En Jarez, France|Local Institution, Strasbourg, France|Local Institution, Toulon, France|Zentralklinik Bad Berka Gmbh, Bad Berka, Thuringen, Germany|Local Institution, Berlin, Germany|Universitaetsklinikum Essen, Essen, Germany|Universitatsklinikum Frankfurt, Frankfurt, Germany|SRH WALD KLINIKUM GERA gGmbH, Gera, Germany|Klinik Schillerhoehe, Gerlingen, Germany|Krankenhaus Grosshansdorf, Grosshansdorf, Germany|Stadtisches Krankenhaus Martha Maria Halle-Dolau, Halle, Germany|Thoraxklinik-Heidelberg Ggmbh, Heidelberg, Germany|Lungenklinik Hemer, Hemer, Germany|Klinikverbund Kempten-Oberallgau, Immenstadt, Germany|Universitaetsklinikum Magdeburg A. o. R., Magdeburg, Germany|Klinikum Bogenhausen, Muenchen, Germany|Hsk Dr.-Horst-Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany|Local Institution, Athens, Greece|Local Institution, Heraklio, Greece|Local Institution, Neo Faliro, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Matrahaza, Hungary|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Limerick, Ireland|Local Institution, Jerusalem, Israel|Local Institution, Kfar-saba, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Tel-hashomer, Israel|Local Institution, Zerifin, Israel|Local Institution, Avellino, Italy|Local Institution, Bergamo, Italy|Local Institution, Bologna, Italy|Local Institution, Livorno, Italy|Local Institution, Messina, Italy|Local Institution, Milano, Italy|Local Institution, Milan, Italy|Local Institution, Napoli, Italy|Local Institution, Ravenna, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, S.Andrea Fratte PG, Italy|Local Institution, Terni, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Ota-shi, Gunma, Japan|Local Institution, Hiroshima-shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Yokohama-Shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osakasayama-shi, Osaka, Japan|Local Institution, Takatsuki-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Wakayama-shi, Wakayama, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Local Institution, Cheongju-si, Chungcheonbuk-do, Korea, Republic of|Local Institution, Seongnam-si, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Beirut, Lebanon|Local Institution, Beirut, Lebanon|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Phylasis Clinicas Research S de R. L. de C. V., Cuautitlan, Estado DE Mexico, Mexico|Local Institution, Toluca, Estado DE Mexico, Mexico|Instituto Jalisciense De Cancerologia, Guadalajara, Jalisco, Mexico|Local Institution, Morelia, Michoacan, Mexico|Axis Heilsa S de Rl de Cv, Monterrey, Nuevo LEON, Mexico|Medical Care & Research, Merida, Yucatan, Mexico|Local Institution, Chihuahua, Mexico|Local Institution, San Luis Potosi, Mexico|Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi S.C., San Luis Potosi, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Amsterdam, Netherlands|Local Institution, Breda, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Veldhoven, Netherlands|Clinica Ricardo Palma, Lima, Peru|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Clinica San Felipe- Unidad de Oncologia Medica, Lima, Peru|Instituto Oncologico Miraflores, Lima, Peru|Oncocenter Peru SAC - Oncosalud, Lima, Peru|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Oddzial Onkologii I Radioterapii Szpital Morski Im. Pck, Gdynia, Poland|Centrum Onkologii-Inst.Im.M.Sklodowskiej-Curie O.W Gliwicach, Gliwice, Poland|Regionalny Osrodek Onkologiczny, Lodz, Poland|Klinika Nowotworow Pluca i Klatki Piersiowej, Warszawa, Poland|ORTHOS Szpital Wielospecjalistyczny Sp. z o.o., Wroclaw, Poland|Institute Of Oncology "Prof.Dr.Alexandru Trestioreanu" Bucha, Bucharest, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|S.C. Radiotherapy Center Cluj S.R.L., Floresti, Romania|Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep, Romania, Romania|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Kazan, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Ufa, Russian Federation|Local Institution, Riyadh 11426, Saudi Arabia|Local Institution, Riyadh-11211, Saudi Arabia|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Saxonwold, Johannesburg, Gauteng, South Africa|Local Institution, Vereeniging, South Africa|Local Institution, Majadahonda, Madrid, Spain|Local Institution, Badalona (Barcelona), Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Klinik Fur Onkologie, Basel, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|Local Institution, Winterthur, Switzerland|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Tao-Yuan County, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Kayseri, Turkey|Local Institution, Al Ain, United Arab Emirates|Local Institution, Middlesborough, Cleveland, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Leicester, Leicestershire, United Kingdom|Local Institution, Birmingham, WEST Midlands, United Kingdom|Local Institution, Cambridgeshire, United Kingdom|Local Institution, Edinburgh, United Kingdom|Local Institution, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT02477826
20	NCT03444753	An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed		Recruiting	No Results Available	Advanced Cancer	Biological: BMS-986299|Biological: Nivolumab|Biological: Ipilimumab	Incidence of dose-limiting toxicities (DLTs)|Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of AEs leading to discontinuation and deaths|Incidence of clinical laboratory abnormalities|Maximum observed plasma concentration (Cmax)|Time of maximum observed plasma concentration (Tmax)|Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]|Area under the plasma concentration-time curve from time zero to 24 hours postdose [AUC(0-24)]	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	90	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA039-001	March 20, 2018	November 14, 2021	December 19, 2021	February 23, 2018	null	October 4, 2018	University Of California San Diego Moores Cancer Center, La Jolla, California, United States|Washington University, Saint Louis, Missouri, United States|MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03444753
21	NCT00083278	Study of MDX-010 in Stage IV Breast Cancer		Completed	No Results Available	Breast Cancer|Adenocarcinoma	Drug: MDX-010		Bristol-Myers Squibb	Female	18 Years and older   (Adult, Older Adult)	Phase 2	33	Industry	Interventional	Allocation: Non-Randomized|Masking: None (Open Label)|Primary Purpose: Treatment	MDX010-12|CA184-015	May 2003	null	February 2006	May 20, 2004	null	April 27, 2012	Sharp Clinical Oncology Research, San Diego, California, United States|Wishard Health Services, Indianapolis, Indiana, United States|Section of Hematology/Oncology, Indiana Cancer Pavilion, Indianapolis, Indiana, United States|Indiana University, Clarian Health Partners, Indianapolis, Indiana, United States|Medical Arts Building, Jeffersonville, Indiana, United States|Kansas City Oncology and Hematology Group, Kansas City, Kansas, United States|Kansas City Oncology and Hematology Group, Overland Park, Kansas, United States|LaGrange, LaGrange, Kentucky, United States|Norton Healthcare Inc, Loiusville Oncology Clinical Research Program, Louisville, Kentucky, United States|Suburban Medical Plaza II, Louisville, Kentucky, United States|Audubon Oncology/Hematology, Louisville, Kentucky, United States|Kansas City Oncology and Hematology Group, Kansas City, Missouri, United States|Kansas City Oncology and Hematology Group, Lee's Summit, Missouri, United States|Arlington Cancer Center, Arlington, Texas, United States		https://ClinicalTrials.gov/show/NCT00083278
22	NCT03130959	An Investigational Immuno-therapy Study of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Patients With High Grade Primary CNS Malignancies	CheckMate 908	Recruiting	No Results Available	Various Advanced Cancer	Biological: Nivolumab|Biological: Ipilimumab	Incidence of dose limiting toxicity (DLT)|Incidence of serious adverse events (SAEs)|Incidence of adverse events (AEs)|Overall Survival (OS)|Progression Free Survival (PFS)|Incidence of AEs|Incidence of SAEs|Incidence of laboratory abnormalities|Overall Survival|Progression Free Survival	Bristol-Myers Squibb	All	6 Months to 21 Years   (Child, Adult)	Phase 2	170	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-908|2016-004441-82	June 6, 2017	June 14, 2021	June 15, 2021	April 27, 2017	null	September 11, 2018	Children's Hospital Of Los Angeles, Los Angeles, California, United States|Local Institution, San Francisco, California, United States|Children'S Hospital, Aurora, Colorado, United States|Local Institution, New Haven, Connecticut, United States|Mcknight Brain Institute, Gainesville, Florida, United States|Children'S Memorial Hospital, Chicago, Illinois, United States|The Johns Hopkins Hospital, Baltimore, Maryland, United States|Dana-Farber Cancer Inst, Boston, Massachusetts, United States|Washington University, Saint Louis, Missouri, United States|The Herbert Irving Pavilion, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Local Institution, Rochester, New York, United States|Cincinnati Children'S Hospital Medical Center, Cincinnati, Ohio, United States|Children'S Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|St Jude Children'S Research Hospital, Memphis, Tennessee, United States|Baylor College Of Medicine, Houston, Texas, United States|Local Institution, Randwick, New South Wales, Australia|Local Institution, Sth Brisbane, Queensland, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Parkville, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Curitiba, Parana, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Ribeirao Preto, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Toronto, Ontario, Canada|The Montreal Children's Hospital of the MUHC, Montreal, Quebec, Canada|CHU de Quebec, Quebec, Canada|Local Institution, Angers, France|Local Institution, Bordeaux Cedex, France|Local Institution, Lille, France|Local Institution, Lyon, France|Local Institution, Marseille, France|Local Institution, Paris, France|Local Institution, Vandoeuvre les Nancy, France|Local Institution, VIillejuif, France|Universitaetsklinik Essen, Essen, Germany|Universitaetsklinikum Hamburg, Hamburg, Germany|Hopp Children?s Cancer Center at NCT Heidelberg, Heidelberg, Germany|Univ. Klinikum Wuerzburg, Wuerzburg, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Haifa, Israel|Local Institution, Ramat Gan, Israel|Erasmus Mc , Locatie Sophia, Rotterdam, Netherlands|Prinses Maxima Centrum voor Kinderoncologie, Utrecht, Netherlands|Local Institution, Oslo, Norway|Local Institution, Warszawa, Poland|Local Institution, Moscow, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Esplugues de Llobregat, Spain|Local Institution, Madrid, Spain|Local Institution, Valencia, Spain|Local Institution, Solna, Sweden|Great Ormond Street Hospital For Children, London, Greater London, United Kingdom|Alder Hey Children'S Hospital, Liverpool, Merseyside, United Kingdom|Royal Victoria Infirmary, Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Local Institution, Birmingham, United Kingdom		https://ClinicalTrials.gov/show/NCT03130959
23	NCT03377361	An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Patients With Previously Treated Cancer of the Colon or Rectum That Has Spread	CheckMate9N9	Recruiting	No Results Available	Colorectal Cancer|Colorectal Tumors|Colorectal Carcinoma|Colorectal Neoplasm	Biological: Nivolumab|Drug: Trametinib|Biological: Ipilimumab	Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Objective response rate (ORR)|Disease control rate (DCR)|Duration of response (DoR)|Time to response (TTR)|Progression free survival (PFS)|Overall survival (OS)	Bristol-Myers Squibb|Novartis	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	345	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-9N9|2017-001830-24	January 22, 2018	September 21, 2021	November 24, 2022	December 19, 2017	null	October 9, 2018	University Of Alabama At Birmingham, Birmingham, Alabama, United States|Local Institution, Phoenix, Arizona, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Usc, Los Angeles, California, United States|University of California San Francisco (UCSF), San Francisco, California, United States|Local Institution, Fort Collins, Colorado, United States|Local Institution, New Haven, Connecticut, United States|Local Institution, Indianapolis, Indiana, United States|Local Institution, Baltimore, Maryland, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Rochester, Minnesota, United States|Local Institution, New York, New York, United States|Local Institution, New York, New York, United States|Local Institution, Charlotte, North Carolina, United States|Local Institution, Durham, North Carolina, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Local Institution, Houston, Texas, United States|University Of Wisconsin, Madison, Wisconsin, United States|Local Institution, Blacktown, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Brussels, Belgium|Local Institution, Brussel, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Leuven, Belgium|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Quebec, Canada|Local Institution, Cologne, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Heilbronn, Germany|Local Institution, Mannheim, Germany|Local Institution, Munich, Germany|Local Institution, Ulm, Germany|Local Institution, Wuerzburg, Germany|Local Institution, Milano, Italy|Local Institution, Modena, Italy|Local Institution, Padova, Italy|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Aberdeen, Aberdeenshire, United Kingdom|Local Institution, Bristol, Avon, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Coventry, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT03377361
24	NCT01714739	A Study of an Anti-KIR Antibody Lirilumab in Combination With an Anti-PD1 Antibody Nivolumab and Nivolumab Plus an Anti-CTLA-4 Ipilimumab Antibody in Patients With Advanced Solid Tumors		Active, not recruiting	No Results Available	CANCER,NOS	Drug: Lirilumab|Drug: Nivolumab|Drug: Ipilimumab	Safety and tolerability of BMS-986015 given in combination with BMS-936558 or BMS-936558 plus BMS-734016 as measured by incidence of adverse events|Safety and tolerability of BMS-986015 given in combination with BMS-936558 or BMS-936558 plus BMS-734016 as measured by incidence of clinical laboratory test abnormalities including hematology, serum chemistry, and thyroid panel abnormalities|Objective response rate (ORR)|Maximum observed serum concentration (Cmax) of BMS-986015 derived from serum concentration versus time|Time of maximum observed serum concentration (Tmax) of BMS-986015 derived from serum concentration versus time|Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of BMS-986015 derived from serum concentration versus time|Area under the plasma concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986015 derived from serum concentration versus time|Trough observed serum concentration (Ctrough) of BMS-986015 derived from serum concentration versus time|Area under the concentration-time curve in one dosing interval [AUC(TAU)] of BMS-986015 derived from serum concentration versus time|Clearance (CL) of BMS-986015 derived from serum concentration versus time|Volume of distribution at steady state (Vss) of BMS-986015 derived from serum concentration versus time|Half-life (t1/2) of BMS-986015 derived from serum concentration versus time|Anti-drug antibody (ADA) response to BMS-986015 in combination with BMS-936558 or BMS-734016|Overall survival (OS)|Progression-Free Survival (PFS)|Duration of response (DOR)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	337	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	CA223-001	October 7, 2012	October 15, 2019	October 16, 2019	October 26, 2012	null	September 5, 2018	Ucsf, San Francisco, California, United States|Florida Cancer Affiliates - Ocala, Ocala, Florida, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Lutherville, Maryland, United States|Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|The Ohio State University Wexner Medical Center, Columbus, Ohio, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|UPMC Eye and Ear Institute, Pittsburgh, Pennsylvania, United States|West Cancer Center, Germantown, Tennessee, United States|Texas Oncology-Central Austin Cancer Center, Austin, Texas, United States|University Of Texas Medical Branch Of Galveston, Galveston, Texas, United States|University Of Washington, Seattle, Washington, United States|Juravinski Cancer Center, Hamilton, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Bordeaux, France|Local Institution, Lyon Cedex 08, France|Local Institution, Nice Cedex 2, France|Local Institution, Paris, France|Local Institution, Villejuif Cedex, France|Local Institution, Milano, MI, Italy|Local Institution, Siena, Italy|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Kantonsspital Graubuenden, Chur, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland		https://ClinicalTrials.gov/show/NCT01714739
25	NCT02737475	An Investigational Immuno-therapy Study of Experimental Medication BMS-986178 by Itself or in Combination With Nivolumab and/or Ipilimumab in Patients With Solid Cancers That Are Advanced or Have Spread		Recruiting	No Results Available	Advanced Cancer	Drug: BMS-986178|Drug: Nivolumab|Drug: Ipilimumab	Incidence of AE's (adverse events) and SAE's (serious adverse events), AE's leading to discontinuation, deaths and clinical laboratory test abnormalities|Cmax (maximum observed serum concentration) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|Tmax (time of maximum observed concentration) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|AUC(0-t) (area under the concentration-time curve from time zero to the time) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|AUC(TAU) (area under the concentration-time curve in 1 dosing interval) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|Ctau (the observed concentration at the end of a dosing interval) for BMS- 986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|CLT (total body clearance) for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|Css-avg [average concentration over a dosing interval (AUC(TAU)/tau)] for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|AI [ratio of an exposure measure at steady state to that after the first dose (exposure measure includes AUC(TAU), Cmax and Ctau)] for BMS- 986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|T-HALFeff [effective elimination half-life to explain degree of accumulation for a specific exposure measure (exposure measure includes AUC(TAU), Cmax and Ctau)] for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|Ctrough [trough observed plasma concentrations (this includes pre-dose concentrations (C0) and Ctau)] for BMS-986178 alone and in combination with nivolumab and/or ipilimumab, if data permits|Immunoassay of anti-nivolumab antibody in combination with anti-BMS- 986178 antibody|Immunoassay of anti-ipilimumab antibody in combination with anti-BMS-986178 antibody|Objective Response Rate (ORR)|Progression Free Survival Rate (PFSR)|Immunoassay of anti-BMS-986178 antibody alone|Number of participants showing a change in one of the pharmacodynamic biomarkers of BMS-986178 administered in combination with nivolumab	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	435	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA012-004|2015-004816-39	June 16, 2016	May 12, 2021	October 15, 2021	April 14, 2016	null	October 3, 2018	University Of Colorado, Aurora, Colorado, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Cross Cancer Institute, Edmonton, Alberta, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Local Institution, Ramat Gan, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Milano, Italy|Local Institution, Rozzano, Italy|Local Institution, Amsterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|H. Univ. Vall dHebron, Barcelona, Spain|Fundacion Jimenez Diaz, Madrid, Spain|Hosp. Univ. Puerta De Hierro, Majadahonda - Madrid, Spain|Hospital Universitario Virgen De La Victoria, Malaga, Spain|Clinica Universitaria De Navarra, Pamplona, Spain		https://ClinicalTrials.gov/show/NCT02737475
26	NCT03036098	Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Patients With Untreated Inoperable or Metastatic Urothelial Cancer	CheckMate901	Recruiting	No Results Available	Urothelial Cancer	Biological: nivolumab|Biological: ipilimumab|Drug: gemcitabine|Drug: cisplatin|Drug: carboplatin	Progression free survival (PFS) in cisplatin-ineligible participants using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Overall survival (OS) of cisplatin-ineligible participants|PFS based on BICR assessment of nivolumab combined with standard of care (SOC) chemotherapy to SOC chemotherapy in cisplatin-ineligible participants with previously untreated, unresectable or metastatic Urothelial Cancer (UC)|Progression free survival (PFS) in all participants using Response Evaluation Criteria in Solid Tumors (RECIST 1.1)|Overall survival (OS) in all participants|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire- Core 30 (EORTC QLQ-C30) Global Health Status score|OS in cisplatin-eligible participants with previously untreated, unresectable or metastatic UC.	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	897	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-901|2016-003881-14	March 24, 2017	April 26, 2020	December 23, 2022	January 30, 2017	null	November 6, 2018	Local Institution, Birmingham, Alabama, United States|Local Institution, Birmingham, Alabama, United States|Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States|Local Institution, Little Rock, Arkansas, United States|VA of Central California Health Care System, Fresno, California, United States|St Joseph Heritage Healthcare, Santa Rosa, California, United States|Boca Raton Regional Hospital, Boca Raton, Florida, United States|Holy Cross Hospital, Fort Lauderdale, Florida, United States|Cancer Specialists of North FL, Jacksonville, Florida, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Lewis Hall Singletary Oncology Center, Thomasville, Georgia, United States|University Of Illinois At Chicago, Chicago, Illinois, United States|Local Institution, Iowa City, Iowa, United States|Ochsner Clinic, New Orleans, Louisiana, United States|Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Milford Regional Medical Center, Boston, Massachusetts, United States|South Shore Hospital Cancer Center, Boston, Massachusetts, United States|St. Joseph Mercy Hospital, Ypsilanti, Michigan, United States|Ridges Cancer Clinic, Burnsville, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|St Lukes Hospital, Kansas City, Missouri, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|GU Research Network, LLC, Omaha, Nebraska, United States|Nh Hematology - Oncology, Hooksett, New Hampshire, United States|University Of New Mexico, Albuquerque, New Mexico, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Winthrop University Hospital, Mineola, New York, United States|Icahn School Of Medicine At Mount Sinai, New York, New York, United States|Local Institution, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Local Institution, Houston, Texas, United States|Local Institution, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance, Kirkland, Washington, United States|Local Institution, Milwaukee, Wisconsin, United States|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Privado De Comunidad, Mar Del Plata, Buenos Aires, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro De Diagnostico Urologico S.R.L., Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Clinica Privada Universitaria Reina Fabiola, Cordoba, Argentina|Local Institution, Darlinghurst, New South Wales, Australia|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Chermside, Queensland, Australia|Local Institution, Tugun, Queensland, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Doubleview, Western Australia, Australia|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Passo Fundo, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Florianopolis, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose do Rio Preto, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Nova Scotia Health Authority QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada|Centre integre universitaire de sante et de service sociaux de l'estrie - CHUS, Sherbrooke, Quebec, Canada|CHU de Quebec - L'Hotel-Dieu de Quebec, Quebec, Canada|Local Institution, Santiago, Metropolitana, Chile|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Hospital Clinico Vina Del Mar, Vina Del Mar, Valparaiso, Chile|Local Institution, Vitacura, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Wuhan, Hubei, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, China|Local Institution, Shanghai, China|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Local Institution, Aalborg, Denmark|Local Institution, Herlev, Denmark|Local Institution, Helsinki, Finland|Local Institution, Lille, France|Local Institution, Marseille Cedex 9, France|Local Institution, Nimes Cedex 09, France|Local Institution, Saint Priest En Jarez, France|Local Institution, Suresnes, France|Local Institution, Tours Cedex, France|Local Institution, Villejuif, France|Universitat Dresden, Dresden, Germany|Universitaetsklinikum Essen, Essen, Germany|Medizinische Universitaetsklinik Freiburg, Freiburg, Germany|Asklepios Klinik Altona, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinikum Jena, Jena, Germany|Local Institution, Muenchen, Germany|Klinikum Nuernberg Nord, Urologische Klinik, Nuernberg, Germany|Uniklinik Tuebingen, Tuebingen, Germany|Kliniken Nordoberpfalz AG, Weiden, Germany|Univ. Klinikum Wuerzburg, Wuerzburg, Germany|Alexandra General Hospital, Athens, Greece|Ioannina University Hospital, Ioannina, Greece|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Miskolc, Hungary|Local Institution, Kfar Saba, Israel|Local Institution, Ramat Gan, Israel|Ospedale S. Donato - Usl 8, Arezzo, Italy|Ospedale Per Gli Infermi, Faenza, Italy|Istituto Romagnolo Per Lo Studio E La Cura Dei Tumori, Forli, Italy|Ospedale Della Misericordia Grosseto, Grosseto, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Napoli, Italy|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Sapporo-city, Hokkaido, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kita-Gun, Kagawa, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osakasayama, Osaka, Japan|Local Institution, Takatsuki-shi, Osaka, Japan|Local Institution, Hamamatsu-shi, Shizuoka, Japan|Local Institution, Arakawa-ku,tokyo, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Ube City, Yamaguchi, Japan|Local Institution, Goyang-si, Korea, Republic of|Local Institution, Seongnam-si, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Comite Mexicano para la Prevenion de la Osteoporosis A.C., Ciudad de Mexico, Distrito Federal, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Centro Universitario Contra el Cancer UANL, Monterrey, Nuevo LEON, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Enschede, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Leeuwarden, Netherlands|Local Institution, Bergen, Norway|Local Institution, Lorenskog, Norway|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Clinica El Golf, Lima, Peru|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Local Institution, Koszalin, Poland|Klinika Nowotworow Ukladu Moczowego Centrum Onkologii - Inst, Warszawa, Poland|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Novosibirsk, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Comp. Hosp. Univ. A Coruna, A Coruna, Spain|Hospital Santa Creu I Sant Pau, Barcelona, Spain|Hospital Universitario Ramon Y Cajal, Madrid, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|H. U. Marques de Valdecilla, Santander, Spain|Hospital Universitario Virgen Del Rocio, Sevilla, Spain|Instituto Valenciano De Oncologia, Valencia, Spain|Local Institution, Jonkoping, Sweden|Local Institution, Linkoping, Sweden|Local Institution, Lund, Sweden|Kantonsspital Baden, Baden, Switzerland|Kantonsspital Graubuenden, Chur, Switzerland|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Izmir, Turkey		https://ClinicalTrials.gov/show/NCT03036098
27	NCT00527735	Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC)		Completed	Has Results	Lung Cancer|Small Cell Lung Cancer|Carcinoma, Non-Small-Cell Lung	Drug: Ipilimumab|Drug: Placebo|Drug: Paclitaxel|Drug: Carboplatin	Immune-related Progression-free Survival (irPFS) in Participants With Nonsmall-cell Lung Cancer (NSCLC) Per Immune-related Response Criteria (irRC)|Progression-free Survival (PFS) in Participants With NSCLC Per Modified World Health Organization (mWHO) Criteria|Overall Survival in Participants With NSCLC|Best Overall Response Rate (BORR) Per mWHO Criteria in Participants With NSCLC and SCLC|Immune-related Best Overall Response Rate (irBORR) Per irRC in Participants With NSCLC and Small-cell Lung Cancer (SCLC)|Immune-related Disease Control Rate (irDCR) Per irRC and Disease Control Rate (DCR) Per mWHO Criteria in Participants With NSCLC and SCLC|Immune-related Duration of Response (irDoR) Per irRC and DoR Per mWHO Criteria in Participants With NSCLC and SCLC|Number of Participants With NSCLC Who Have Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs), AEs Leading to Discontinuation, and Drug-related AEs by Worst Common Terminology Criteria (CTC) Grade|Percentage of Participants With NSCLC Who Have Abnormalities in On-study Hematology Laboratory Test Results by Worst CTC Grade|irPFS in Participants With SCLC Per irRC|Number of Participants With NSCLC Who Have Abnormalities in On-Study Liver Function Test Results By Worst CTC Grade|Number of Participants With NSCLC Who Had Abnormalities in Vital Sign Measurements and Physical Examination Findings|Percentage of Participants With NSCLC Who Have Abnormalities in Pancreatic Enzyme Clinical Laboratory Test Results by Worst CTC Grade|Number of Participants With NSCLC Who Have Positive Human Antihuman Antibody (HAHA) Status Postbaseline|Number of Participants With SCLC With Death as Outcome, Serious Adverse Events (SAEs), Drug-related SAEs, Adverse Events (AEs), AEs Leading to Discontinuation, Drug-related AEs by Worst CTC Grade|Number of Participants With SCLC Who Have Abnormalities in On-study Hematology Laboratory Test Results by Worst CTC Grade|Number of Participants With SCLC Who Have Abnormalities in Liver Function Test Results by Worst CTC Grade|Percentage of Participants With SCLC Who Have Abnormalities in Pancreatic Enzyme and Other Clinical Laboratory Test Results by Worst CTC Grade|Progression-free Survival (PFS) in Participants With SCLC Per mWHO Criteria|Number of Participants With SCLC Who Had Abnormalities in Vital Sign Measurements and Physical Examination Findings|Number of Participants With SCLC Who Have Positive HAHA Status Postbaseline|Overall Survival in Participants With SCLC	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	334	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA184-041	February 2008	October 2009	December 2011	September 11, 2007	July 16, 2012	July 18, 2018	Birmingham Hematology & Oncology Assoc. Llc, Birmingham, Alabama, United States|Mayo Clinic, Scottsdale, Arizona, United States|Acrc/Arizona Clinical Research Center, Inc., Tucson, Arizona, United States|Compassionate Cancer Care Medical Group, Corona, California, United States|Compassionate Cancer Care Medical Group, Inc., Fountain Valley, California, United States|The Angeles Clinic & Research Institute, Inc, Los Angeles, California, United States|Oncology Care Medical Associates, Montebello, California, United States|Compassionate Cancer Care Medical Group, Riverside, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|M D Anderson Cancer Center- Orlando, Orlando, Florida, United States|Georgia Cancer Specialists, Atlanta, Georgia, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Local Institution, Park Ridge, Illinois, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|The John R. Marsh Cancer Center, Hagerstown, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|The Cancer Center, Minneapolis, Minnesota, United States|Nevada Cancer Institute, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Local Institution, New York, New York, United States|Cmc-Northeast/ Northeast Oncology Associates, Concord, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Hematology Oncology Consultants, Inc, Columbus, Ohio, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Guthrie Clinical Research, Sayre, Pennsylvania, United States|Santee Hematology/Oncology, Sumter, South Carolina, United States|Southwest Cancer Treatment And Research Center, Lubbock, Texas, United States|Local Institution, Belfort, France|Local Institution, Caen, France|Local Institution, Marseille Cedex 9, France|Local Institution, Rennes Cedex 9, France|Local Institution, Bochum, Germany|Local Institution, Coswig, Germany|Local Institution, Ebensfeld, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Halle (Saale), Germany|Local Institution, Hamburg, Germany|Local Institution, Koeln, Germany|Local Institution, Leipzig, Germany|Local Institution, Mainz, Germany|Local Institution, Muenchen, Germany|Local Institution, Hyderabad, Andhra Pradesh, India|Local Institution, Navrangpura, Ahmedabad, Gujarat, India|Local Institution, Manipal, Karnataka, India|Local Institution, Trivandrum, Kerala, India|Local Institution, Vellore, India|Local Institution, Genova, Italy|Local Institution, Siena, Italy|Local Institution, Torino, Italy|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Olsztyn, Poland|Local Institution, Szczecin, Poland|Local Institution, Arkhangelsk, Russian Federation|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Ivanovo, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Pyatigorsk, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, Sochi, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Dnipropetrovsk, Ukraine|Local Institution, Donetsk, Ukraine|Local Institution, Kharkov, Ukraine|Local Institution, Lviv, Ukraine|Local Institution, Ternopol, Ukraine|Local Institution, Uzhgorod, Ukraine		https://ClinicalTrials.gov/show/NCT00527735
28	NCT03203876	A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors		Active, not recruiting	No Results Available	Advanced Cancer	Biological: Lirilumab|Biological: Nivolumab|Biological: Ipilimumab	Incidence of dose-limiting toxicity (DLT)|Incidence of adverse events (AEs)|Incidence of serious adverse events (SAEs)|Incidence of death|Frequency of laboratory test toxicity grade shifting from baseline|Incidence of AEs leading to discontinuation|Maximum serum observed concentration (Cmax)|Time of maximum observed serum concentration (Tmax)|Area under the serum concentration-time curve from time zero to the time of last quantifiable concentration [AUC(0-T)]|Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)]|Trough observed serum concentration (Ctrough)|Area under the serum concentration-time curve in one dosing interval [AUC(TAU)]|Clearance (CL)|Volume of distribution at steady state (Vss)|Ratio of an exposure measure at steady-state to that after the first dose (AI)|Half-life (T-HALF)|Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (T-HALF eff)|Best overall response (BOR)|Duration of response (DOR)|Incidence of anti-drug antibody (ADA)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	20 Years and older   (Adult, Older Adult)	Phase 1	21	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA223-030	July 5, 2017	December 9, 2018	December 10, 2018	June 29, 2017	null	August 29, 2018	Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Kobe-shi, Hyogo, Japan		https://ClinicalTrials.gov/show/NCT03203876
29	NCT03195478	Study of Nivolumab in Combination With Ipilimumab in Chinese Subjects With Previously Treated Advanced or Recurrent Solid Tumors		Recruiting	No Results Available	Solid Tumor	Drug: Nivolumab|Drug: Ipilimumab	Composite of Number and percent of all treated subjects that experience Adverse Events (AEs)|Composite of Number and percent of all treated subjects that experience serious adverse events (SAEs)|Composite of Number and percent of all treated subjects that experience AEs leading to discontinuation|Composite of Number and percent of all treated subjects that experience AEs leading to death|Composite of Number and percent of subjects with clinical laboratory abnormalities|Maximum observed serum concentration (Cmax)|Time of maximum observed serum concentration (Tmax)|Area under the plasma concentration-time curve from time zero to the last time of the last quantifiable concentration (AUC[0-T])|Area under the concentration-time curve in one dosing interval (AUC[TAU])|Serum concentration achieved at the end of study drug infusion (Ceoinf)|Trough observed serum concentration at the end of dosing interval (Ctrough)|Concentration at the end of dosing interval (Ctau)|Anti-drug Antibody (ADA)|Best overall response (BOR) by investigator using Response Evaluation Criteria in Solid Tumor (RECIST v1.1)|Objective response rate (ORR)|Progression Free Survival Rate (PFSR) at 6 months	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	27	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-672	July 27, 2017	November 26, 2019	June 25, 2020	June 22, 2017	null	July 25, 2018	Local Institution, Beijing, China		https://ClinicalTrials.gov/show/NCT03195478
30	NCT01454102	Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)		Active, not recruiting	No Results Available	Non-small Cell Lung Cancer	Biological: Nivolumab|Drug: Gemcitabine|Drug: Cisplatin|Drug: Pemetrexed|Drug: Paclitaxel|Drug: Carboplatin|Drug: Bevacizumab|Drug: Erlotinib|Biological: Ipilimumab	Safety and tolerability of Nivolumab in combination with chemotherapy measured by frequency of drug related adverse events|Safety and tolerability of Nivolumab in combination with chemotherapy measured by frequency of serious adverse events|Safety and tolerability of Nivolumab in combination with chemotherapy measured by frequency of clinical laboratory test by worst toxicity grade|ORR based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of subjects treated in arms A, B, C and D|PFSR based on RECIST 1.1 of subjects treated in arms A, B, C and D|ORR based on RECIST 1.1 of subjects treated in arms E, F, K, L, M, O, P, Q, R, S|PFSR based on RECIST 1.1 of subjects treated in arms E, F, K, L, M, O, P, Q, R, S|ORR based on RECIST 1.1 of subjects treated in arms G, H, I, J and N|PFSR based on RECIST 1.1 of subjects treated in arms G, H, I, J and N	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	472	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-012	December 9, 2011	July 20, 2016	December 29, 2018	October 18, 2011	null	November 7, 2017	Ucla, Santa Monica, California, United States|Yale University, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Ut Southwestern Medical Center At Dallas, Dallas, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Hamilton, Ontario, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT01454102
31	NCT02998528	A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)	CheckMate 816	Recruiting	No Results Available	Non Small Cell Lung Cancer	Biological: Nivolumab|Biological: ipilimumab|Drug: cisplatin|Drug: vinorelbine|Drug: gemcitabine|Drug: docetaxel|Drug: pemetrexed|Drug: carboplatin	Event-Free Survival|Pathological Complete Response|Overall survival (OS)|Major pathological response (MPR)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	642	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-816|2016-003536-21	January 13, 2017	May 8, 2023	November 8, 2028	December 20, 2016	null	October 3, 2018	Arizona Oncology Assoc, Pc-Hal, Phoenix, Arizona, United States|HOPE Cancer Center of East Texas, Phoenix, Arizona, United States|Local Institution, Phoenix, Arizona, United States|Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Sacramento, California, United States|Local Institution, Santa Barbara, California, United States|Local Institution, Santa Rosa, California, United States|Rocky Mountain Cancer Center, Denver, Colorado, United States|Cancer Center Of Central Connecticut, Plainville, Connecticut, United States|University of Miami, Deerfield Beach, Florida, United States|Local Institution, Hollywood, Florida, United States|Local Institution, Jacksonville, Florida, United States|Cancer Institute Of Florida, Orlando, Florida, United States|Local Institution, Orlando, Florida, United States|Indian River Medical Center, Vero Beach, Florida, United States|Local Institution, Athens, Georgia, United States|Local Institution, Fort Gordon, Georgia, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Northwestern Medicine, Chicago, Illinois, United States|University Of Chicago Medical Center, Chicago, Illinois, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Local Institution, Tinley Park, Illinois, United States|Local Institution, Fort Wayne, Indiana, United States|Local Institution, Wichita, Kansas, United States|Local Institution, Elizabethtown, Kentucky, United States|Local Institution, Lexington, Kentucky, United States|Local Institution, Louisville, Kentucky, United States|University Medical Center New Orleans, New Orleans, Louisiana, United States|Medstar Franklin Sqaure Medical Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Fairhaven, Massachusetts, United States|Local Institution, Worcester, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Local Institution, Columbia, Missouri, United States|St Vincent Frontier Cancer Center, Billings, Montana, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States|Valley Hospital Luckow Pavili, Westwood, New Jersey, United States|New York Oncology Hematology, Pc, Albany, New York, United States|Laura & Isaac Perlmutter Cancer Center, New York, New York, United States|Local Institution, New York, New York, United States|Local Institution, High Point, North Carolina, United States|Christ Hospital, Cincinnati, Ohio, United States|MetroHealth Medical Center, Cleveland, Ohio, United States|Genesis Health Care System, Zanesville, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Local Institution, Philadelphia, Pennsylvania, United States|Allegheny General Hospital, Pittsburgh, Pennsylvania, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Bon Secours-St Francis Hosp, Greenville, South Carolina, United States|Tennessee Oncology, Pc, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology, PA - South Austin Cancer Center, Austin, Texas, United States|Texas Oncology, Bedford, Texas, United States|WBAMC Oncology Department, El Paso, Texas, United States|Local Institution, Fort Worth, Texas, United States|Local Institution, Houston, Texas, United States|Millenium Oncology, Houston, Texas, United States|Local Institution, Lubbock, Texas, United States|Texas Cancer Center - Sherman, Sherman, Texas, United States|Texas Oncology, Waco, Texas, United States|Intermountain Medical Center, Murray, Utah, United States|Local Institution, Saint George, Utah, United States|Southwest Regional Cancer Clinic, Saint George, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Vermont Cancer Center, Burlington, Vermont, United States|Virginia Cancer Specialists, PC, Fairfax, Virginia, United States|Local Institution, Fredericksburg, Virginia, United States|Instituto Medico Especializado Alexander Fleming, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Belo Horizonte, MG, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Ijui, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|CISSS de l'Outaouais, Gatineau, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Mcgill University Health Center, Montreal, Quebec, Canada|Local Institution, St. Jerome, Quebec, Canada|Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-Centre-du-Quebec, Trois-Rivieres, Quebec, Canada|Saskatoon Cancer Centre, Saskatoon, Saskatchewan, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Shanghai, China|Local Institution, Marseille Cedex 20, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Rennes Cedex 9, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulouse, France|Local Institution, Tours Cedex, France|Sotiria General Hospital, Athens, Greece|Interbalkan European Medical Center, Thessaloniki, Greece|Local Institution, Budapest, Hungary|Local Institution, Szekesfehervar, Hungary|Local Institution, Bari, Italy|Local Institution, Genova, Italy|Local Institution, Perugia, Italy|Local Institution, Ravenna, Italy|Local Institution, Roma, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Kitakyushu-shi, Fukuoka, Japan|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sakai-shi, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Tokyo, Japan|Local Institution, Hwasun-gun, Jeonnam, Korea, Republic of|Local Institution, Busan, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Institute Of Oncology "Prof.Dr.Alexandru Trestioreanu" Bucha, Bucharest, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Dep, Romania, Romania|Local Institution, Parktown, Johannesburg, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|H. Univ. Vall dHebron, Barcelona, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hosp. Univ. Puerta De Hierro, Majadahonda - Madrid, Spain|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, ?stanbul, Turkey|Local Institution, Adana, Turkey|Local Institution, Ankara, Turkey|Local Institution, Ankara, Turkey|Local Institution, Istanbul, Turkey		https://ClinicalTrials.gov/show/NCT02998528
32	NCT03668119	A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)	CheckMate 848	Recruiting	No Results Available	Pan Tumor	Biological: Nivolumab|Biological: Ipilimumab	Objective Response Rate (ORR)|Duration of response (DOR)|ORR|TTR|Clinical benefit rate (CBR)|Overall survival (OS)|PFS|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|Incidence of laboratory abnormalities|Incidence of anti-drug antibody (ADA)	Bristol-Myers Squibb	All	12 Years and older   (Child, Adult, Older Adult)	Phase 2	159	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-848|2016-002898-35	October 29, 2018	March 14, 2021	September 8, 2023	September 12, 2018	null	November 20, 2018	Local Institution, Birmingham, Alabama, United States|Local Institution, Bakersfield, California, United States|Local Institution, Los Angeles, California, United States|Local Institution, Orange, California, United States|Local Institution, Santa Monica, California, United States|Local Institution, Truckee, California, United States|Local Institution, Lakewood, Colorado, United States|Local Institution, Hollywood, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Local Institution, Niles, Illinois, United States|Local Institution, Fort Wayne, Indiana, United States|Local Institution, Minneapolis, Minnesota, United States|Local Institution, Rochester, Minnesota, United States|Local Institution, Saint Louis, Missouri, United States|Local Institution, Livingston, New Jersey, United States|Local Institution, Johnson City, New York, United States|Local Institution, Durham, North Carolina, United States|Local Institution, Columbus, Ohio, United States|Local Institution, Portland, Oregon, United States|Local Institution, Philadelphia, Pennsylvania, United States|Local Institution, Germantown, Tennessee, United States|Local Institution, Austin, Texas, United States|Local Institution, Dallas, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, Houston, Texas, United States|Local Institution, Tyler, Texas, United States|Local Institution, Charlottesville, Virginia, United States|Local Institution, Madison, Wisconsin, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma Beunos Aires, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina|Local Institution, Viedma, RIO Negro, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Caba, Argentina|Local Institution, Caba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Darlinghurst, New South Wales, Australia|Local Institution, St Leonards, New South Wales, Australia|Local Institution, Sydney, New South Wales, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Leuven, Belgium|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Passo Fundo, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose Do Rio Preto, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Hamilton, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Santiago de Chile, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Santiago, Metropolitana, Chile|Local Institution, Vina Del Mar, Valparaiso, Chile|Local Institution, Copenhagen, Denmark|Local Institution, Herlev, Denmark|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris Cedex 5, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Bonn, Germany|Local Institution, Dresden, Germany|Local Institution, Essen, Germany|Local Institution, Heidelberg, Germany|Local Institution, Wuerzburg, Germany|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Surquillo, Lima, Peru|Local Institution, Arequipa, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Warszawa, Mazowieckie, Poland|Local Institution, Gdansk, Poland|Local Institution, San Juan, Puerto Rico|Local Institution, Bucuresti, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Floresti, Romania|Local Institution, Timisoara, Timis, Romania|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Preston, United Kingdom|Local Institution, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT03668119
33	NCT01688492	Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer		Active, not recruiting	No Results Available	Prostate Cancer	Drug: Ipilimumab	safety (Phase I)|progression-free survival (PFS) Phase II|Changes in PSA kinetics|Measurable disease when present|Evaluate changes in radionuclide bone scan	Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb|Northwestern University|Oregon Health and Science University	Male	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	57	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	12-120	September 2012	September 2019	September 2019	September 20, 2012	null	September 11, 2018	Northwestern University, Evanston, Illinois, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Oregon Health & Science University, Portland, Oregon, United States		https://ClinicalTrials.gov/show/NCT01688492
34	NCT02658890	An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread		Recruiting	No Results Available	Advanced Cancer|Melanoma|Non-Small Cell Lung Cancer	Drug: BMS-986205|Drug: Nivolumab|Drug: Ipilimumab	Safety and tolerability of BMS-986205 as measured by a composite of the incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, deaths, and clinical laboratory test abnormalities.|Safety of BMS-986205 plus nivolumab as measured by a composite of the incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, deaths, and clinical laboratory test abnormalities.|Safety of BMS-986205 plus both nivolumab and ipilimumab as measured by incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to discontinuation, deaths, and clinical laboratory test abnormalities.|Anti-tumor activity of BMS 986205 administered in combination with nivolumab as measured by the best overall response (BOR)|Anti-tumor activity of BMS 986205 administered in combination with nivolumab as measured by the duration of response (DOR)|Anti-tumor activity of BMS 986205 administered in combination with nivolumab as measured by progression-free survival rates (PFSRs)|Anti-tumor activity of BMS 986205 administered in combination with both nivolumab and ipilimumab as measured by the best overall response (BOR)|Anti-tumor activity of BMS 986205 administered in combination with both nivolumab and ipilimumab as measured by the duration of response (DOR)|Anti-tumor activity of BMS 986205 administered in combination with both nivolumab and ipilimumab as measured by progression-free survival rates (PFSRs)|Maximum observed plasma concentration (Cmax) of BMS-986205|Time of maximum observed plasma concentration (Tmax) of BMS-986205|Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-986205|Area under the concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)] of BMS-986205|Area under the concentration-time curve in 1 dosing interval [AUC(TAU)] of BMS-986205|Trough observed plasma concentration at the end of the dosing interval (Ctrough) of BMS-986205|Observed plasma concentration at 24 hours (C24) of BMS-986205|Apparent terminal phase half-life (T-HALF) of BMS-986205|Apparent total body clearance (CLT/F) of BMS-986205|Apparent renal clearance (CLR/F) of BMS-986205|Volume of distribution of terminal phase (Vz/F) of BMS-986205|Apparent volume of distribution at steady state (Vss/F) of BMS-986205|Accumulation index (AI) of BMS-986205|Percent urinary recovery (%UR) of BMS-986205|Percent urinary recovery over 24 hours(%UR24) of BMS-986205|Ratio of metabolite Cmax to parent Cmax, corrected for molecular weight (MR_Cmax) of BMS-986205|Ratio of metabolite AUC(0-T) to parent AUC(0-T), corrected for molecular weight (single dose in clinical pharmacology substudy only) [MR_AUC(0-T)] of BMS-986205|Ratio of metabolite AUC(TAU) to parent AUC(TAU), corrected for molecular weight [MR_AUC(TAU)] of BMS-986205|Ratio of metabolite AUC(INF) to parent AUC(INF), corrected for molecular weight (single dose in clinical pharmacology substudy only) [MR_AUC(INF)] of BMS-986205|Anti-drug antibody (ADA) response to Nivolumab in combination with BMS-986205|Anti-drug antibody (ADA) response to Ipilimumab in combination with BMS-986205	Bristol-Myers Squibb	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 1|Phase 2	907	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA017-003|2015-004914-79	February 18, 2016	April 29, 2019	February 28, 2020	January 20, 2016	null	October 4, 2018	Local Institution, Phoenix, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|UCSD Moores Cancer Center, La Jolla, California, United States|Local Institution, Jacksonville, Florida, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Emory Winship Cancer Institute, Atlanta, Georgia, United States|Northside Hospital, Inc, Atlanta, Georgia, United States|University Of Chicago, Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Lutherville, Maryland, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|Local Institution, Rochester, Minnesota, United States|Washington University, Saint Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|New York University, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia|Melanoma Institute Australia, North Sydney, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Princess Alexandra Hospital, Brisbane, Queensland, Australia|Local Institution, Clayton, Victoria, Australia|Royal Melbourne Hospital, Melbourne, Victoria, Australia|Linear Clinical Research Ltd, Nedlands, Western Australia, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Greenfield Park, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Local Institution, Helsinki, Finland|Local Institution, Helsinki, Finland|Local Institution, Lille CEDEX, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex 01, France|Local Institution, Paris, France|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Local Institution, Essen, Germany|Local Institution, Heilbronn, Germany|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Rozzano MI, Italy|Local Institution, Oslo, Norway|Oddzial Badan Wczesnych Faz, Warszawa, Mazowieckie, Poland|Local Institution, Gdansk, Poland|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Solna, Sweden		https://ClinicalTrials.gov/show/NCT02658890
35	NCT03143153	A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin	CheckMate 648	Recruiting	No Results Available	Various Advanced Cancer	Biological: Nivolumab|Biological: Ipilimumab|Drug: Cisplatin|Drug: Fluorouracil	Overall survival (OS)|Progression-free Survival (PFS)|Objective Response Rate (ORR)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	939	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-648|2016-001514-20	June 19, 2017	May 25, 2020	December 30, 2021	May 8, 2017	null	November 20, 2018	Southern Cancer Center, Inc., Mobile, Alabama, United States|Local Institution, Tucson, Arizona, United States|Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|University Of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Baptist Health Medical Group Oncology LLC, Miami, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Local Institution, Chicago, Illinois, United States|Jersey Shore University Medical Center, Neptune, New Jersey, United States|Local Institution, Durham, North Carolina, United States|Oncology Associates Of Oregon, Pc, Eugene, Oregon, United States|Northwest Cancer Specialists, P.C., Portland, Oregon, United States|Local Institution, Austin, Texas, United States|Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Oncology & Hematology Associates Of Southwest Virginia, Inc., Roanoke, Virginia, United States|West Virginia University-Mbrcc, Morgantown, West Virginia, United States|Hospital Municipal De Gastroenterologia Dr.Udaondo, Capital Federal, Buenos Aires, Argentina|Hospital Provincial Del Centenario, Rosario, Santa FE, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Centro Oncologico Riojano Integral, La Rioja, Argentina|Local Institution, Randwick, New South Wales, Australia|Local Institution, Tamworth, New South Wales, Australia|Local Institution, Douglas, Queensland, Australia|Local Institution, Murdoch, Western Australia, Australia|Local Institution, Salzburg, Austria|Local Institution, Salvador, Bahia, Brazil|Local Institution, Ipatinga, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Jau, SAO Paulo, Brazil|Local Institution, Sao Jose Do Rio Preto, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Trois-Rivieres, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Local Institution, Independencia, Santiago, Chile|Local Institution, Santiago, Chile|Local Institution, Hefei, Anhui, China|Local Institution, Hefei, Anhui, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Shantou, Guangdong, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Xian, Shaanxi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Shanghai, China|Oncologos Del Occidente Sa, Pereira, Risaralda, Colombia|Instituto Nac. de Cancerologia, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Interni hematologicka a onkologicka klinika, Brno, Czechia|Klinika komplexni onkologicke pece, Brno, Czechia|Komplexni onkologicke centrum, Novy Jicin, Czechia|Local Institution, Odense, Denmark|Local Institution, Caen, France|Local Institution, Lille, France|Local Institution, Montpellier, France|Local Institution, Rennes Cedex, France|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Local Institution, Hong Kong, Hong Kong|Local Institution, Kowloon, Hong Kong|ASST Papa Giovanni XXIII, Bergamo, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|I.O.V. Istituto Oncologico Veneto Ircss, Padova, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Gifu City, Gifu, Japan|Local Institution, Ota, Gunma, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kobe, Hyogo, Japan|Local Institution, Kanazawa, Ishikawa, Japan|Local Institution, Kagoshima-shi, Kagoshima, Japan|Local Institution, Isehara, Kanagawa, Japan|Local Institution, Kawasaki-shi, Kanagawa, Japan|Local Institution, Sagamihara-shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Sendai, Miyagi, Japan|Local Institution, Niigata-City, Niigata, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Chuo-ku, Osaka, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Osaka Sayama-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Takatsuki City, Osaka, Japan|Local Institution, Hidaka, Saitama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Shimotsuga-gun, Tochigi, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Shinagawa-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Shinjuku-ku, Tokyo, Japan|Local Institution, Toyama-shi, Toyama, Japan|Local Institution, Wakayama-shi, Wakayama, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Local Institution, Akashi, Japan|Local Institution, Chiba, Japan|Local Institution, Kyoto, Japan|Local Institution, Shizuoka, Japan|Local Institution, Yokohama, Japan|Local Institution, Busan, Korea, Republic of|Local Institution, Daegu, Korea, Republic of|Local Institution, Daejeon, Korea, Republic of|Local Institution, Jeonju-si, Korea, Republic of|Local Institution, Seongnam-si, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Ulsan, Korea, Republic of|Local Institution, Tuxtla Gutierrez, Chiapas, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Merida, Yucatan, Mexico|Hospital Nacional Daniel Alcides Carrion, Callao, Peru|Local Institution, Lima, Peru|Instituto Nacional De Enfermedades Neoplasicas, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|II Klinika Chirurgii Ogolnej, Gastroenterologicznej i Nowotworow Ukladu Pokarmowego, Lublin, Poland|Klinika Gastroenterologii Onkologicznej, Warszawa, Poland|Local Institution, Lisboa, Portugal|Local Institution, Porto, Portugal|Focus Lab Plus SRL, Bucuresti, Romania|CF Clinical Hospital Cluj-Napoca, Cluj-Napoca, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|County Emergency Hospital Suceava, Suceava, Romania|Local Institution, Moscow, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Changhua, Taiwan|Local Institution, Kaohsiung City, Taiwan|Local Institution, Kaohsiung, Taiwan|Local Institution, Kaohsiung, Taiwan|Local Institution, Keelung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan City, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei City, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Diyarbak?r, Turkey|Local Institution, Edrine, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT03143153
36	NCT02935634	A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer	FRACTION-GC	Recruiting	No Results Available	Advanced Gastric Cancer	Biological: Nivolumab|Biological: Ipilimumab|Biological: Relatlimab|Biological: BMS-986205	Objective Response Rate (ORR)|Duration of Response (DOR)|Progression-free Survival Rate (PFSR)|Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|AEs leading to discontinuation|AEs leading to death	Bristol-Myers Squibb	All	18 Years to 110 Years   (Adult, Older Adult)	Phase 2	300	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA018-003|2016-002807-24	November 23, 2016	November 17, 2021	November 18, 2021	October 17, 2016	null	November 28, 2018	Local Institution, Phoenix, Arizona, United States|City Of Hope National Medical Center, Duarte, California, United States|University Of Colorado, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Georgetown University Med Ctr, Washington, District of Columbia, United States|UF Health Medical Oncology - Davis Cancer Pavilion, Gainesville, Florida, United States|Mayo Clinic Jacksonville, Jacksonville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Emory University, Atlanta, Georgia, United States|John Hopkins, Baltimore, Maryland, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|UPMC, Pittsburgh, Pennsylvania, United States|Seattle Cancer Care Assoc. Univ of Washington, Seattle, Washington, United States|Westmead Hospital, Westmead, New South Wales, Australia|Austin Health, Heidelberg, Victoria, Australia|Local Institution, Randwick, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Ottawa, Ontario, Canada|Local Institution, Toronto,, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Montpellier Cedex 5, France|Local Institution, Villejuif, France|Nationales Centrum Fur Tumorerkrankungen (Nct), Heidelberg, Germany|Universitaetsklinikum Leipzig, Leipzig, Germany|Local Institution, Ramat Gan, Israel|Local Institution, Tel Aviv, Israel|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Istituto Europeo Di Oncologia, Milan, Italy|Amsterdam UMC ? locatie AMC, Amsterdam, Netherlands|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Local Institution, Singapore, Singapore|Local Institution, Badalona-barcelona, Spain|Local Institution, Madrid, Spain|Kantonsspital Graubunden, Chur, Switzerland|Local Institution, Zuerich, Switzerland		https://ClinicalTrials.gov/show/NCT02935634
37	NCT03459222	An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread		Recruiting	No Results Available	Advanced Cancer	Biological: Relatlimab|Biological: Nivolumab|Drug: BMS-986205|Biological: Ipilimumab	Number of clinical laboratory test abnormalities|Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Number of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria|Number of AEs leading to discontinuation and deaths|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Median Duration of Response (mDOR)|Progression Free Survival (PFS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	230	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA224-048|2018-000058-22	May 25, 2018	April 4, 2022	May 16, 2022	March 8, 2018	null	November 20, 2018	City of Hope National Medical Center, Duarte, California, United States|University Of Colorado, Aurora, Colorado, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|The West Clinic, P.C., Germantown, Tennessee, United States|Local Institution, Seattle, Washington, United States|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Marseille Cedex 5, France|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Local Institution, Lausanne, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Newcastle Upon Tyne, United Kingdom|Local Institution, Oxford, United Kingdom		https://ClinicalTrials.gov/show/NCT03459222
38	NCT01450761	Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone		Completed	Has Results	Small Cell Lung Carcinoma	Biological: Ipilimumab|Biological: Placebo matching Ipilimumab|Drug: Etoposide|Drug: Cisplatin|Drug: Carboplatin	Overall Survival (OS) in Participants Who Received at Least One Dose of Blinded Study Therapy|Overall Survival in All Randomized Participants|Progression Free Survival (PFS) Time in Participants Who Have Received at Least One Dose of Blinded Study Therapy	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	1351	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA184-156|2011-000850-48	December 13, 2011	March 19, 2015	May 17, 2017	October 12, 2011	July 18, 2016	July 12, 2018	Genesis Cancer Center, Hot Springs, Arkansas, United States|Sutter Medical Center, Auburn, California, United States|Providence St. Joseph Medical Center, Burbank, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|University Of Colorado Cancer Center, Aurora, Colorado, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|Cancer Specialists, LLC, Jacksonville, Florida, United States|Lake City Cancer Care, Lake City, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Medical Oncology, LLC, Augusta, Georgia, United States|Straub Clinic And Hospital, Honolulu, Hawaii, United States|Quincy Medical Group, Quincy, Illinois, United States|Presence Medical Group Hematology Oncology, Skokie, Illinois, United States|SIU School Of Medicine, Springfield, Illinois, United States|St. Francis Medical Group Oncology And Hematology Specialist, Indianapolis, Indiana, United States|Floyd Memorial Cancer Center Of Indiana, New Albany, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Ashland Bellefonte Cancer Center, Ashland, Kentucky, United States|University Of Kentucky, Lexington, Kentucky, United States|Montgomery Cancer Center, Mount Sterling, Kentucky, United States|Mary Bird Perkins Cancer Center, Baton Rouge, Louisiana, United States|St Joseph Mercy Hospital, Ypsilanti, Michigan, United States|St. Luke'S Cancer Institute, Kansas City, Missouri, United States|Southeast Nebraska Hematology & Oncology Consultants, P.C., Lincoln, Nebraska, United States|Regional Cancer Care Associates, LLC/Cherry Hill Division, Cherry Hill, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Durham Va Medical Center (111g), Durham, North Carolina, United States|Gabrail Cancer Center, Canton, Ohio, United States|Oncology Hematology Care, Incorporated, Cincinnati, Ohio, United States|University Hospitals, Cleveland, Ohio, United States|Mid-Ohio Oncology/Hematology, Inc. Dba, Columbus, Ohio, United States|Signal Point Clinical Research Center, Llc, Middletown, Ohio, United States|Mercy Clinic Oklahoma Communities, Inc, Oklahoma City, Oklahoma, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|Kaiser Permanente, Portland, Oregon, United States|Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee, United States|Associated in Oncology and Hematology, Chattanooga, Tennessee, United States|The Jones Clinic, Pc, Germantown, Tennessee, United States|Tennessee Cancer Specialists, Knoxville, Tennessee, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Henry-Joyce Cancer Center, Nashville, Tennessee, United States|University Of Texas, M. D. Anderson Cancer Center, Houston, Texas, United States|Joe Arrington Cancer Research And Treatment Center, Lubbock, Texas, United States|Huntsman Cancer Hospital, Salt Lake City, Utah, United States|Peninsula Cancer Institute, Newport News, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Virginia Commonwealth University, Richmond, Virginia, United States|Providence Regional Medical Center Everett, Everett, Washington, United States|Mary Babb Randolph Cancer Center, Morgantown, West Virginia, United States|Local Institution, Berazategui, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Ciudad Autonoma de Buenos Aires, Argentina|Local Institution, Provincia De Sante Fe, Argentina|Local Institution, Kogarah, New South Wales, Australia|Local Institution, Wollongong, New South Wales, Australia|Local Institution, Chermside, Queensland, Australia|Local Institution, Townsville, Queensland, Australia|Local Institution, Bedford Park, South Australia, Australia|Local Institution, Fitzroy, Victoria, Australia|Local Institution, Wodonga, Victoria, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Linz, Austria|Local Institution, Salzburg, Austria|Local Institution, Wien, Austria|Local Institution, Wien, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Edegem, Belgium|Local Institution, Leuven, Belgium|Local Institution, Sint Niklaas, Belgium|Local Institution, Yvoir, Belgium|Local Institution, Centro, Joinville/sc, Brazil|Local Institution, Curitiba/PR, Brazil|Local Institution, Passo Fundo, RS, Brazil|Local Institution, Porto Alegre, RS, Brazil|Local Institution, Sao Paulo/SP, Brazil|Local Institution, SP, Brazil|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Vitacura, Santiago, Chile|Local Institution, Vina Del Mar, Valparaiso, Chile|Local Institution, Santiago, Chile|Local Institution, Santiago, Chile|Local Institution, Valparaiso, Chile|Local Institution, Guangzhou, Guangdong, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Harbin, Heilongjiang, China|Local Institution, Wuhan, Hubei, China|Local Institution, Nangjing, Jiangsu, China|Local Institution, Soochow, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Xi'an, Shaanxi, China|Local Institution, Xi'an, Shaanxi, China|Local Institution, Chengdu City, Sichuan, China|Local Institution, Urumqi, Xinjiang, China|Local Institution, Hangzhou City, Zhejiang, China|Local Institution, Hangzhou City, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Beijing, China|Local Institution, Shanghai, China|Local Institution, Shanghai, China|Local Institution, Cordoba, Colombia|Local Institution, Ostrava - Poruba, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Praha 8, Czechia|Local Institution, Espoo, Finland|Local Institution, Helsinki, Finland|Local Institution, Turku, Finland|Local Institution, Caen, France|Local Institution, Rennes Cedex 9, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Vandoeuvre-les-nancy, France|Local Institution, Bad Berka, Germany|Local Institution, Bochum, Germany|Local Institution, Dresden, Germany|Local Institution, Erlangen, Germany|Local Institution, Frankfurt am Main, Germany|Local Institution, Gauting, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kassel, Germany|Local Institution, Mainz, Germany|Local Institution, Mannheim, Germany|Local Institution, Munchen, Germany|Local Institution, Oldenburg, Germany|Local Institution, Ulm, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Kowloon, Hong Kong|Local Institution, Tuen Mun, New Territories, Hong Kong|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Budapest, Hungary|Local Institution, Farkasgyepu, Hungary|Local Institution, Matrahaza, Hungary|Local Institution, Pecs, Hungary|Local Institution, Sopron, Hungary|Local Institution, Szekesfehervar, Hungary|Local Institution, Szolnok, Hungary|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Limerick, Ireland|Local Institution, Beer Sheva, Israel|Local Institution, Kfar-saba, Israel|Local Institution, Petah-tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Zerifin, Israel|Local Institution, Livorno, Italy|Local Institution, Lucca, Italy|Local Institution, Meldola (FC), Italy|Local Institution, Siena, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Nagoya, Aichi, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Yokohama-Shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Natori, Miyagi, Japan|Local Institution, Sendai, Miyagi, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Kurashiki-shi, Okayama, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Takatsuki, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Local Institution, Akashi, Hyogo, Japan|Local Institution, Fukoka, Japan|Local Institution, Fukuoka, Japan|Local Institution, Osaka, Japan|Local Institution, Oskaka, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Sendai, Miyagi, Japan|Local Institution, Tokyo, Japan|Local Institution, Suwon, Gyeonggi-do, Korea, Republic of|Local Institution, Goyang-si, Gyeonggji-do, Korea, Republic of|Local Institution, Hwasun-eup, Hwasun-gun, Jeonnam, Korea, Republic of|Local Institution, Busan, Korea, Republic of|Local Institution, Cheongju-si, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Suwon, Korea, Republic of|Local Institution, Leon, Guanajato, Guanajuato, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Local Institution, San Luis Potosi, S.l.p., Mexico|Local Institution, 's-Hertogenbosch, Netherlands|Local Institution, Breda, Netherlands|Local Institution, Eindhoven, Netherlands|Local Institution, Nieuwegein, Netherlands|Local Institution, Cercado, Peru|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Elblag, Poland|Local Institution, Gdansk, Poland|Local Institution, Karkow, Poland|Local Institution, Katowice - Ochojec, Poland|Local Institution, Lublin, Poland|Local Institution, Otwock, Poland|Local Institution, Poznan, Poland|Local Institution, Torun, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland|Local Institution, Coimbra, Portugal|Local Institution, Lisboa, Portugal|Local Institution, Vila Nova De Gaia, Portugal|Local Institution, Cluj Napoca, Judetul CLUJ, Romania|Local Institution, Craiova, Judetul DOLJ, Romania|Local Institution, Bucuresti, Romania|Local Institution, Cluj, Romania|Local Institution, Chelyabinsk, Russian Federation|Local Institution, Krasnodar, Russian Federation|Local Institution, Kursk, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Pyatigorsk, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, Saint Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Port Elizabeth, Eastern CAPE, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Pretoria, South Africa|Local Institution, A Coruna, Galicia, Spain|Local Institution, Barcelona, Spain|Local Institution, Benidorm-alicante, Spain|Local Institution, Castellon, Spain|Local Institution, Lleida, Spain|Local Institution, Majadahonda, Spain|Local Institution, Malaga, Spain|Local Institution, Valencia, Spain|Local Institution, Linkoping, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Basel, Switzerland|Local Institution, Winterthur, Switzerland|Local Institution, Zuerich, Switzerland|Local Institution, Changhua City, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan County, Taiwan|Local Institution, Rachathewi, Bangkok, Thailand|Local Institution, Bangkok, Thailand|Local Institution, Chiang Mai, Thailand|Local Institution, Songkhla, Thailand|Local Institution, Withington, Manchester, United Kingdom|Local Institution, London, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Preston, United Kingdom|Local Institution, Sutton, United Kingdom|Local Institution, Truro, United Kingdom		https://ClinicalTrials.gov/show/NCT01450761
39	NCT01928394	A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors		Active, not recruiting	No Results Available	Advanced or Metastatic Solid Tumors	Biological: Nivolumab|Biological: Ipilimumab|Drug: Cobimetinib	Objective response rate (ORR)|Number of treatment-related adverse events (AEs) leading to drug discontinuations|Progression Free Survival (PFS)|Overall Survival (OS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	1620	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-032|2013-002844-10	October 7, 2013	May 31, 2019	December 22, 2020	August 23, 2013	null	November 19, 2018	Northwest Alabama Cancer Center, Pc, Muscle Shoals, Alabama, United States|University Of Colorado, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|University Of Florida, Gainesville, Florida, United States|H. Lee Moffitt Cancer Center & Research Inst, Inc, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Dana Farber/Partners Cancercare, Inc., Boston, Massachusetts, United States|Dana-Farber/ Partners Cancer Care, Inc., Boston, Massachusetts, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Winthrop University Hospital, Mineola, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke Cancer Institute, Durham, North Carolina, United States|Oregon Health & Science University, Portland, Oregon, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Swedish Cancer Institute, Seattle, Washington, United States|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Bonn, Germany|Local Institution, Frankfurt, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kassel, Germany|Azienda Ospedaliera S.Orsola-Malpighi, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Istituto Oncologico Veneto IOV, Padova, Italy|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT01928394
40	NCT03215706	A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC	CheckMate 9LA	Recruiting	No Results Available	Non-Small Cell Lung Cancer	Biological: Ipilimumab|Biological: Nivolumab|Drug: Carboplatin|Drug: Paclitaxel|Drug: Pemetrexed|Drug: Cisplatin	Overall Survival (OS)|Progression Free Survival (PFS)|Overall Response Rate (ORR)|ORR|PFS|OS	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	700	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-9LA|2017-001195-35	July 20, 2017	August 25, 2019	May 20, 2020	July 12, 2017	null	November 29, 2018	Memorial Health Systems, Colorado Springs, Colorado, United States|Cancer Center Of Central Connecticut, Plainville, Connecticut, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, LaGrange, Georgia, United States|Northwest Georgia Oncology Center, P.C., Marietta, Georgia, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Baptist Health Lexington, Lexington, Kentucky, United States|Henry Ford Health System, Detroit, Michigan, United States|Broome Oncology, Johnson City, New York, United States|Winthrop University Hospital, Mineola, New York, United States|The Ohio State University, Columbus, Ohio, United States|Lancaster General Hospital, Lancaster, Pennsylvania, United States|West Penn Hospital, Pittsburgh, Pennsylvania, United States|UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Southwest Regional Cancer Clinic, Saint George, Utah, United States|University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States|Local Institution, Milwaukee, Wisconsin, United States|Instituto Alexander Fleming, Caba, Buenos Aires, Argentina|Instituto Medico Rio Cuarto S.A., Rio Cuarto, Cordoba, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Sanatorio Parque, Rosario, Santa FE, Argentina|Local Institution, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Gosford, New South Wales, Australia|Local Institution, Bedford Park, South Australia, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|St John of God Murdoch Hospital, Murdoch, Western Australia, Australia|Local Institution, Charleroi, Belgium|Local Institution, Leuven, Belgium|Local Institution, Roeselare, Belgium|Local Institution, Natal, RIO Grande DO Norte, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Blumenau, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose De Rio Preto, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Montreal, Quebec, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Mcgill University Health Center - Royal Victoria Hospital, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|CISSS du Bas-Saint-Laurent Hopital Regional de Rimouski, Rimouski, Quebec, Canada|Bradford Hill Centro de Investigaciones Clinicas, Santiago de Chile, Metropolitana, Chile|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Hospital Clinico Vina Del Mar, Vina Del Mar, Valparaiso, Chile|Local Institution, Changchun, Jilin, China|Local Institution, Xi'an, Shan3xi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Amiens Cedex 1, France|Local Institution, Caen, France|Local Institution, Lille Cedex, France|Local Institution, Lyon Cedex 08, France|Local Institution, Montpellier Cedex, France|Local Institution, Nantes, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Saint-Brieuc, France|Local Institution, Berlin, Germany|Asklepios Fachkliniken Munchen-Gauting Thorakale Onkologie, Gauting, Germany|Klinik Schillerhoehe, Gerlingen, Germany|Krankenhaus Grosshansdorf, Grosshansdorf, Germany|Lungenklinik Hemer, Hemer, Germany|Fachklinik Fuer Lungenkrankheiten, Immenhausen, Germany|Universitaetsklinikum Magdeburg A. o. R., Magdeburg, Germany|Klinikum Bogenhausen, Muenchen, Germany|Local Institution, Dublin, Ireland|Local Institution, Limerick, Ireland|Ospedale San Luca, Lucca, Italy|Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliera Monaldi, Napoli, Italy|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Maebashi-shi, Gunma, Japan|Local Institution, Ota-shi, Gunma, Japan|Local Institution, Hiroshima-shi, Hiroshima, Japan|Local Institution, Hiroshima-shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Himeji-shi, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Kanazawa-shi, Ishikawa, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama-Shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Habikino-shi, Osaka, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Oncotech, La Paz, BAJA Californa SUR, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Faicic S. de Rl. de Cv, Veracruz, Veracruz, Mexico|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Oddzial Onkologii, Bytom, Poland|Local Institution, Elblag, Poland|Local Institution, Gdansk, Poland|Local Institution, Bucharest, Romania|Local Institution, Cluj-Napoca, Romania|Local Institution, Craiova, Romania|Local Institution, Moscow, Russian Federation|Local Institution, St.petersburg, Russian Federation|Comp. Hosp. Univ. A Coruna, A Coru?a, Spain|H. Univ. Vall dHebron, Barcelona, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hospital Carlos Haya De Malaga, Malaga, Spain|Hospital Universitario La Fe, Valencia, Spain|Local Institution, London, Greater London, United Kingdom|Local Institution, Maidstone, Kent, United Kingdom|Local Institution, Guildford, Surrey, United Kingdom|Local Institution, Tauton, United Kingdom		https://ClinicalTrials.gov/show/NCT03215706
41	NCT03251924	A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors		Recruiting	No Results Available	Cancer|Tumors|Neoplasm|Malignancy	Drug: BMS-986226|Biological: Nivolumab|Biological: Ipilimumab	Incidence of adverse events (AE)|Incidence of serious adverse events (SAE)|Incidence of AE due to discontinuation|Incidence of AE resulting in death|Incidence of AEs meeting protocol defined dose-limiting toxicity (DLT) criteria|Incidence of clinical laboratory test abnormalities graded according to common terminology criteria for adverse events (CTCAE)|Objective response rate (ORR) measure by Clopper-Pearson method|Median Duration of Response (mDOR) measured by Kaplan-Meier method|Progression Free Survival (PFS) measured by Kaplan-Meier method|Maximum observed plasma concentration (Cmax)|Time of maximum observed plasma concentration (Tmax)|Area under the concentration-time curve from time 0 to the time of the last [AUC (0-T)]|Area under the concentration-time curve in 1 dosing interval [AUC(TAU)]|Incidence of anti-drug antibodies to BMS-986226 assessed by immunoassay|Change from baseline in immunoassay for BMS-986226	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	277	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA021-002|2017-000238-73	August 31, 2017	April 6, 2020	December 5, 2020	August 16, 2017	null	October 4, 2018	Local Institution, Boston, Massachusetts, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Local Institution, Hamilton, Ontario, Canada|Local Institution, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT03251924
42	NCT02823574	Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	CheckMate 714	Active, not recruiting	No Results Available	Head and Neck Cancer	Biological: Nivolumab|Biological: Ipilimumab|Other: Placebo	Overall response rate (ORR) in platinum refractory subgroup|Duration of Response (DOR) in platinum refractory subgroup|ORR in platinum eligible subgroup|Progression Free Survival (PFS) in platinum eligible and refractory subgroups|Overall Survival (OS) in platinum eligible and refractory subgroups|DOR in platinum eligible subgroup|Tumor mutation burden (TMB) in platinum eligible and refractory subgroups	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	400	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA209-714|2016-001645-64	September 22, 2016	January 30, 2019	January 30, 2024	July 6, 2016	null	November 6, 2018	University of Arizona Cancer Center, Tucson, Arizona, United States|City Of Hope, Duarte, California, United States|Los Angeles Cancer Network, Los Angeles, California, United States|Ucla Department Of Medicine, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Sutter Cancer Center, Sacramento, California, United States|Ucsf, San Francisco, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Dekalb Medical Center, Decatur, Georgia, United States|University Of Chicago, Chicago, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|University Of Louisville, Louisville, Kentucky, United States|Oncology Associated Of Western Kentucky, Paducah, Kentucky, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mass General Hospital, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Mission Hospital, Inc, Asheville, North Carolina, United States|University Of Cincinnati Medical School, Cincinnati, Ohio, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|UPMC, Pittsburgh, Pennsylvania, United States|Donald Guthrie Foundation, Sayre, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University Of Washington, Seattle, Washington, United States|Centro de Investigacion Pergamino SA- Clinica Pergamino, Pergamino, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Buenos Aires, Argentina|Universitair Ziekenhuis Gent, Gent, Belgium|Az Nikolaas, Sint-Niklaas, Belgium|Ucl Mont-Godinne, Yvoir, Belgium|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ipatinga, Minas Gerais, Brazil|Local Institution, Curitiba, Parana, Brazil|Local Institution, Caxias do Sul, RIO Grande DO SUL, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Santo Andre, SAO Paulo, Brazil|Local Institution, Sao Jose do Rio Preto, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Cross Cancer Institute., Edmonton, Alberta, Canada|The Ottawa General Hospital, Ottawa, Ontario, Canada|University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Centre Hospitalier De L'Universite De Montreal, Montreal, Quebec, Canada|CHU de Quebec - Universite Laval - Hopital de l'Enfant Jesus, Quebec, Canada|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Helsinki University Hospital, Helsinki, Finland|Chu Amiens - Groupe Hospitalier Sud, Amiens Cedex 1, France|Local Institution, Bordeaux, France|Centre Jean Perrin, Clermont Ferrand cedex 01, France|Local Institution, Clichy, France|Centre Leon Berard, Lyon Cedex 08, France|Hopital De La Timone, Marseille Cedex 5, France|Local Institution, Nice, France|Local Institution, Rennes Cedex, France|Local Institution, Villejuif, France|St. James'S Hospital, Dublin 8, Dublin, Ireland|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Local Institution, Merida, Yucatan, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Oaxaca, Mexico|NKI AVL, Amsterdam, Netherlands|Vu Medical Centre, Amsterdam, Netherlands|Umcg, Universitair Medisch Centrum Groningen, Groningen, Netherlands|Haukeland University Hospital, Bergen, Norway|The Norwegian Radium Hospital, Oslo, Norway|Centrul Medical Sanador, Bucharest, Romania|CF Clinical Hospital Cluj-Napoca, Cluj-Napoca, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Institutul Regional de Oncologie Iasi, Iasi, Romania|County Emergency Hospital Suceava, Suceava, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Ryazan, Russian Federation|Local Institution, Port Elizabeth, Eastern CAPE, South Africa|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, A Coruna, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Marbella, Spain|Local Institution, San Sabastian Gipuzkoa, Spain|Sahlgrenska University Hospital, Goteborg, Sweden|Local Institution, Lund, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Adana, Turkey|Local Institution, Antalya, Turkey|Local Institution, Izmir, Turkey|Aberdeen Royal Infirmary, Aberdeen, Aberdeenshire, United Kingdom|Royal Marsden Nhs Foundation Trust, London, Greater London, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, Merseyside, United Kingdom|Royal Marsden Hospital, Sutton, Surrey, United Kingdom|Freeman Hospital, Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Local Institution, Cardiff, United Kingdom|Beatson Oncology Centre, Glasgow, United Kingdom		https://ClinicalTrials.gov/show/NCT02823574
43	NCT03110107	First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors		Recruiting	No Results Available	Advanced Cancer	Biological: Ipilimumab|Biological: BMS-986218|Biological: Nivolumab	Incidence of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs)|Objective Response Rate (ORR) of BMS-986218 monotherapy relative to Ipilimumab in immuno-oncology (IO) progressed melanoma cohort|Median Duration of Response (mDOR) of BMS-986218 monotherapy relative to Ipilimumab in IO progressed melanoma cohort|Progression Free Survival (PFS) of BMS-986218 monotherapy relative to Ipilimumab in IO progressed melanoma cohort|ORR of BMS-986218 alone or in combination with Nivolumab|mDOR of BMS-986218 alone or in combination with Nivolumab|PFS of BMS-986218 alone or in combination with Nivolumab|Incidence of anti-drug antibody (ADA) to BMS-986218|Percentage of change from baseline in T-regulatory cells (Tregs)|Maximum observed serum concentration (Cmax)|Time of maximum observed concentration (Tmax)|Area under the concentration-time curve from time zero to the time of the|Area under the concentration-time curve in 1 dosing interval [AUC(TAU)]|Trough observed serum concentration (Ctrough)|Total body clearance (CLT)|Average serum concentration over a dosing interval (AUC[TAU]/tau) at steady state (Css-avg)|Ratio of an exposure measure at steady state to that after the first dose [exposure measure includes AUC[TAU] and Cmax (AI)]|Terminal serum half-life if data permit (T-HALF)|Observed concentration at the end of a dosing interval (Ctau)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	452	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA022-001|2017-000597-11	April 28, 2017	April 6, 2020	March 20, 2021	April 12, 2017	null	October 3, 2018	Local Institution, Aurora, Colorado, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Las Vegas, Nevada, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Lyon Cedex 08, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Villejuif, France|Local Institution, Ramat Gan, Israel|Local Institution, Napoli, Italy|Local Institution, Siena, Italy|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain		https://ClinicalTrials.gov/show/NCT03110107
44	NCT02741570	Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck	CheckMate 651	Recruiting	No Results Available	Head and Neck Cancer	Biological: Nivolumab|Biological: Ipilimumab|Drug: Cetuximab/Erbitux|Drug: Cisplatin/Platinol|Drug: Carboplatin/Paraplatin|Drug: Fluorouracil/Adrucil	Overall Survival (OS) in participants with PD-L1 expressing tumors|Progression Free Survival (PFS) in pariticipants with PD-L1 expressing tumors|OS in all participants|PFS in all pariticipants|Objective Response Rate (ORR) in all participants|Duration of Response (DOR) in all participants	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	930	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-651|2016-000725-39	August 4, 2016	August 14, 2020	August 15, 2025	April 18, 2016	null	July 6, 2018	University of Arizona Cancer Center, Tucson, Arizona, United States|City Of Hope, Duarte, California, United States|Local Institution, San Francisco, California, United States|Board of Trustees of the Leland Stanford Junior University, Stanford, California, United States|21st Century Oncology Of Jacksonville, Llc, Jacksonville, Florida, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Univ Of Chicago, Chicago, Illinois, United States|Mass General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan, Ann Arbor, Michigan, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|James Cancer Hospital, Columbus, Ohio, United States|St. Mary Medical Center, Langhorne, Pennsylvania, United States|Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States|UPMC Cancer Center, Pittsburgh, Pennsylvania, United States|UT Southwestern Medical Center, Dallas, Texas, United States|Houston Methodist Medical Center, Houston, Texas, United States|Univ Of Tx. Md Anderson, Houston, Texas, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|Local Institution, Fairfax, Virginia, United States|West Virginia University, Morgantown, West Virginia, United States|Blacktown Hospital, Blacktown, New South Wales, Australia|St Vincent'S Hospital (Nsw), Darlinghurst, New South Wales, Australia|Local Institution, Gosford, New South Wales, Australia|Royal North Shore Hospital, St. Leonards, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Douglas, Queensland, Australia|Lyell McEwin Hospital, Elizabeth Vale, South Australia, Australia|Monash Medical Center, Clayton, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Melbourne, Australia|Krankenhaus Der Barmherzigen Schwestern, Linz, Austria|Medical University Of Vienna, Wien, Austria|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RS, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose De Rio Preto, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Amiens, France|Local Institution, Bordeaux, France|Local Institution, La Tronche, France|Local Institution, Lille, France|Local Institution, Lyon, France|Local Institution, Lyon, France|Local Institution, Marseille, France|Local Institution, Nice Cedex 2, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Strasbourg, France|Local Institution, Villejuif Cedex, France|Universitaetsklinikum Bonn, Bonn, Germany|Klinikum Der Albrecht-Ludwigs-Universitat, Freiburg, Germany|Uniklinikum Hamburg-Eppendorf, Hamburg, Germany|Klinikum Der Universitaet, Hannover, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Universitaetsklinikum Leipzig, Leipzig, Germany|Universitaetsmedizin Der Johannes Gutenberg-Universitaet, Mainz, Germany|Klinikum rechts der Isar der Technischen Universitat Munchen, Muenchen, Germany|Universitaetsklinikum Ulm, Ulm, Germany|Universitat Wurzburg, Wuerzburg, Germany|Local Institution, Athens, Greece|Local Institution, Nea Kifissia, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Dublin 8, Dublin, Ireland|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Petah-tikva, Israel|Local Institution, Ramat-gan, Israel|Local Institution, Tel Aviv, Israel|Istituto Romagnolo Per Lo Studio E La Cura Dei Tumori, Meldola, FC, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, MI, Italy|Azienda Ospedaliera Citta della Salute e della Scienza, Torino, TO, Italy|Local Institution, Mestre, VE, Italy|A.O. Santa Croce E Carle, Cuneo, Italy|Azienda Ospedaliera Universitaria Di Modena, Modena, Italy|Aorn Dei Colli, Napoli, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Local Institution, Perugia, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Kashiwa, Chiba, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Akashi-shi, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Isehara, Kanagawa, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Natori, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Osakasayaha, Osaka, Japan|Local Institution, Takatsuki-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Shimotsuke-shi, Tochigi, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Kita-gun, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico City, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Leon de los Aldama, Guanajuato, Mexico|Local Institution, Morelia, Michoacan, Mexico|Joaquin Gabriel Reinoso Toledo, Monterrey, Nuevo LEON, Mexico|Local Institution, Oaxaca, Mexico|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Klinika Onkologii i Radioterapii, Gdansk, Poland|Centrum Onkologii-Inst.Im.M.Sklodowskiej-Curie O.W Gliwicach, Gliwice, Poland|Osrodek Badan Klinicznych, Krakow, Poland|Klinika Nowotworow Glowy i Szyi, Warszawa, Poland|Local Institution, Barcelona, Spain|Local Institution, L?Hospitalet De Llobregat, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Klinik Fur Onkologie, Basel, Switzerland|Universitatsspital Zurich, Zuerich, Switzerland|Local Institution, Taichung, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Newcastle Upon Tyne, Durham, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom|Local Institution, Birmingham, WEST Midlands, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Sheffield, United Kingdom		https://ClinicalTrials.gov/show/NCT02741570
45	NCT01585987	An Efficacy Study in Gastric and Gastroesophageal Junction Cancer Comparing Ipilimumab Versus Standard of Care Immediately Following First Line Chemotherapy		Completed	Has Results	Locally Advanced (Unresectable) or Metastatic Adenocarcinoma of the Gastric and Gastro-esophageal Junction	Biological: Ipilimumab|Other: Best Supportive care (BSC)	Immune-related Progression Free Survival (irPFS) as Per Assessment of a Blinded Independent Review Committee (IRC) According to Immune Related Response Criteria (irRC) Guidelines|Progression Free Survival (PFS) Per Modified World Health Organization (mWHO) Criteria|Overall Survival (OS) at Primary Endpoint|Overall Survival (OS) at Study Completion|Percentage of Participants With Immune-Related Best Overall Response (irBOR)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	143	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-162|2011-000853-22	July 2012	July 2014	April 2015	April 26, 2012	November 18, 2015	May 17, 2016	Mount Sinai Medical Center, Miami Beach, Florida, United States|Nyu Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|Local Institution, Montpellier Cedex, France|Local Institution, Nice Cedex 03, France|Local Institution, Rennes, France|Local Institution, Toulouse Cedex 09, France|Local Institution, Mainz, Germany|Local Institution, Hong Kong, Hong Kong|Local Institution, Firenze, Italy|Local Institution, Milano, Italy|Local Institution, Padova, Italy|Local Institution, Pisa, Italy|Local Institution, Roma, Italy|Local Institution, Nagoya, Aichi, Japan|Local Institution, Saku-shi, Nagano, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Katowice, Ochojec, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Olsztyn, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan		https://ClinicalTrials.gov/show/NCT01585987
46	NCT02996110	A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma	FRACTION-RCC	Recruiting	No Results Available	Advanced Cancer	Biological: Nivolumab|Biological: Ipilimumab|Biological: Relatlimab|Drug: BMS-986205	Objective Response Rate (ORR)|Duration of Response (DOR)|Progression-free Survival Rate (PFSR)|Safety as measured by incidence of AEs (Adverse Events)|Safety as measured by incidence of SAEs (Serious Adverse Events)|Tolerability as measured by incidence of AEs|Tolerability as measured by SAEs	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA018-005|2016-003082-26	January 17, 2017	January 17, 2022	January 18, 2022	December 19, 2016	null	November 28, 2018	Local Institution, San Francisco, California, United States|Yale Cancer Center, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Augusta University, Augusta, Georgia, United States|Rush University Med Ctr, Chicago, Illinois, United States|Sidney Kimmel Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Karmanos Cancer Center, Detroit, Michigan, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Columbia University Medical Center (Cumc), New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Tennessee Oncology, Pc, Nashville, Tennessee, United States|UT Southwestern Medical Center, Dallas, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Westmead Hospital, Westmead, New South Wales, Australia|Monash Medical Centre Clayton, Bentleigh, Victoria, Australia|Krankenhaus Der Barmherzigen Schwestern, Linz, Austria|Local Institution, Halifax, Nova Scotia, Canada|Local Institution, Hamilton, Ontario, Canada|Local Institution, Oshawa, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Jewish General Hospital, Montreal, Quebec, Canada|Local Institution, Quebec, Canada|Local Institution, Haifa, Israel|Local Institution, Ramat Gan, Israel|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy		https://ClinicalTrials.gov/show/NCT02996110
47	NCT00112580	MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery		Completed	No Results Available	Pancreatic Cancer	Biological: ipilimumab	Clinical response (complete and partial)|Incidence of autoimmunity	Bristol-Myers Squibb|National Cancer Institute (NCI)	All	18 Years to 120 Years   (Adult, Older Adult)	Phase 2	82	Industry|NIH	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000430666|NCI-05-C-0141|NCI-P6557|MDX-010-24	July 2005	June 2009	June 2009	June 3, 2005	null	October 12, 2015	Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States|NCI - Surgery Branch, Bethesda, Maryland, United States		https://ClinicalTrials.gov/show/NCT00112580
48	NCT00623766	Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases		Completed	Has Results	Melanoma	Drug: Ipilimumab|Drug: Corticosteroid: Betamethasone|Drug: Corticosteroid: Dexamethasone|Drug: Corticosteroid: Fludrocortisone|Drug: Corticosteroid: Hydrocortisone|Drug: Corticosteroid: Meprednisone|Drug: Corticosteroid: Methylprednisolone|Drug: Corticosteroid: Prednisolone|Drug: Corticosteroid: Prednisone|Drug: Corticosteroid: Triamcinolone	Disease Control Rate by Modified World Health Organization (mWHO) Tumor Assessment Criteria|Disease Control Rate by Immune-related Response Criteria (irRC)|Best Overall Response Rate (BORR) by Modified World Health Organization (mWHO) Criteria and by Immune-relate Response Criteria (irRC)|Duration of Response (DOR) by Modified World Health Organization (mWHO) Criteria and by Immune-related Response Criteria (irRC)|Progression-free Survival (PFS) by Modified World Health Organization (mWHO) Criteria and by Immune-related Response Criteria (irRC)|Number of Participants Surviving at 6, 12, 18, 24, and 36 Months (Overall Survival [OS] Rate)|Number of Participants Who Died or Had a Treatment-related Adverse Event (AE), Immune-related AE, Immune-related Serious Adverse Event (SAE), Nervous System Disorder, Treatment-related Nervous System Disorder, SAE, and AE Leading to Discontinuation|Onset of Response by Modified World Health Organization (mWHO) Criteria and Immune-related Response Criteria (irRC)|Overall Survival (OS)	Bristol-Myers Squibb|Medarex	All	16 Years and older   (Child, Adult, Older Adult)	Phase 2	99	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-042	July 2008	September 2009	October 2012	February 26, 2008	June 9, 2014	June 9, 2014	Mayo Clinic Arizona, Scottsdale, Arizona, United States|City Of Hope, Duarte, California, United States|The Angeles Clinic & Research Institute, Los Angeles, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Loyola University Medical Center, Maywood, Illinois, United States|Oncology Specialists, S.C., Park Ridge, Illinois, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States|Local Institution, Bronx, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Providence Portland Med Ctr, Portland, Oregon, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00623766
49	NCT02750514	An Investigational Immuno-therapy Study to Test Combination Treatments in Patients With Advanced Non-Small Cell Lung Cancer	FRACTION-Lung	Recruiting	No Results Available	Advanced Cancer	Biological: Nivolumab|Drug: Dasatinib|Biological: Relatlimab|Biological: Ipilimumab|Drug: BMS-986205	Objective Response Rate (ORR)|Duration of Response (DOR)|Progression-free Survival Rate (PFSR)|Safety and tolerability of Nivolumab based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths|Safety and tolerability of Nivolumab & Dasatinib combination based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths|Safety and tolerability of Nivolumab & BMS-986016 combination based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths|Safety and tolerability of Nivolumab & Ipilimumab combination based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths|Safety and tolerability of Nivolumab & BMS-966205 combination based on incidence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	504	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA018-001	May 6, 2016	April 28, 2021	April 29, 2021	April 25, 2016	null	October 4, 2018	City of Hope National Medical Center, Duarte, California, United States|University of California San Diego (UCSD), La Jolla, California, United States|University of Southern California (USC), Los Angeles, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|University of Californa, Los Angeles (UCLA), Los Angeles, California, United States|Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Yale Cancer Center, New Haven, Connecticut, United States|Local Institution, Washington, District of Columbia, United States|Local Institution, Atlanta, Georgia, United States|University of Kansas Cancer Center, Westwood, Kansas, United States|University of Maryland - Marlene and Stewart Greenebaum Cancer Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute (DFCI), Boston, Massachusetts, United States|University of Michigan, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Washington University, The Center for Advanced Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Univ of NC Shool of Medicine, Chapel Hill, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Northwest Cancer Specialists, Portland, Oregon, United States|Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|The West Clinic, P.C. d/b/a West Cancer Center, Germantown, Tennessee, United States|Sarah Cannon Cancer Center, Nashville, Tennessee, United States|Sammons Cancer Center (Uso), Dallas, Texas, United States|Texas Oncology, P.A., Fort Sam Houston, Texas, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Us Oncology, Tyler, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Virginia Cancer Care Specialist, PC, Fairfax, Virginia, United States|University of Washington-Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Clayton, Australia|Local Institution, Salzburg, Austria|Juravinski Cancer Centre, Hamilton Health Sciences-Mcmaster Univeristy's Faculty Of Health Sciences, Hamilton, Ontario, Canada|University Of Ottawa - The Ottawa Hospital Cancer centre, Ottawa, Ontario, Canada|Local Institution, Edmonton, Canada|Local Institution, Copenhagen, Denmark|Local Institution, Paris, France|Local Institution, Toulouse, France|Local Institution, Villejuif Cedex, France|Local Institution, Milano, Italy|Local Institution, Milan, Italy|Local Institution, Rozzano, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Oslo, Norway|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Local Institution, Stockholm, Sweden|Local Institution, Lausanne, Switzerland|Local Institution, London, Greater London, United Kingdom		https://ClinicalTrials.gov/show/NCT02750514
50	NCT02516527	A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors		Recruiting	No Results Available	Melanoma	Drug: Ipilimumab	The safety of ipilimumab measured by the occurrence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths|The tolerability of ipilimumab measured by the occurrence of adverse events, serious adverse events, adverse events leading to discontinuation and deaths|Identify dose limiting toxicities in Chinese subjects with select advanced (unresectable, metastatic, or recurrent) solid tumors measured by the occurrence of adverse events, serious adverse events, adverse events leading to discontinuation, and deaths	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	36	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	CA184-247	October 16, 2015	May 25, 2020	May 26, 2020	August 6, 2015	null	September 26, 2018	Local Institution, Guangzhou, Guangdong, China		https://ClinicalTrials.gov/show/NCT02516527
51	NCT02864251	A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy	CheckMate722	Recruiting	No Results Available	Non-Small-Cell Lung Carcinoma	Biological: Nivolumab|Biological: Ipilimumab|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin	Progression free survival (PFS) in subjects with epidermal growth factor receptor (EGFR) mutation, T790M negative non-small cell lung carcinoma (NSCLC)|Overall survival (OS)|Objective response rate (ORR)|Duration of response (DOR)|Progression free survival (PFS) rate	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	465	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-722	October 20, 2016	September 30, 2019	December 31, 2023	August 11, 2016	null	September 25, 2018	Pacific Shores Medical Group, Long Beach, California, United States|Los Angeles Hematology Oncology Medical Group, Los Angeles, California, United States|UCLA Cancer Hematology Oncology, Los Angeles, California, United States|St Joseph Hospital, Orange, California, United States|Torrance Memorial Physican Network, Redondo Beach, California, United States|Yale University School of Medicine, New Haven, Connecticut, United States|University of Chicago, Chicago, Illinois, United States|Johns Hopkins University, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|NYU Langone Medical Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Texas Health Physicians Group, Fort Worth, Texas, United States|Baylor Scott and White Research Institute, Temple, Texas, United States|Tyler Hematology/Oncology PA, Tyler, Texas, United States|Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Chongqing, Chongqing, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Zhengzhou, Henan, China|Local Institution, Changsha, Hunan, China|Local Institution, Changchun, Jilin, China|Local Institution, Changchun, Jilin, China|Local Institution, Xi`an, Shan1xi, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Hanghzou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Shanghai, China|Local Institution, Marseille, France|Local Institution, Paris, France|Local Institution, Rennes, France|Local Institution, Toulouse, France|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Local Institution, Hong Kong, Hong Kong|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Matsuyama-shi, Ehime, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Iizuka-shi, Fukuoka, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Fukushima-shi, Fukushima, Japan|Local Institution, Fukuyama, Hiroshima, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Himeji, Hyogo, Japan|Local Institution, Itami, Hyogo, Japan|Local Institution, Kobe City, Hyogo, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Yokohama-Shi, Kanagawa, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Sendai-shi, Miyagi, Japan|Local Institution, Kiriyama-shi, Niigata, Japan|Local Institution, Hirakata-shi, Osaka, Japan|Local Institution, Kishiwada shi, Osaka, Japan|Local Institution, Osakasayama-shi, Osaka, Japan|Local Institution, Sakai-shi, Osaka, Japan|Local Institution, Hidaka, Saitama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Chuo, Tokyo, Japan|Local Institution, Koto, Tokyo, Japan|Local Institution, Ube, Yamaguchi, Japan|Local Institution, Chiba, Japan|Local Institution, Fukuoka, Japan|Local Institution, Niigata, Japan|Local Institution, Tokyo, Japan|Local Institution, Toyama, Japan|Local Institution, Wakayama, Japan|Local Institution, Cheogju-si, Korea, Republic of|Local Institution, Goyang, Korea, Republic of|Local Institution, Gyeonggi-do, Korea, Republic of|Local Institution, Inchoen, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, L'Hospitalet de Llobregat, Spain|Local Institution, Madrid, Spain|Local Institution, Majadahonda, Spain|Local Institution, Malaga, Spain|Local Institution, Zaragoza, Spain|Local Institution, Chiayi, Taiwan|Local Institution, Kaohsiung City, Taiwan|Local Institution, Kaohsiung city, Taiwan|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Tainan, Taiwan|Local Institution, Taipei City, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan		https://ClinicalTrials.gov/show/NCT02864251
52	NCT02060188	An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread	CheckMate142	Recruiting	No Results Available	Microsatellite Unstable Colorectal Cancer|Microsatellite Stable Colorectal Cancer|Mismatch Repair Proficient Colorectal Cancer|Mismatch Repair Deficient Colorectal Cancer	Drug: Ipilimumab|Drug: Nivolumab|Drug: Cobimetinib|Drug: Daratumumab|Drug: anti-LAG-3 antibody	Objective response rate (ORR) in all MSI-High and non-MSI-High subjects as determined by Investigators|ORR in all MSI-H and non-MSI-H subjects based on IRRC determination	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	340	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-142|2013-003939-30	March 7, 2014	December 3, 2019	December 30, 2020	February 11, 2014	null	November 20, 2018	Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Pacific Hematology Oncology Associates, San Francisco, California, United States|Emory University, Atlanta, Georgia, United States|Dana Farber Cancer Institute., Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Allina Health System, Minneapolis, Minnesota, United States|Duke University Office of Research Administration, Durham, North Carolina, United States|Novant Health Oncology Specialists, Winston-Salem, North Carolina, United States|Providence Cancer Center Oncology and Hematology Care- Eastside, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|University Of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Vanderbilt University Med Ctr, Nashville, Tennessee, United States|Md Anderson Can Cnt, Houston, Texas, United States|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Tasman Oncology Research Pty Ltd, Southport, Queensland, Australia|Royal Melbourne Hospital, Parkville, Victoria, Australia|Local Institution, Brussels, Belgium|Local Institution, Brussels, Belgium|Local Institution, Leuven, Belgium|Local Institution, Edmonton, Alberta, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Paris, France|Local Institution, Dublin 4, Ireland|Local Institution, Dublin 9, Ireland|Local Institution, Galway, Ireland|Local Institution, Candiolo, TO, Italy|Local Institution, Modena, Italy|Local Institution, Padova, Italy|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain		https://ClinicalTrials.gov/show/NCT02060188
53	NCT03246958	Nivolumab Plus Ipilimumab in Thyroid Cancer		Recruiting	No Results Available	Thyroid Cancer	Drug: Nivolumab|Drug: Ipilimumab	Radiographic Response Rate|Progression Free Survival|Overall Survival|Tolerability	Dana-Farber Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	54	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-255	September 20, 2017	March 31, 2021	March 31, 2025	August 11, 2017	null	August 24, 2018	Dana Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03246958
54	NCT03104439	Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer		Recruiting	No Results Available	Microsatellite Stable Colorectal Cancer|Pancreatic Cancer|MSI High Colorectal Cancer	Drug: Nivolumab|Drug: Ipilimumab|Radiation: Radiation Therapy	Disease Control Rate|Median Progression free Survival|Median Overall Survival	Massachusetts General Hospital|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	80	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-021	May 10, 2017	October 31, 2020	October 31, 2024	April 7, 2017	null	October 12, 2018	Massachusetts general Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03104439
55	NCT03061539	Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature		Recruiting	No Results Available	Prostate Cancer	Drug: Nivolumab & Ipilimumab	Composite response rate|Overall survival|Radiological progression free survival|PSA progression free survival|Change in patient reported outcome measures (NCI's PRO-CTCAE)|Frequency and severity of adverse events	University College, London|Bristol-Myers Squibb	Male	18 Years and older   (Adult, Older Adult)	Phase 2	175	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-935	February 6, 2018	April 2019	July 2024	February 23, 2017	null	July 12, 2018	University College London Hospital, London, United Kingdom		https://ClinicalTrials.gov/show/NCT03061539
56	NCT02488759	An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors	CheckMate358	Recruiting	No Results Available	Various Advanced Cancer	Drug: Nivolumab|Drug: Ipilimumab|Drug: Relatlimab|Drug: Daratumumab	The safety and tolerability will be measured by the incidence of drug-related adverse events (AEs) and serious adverse events (SAEs)|Objective response rate|Rate of surgery delay|Progression-free survival|Overall survival|Duration of response	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	600	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-358|2015-000230-29	October 8, 2015	May 13, 2019	December 31, 2019	July 2, 2015	null	October 19, 2018	H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Local Institution, New Orleans, Louisiana, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Lutherville, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Desc. Med Ctr, Boston, Massachusetts, United States|University Of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Memorial Sloan-Kettering Cancer Center-Breast Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Stephenson Cancer Center, Oklahoma City, Oklahoma, United States|Providence Portland Medical Center, Portland, Oregon, United States|UPMC Eye and Ear Institute, Pittsburgh, Pennsylvania, United States|Sanford Clinic Clinical Research, Sioux Falls, South Dakota, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, Brussels, Belgium|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Marseille Cedex 9, France|Local Institution, Paris, France|Centre Claudius Regaud, Toulouse Cedex 9, France|Institut Gustave Roussy, Vlllejuif, France|Local Institution, Essen, Germany|Local Institution, Heidelberg, Germany|Local Institution, Heilbronn, Germany|Local Institution, Wuerzburg, Germany|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Ciudad de Mexico, Distrito Federal, Mexico|Local Institution, Oaxaca de Juarez, Oaxaca, Mexico|Local Institution, Merida, Yucatan, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Utrecht, Netherlands|Local Institution, Craiova, Romania|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Madrid Norte Sanchinarro, Madrid, Spain|Clinica Universitaria De Navarra, Navarra, Spain|Local Institution, Tainan, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Birmingham, WEST Midlands, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, London, United Kingdom		https://ClinicalTrials.gov/show/NCT02488759
57	NCT01194271	Neoadjuvant Ipilimumab in Prostate Cancer		Completed	No Results Available	Prostate Cancer	Drug: Leuprolide Acetate|Drug: Ipilimumab|Procedure: Radical Prostatectomy	Longitudinal Peripheral Blood Values	M.D. Anderson Cancer Center|Bristol-Myers Squibb	Male	18 Years and older   (Adult, Older Adult)	Phase 2	19	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2009-0135|NCI-2010-01974	September 2010	October 2015	October 2015	September 2, 2010	null	August 22, 2016	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT01194271
58	NCT02221739	Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)		Completed	No Results Available	Non-small Cell Lung Cancer (NSCLC)	Drug: Ipilimumab|Radiation: Radiotherapy (IMRT or 3-D CRT)	Therapeutic efficacy of anti-CTLA-4 mAb and concurrent local RT in NSCLC patients with metastatic disease.|The effects of RT and anti-CTLA-4 mAb on development of anti-tumor immunity.	New York University School of Medicine|Bristol-Myers Squibb	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2	39	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	S14-00208	June 2014	July 2015	October 2016	August 20, 2014	null	October 12, 2016	NYU Clinical Cancer Center, New York, New York, United States|NYU Langone Medical Center, Tisch Hospital, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02221739
59	NCT02239900	Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors		Active, not recruiting	No Results Available	Liver Cancer|Lung Cancer	Drug: Ipilimumab|Radiation: Stereotactic Body Radiation Therapy (SBRT)	Maximum Tolerated Dose (MTD) of Ipilimumab and Stereotactic Body Radiation Therapy (SBRT)|Response Rate of Ipilimumab and Stereotactic Body Radiation Therapy (SBRT)	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	143	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2013-0882|NCI-2015-00042	August 26, 2014	August 2019	August 2019	September 15, 2014	null	May 16, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02239900
60	NCT03172624	Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer		Recruiting	No Results Available	Salivary Gland Cancer	Drug: Nivolumab|Drug: Ipilimumab	best overall response rate	Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	64	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-219	May 26, 2017	May 2019	May 2019	June 1, 2017	null	August 20, 2018	Memoral Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memoral Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States|Memorial Sloan Kettering Commack, Commack, New York, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Memorial Sloan Kettering Rockville Centre, Rockville Centre, New York, United States		https://ClinicalTrials.gov/show/NCT03172624
61	NCT02982954	A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer	CHECKMATE 920	Active, not recruiting	No Results Available	Renal Cell Carcinoma	Drug: Nivolumab|Drug: Ipilimumab	Incidence of high grade immune-mediated adverse events (IMAEs)|Time to onset of all high grade IMAEs|Time to resolution of all high grade IMAEs|Percentage of patients who received immune modulating medication due to high grade IMAEs|Progression-free survival at time of initial progression (PFS 1) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator|Objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator|Time to response (TTR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator|Duration of response (DOR) using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria as assessed by the investigator	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 4	200	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-920	December 7, 2016	March 30, 2020	February 28, 2023	December 6, 2016	null	July 18, 2018	Northwest Alabama Cancer Center, Pc, Muscle Shoals, Alabama, United States|Alaska Urological Institute dba Alaska Clinical Research Center, Anchorage, Alaska, United States|Ironwood Cancer And Research Centers, Pc, Chandler, Arizona, United States|Highlands Oncology Group, P.A., Fayetteville, Arkansas, United States|eCare, Encinitas, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Los Angeles Cancer Network, Los Angeles, California, United States|UCLA Hematology Oncology, Los Angeles, California, United States|Torrance Health Association, Redondo Beach, California, United States|Kaiser Permanente Medical Group - Southern California, Riverside, California, United States|Sharp Memorial Hospital, San Diego, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|Florida Cancer Specialists S., Fort Myers, Florida, United States|University Of Miami/Sylvester Cancer Center, Miami, Florida, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|Florida Cancer Specialists, Saint Petersburg, Florida, United States|Emory University - Winship Cancer Institute, Atlanta, Georgia, United States|Illinois Cancer Specialists, Niles, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Minnesota Oncology Hematology, Minneapolis, Minnesota, United States|Southdale Cancer Clinic, Minneapolis, Minnesota, United States|Park Nicollet Clinic Cancer Center, Saint Louis Park, Minnesota, United States|Hattiesburg Clinic, Hattiesburg, Mississippi, United States|Jackson Oncology Associates, Pllc, Jackson, Mississippi, United States|HCA Midwest Division, Kansas City, Missouri, United States|St. Francis Cancer Treatment Center, Grand Island, Nebraska, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|University Of New Mexico, Albuquerque, New Mexico, United States|Montefiore Medical Center, Bronx, New York, United States|Maimonides Medical Center, Brooklyn, New York, United States|Broome Oncology, Johnson City, New York, United States|Laura & Isaac Perlmutter Cancer Center, New York, New York, United States|Weill Cornell Medical College, New York, New York, United States|SUNY Upstate Medical University, Syracuse, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|Southeastern Medical Oncology Center, Goldsboro, North Carolina, United States|Oklahoma Cancer Specialists and Research Institute, LLC, Tulsa, Oklahoma, United States|Va Medical Center Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, United States|Charleston Hematology Oncology Associates, Pa, Charleston, South Carolina, United States|Hollings Cancer Center, Charleston, South Carolina, United States|Avera Cancer Institute, Sioux Falls, South Dakota, United States|Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States|Tennessee Oncology PLLC, Nashville, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Texas Oncology, Austin, Texas, United States|Texas Oncology, Dallas, Texas, United States|Texas Oncology-Fort Worth 12th Ave, Fort Worth, Texas, United States|Texas Oncology-Midland Allison Cancer Center, Midland, Texas, United States|Texas Oncology, San Antonio, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Inova Research Center, Fairfax, Virginia, United States|Bon Secours St Francis Hospital, Midlothian, Virginia, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Medical Oncology Associates, Spokane, Washington, United States|Yakima Valley Memorial Hospital/North Star Lodge, Yakima, Washington, United States|University of Wisconsin Clinical Science Center, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT02982954
62	NCT03026166	A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer		Active, not recruiting	No Results Available	Small Cell Lung Cancer	Drug: ipilimumab|Drug: nivolumab|Drug: rovalpituzumab tesirine	Number of participants with dose-limiting toxicities (DLT)|Clinical benefit rate (CBR)|Duration of response (DOR)|PFS status after 6 months from the initiation of study treatment|Objective Response Rate (ORR)|Progression-free survival (PFS)|Overall survival (OS)	AbbVie|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	42	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	M16-300|2016-003686-26	March 31, 2017	July 3, 2019	July 3, 2019	January 20, 2017	null	October 26, 2018	Ucsd /Id# 161030, La Jolla, California, United States|Florida Hospital /ID# 161017, Orlando, Florida, United States|University Cancer & Blood Cent /ID# 161028, Athens, Georgia, United States|University of Chicago /ID# 161006, Chicago, Illinois, United States|The University of Kansas Clini /ID# 162915, Fairway, Kansas, United States|Washington University-School of Medicine /ID# 161011, Saint Louis, Missouri, United States|Rutgers Cancer Institute of NJ /ID# 161032, New Brunswick, New Jersey, United States|Memorial Sloan Kettering Cancer Center /ID# 161010, New York, New York, United States|Duke Univ Med Ctr /ID# 161009, Durham, North Carolina, United States|Oregon Health and Science University /ID# 161029, Portland, Oregon, United States|Medical University of South Carolina /ID# 161007, Charleston, South Carolina, United States|Tennessee Oncology, PLLC /ID# 161012, Nashville, Tennessee, United States|Vanderbilt University Med Ctr /ID# 162916, Nashville, Tennessee, United States|Virginia Cancer Institute /ID# 161025, Richmond, Virginia, United States|University of Wisconsin Clinic /ID# 161013, Madison, Wisconsin, United States|CHU de Besancon - Jean Minjoz /ID# 165173, Besancon, Doubs, France|Centre Oscar Lambret /ID# 165169, Lille, Hauts-de-France, France|Institut Gustave Roussy /ID# 165168, Villejuif, Val-de-Marne, France|Institut Sainte Catherine /ID# 165172, Avignon, France|CHRU de Brest - Hospital Morva /ID# 165170, Brest Cedex, France|Hopital La Timone /ID# 165171, Marseille, France|Universitaetsklinik Heidelberg /ID# 165184, Heidelberg, Baden-Wuerttemberg, Germany|KH Martha-Maria Halle Dolau /ID# 165180, Halle (Saale), Sachsen-Anhalt, Germany|Asklepios Fachkliniken M. Gaut /ID# 165183, Gauting, Germany|Lungen Clinic Grosshansdorf /ID# 165182, Grosshansdorf, Germany|Lungenfachklinik Immenhausen /ID# 165181, Immenhausen, Germany|Istituto Clinico Humanitas /ID# 165176, Rozzano, Milano, Italy|Centro di Riferimento Oncologi /ID# 165174, Aviano, Italy|Universitaria di Bologna Polic /ID# 165179, Bologna, Italy|A.O. Uni Policlinico Vittorio /ID# 165178, Catania, Italy|Istituto Europeo di Oncologia /ID# 165175, Milan, Italy|AO Univ di Modena /ID# 165177, Modena, Italy|Clinica Universitar de Navarra - Pamplona /ID# 165165, Pamplona, Navarra, Comunidad, Spain|Hosp Univ Quiron Dexues /ID# 165166, Barcelona, Spain|ICO l´Hosp- Hosp Duran Reynals /ID# 165167, Barcelona, Spain|Hospital Genl Gregorio Maranon /ID# 165162, Madrid, Spain|Hospital Universitario Fundaci /ID# 165164, Madrid, Spain|Hospital Universitario Madrid /ID# 165163, Madrid, Spain		https://ClinicalTrials.gov/show/NCT03026166
63	NCT02923934	A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers		Recruiting	No Results Available	Gastrointestinal Cancer|Neuroendocrine Tumours|Malignant Female Reproductive System Neoplasm	Drug: Ipilimumab|Drug: Nivolumab	To determine the clinical efficacy of the combination treatment of ipilimumab with nivolumab in rare cancers.|To identify whether a common predictive biomarker or immune signature can be identified in responding patients that can occur irrespective of tumour type.	Olivia Newton-John Cancer Research Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	120	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ONJ2016-001	August 22, 2017	August 2023	December 2023	October 5, 2016	null	November 14, 2018	Border Medical Oncology Unit, Albury, New South Wales, Australia|Blacktown Hospital, Sydney, New South Wales, Australia|Monash Health, Clayton, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia		https://ClinicalTrials.gov/show/NCT02923934
64	NCT03043599	Ipilimumab + Nivolumab w/Thoracic Radiotherapy for Extensive-Stage Small Cell Lung Cancer		Active, not recruiting	No Results Available	Small Cell Lung Cancer|Extensive-stage Small Cell Lung Cancer	Radiation: Thoracic Radiation Therapy|Drug: Ipilimumab|Drug: Nivolumab	Phase I: Confirmation of Recommended Phase II Dose|Phase II: Progression Free Survival (PFS)|Overall Survival (OS)	H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	21	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-18914|CA209-840	February 13, 2017	April 2021	April 2022	February 6, 2017	null	October 3, 2018	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT03043599
65	NCT03670056	A Pilot Study of Combination Immunotherapy With Ipilimumab and Nivolumab in Patients With Recurrent Extensive Stage Small Cell Lung Cancer (SCLC) Who Have Previously Received Platinum-based Chemotherapy		Not yet recruiting	No Results Available	Small Cell Lung Cancer	Drug: Combination immunotherapy with Ipilimumab and Nivolumab	Change in the ratio of Teff/Treg cells|Response rate|Duration of response|Progression-free survival	Yale University|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2000023361|CA209-9YT	September 15, 2018	September 30, 2020	September 30, 2022	September 13, 2018	null	September 13, 2018	Yale University, Yale Cancer Center, New Haven, Connecticut, United States		https://ClinicalTrials.gov/show/NCT03670056
66	NCT03425331	Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC		Recruiting	No Results Available	Non-small Cell Lung Cancer	Drug: Ipilimumab|Drug: Nivolumab	Best overall objective response rate|Progression-free survival (PFS)|Overall survival|Duration of response|Toxicity	Dana-Farber Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	80	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-566	February 28, 2018	August 28, 2021	August 28, 2025	February 7, 2018	null	June 28, 2018	Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03425331
67	NCT03350126	Interest of iRECIST Evaluation for DCR for Evaluation of Patients With Deficient MMR and /or MSI Metastatic Colorectal Cancer Treated With Nivolumab and Ipilimumab	NIPICOL	Recruiting	No Results Available	Metastatic Cancer Colorectal	Drug: Ipilimumab 200 MG in 40 ML Injection|Drug: Nivolumab 10 MG/ML	Disease Control Rate (DCR)|Progression Free Survival (PFS)|Overall Response Rate (ORR)|Overall Survival (OS)|Toxicity according to NCI-CTCAE version 4.0 (National Cancer Institute Common Terminology Criteria for Adverse Events),	GERCOR - Multidisciplinary Oncology Cooperative Group|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	57	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NIPICOL C17-01	December 4, 2017	December 2018	December 2019	November 22, 2017	null	January 23, 2018	Institut Sainte Catherine, Avignon, France|CHRU Besançon, Besançon, France|Henri Mondor Hospital, Créteil, France|IHFB, Levallois-Perret, France|Centre Leon Berard, Lyon, France|CHU Nantes - Hôtel Dieu, Nantes, France|Hospital Saint Antoine, Paris, France|CHU Poitiers, Poitiers, France		https://ClinicalTrials.gov/show/NCT03350126
68	NCT02950766	A Study Combining NeoVax, a Personalized NeoAntigen Cancer Vaccine, With Ipilimumab to Treat High-risk Renal Cell Carcinoma		Not yet recruiting	No Results Available	Kidney Cancer	Drug: NeoVax|Drug: Ipilimumab	Number of participants with dose-limiting toxicity (DLT) experienced within 49 days (7 weeks) of treatment initiation as assessed by CTCAE v4.0|Number of participants with NeoVax induced IFN γ (interferon γ) T-cell Response against neoepitopes measured by ELISPOT at week 16|Number of participants alive at 2 years	Patrick Ott, MD|Bristol-Myers Squibb|Oncovir, Inc.|Dana-Farber Cancer Institute	All	18 Years and older   (Adult, Older Adult)	Phase 1	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-097	September 3, 2018	September 2019	September 2022	November 1, 2016	null	August 15, 2018	Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT02950766
69	NCT02866383	Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients	CheckPAC	Recruiting	No Results Available	Metastatic Pancreatic Cancer|Metastatic Biliary Tract Cancer	Drug: Nivolumab|Drug: Ipilimumab|Radiation: Radiotherapy	Clinical benefit rate (CBR)|Incidence of Treatment-Emergent Adverse Events [Safety]|CBR|Overall response rate (ORR) according to RECIST 1.1|Overall response rate (ORR) according to modified irRC|Progression free survival (PFS) per RECIST 1.1|Progression free survival (PFS) per modified irRC|Overall survival (OS) probability at 6 months|OS|Quality of Life	Herlev Hospital|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	160	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GI 1616	November 2016	November 2018	November 2019	August 15, 2016	null	September 13, 2018	Herlev & Gentofte Hospital, Herlev, Denmark		https://ClinicalTrials.gov/show/NCT02866383
70	NCT02696993	Trial of Nivolumab With Radiation or Nivolumab and Ipilimumab With Radiation for the Treatment of Intracranial Metastases From Non-Small Cell Lung Cancer		Recruiting	No Results Available	Metastatic Brain Cancer	Drug: Nivolumab|Drug: Ipilimumab|Radiation: Stereotactic Radiosurgery (SRS)|Radiation: Whole Brain Radiation Therapy (WBRT)|Behavioral: Neurocognitive Exam	Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Stereotactic Radiosurgery (SRS)|Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Whole Brain Radiation Therapy (WBRT)|Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Ipilimumab and Stereotactic Radiosurgery (SRS)|Recommended Phase 2 Dose (RP2D) of Nivolumab in Combination with Ipilimumab and Whole Brain Radiation Therapy (WBRT)|Intracranial Progression Free Survival|Neurocognitive Changes	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	80	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2015-0883|NCI-2016-00661	December 2016	December 2020	December 2020	March 2, 2016	null	May 31, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02696993
71	NCT01377389	Ipilimumab + Androgen Deprivation Therapy in Prostate Cancer		Completed	No Results Available	Prostate Cancer	Drug: Ipilimumab|Drug: Leuprolide|Drug: Goserelin|Drug: Degarelix	Proportion of Participants achieving a PSA ≤ 0.2ng/mL at Month 7	M.D. Anderson Cancer Center|Bristol-Myers Squibb	Male	18 Years and older   (Adult, Older Adult)	Phase 2	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2009-0378|NCI-2011-01125	June 17, 2011	April 7, 2017	April 7, 2017	June 21, 2011	null	April 12, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT01377389
72	NCT03256136	Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC		Recruiting	No Results Available	Lung Cancer	Drug: Carboplatin|Drug: Nivolumab|Drug: pemetrexed|Drug: Ipilimumab	Objective Response Rate (ORR)|Disease Control Rate (DCR)|Progression Free Survival (PFS)|Overall Survival (OS)|Duration Of Response	Massachusetts General Hospital|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-011	November 22, 2017	October 31, 2020	October 31, 2024	August 21, 2017	null	June 12, 2018	Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts general Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT03256136
73	NCT03271047	Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation		Active, not recruiting	No Results Available	MSS|RAS-mutant Colorectal Cancer	Drug: binimetinib|Drug: nivolumab|Drug: ipilimumab	(Phase 1b) Incidence of dose-limiting toxicities (DLTs) resulting from binimetinib in combination with nivolumab|(Phase 1b) Incidence of dose-limiting toxicities (DLTs) resulting from binimetinib in combination with nivolumab plus ipilimumab|(Phase 2) Objective Response Rate (ORR)|(Phase 1b) Objective Response Rate (ORR)|(Phase 1b and Phase 2) Duration of Response (DOR)|(Phase 1b and Phase 2) Rate of complete response (CR)|(Phase 1b and Phase 2) Incidence and severity of adverse events (AEs)|(Phase 1b and Phase 2) Sparse plasma concentrations for binimetinib	Array BioPharma|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	90	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ARRAY-162-202	October 4, 2017	June 2019	January 2020	September 1, 2017	null	October 2, 2018	Array BioPharma Investigative Site, Encinitas, California, United States|Array BioPharma Investigative Site, Laguna Hills, California, United States|Array BioPharma Investigative Site, Santa Monica, California, United States|Array BioPharma Investigative Site, Newark, Delaware, United States|Array BioPharma Investigative Sites (2), Port Saint Lucie, Florida, United States|Array BioPharma Investigative Site, Indianapolis, Indiana, United States|Array BioPharma Investigative Site, Saint Louis, Missouri, United States|Array BioPharma Investigative Sites (2), Philadelphia, Pennsylvania, United States|Array BioPharma Investigative Site, Chattanooga, Tennessee, United States|Array BioPharma Investigative Site, Nashville, Tennessee, United States|Array BioPharma Investigative Site, Houston, Texas, United States|Array BioPharma Investigative Site, Leuven, Belgium|Array BioPharma Investigative Site, Amsterdam, Noord-Holland, Netherlands|Array BioPharma Investigative Site, Amsterdam, Noord-Holland, Netherlands|Array BioPharma Investigative Site, Santander, Canabria, Spain|Array BioPharma Investigative Site, Madrid, Madrid, Communidad Delaware, Spain|Array BioPharma Investigative Site, Barcelona, Spain|Array BioPharma Investigative Site, Madrid, Spain|Array BioPharma Investigative Site, Madrid, Spain|Array BioPharma Investigative Sites (2), London, United Kingdom|Array BioPharma Investigative Site, Oxford, United Kingdom		https://ClinicalTrials.gov/show/NCT03271047
74	NCT03391869	Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab (LONESTAR)		Recruiting	No Results Available	Malignant Neoplasms of Respiratory and Intrathoracic Organs|Non-small Cell Lung Cancer	Drug: Ipilimumab|Drug: Nivolumab|Procedure: Local Consolidative Therapy (LCT)	Overall Survival (OS)|Overall Survival (OS) in Oligometastatic Patients|Progression-Free Survival (PFS)|Time to Appearance of New Metastases (TANM)|Progression of Target lesions Defined by RECIST 1.1 Criteria|Progression of Non-Target Lesions by RECIST 1.1 Criteria|Toxicity Evaluated Using CTCAE v4.0 Criteria|Quality of Life (QOL)	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	270	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-0311|NCI-2018-00825	December 29, 2017	December 2022	December 2022	January 5, 2018	null	November 26, 2018	MD Anderson Cancer Center Memorial City, Houston, Texas, United States|University of Texas MD Anderson Cancer Center, Houston, Texas, United States|MD Anderson Cancer Center Katy, Houston, Texas, United States|MD Anderson Cancer Center Bay Area, Nassau Bay, Texas, United States|MD Anderson Cancer Center Sugar Land, Sugar Land, Texas, United States|MD Anderson Cancer Center The Woodlands, The Woodlands, Texas, United States		https://ClinicalTrials.gov/show/NCT03391869
75	NCT03532217	Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer		Recruiting	No Results Available	Metastatic Hormone-Sensitive Prostate Cancer	Biological: PROSTVAC-V|Biological: PROSTVAC-F|Drug: Nivolumab|Drug: Ipilimumab|Biological: Neoantigen DNA vaccine|Device: TriGrid Delivery System|Procedure: Tumor biopsy|Procedure: Peripheral blood|Procedure: Fecal samples	Safety and tolerability of regimen as defined by incidence of adverse events|Immune response as measured by tetramers|Immune response as measured by genomic studies|Immune response as measured by flow cytometry|Safety and tolerability of regimen as defined by incidence of dose-limiting toxicities (DLTs)|Failure-free survival (FFS)|Milestone survival|Number of participants who have PSA responses at 30% reduction level|Number of participants who have PSA responses at 50% reduction level|Radiographic progression as determined by RECIST 1.1|Radiographic progression as determined by Prostate Cancer Working Group 3 (PCWG3)|Radiographic progression free survival (rPFS)|Comparison of the immune correlates on matched tumor tissue and peripheral blood	Washington University School of Medicine|Bristol-Myers Squibb	Male	18 Years and older   (Adult, Older Adult)	Phase 1	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	201808043|CA209-9MW	September 14, 2018	October 14, 2021	September 14, 2023	May 22, 2018	null	September 19, 2018	National Cancer Institute (GU Malignancies Branch), Bethesda, Maryland, United States|Washington University School of Medicine, Saint Louis, Missouri, United States		https://ClinicalTrials.gov/show/NCT03532217
76	NCT03333616	Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors		Recruiting	No Results Available	Genitourinary Cancer|Adrenocortical Carcinoma|Non-urothelial Bladder|Non-urothelial Upper Tract|Penile Cancer|Non-adenocarcinoma Prostate Cancer|Refractory Germ-cell	Drug: Ipilimumab|Drug: Nivolumab	Objective Response Rate|Objective Response Rate for all rare GU tumor types|Duration of Response|Immune related objective response rate|Progression-Free Survival for the total cohort and by tumor cohort|Overall Survival for all patients and by tumor cohort|Safety and tolerability according to Common Terminology Criteria for Adverse Events (CTCAE).	Dana-Farber Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	57	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-423	December 28, 2017	May 31, 2021	May 31, 2025	November 7, 2017	null	September 21, 2018	University of California, San Diego Moores Cancer Center, La Jolla, California, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03333616
77	NCT01530984	Ipilimumab and GMCSF Immunotherapy for Prostate Cancer		Withdrawn	No Results Available	Prostate Cancer	Drug: Ipilimumab|Drug: GM-CSF	To assess for clinical activity by PSA response, of both single agent ipilimumab and the combination of GM-CSF and ipilimumab in chemotherapy-naïve patients with metastatic castrate resistant prostate cancer.|To evaluate the duration of PSA response and time to PSA progression. To quantify the frequency of immune toxicities. To evaluate T cell activation. To assess for clinical activity by objective response.	Lawrence Fong|Bristol-Myers Squibb|Sanofi|University of California, San Francisco	Male	18 Years and older   (Adult, Older Adult)	Phase 2	0	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CC# 12552	June 2015	December 2017	December 2018	February 10, 2012	null	October 5, 2015	University of California, San Francisco, California, United States		https://ClinicalTrials.gov/show/NCT01530984
78	NCT02259621	Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC	NA_00092076	Recruiting	No Results Available	Non-Small Cell Lung Cancer	Drug: Nivolumab|Drug: Ipilimumab	Safety|Feasibility|Pathologic Reponse|Radiographic Response	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	30	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J1414|NA_00092076	September 2014	January 2023	January 2023	October 8, 2014	null	October 5, 2018	Sibley Memorial Hospital, Washington, District of Columbia, United States|Johns Hopkins at Bayview Medical Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Memorial Sloan Kettering, New York, New York, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/21/NCT02259621/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT02259621
79	NCT02833233	A Study of Pre-Operative Treatment With Cryoablation and Immune Therapy in Early Stage Breast Cancer		Active, not recruiting	No Results Available	Breast Cancer	Procedure: Cryoablation|Drug: Ipilimumab|Drug: Nivolumab	Number of adverse events	Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb	Female	18 Years and older   (Adult, Older Adult)	Not Applicable	5	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-495	June 2016	June 2019	June 2019	July 14, 2016	null	July 3, 2018	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02833233
80	NCT02812524	Ipilimumab for Head and Neck Cancer Patients		Recruiting	No Results Available	Squamous Cell Carcinoma of the Head and Neck	Drug: Intratumoral Ipilimumab	Surgery delay|Feasibility of paired tissue sample acquisition|Acceptance of study	Providence Health & Services|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	18	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-042	November 18, 2016	July 2020	July 2021	June 24, 2016	null	August 29, 2018	Portland Providence Medical Center, Portland, Oregon, United States		https://ClinicalTrials.gov/show/NCT02812524
81	NCT03651271	Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer		Not yet recruiting	No Results Available	Advanced Metastatic Cancer	Biological: Nivolumab|Biological: Ipilimumab	Clinical benefit rate (CBR) of nivolumab with or without ipilimumab|Percentage of CD8 cells in on-treatment biopsies|Safety of nivolumab with or without ipilimumab measured by AEs based on CTCAE v5.0|Objective response rate (ORR) of nivolumab with or without ipilimumab in participants|The association of the percentage of CD8 cells in tumor samples with clinical outcomes	Parker Institute for Cancer Immunotherapy|Bristol-Myers Squibb|Cancer Research Institute, New York City	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PICI0025	October 17, 2018	September 14, 2020	September 14, 2022	August 29, 2018	null	October 22, 2018	M.D. Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03651271
82	NCT03158129	Study Of Induction Checkpoint Blockade For Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable For Surgical Resection		Recruiting	No Results Available	Non-Small Cell Lung Cancer	Drug: Nivolumab|Drug: Ipilimumab|Procedure: Thoracic Surgery	Major Pathologic Response (mPR)|Toxicity Assessed by the NCI CTCAE Version 4|Quantification of CD8+ TILs|Response Rates to Induction Treatment by RECIST version 1.1	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	66	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2016-0982|NCI-2018-01210	June 9, 2017	June 2021	June 2022	May 17, 2017	null	September 14, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03158129
83	NCT03650894	Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients		Not yet recruiting	No Results Available	Breast Neoplasm Female|Breast Cancer|Breast Carcinoma|Breast Tumor	Drug: Nivolumab|Drug: Ipilimumab|Drug: Bicalutamide	iRECIST Clinical Benefit Rate (the number of patients with objective response or ongoing stable disease at week 24 using iRECIST guidelines)|RECIST Clinical Benefit Rate (the number of patients who have a response according to RECIST criteria at week 12)	Providence Health & Services|Bristol-Myers Squibb|Memorial Sloan Kettering Cancer Center	Female	18 Years and older   (Adult, Older Adult)	Phase 2	138	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-8H3	October 2018	October 2022	October 2023	August 29, 2018	null	August 29, 2018	Providence Oncology & Hematology Care Clinic - Eastside, Portland, Oregon, United States		https://ClinicalTrials.gov/show/NCT03650894
84	NCT03406715	Combination Immunotherapy-Ipilimumab-Nivolumab-Dendritic Cell p53 Vac - Patients With Small Cell Lung Cancer (SCLC)		Recruiting	No Results Available	Small Cell Lung Cancer|Lung Cancer|Relapsed Small Cell Lung Cancer	Drug: Nivolumab|Drug: Ipilimumab|Biological: Dendritic Cell based p53 Vaccine	Disease Control Rate (DCR)|Progression Free Survival (PFS)|Overall Survival (OS)|Overall Response Rate (ORR)|Immune Response (IR)	H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|MultiVir, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 2	41	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-19163|CA209-9KN|MVIR-Adp53DC-001	March 29, 2018	April 2020	April 2021	January 23, 2018	null	September 18, 2018	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT03406715
85	NCT03416244	A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer	RAMONA	Recruiting	No Results Available	Esophageal Cancer|Oesophageal Cancer|Oesophageal Cancer Metastatic|Esophageal Cancer Metastatic|Esophageal Cancers NOS|Oesophageal Cancer Nos|GastroEsophageal Cancer|Gastrooesophageal Cancer	Drug: Nivolumab|Drug: Ipilimumab	Overall survival|Time to QoL deterioration|Progression free survival|Objective Response rate|Duration of response|Duration of treatment|Cumulative dose intensity|Quality of Life|Incidence of Treatment-Emergent Adverse Events	AIO-Studien-gGmbH|Bristol-Myers Squibb	All	65 Years and older   (Older Adult)	Phase 2	75	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AIO-STO-0117|2017-002056-86|CA209-9DD	February 21, 2018	September 2019	January 2021	January 31, 2018	null	March 23, 2018	Universitätsmedizin Mannheim, Heidelberg University, II. Medizinische Klinik, Mannheim, Germany		https://ClinicalTrials.gov/show/NCT03416244
86	NCT01998126	Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer		Completed	No Results Available	Non-small Cell Lung Cancer	Drug: Ipilimumab|Drug: Erlotinib|Drug: Crizotinib|Drug: Nivolumab	toxicity of ipilimumab and erlotinib in EGFR mutated patients|toxicity of ipilimumab and crizotinib in ALK mutated patients|toxicity of nivolumab and erlotinib in EGFR mutated patients|toxicity of nivolumab and crizotinib in ALK mutated patients|Response rate|Progression Free Survival (PFS)|Overall Survival|immune function pre and post immune therapy	University of Utah|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	14	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCI66705	December 2, 2013	May 9, 2017	March 29, 2018	November 28, 2013	null	April 2, 2018	Huntsman Cancer Institute, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT01998126
87	NCT02919683	Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity		Recruiting	No Results Available	Head and Neck Cancer	Drug: Nivolumab|Drug: Ipilimumab|Procedure: Standard of Care Surgery	Response rates to treatment|Pathological Response|Local failure Rate|Regional Failure Rate|Local Progression Free Survival|Regional Progression Free Survival|Disease Free Survival|Overall Survival|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0	Dana-Farber Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-284	November 2016	April 2020	April 2024	September 29, 2016	null	October 16, 2018	Dana Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT02919683
88	NCT03026140	Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity	NICHE	Recruiting	No Results Available	Colon Carcinoma	Drug: Nivolumab|Drug: Ipilimumab|Drug: Celecoxib 200mg	Incidence of adverse events during the treatment and follow-up (safety)|Immune activating capacity of short-term pre-operative immunotherapy|Relapse free survival	The Netherlands Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	N16NCI	March 29, 2017	June 2019	January 2020	January 20, 2017	null	August 2, 2018	Antoni van Leeuwenhoek, Amsterdam, Netherlands|OLVG, Amsterdam, Netherlands		https://ClinicalTrials.gov/show/NCT03026140
89	NCT03162731	Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer		Recruiting	No Results Available	Larynx|Lip, Oral Cavity and Pharynx	Biological: Nivolumab|Biological: Ipilimumab|Radiation: Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy|Radiation: Volume Modulated Arc Therapy	Incidence of adverse events assessed using Common Terminology Criteria for Adverse Events version 4.03	Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	24	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17P.082	May 11, 2017	November 2021	January 2022	May 22, 2017	null	October 9, 2018	Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03162731
90	NCT03285321	Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)		Recruiting	No Results Available	Non-small Cell Lung Cancer	Drug: Nivolumab|Drug: Ipilimumab	Progression Free Survival (PFS)|Overall Survival (OS)|Time to Metastatic Disease|Assess Adverse Events	Greg Durm, MD|Bristol-Myers Squibb|Big Ten Cancer Research Consortium	All	18 Years and older   (Adult, Older Adult)	Phase 2	108	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BTCRC-LUN16-081	September 15, 2017	September 30, 2021	September 30, 2022	September 18, 2017	null	August 15, 2018	University of Illinois Cancer Center, Chicago, Illinois, United States|Indiana University, Indianapolis, Indiana, United States|Johns Hopkins Sidney Kimmel Comprehensive, Baltimore, Maryland, United States|Karmanos Cancer Center (Wayne State University), Detroit, Michigan, United States|Michigan State University, Lansing, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States		https://ClinicalTrials.gov/show/NCT03285321
91	NCT03203473	Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)		Recruiting	No Results Available	Renal Cancer	Drug: Ipilimumab|Drug: Nivolumab	Number of subjects with persistent Partial Response (PR) or Complete Response (CR) at 1 year since nivolumab discontinuation (Arm A)|Number of subjects with Progressive Disease (PD) or Stable Disease (SD) that convert to PR or CR at 1 year upon the addition of ipilimumab to nivolumab (Arm B)|Progression Free Survival|Overall Survival|Salvage therapy-free interval|Immune related objective response rate (irORR)|Safety and tolerability according to Common Terminology Criteria for Adverse Events (CTCAE) version 4.	Dana-Farber Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	58	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	17-064	September 26, 2017	November 30, 2020	November 30, 2024	June 29, 2017	null	July 16, 2018	University of California, San Diego Moores Cancer Center, La Jolla, California, United States|University of Chicago Medical Center, Chicago, Illinois, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Lifespan Comprehensve Cancer Center, Providence, Rhode Island, United States|University of Utah, Huntsman Cancer Center, Salt Lake City, Utah, United States|Unviersity of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States		https://ClinicalTrials.gov/show/NCT03203473
92	NCT01658878	An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer	CheckMate040	Active, not recruiting	No Results Available	Hepatocellular Carcinoma	Biological: Nivolumab|Drug: Sorafenib|Drug: Ipilimumab|Drug: Cabozantinib	Safety of nivolumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Tolerability of nivolumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Objective response rate (ORR) for Expansion phase of nivolumab|ORR for Nivolumab vs Sorafenib Cohort|Safety of nivolumab plus ipilimumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Tolerability of nivolumab plus ipilimumab as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|ORR for Nivolumab plus Ipilimumab Combination Cohort|ORR for Child-Pugh B Cohort|Safety of nivolumab plus ipilimumab plus cabozantinib as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Tolerability of nivolumab plus ipilimumab plus cabozantinib as evaluated by incidence of adverse events (AEs), serious adverse events (SAEs), adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|ORR for Nivolumab plus Ipilimumab plus Cabozantinib Combination Cohort|Complete response (CR) Rate|Disease control rate (DCR)|Duration of response (DOR)|Time to response (TTR)|Time to progression (TTP)|TTP Rate|Progression free survival (PFS)|Overall survival (OS)|Overall survival rate (OSR)|PD-L1 expression|Maximum observed serum concentration (Cmax) of nivolumab|Time of maximum observed serum concentration (Tmax) of nivolumab|Area under the serum concentration time curve in the dosing interval AUC(TAU) of nivolumab|Serum concentration achieved at the end of dosing interval (trough concentration) (Ctrough) of nivolumab|Serum concentration achieved at the end of the infusion (Ceoinf) of nivolumab|Cmax at Cycle 3/ Cmax at Cycle 1 (AI_Cmax) of nivolumab|AUC(TAU) at Cycle 3/ AUC(TAU) at Cycle 1 (AI_AUC) of nivolumab|Effective T-Half of nivolumab	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	620	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-040|2012-001514-42	September 26, 2012	March 31, 2019	December 26, 2019	August 7, 2012	null	November 6, 2018	USC Norris Comprehensive Cancer Center, Los Angeles, California, United States|Georgetown University Medical Center Lombardi Cancer Center, Washington, District of Columbia, United States|Sacred Heart Medical Group, Pensacola, Florida, United States|Emory University, Atlanta, Georgia, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Univ Of Michigan, Ann Arbor, Michigan, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Saint Joseph's Regional Medical Center, Paterson, New Jersey, United States|Providence Portland Medical Center, Portland, Oregon, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|QEII Health Sciences Centre, Halifax, Nova Scotia, Canada|University Health Network - Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHUM, Montreal, Quebec, Canada|Local Institution, Angers, France|Local Institution, Creteil Cedex, France|Local Institution, Marseille Cedex 5, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris Cedex 13, France|Local Institution, Reims Cedex, France|Local Institution, Vandoeuvre les Nancy, France|Universitaetsklinikum Essen, Essen, Germany|Johann Wolfgang Goethe Universitaet, Frankfurt, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinik Heidelberg, Heidelberg, Germany|Local Institution, Hong Kong, Hong Kong|Azienda Ospedaliera Di Bologna S. Orsola-Malpighi, Bologna, Italy|A.O.U. Careggi, Firenze, Italy|Istituto Romagnolo Per Lo Studio E La Cura Dei Tumori, Meldola (FC), Italy|Istituto Europeo Di Oncologia, Milano, Italy|Istituto Nazionale Tumori, Napoli, Italy|I.O.V. Istituto Oncologico Veneto Ircss, Padova, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Local Institution, Kashiwa-shi, Chiba, Japan|Local Institution, Kurume-shi, Fukuoka, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Osaka-sayama-shi, Osaka, Japan|Local Institution, Saga, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, San Juan, Puerto Rico|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Clinica Universitaria De Navarra, Pamplona, Spain|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, Wirral, Merseyside, United Kingdom|Local Institution, Birmingham, WEST Midlands, United Kingdom|Local Institution, London, United Kingdom		https://ClinicalTrials.gov/show/NCT01658878
93	NCT02892734	Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer		Recruiting	No Results Available	HER2/Neu Negative|Recurrent Inflammatory Breast Carcinoma|Stage IV Breast Cancer|Stage IV Inflammatory Breast Carcinoma	Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab	Progression Free Survival (PFS)|Overall Response Rate (ORR)|Clinical Benefit Rate (CBR)|Overall survival|Incidence of Adverse Events	Northwestern University|Bristol-Myers Squibb|National Cancer Institute (NCI)	Female	18 Years and older   (Adult, Older Adult)	Phase 2	29	Other|Industry|NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 16B07|STU00203191|P30CA060553|NCI-2016-01038	September 5, 2017	April 2019	September 2020	September 8, 2016	null	September 11, 2017	Northwestern University, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT02892734
94	NCT03190265	Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer		Recruiting	No Results Available	Pancreatic Cancer	Drug: Cyclophosphamide|Drug: Nivolumab|Drug: Ipilimumab|Drug: GVAX Pancreas Vaccine|Drug: CRS-207	Objective response rate (ORR) using Response Evaluation Criteria for Solid Tumors (RECIST 1.1)|Number of participants experiencing study drug-related toxicities|Overall survival (OS)|Progression free survival (PFS)|Duration of response (DOR)|Time to progression (TTP)|Tumor marker kinetics (CA19-9)	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Aduro Biotech, Inc.|Bristol-Myers Squibb	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2	63	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J1790|IRB00137389	December 5, 2017	October 2019	October 2019	June 16, 2017	null	April 18, 2018	Johns Hopkins SKCCC, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03190265
95	NCT02983045	A Dose Escalation and Cohort Expansion Study of CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 Antibody (Nivolumab) or in Combination With Nivolumab and Anti-CTLA4 Antibody (Ipilimumab) in Patients With Select Advanced or Metastatic Solid Tumors	PIVOT-02	Recruiting	No Results Available	Melanoma|Renal Cell Carcinoma|Non Small Cell Lung Cancer|Urothelial Carcinoma|Triple Negative Breast Cancer	Drug: Combination of NKTR-214 + nivolumab|Drug: Combination of NKTR-214 + nivolumab + ipilimumab	Safety of NKTR-214 in combination with nivolumab as evaluated by incidence of drug-related Adverse Events (AEs), Serious Adverse Events (SAEs), and adverse events leading to discontinuation, deaths, and clinical laboratory test abnormalities|Safety of NKTR-214 in combination with nivolumab and ipilmumab as evaluated by incidence of drug-related AEs, SAEs, and adverse events leading to discontinuation, deaths, and clinical laboratory test abnormalities|Tolerability of NKTR-214 in combination with nivolumab as evaluated by incidence of Dose Limiting Toxicities (DLTs), drug-related AEs, SAEs, adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Tolerability of NKTR-214 in combination with nivolumab and ipilmumab as evaluated by incidence of Dose Limiting Toxicities (DLTs), drug-related AEs, SAEs, adverse events leading to discontinuation, deaths and clinical laboratory test abnormalities|Efficacy of NKTR-214 in combination with nivolumab as assessed by the Objective Response Rate (ORR) based on RECIST 1.1|Efficacy of NKTR-214 in combination with nivolumab and ipilmumab as assessed by the Objective Response Rate (ORR) based on RECIST 1.1|Overall Survival (OS)|Progression-Free Survival (PFS)	Nektar Therapeutics|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	480	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-214-02	October 2016	June 2020	June 2021	December 6, 2016	null	October 22, 2018	Local Institution - La Jolla, La Jolla, California, United States|Local Institution - Los Angeles, Los Angeles, California, United States|Local Institution- Palo Alto, Stanford, California, United States|Local Institution - Aurora, Aurora, Colorado, United States|Local Institution - New Haven, New Haven, Connecticut, United States|Local Institution - Gainesville, Gainesville, Florida, United States|Local Institution - Tampa, Tampa, Florida, United States|Local Institution - Atlanta, Atlanta, Georgia, United States|Local Institution - Maywood, Maywood, Illinois, United States|Local Institution - Indianapolis, Indianapolis, Indiana, United States|Local Institution - Kansas City, Kansas City, Kansas, United States|Local Institution - Boston, Boston, Massachusetts, United States|Local Institution - Detroit, Detroit, Michigan, United States|Local Institution - St. Louis, Saint Louis, Missouri, United States|Local Institution - Buffalo, Buffalo, New York, United States|Local Institution - New York 1, New York, New York, United States|Local Institution - New York 2, New York, New York, United States|Local Institution - Cleveland, Cleveland, Ohio, United States|Local Institution - Portland, Portland, Oregon, United States|Local Institution - Nashville, Nashville, Tennessee, United States|Local Institution - Houston, Houston, Texas, United States|Local Institution - Fairfax ISC, Fairfax, Virginia, United States|Local Institution - Fairfax VCS, Fairfax, Virginia, United States|Local Institution - Seattle, Seattle, Washington, United States|Local Institution - Edegem, Edegem, Belgium|Local Institution - Kortrijk, Kortrijk, Belgium|Local Institution - Leuven, Leuven, Belgium|Local Institution - Liège, Liège, Belgium|Local Institution - Wilrijk, Wilrijk, Belgium|Local Institution - Vancouver, Vancouver, British Columbia, Canada|Local Institution - Toronto SBH, Toronto, Ontario, Canada|Local Institution - Toronto PMH, Toronto, Ontario, Canada|Local Institution - Montreal, Montréal, Quebec, Canada|Local Institution - Montréal, Montréal, Quebec, Canada|Local Institution - Marseille LPC, Marseille, Brouches-duRhone, France|Local Institution - Saint-Herblain, Saint-Herblain, Loire-Atlantique, France|Local Institution - Lyon, Lyon, France|Local Institution - Marseille HN, Marseille Cedex 20, France|Local Institution - Villejuif Cedex, Villejuif, France|Local Institution - Milano FIIN, Milano, Italy|Local Institution - Milano 2, Milano, Italy|Local Institution - Napoli, Napoli, Italy|Local Institution - Roma, Roma, Italy|Local Institution - Siena, Siena, Italy|Local Institution - Buriasco (Turin), Turin, Italy|Local Institution - Brzozów, Brzozów, Poland|Local Institution - Gdynia, Gdynia, Poland|Local Institution - Kraków, Kraków, Poland|Local Institution - Otwock, Otwock, Poland|Local Institution - Poznań WCPT, Poznań, Poland|Local Institution - Poznań MPS, Poznań, Poland|Local Institution - Lodz, Łódź, Poland|Local Institution - Barcelona HQB, Barcelona, Spain|Local Institution - Barcelona HCB, Barcelona, Spain|Local Institution - Madrid HURCPO, Madrid, Spain|Local Institution - Madrid HU12, Madrid, Spain|Local Institution - Madrid CIOCC, Madrid, Spain|Local Institution - Pamplona, Pamplona, Spain|Local Institution - Sevilla, Sevilla, Spain|Local Institution - London, London, United Kingdom|Local Institution - Northwood, Northwood, United Kingdom|Local Institution - Withington, Withington, United Kingdom		https://ClinicalTrials.gov/show/NCT02983045
96	NCT01331525	The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer	ICE	Completed	No Results Available	Extensive Stage Small Cell Lung Cancer	Biological: Ipilimumab	To establish the progression free survival at 1 year in patients with extensive stage small cell lung cancer treated with ipilimumab, carboplatin and etoposide.|Assess tumour response and toxicity of ICE combination. Response measured by RECIST and immune related response criteria. Toxicity via physical exam, adverse event review, assessing signs and symptoms, quality of life assessment and blood testing.	University Hospital Southampton NHS Foundation Trust|Cancer Research UK|Institute of Cancer Research, United Kingdom|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	42	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	RHM CAN0739	June 2011	June 2015	June 2015	April 8, 2011	null	April 14, 2016	Royal Bournemouth Hospital, Bournemouth, United Kingdom|Leeds Teaching Hospitals NHS Foundation Trust, Leeds, United Kingdom|Barts and The London NHS Trust, London, United Kingdom|Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom|Weston Park Clinical Trials Centre, Sheffield, United Kingdom|Southampton University Hospitals NHS Trust, Southampton, United Kingdom|The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, United Kingdom		https://ClinicalTrials.gov/show/NCT01331525
97	NCT02763761	An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo		Withdrawn	No Results Available	Renal Cell Carcinoma|Melanoma|Lung Cancer	Drug: Infliximab + Prednisone|Drug: Methylprednisolone + Prednisone	Improvement in management of immune related grade 3 and 4 diarrhea as measured by proportion of responders to less than or equal to grade 1|Improvement in management of persistent grade 2 diarrhea as measured by proportion of responders to less than or equal to grade 1|Number of days to improvement to less than grade 1 diarrhea|Quality of life as measured by European Quality of Life-5 Dimensions Questionnaire (EQ-5D)|Number of hospitalizations|Duration of hospitalizations|Number of patients with adverse events (AEs)|Number of patients with AEs related to steroid use|Number of patients with Gastrointestinal (GI) specific AEs	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	0	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-601	August 16, 2016	March 31, 2017	March 31, 2017	May 5, 2016	null	October 8, 2018	University of California Los Angeles, Los Angeles, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|University of Louisville, Louisville, Kentucky, United States|University of Michigan, Ann Arbor, Michigan, United States|Atlantic Health System, Morristown, New Jersey, United States|Local Institution, Albuquerque, New Mexico, United States|NYU Langone Medical Center, New York, New York, United States|Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT02763761
98	NCT02113657	T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate Cancer		Active, not recruiting	No Results Available	Prostate Cancer	Drug: Ipilimumab	Impact of Ipilimumab on T Cell Responses to prostate cancer neoantigens in both primary tumor and metastatic sites in men with metastatic CRPC	M.D. Anderson Cancer Center|Bristol-Myers Squibb|Stand Up To Cancer|High Impact Clinical Research Support Program	Male	18 Years and older   (Adult, Older Adult)	Early Phase 1	30	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2013-0444|NCI-2014-01205|SUC2CR-AACR-DT10	August 20, 2014	August 2019	August 2020	April 14, 2014	null	November 14, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02113657
99	NCT03071406	Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma		Recruiting	No Results Available	Merkel Cell Carcinoma|Skin Cancer	Drug: Nivolumab|Drug: Ipilimumab|Radiation: Stereotactic Body Radiation Therapy (SBRT)	Overall Response Rate|Progression Free Survival (PFS)|Overall Survival (OS)	H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	50	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-18786|CA209-737	March 3, 2017	July 2023	July 2023	March 6, 2017	null	August 1, 2018	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT03071406
100	NCT03639714	A Study of a Personalized Neoantigen Cancer Vaccine		Not yet recruiting	No Results Available	Non Small Cell Lung Cancer|Colorectal Cancer|Gastroesophageal Adenocarcinoma|Urothelial Carcinoma	Biological: GRT-C901|Biological: GRT-R902|Biological: nivolumab|Biological: ipilimumab	Incidence of adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)|Objective Response Rate (ORR) in Phase 2 using RECIST v1.1|Identify the recommended Phase 2 dose (RP2D) of GRT-C901 and GRT-R902|Measure the immune response to neoantigens encoded by GRT-C901 and GRT-R902|Objective Response Rate (ORR) in Phase 1 using RECIST v1.1|Duration of response (DOR) using RECIST v1.1|Clinical benefit rate (using RECIST v1.1)|Progression-free survival (PFS)|Overall survival (OS)|Percentage of patients for whom vaccine is successfully manufactured and timeframe for vaccine manufacturing	Gritstone Oncology, Inc.|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	214	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GO-004	October 2018	July 2022	March 2023	August 21, 2018	null	October 23, 2018			https://ClinicalTrials.gov/show/NCT03639714
101	NCT03262779	Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.		Recruiting	No Results Available	Carcinoma, Non-Small-Cell Lung	Biological: combination nivolumab and ipilimumab	Objective response rate using RECIST v1.1 to nivolumab and ipilimumab when administered in combination to patients with pre-treated advanced NSCLC who have experienced primary resistance to anti-PD-1 axis therapy as their last line of systemic therapy.|Progression-free survival with nivolumab and ipilimumab when administered in combination to patients with pre- treated advanced NSCLC who have experienced primary resistance to anti-PD-1 axis therapy as their last line of systemic therapy|Overall survival (OS) with nivolumab and ipilimumab when administered in combination to patients with pre- treated advanced NSCLC who have experienced PRIMARY resistance to anti-PD-1 axis therapy as their last line of systemic therapy.|Objective response rate using irRC to nivolumab and ipilimumab when administered in combination to patients with pre-treated advanced NSCLC who have experienced primary resistance to anti-PD-1 axis therapy as their last line of systemic therapy.|Objective response rate in in advanced non-small cell lung cancer (NSCLC) with ACQUIRED resistance to anti-programmed death (PD)-1 axis therapy as their last line of systemic therapy.|Progression free survival by RECIST v1.1 with nivolumab and ipilimumab in patients with pre-treated advanced NSCLC who have experienced acquired resistance to anti-PD-1 axis therapy as their last line of systemic therapy.|Overall survival with nivolumab and ipilimumab in patients with pre-treated advanced NSCLC who have experienced ACQUIRED resistance to anti-PD-1 axis therapy as their last line of systemic therapy.|Safety of nivolumab and ipilimumab when administered in combination in patients with pre-treated advanced NSCLC who have experienced PRIMARY or ACQUIRED resistance to anti-PD-1 axis therapy as their last line of systemic therapy.|Feasibility of sequential biopsies (performed or not performed) in patients with pre-treated advanced NSCLC who have experienced PRIMARY or ACQUIRED resistance to anti-PD-1 axis therapy as their last line of systemic therapy,	Yale University|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	50	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2000020343	July 20, 2017	November 1, 2019	November 1, 2020	August 25, 2017	null	May 30, 2018	Yale Cancer Center, New Haven, Connecticut, United States		https://ClinicalTrials.gov/show/NCT03262779
102	NCT03219775	Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma	TITAN-TCC	Recruiting	No Results Available	Transitional Cell Carcinoma|Advanced Cancer|Metastatic Cancer	Biological: Nivolumab/Ipilimumab	Objective Response Rate (ORR)|Remission Rates (RR)|Time to Immunotherapy Resistance (TIR)|Time to Response (TTR)|Duration of Response (DOR)|Progression free survival (PFS)|Overall survival (OS)|Safety - Incidence of adverse events, serious adverse events, deaths and laboratory abnormalities|EORTC QLQ-C30|EQ-5D|EQ-5D VAS	AIO-Studien-gGmbH|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	250	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0416-ASG	July 6, 2017	December 2020	December 2020	July 18, 2017	null	April 27, 2018	Univ. Klinik für Innere Medizin, Graz, Austria|Ordensklinikum Linz - KH Barmherzige Schwestern, Linz, Austria|Universitätsklinikum Salzburg, Salzburg, Austria|Landesklinikum Wiener Neustadt, Wiener Neustadt, Austria|KH der Barmherzigen Brüder Wien, Wien, Austria|Universitätsklinikum Jena und Poliklinik für Urologie, Jena, Thüringen, Germany|Uniklinik der RWTH Aachen, Aachen, Germany|Klinikum Bayreuth, Bayreuth, Germany|Charite Universitätsklinikum Campus Benjamin Franklin, Berlin, Germany|Vivantes Klinikum Neukölln, Berlin, Germany|ATURO, Berlin, Germany|Uniklinik C.-G.-Dresden, Dresden, Germany|Urologicum Duisburg, Duisburg, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Helios Klinikum Erfurt, Erfurt, Germany|Universitätsklinikum Erlangen, Erlangen, Germany|Chirurgische Universitätsklinik Freiburg, Freiburg, Germany|Überörtliche Gemeinschaftspraxis für Urologie GbR, Fürth, Germany|Greifswald Universitätsklinikum, Greifswald, Germany|Universitätsklinikum Heidelberg Chirurgische Klinik Klinik für Urologie, Heidelberg, Germany|Marien Hospital, Herne, Germany|Studienzentrum Bayenthal, Köln, Germany|Universitätsklinikum Magdeburg, Magdeburg, Germany|UKGM Marburg, Marburg an der Lahn, Germany|Klinikum der Universität München - Großhadern, München, Germany|Universitätsklinikum Münster, Münster, Germany|Universtätsmedizin Rostock, Rostock, Germany|Universitätsklinikum Ulm, Ulm, Germany|Kliniken Nordoberpfalz AG, Klinikum Weiden, Weiden, Germany|Urologie Praxis am Wasserturm, Würselen, Germany		https://ClinicalTrials.gov/show/NCT03219775
103	NCT00094653	MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma		Completed	Has Results	Melanoma|Metastases	Drug: MDX-010 (anti-CTLA4) monoclonal antibody|Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine	Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone|Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 Monotherapy Versus gp100 Melanoma Peptide Vaccine Alone and MDX-010 in Combination With gp100 Melanoma Peptide Vaccine Versus MDX-010 Monotherapy|12-, 18-, and 24-Month Survival Rates|Progression Free Survival (PFS)|Percentage of Participants With Progression Free Survival (PFS) at Week 12 and Week 24|Time to Progression (TTP)|Best Overall Response (BOR): Complete Response (CR), Partial Response (PR), Stable Disease (SD), Progressed Disease (PD)|Determination of Best Overall Response Rate (BORR)|Time to Response|Duration of Response|Disease Control Rate (DCR)|Delayed Response (Response Beyond Week 24)|Change From Baseline in Health-Related Quality of Life (QOL) as Measured by the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC QLQ-C30) Instrument at Week 12|Percentage of Participants With On-Study Adverse Events (AEs) and AEs With an Outcome of Death|Percentage of Participants With Immune-Related Adverse Events (irAEs)|Percentage of Participants With Worst On-Study Hematological Abnormalities|Percentage of Participants With Worst On-Study Liver Abnormalities|Percentage of Participants With Worst On-Study Renal Abnormalities|Clinically Meaningful Changes in Vital Signs and Physical Examinations	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	1783	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment	MDX010-20|CA184-002	September 2004	August 2009	October 2009	October 22, 2004	June 23, 2011	July 11, 2011	Arizona Cancer Center, Tucson, Arizona, United States|University Medical Center, Tucson, Arizona, United States|City of Hope National Medical Center, Duarte, California, United States|San Diego Cancer Center, Encinitas, California, United States|La Jolla Hematology and Oncology Medical Group, La Jolla, California, United States|Scripps Cancer Center, La Jolla, California, United States|Moores UCSD Cancer Center, La Jolla, California, United States|Pacific Shores Medical Group, Long Beach, California, United States|Cancer Institute Medical Group, Inc, Los Angeles, California, United States|The Angeles Clinic and Research Institute, Los Angeles, California, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|North County Oncology Medical Clinical, Inc., Oceanside, California, United States|City of Hope Medical Group, Pasadena, California, United States|University of California, San Diego, San Diego, California, United States|St. Mary's Medical Center - Northern California Melanoma Center, San Francisco, California, United States|Cancer Institute Medical Group, Inc, Santa Monica, California, United States|San Diego Cancer Center, Vista, California, United States|Anschutz Cancer Pavilion, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|University of Colorado Health Sciences Center, Aurora, Colorado, United States|Rocky Mountain Cancer Centers, Boulder, Colorado, United States|Rocky Mountain Cancer Centers, Colorado Springs, Colorado, United States|Rocky Mountain Cancer Centers, Denver, Colorado, United States|University of Colorado Hospital, Denver, Colorado, United States|Rocky Mountain Cancer Centers, Lakewood, Colorado, United States|Rocky Mountain Cancer Centers, Littleton, Colorado, United States|Rocky Mountain Cancer Centers, Lone Tree, Colorado, United States|Rocky Mountain Cancer Centers, Longmont, Colorado, United States|Yale University School of Medicine - Oncology Outpatient Clinic, New Haven, Connecticut, United States|Mount Sinai Comprehensive Cancer Center at Aventura, Aventura, Florida, United States|Memorial Regional Cancer Center, Hollywood, Florida, United States|Shands Jacksonville, Jacksonville, Florida, United States|University of Florida/Jacksonville Faculty Clinic, Jacksonville, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Mount Sinai Medical Center, Miami Beach, Florida, United States|Jackson Memorial Hospital & Clinics, Miami, Florida, United States|University of Miami Hospital & Clinics, Miami, Florida, United States|M.D. Anderson Cancer Center Orlando, Orlando, Florida, United States|Palm Beach Cancer Institute, Palm Beach Gardens, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Palm Beach Cancer Institute, Wellington, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Emory University Hospital-Winship Cancer Institute, Atlanta, Georgia, United States|Cancer Care Specialists of Central IL, Decatur, Illinois, United States|Decatur Memorial Hospital, Decatur, Illinois, United States|Cancer Care Specialists of Central IL, Effingham, Illinois, United States|Cardinal Bernardin Cancer Center, Loyola Unv. Med. Ctr., Maywood, Illinois, United States|Center for Cancer Care at Goshen Health System, Goshen, Indiana, United States|Indiana Oncology Hematology Consultants North, Indianapolis, Indiana, United States|American Health Network of IN, LLC, Indianapolis, Indiana, United States|Indiana Oncology Hematology South, Indianapolis, Indiana, United States|Indiana Oncology Hematology Consutants of Noblesville, Noblesville, Indiana, United States|Central Baptist Hospital, Lexington, Kentucky, United States|James Graham Brown Cancer Center, Louisville, Kentucky, United States|Norton Hospital, Louisville, Kentucky, United States|University of Louisville Hospital, Louisville, Kentucky, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States|Franklin Square Hospital Center, Baltimore, Maryland, United States|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Lutherville, Maryland, United States|Beth Isreal Dec Medical Center, Boston, Massachusetts, United States|Brigham and Womens Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Henry Ford Medical Center, Dearborn, Michigan, United States|Henry Ford Hospital, Detroit, Michigan, United States|Henry Ford Medical Center- West Bloomfield, West Bloomfield, Michigan, United States|Humphrey Cancer Center, Coon Rapids, Minnesota, United States|Humphrey Cancer Center, Fridley, Minnesota, United States|Hubert H Humphrey Cancer Center, Robbinsdale, Minnesota, United States|Family Cancer Center, Olive Branch, Mississippi, United States|Ellis Fischel Cancer Center, Columbia, Missouri, United States|St. Joseph Oncology, Inc, St. Joseph, Missouri, United States|Barnes Jewish Hospital, St. Louis, Missouri, United States|Washington Unv. School of Med./ Siteman Cancer Center, St. Louis, Missouri, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|The Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Hematology-Oncology Associates of Northern NJ, PA, Morristown, New Jersey, United States|Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States|The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Overlook Oncology Center, Summit, New Jersey, United States|New Mexico Oncology Hematology Consultants, Ltd., Albuquerque, New Mexico, United States|Hematology-Oncology Associates of CNY, East Syracuse, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Columbia University Medical Center, Irving Center for Clinical Research, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|The Christ Hospital Cancer Center, Cincinnati, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|The Oregon Clinical, Portland, Oregon, United States|Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States|Thomas Jefferson University Hosptital, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Hillman Cancer Research Pavilion, Pittsburgh, Pennsylvania, United States|Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States|Cancer Centers of the Carolinas, Easley, South Carolina, United States|Cancer Centers of the Carolinas, Greenville, South Carolina, United States|Cancer Centers of the Carolinas, Seneca, South Carolina, United States|Cancer Centers of the Carolinas, Spartanburg, South Carolina, United States|Family Cancer Center, Bartlett, Tennessee, United States|Family Cancer Center, Collierville, Tennessee, United States|Family Cancer Center, Memphis, Tennessee, United States|The West Clinic, Memphis, Tennessee, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|Arlington Cancer Center, Arlington, Texas, United States|Center for Oncology Research and Treatment, Dallas, Texas, United States|Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas, United States|Center for Oncology Research and Treatment, Richardson, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|Fletcher Allen Health Care, Burlington, Vermont, United States|Hospital Municipal de Oncoligia Maria Curie, Ciudad de Buenos Aires, Buenos Aires, Argentina|Instituto Medico Platense, La Plata, Provincia de Buenos Aires, Argentina|Hospital Militar Central, Buenos Aires, Argentina|Instituto Medico Especializado Alexander Fleming, Buenos Aires, Argentina|Hospital Britanico de Buenos Aires, Ciudad de Buenos Aires, Argentina|Hospital Municipal de Oncologia Maria Curie, Ciudad de Buenos Aires, Argentina|Hospital General de Agudos Carlos G. Durand, Ciudad de Buenos Aires, Argentina|Instituto de Oncologia Angel H. Roffo, Ciudad de Buenos Aires, Argentina|Hospital Militar Central, Ciudad de Buenos Aires, Argentina|Instituto Alexander Fleming, Ciudad de Buenos Aires, Argentina|Hospital Privado de Cordoba S.A., Cordoba, Argentina|Hospital Privado Centro Medico de Cordoba S.A., Cordoba, Argentina|ISIS Clinica Especializada, Santa Fe, Argentina|ISIS Clinica Especializada, Santa Fe, Argentina|Institut Jules Bordet, Brussels, Belgium|Erasme Hospital, Free Universtiy of Brussels, Brussels, Belgium|Erasme Hospital, Brussels, Belgium|U.Z. Gent, Gent, Belgium|Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium|Cliniques Universitaires UCL de Mont-Godinne, Yvoir, Belgium|Hospital Araujo Jorge da Associacoa de Combate ao Cancer em Goias, Goiania, GO, Brazil|Pro Onco Centro Tratamento Oncologico, Londrina, PR, Brazil|Hospital Sao Lucas da PUCRS, Porto Alegre, RS, Brazil|Fundacao Pio XII - Hospital de Cancer de Barretos, Barretos, SP, Brazil|Fundacoa Hospital Amaral Carvalho, Jau, SP, Brazil|Santo Andre Diagnosticos aTratamentos, Santo Andre, SP, Brazil|Sociedade Beneficante de Sennores - Hospital Sino Libante, Sao Paulo, SP, Brazil|Hospital de Cancer de Barretos - Fundacao Pio XII, Barretos - SP, Brazil|Biocor - Hosp. de Doencas Cardiovasculares Ltda., Belo Horizonte - MG, Brazil|Hospital Araujo Jorge, Goiania - GO, Brazil|Pro Onco Centro Tratemento Oncologico, Londrina - PR, Brazil|Fund. SOAD / HC de Porto Alegre, Porto Alegre - RS, Brazil|Hospital Sao Lucas - PUCRS, Porto Alegre - RS, Brazil|Fundacao Central Sul-Americana para o Desenvolvimento de Drogas Anticancer-SOAD, Porto Alegre, Brazil|Santo Andre Diagnosticos e Tratamentos Ltda., Santo Andre-SP, Brazil|HC-FMUSP, Sao Paulo - SP, Brazil|Hospital Sirio Labanes, Sao Paulo-SP, Brazil|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|CancerCare Manitoba, Winnipeg, Manitoba, Canada|Dr. H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada|Cancer Centre of Southeastern Ontario at KGH, Kingston, Ontario, Canada|London Regional Cancer Program, London, Ontario, Canada|The Ottawa Hospital Regional Cancer Centre, Ottawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|Sir Mortimer B. Davis - Jewish General Hospital, Montreal, Quebec, Canada|Instituto Nacional del Cancer, Independencia, Santiago, Chile|Clinica Davila, Recoleta, Santiago, Chile|Clinica Renaca, Renaca, Vina Del Mar, Chile|Fundacion Arturo Lopez Perez, Santiago, Chile|Hospital Barros Luco, Santiago, Chile|Centre Oscar Lambret, Lille, France|Centre Leon Berard, Lyon, France|Hopital Sainte-Marguerite, Marseille, France|Hopital Saint-Eloi, Montpellier, France|Hotel Dieu, Nantes, France|Centre Antoine Lacassagne, Nice cedex 2, France|Hopital Saint-Louis, Paris, France|Centre Eugene Marquis, Rennes, France|Centre-Hospitalier Universitaire de Saint-Etienne, Saint-Etienne, France|Centre Alexis Vautrin, Vandoeuvre les Nancy, France|Institut Gustave Roussy (IGR), Villejuif, France|Klinik fur und Poliklinik fur Dermatologie, Venerologie und Allergologie, Hufelandstr. 55, Essen, Germany|Klinikum Augsburg, Augsburg, Germany|Charite Universitaets medizin Berlin, Berlin, Germany|Charite-Universitaetsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany|Universitaetsklinikum Dusseldorf, Duesseldorf, Germany|Universitaetsklinikum Erlangen, Erlangen, Germany|Universitaetsklinikum Essen, Essen, Germany|Universitaetsklinikum Heidelberg, Heidelburg, Germany|Klinikum der Friedrich-Schiller-Universitaet Jena, Jena, Germany|Klinikum Mannheim gGmbH, Mannheim, Germany|University of Mannheim, Mannheim, Germany|Klinikum Rechts der Isar / TU Muenchen, Muenchen, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Universitaetsklinikum Wuerzburg, Wuerzburg, Germany|National Institute of Oncology, Budapest, Hungary|University of Debrecen, Medical and Health Sciences Center, Debrecen, Hungary|Semmelweis Hospital, Miskolc, Hungary|University of Szeged, Albert Szent-Gyorgyi Medical and Pharmaceutical Center, Szeged, Hungary|Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands|Vrije Universiteit Medisch Centrum (VUMC), Amsterdam, Netherlands|Academisch Ziekenhuis Maastricht, Maastricht, Netherlands|Mary Potter Oncology Centre, Groenkloof, South Africa|GVI Oncology, Panorama, South Africa|Mary Potter Oncology Centre, Pretoria, South Africa|Sandton Onocology Medical Research, Sandton, South Africa|Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, Rue du Bugnon 46, Switzerland|Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, Switzerland|Dermatologische Klinik Universitatsspital Zurich, Zurich, Switzerland|St. Luke's Cancer Center, The Royal Surrey County Hospital, Guildford, Surry, United Kingdom|Velindre Hospital, Cardiff, United Kingdom|Ninewells Hospital, Dundee, United Kingdom|Christie Hospital, Manchester, United Kingdom|Nottingham City Hospital, Nottingham, United Kingdom|Churchill Hospital, Oxford, United Kingdom|Poole Hospital, Poole, United Kingdom|Weston Park Hospital, Sheffield, United Kingdom|Southampton General, Southampton, United Kingdom		https://ClinicalTrials.gov/show/NCT00094653
104	NCT00084656	Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma		Completed	No Results Available	Intraocular Melanoma|Melanoma (Skin)	Biological: ipilimumab|Biological: Tyrosinase/gp100/MART-1 Peptides	First part of study: To achieve at least a 40% immune-related adverse event rate defined by the induction of Grade 1, grade 2, or acceptable grade 3 drug-related immune-related adverse events|Second part of study: To determine the time to disease relapse and to determine the rate of acceptable immune-related Grade 1, grade 2, or acceptable grade 3 drug-related immune-related adverse events|Determine incidence of drug-related irAEs (1st & 2nd part) through clinical and laboratory assessment of immune-related adverse events|Determine time to disease relapse (1st part) through diagnostic imaging assessments, including brain MRI|Determine immunologic response (1st & 2nd part) through assay of peripheral blood samples|Evaluate toxicity profile (1st & 2nd part) through clinical and laboratory assessment of adverse events	Bristol-Myers Squibb|National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	Phase 2	75	Industry|NIH	Interventional	Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000365467|P30CA076292|P30CA014089|MCC-15241|MDX010-16|NCI-6446|CA184-016	May 2004	October 2009	null	June 11, 2004	null	April 26, 2010	H. Lee Moffitt Cancer Center and Research Institute at University of South Florida, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT00084656
105	NCT03083691	BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer		Enrolling by invitation	No Results Available	Carcinoma, Non-Small-Cell Lung|Carcinoma, Small Cell Lung	Drug: Nivolumab, Ipilimumab	Cohort 1: ORR after addition of ipilimumab to nivolumab treatment.|Cohort 2: ORR of the combination therapy nivolumab and ipilimumab.|Overall survival of nivolumab monotherapy/nivolumab + ipilimumab combination therapy|Progression-free survival of nivolumab monotherapy/nivolumab + ipilimumab combination therapy|Duration of response of nivolumab monotherapy/nivolumab + ipilimumab combination therapy|Incidence, severity and grading of adverse events (AEs) during nivolumab monotherapy/ nivolumab + ipilimumab combination therapy|Incidence, severity and grading of serious adverse events (SAEs) during nivolumab monotherapy/ nivolumab + ipilimumab combination therapy	Lung Cancer Group Cologne|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	106	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Uni-Koeln-2785|2016-003334-25	April 5, 2017	March 2019	August 2020	March 20, 2017	null	May 12, 2017	University Hospital of Cologne, Cologne, NRW, Germany		https://ClinicalTrials.gov/show/NCT03083691
106	NCT01804465	A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer		Recruiting	No Results Available	Prostate Cancer	Drug: SipT Treatment|Drug: Ipilimumab	Impact of the timing of ipilimumab administration on PAP/PA2024specific immune responses by SipT|Prostate Specific Antigen (PSA) Measurements (patient response to therapy)|Radiographic Clinical Responses|Modulation of Effector and Regulatory T Cells|Safety assessment of combining ipilimumab with SipT	University of California, San Francisco|M.D. Anderson Cancer Center|Bristol-Myers Squibb|Dendreon	Male	18 Years and older   (Adult, Older Adult)	Phase 2	54	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CC#12557	January 2014	December 2018	December 2019	March 5, 2013	null	November 24, 2017	University of California San Francisco, San Francisco, California, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT01804465
107	NCT03508570	Nivolumab With or Without Ipilimumab in Treating Participants With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis		Recruiting	No Results Available	Malignant Peritoneal Neoplasm|Malignant Retroperitoneal Neoplasm|Peritoneal Carcinomatosis|Recurrent Cervical Carcinoma|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Recurrent Uterine Corpus Carcinoma|Stage IV Cervical Cancer AJCC v8|Stage IV Fallopian Tube Cancer AJCC v8|Stage IV Ovarian Cancer AJCC v8|Stage IV Primary Peritoneal Cancer AJCC v8|Stage IV Uterine Corpus Cancer AJCC v8|Stage IVA Cervical Cancer AJCC v8|Stage IVA Fallopian Tube Cancer AJCC v8|Stage IVA Ovarian Cancer AJCC v8|Stage IVA Primary Peritoneal Cancer AJCC v8|Stage IVA Uterine Corpus Cancer AJCC v8|Stage IVB Cervical Cancer AJCC v8|Stage IVB Fallopian Tube Cancer AJCC v8|Stage IVB Ovarian Cancer AJCC v8|Stage IVB Primary Peritoneal Cancer AJCC v8|Stage IVB Uterine Corpus Cancer AJCC v8	Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Pharmacokinetic Study	Maximum tolerated dose (MTD)/recommended phase II dose (RP2D) of intraperitoneal (i.p.) nivolumab in combination with ipilimumab|PK Parameters|Clinical Benefit Rate	M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	48	Other|NIH|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-0264|NCI-2018-00282|P30CA016672	September 21, 2018	January 2020	January 2020	April 25, 2018	null	September 25, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03508570
108	NCT03146650	Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer		Recruiting	No Results Available	Major Salivary Gland Carcinoma|Minor Salivary Gland Carcinoma|Recurrent Salivary Gland Carcinoma|Stage IV Major Salivary Gland Carcinoma|Stage IVA Major Salivary Gland Carcinoma|Stage IVB Major Salivary Gland Carcinoma|Stage IVC Major Salivary Gland Carcinoma	Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab	Median PFS (median Progression-Free Survival)|PFS at 6 months|PFS at 12 months|Response Rate (RR)|Disease Control Rate (DCR)|Overall Survival (OS)|PFS (RECIST 1.1 criteria)|Overall Response Rate (ORR)|DCR (irRECIST)|PFS (irRECIST criteria)|OS (irRECIST)|Incidence of Adverse Events	Northwestern University|Bristol-Myers Squibb|National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	Phase 2	63	Other|Industry|NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NU 16N03|STU00204579|P30CA060553|NCI-2017-00406	May 19, 2017	July 2021	June 2022	May 10, 2017	null	August 14, 2018	Northwestern University, Chicago, Illinois, United States		https://ClinicalTrials.gov/show/NCT03146650
109	NCT03222076	Study Evaluating Nivolumab (Anti-PD-1 Antibody) Alone Versus Nivolumab Plus Ipilimumab (Anti-CTLA-4 Antibody) in Patients With Resectable and Potentially Resectable Hepatocellular Carcinoma (HCC) (CA209-956)		Recruiting	No Results Available	Malignant Neoplasms of Digestive Organs|Hepatocellular Carcinoma	Drug: Nivolumab|Drug: Ipilimumab	Safety of Nivolumab Alone or Nivolumab plus Ipilimumab in Participants with Hepatocellular Carcinoma (HCC) Determined by Adverse Events|Objective Response Rate (ORR)|Progression-free survival (PFS)|Conversion Rate to Surgery for Potentially Resectable Participants.	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	45	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-0097|NCI-2018-01106	September 28, 2017	September 2022	September 2022	July 19, 2017	null	November 5, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03222076
110	NCT03409198	Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer	ICON	Recruiting	No Results Available	Breast Cancer|Luminal B	Drug: Ipilimumab|Drug: Nivolumab|Drug: Pegylated liposomal doxorubicin|Drug: Cyclophosphamide	Toxicity: CTCAE v4.0|Progression-free survival (PFS)|Duration of Response (DR)|Overall Survival (OS)|Duration of Response (DR) in cross-over arm|Overall Suvival (OS) in cross-over arm|Toxicity, cross-over arm, CTCAE v4.0|Objective tumor Response Rate (ORR)|Durable tumor Response Rate (DRR)|Objective tumor Response Rate (ORR) in cross-over arm|Durable tumor Response Rate (DRR) in cross-over arm|Clinical Benefit Rate (CBR)|Clinical Benefit Rate (CBR) in cross-over arm|PD-L1 expression|Chalder Fatigue Questionnaire (FQ)|Pain intensity|EORTC QLQ-C15-PAL	Oslo University Hospital|Bristol-Myers Squibb|Helse Stavanger HF|Helse Sor-Ost|Sorlandet Hospital HF	All	18 Years and older   (Adult, Older Adult)	Phase 2	75	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ICON CA209-9FN	January 21, 2018	January 1, 2022	January 1, 2025	January 24, 2018	null	August 20, 2018	Soerlandet Hospital HF Kristiansand, Kristiansand, Norway|Oslo University Hospital, Oslo, Norway|Stavanger University Hospital, Stavanger, Norway		https://ClinicalTrials.gov/show/NCT03409198
111	NCT03283046	Study of Lenalidomide/Dexamethasone With Nivolumab and Ipilimumab in Patients With Newly Diagnosed Multiple Myeloma		Withdrawn	No Results Available	Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic|Multiple Myeloma	Drug: Nivolumab|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Ipilimumab	Maximum Tolerated Dose (MTD) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Adverse Events (AE) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Rate of Response of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Progression Free Survival (PFS) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Overall Survival of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Duration of Response (DOR) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma|Clinical Benefit Rate (CBR) of Nivolumab and Ipilimumab with Dexamethasone and Lenalidomide (NILd) in Participants with Newly Diagnosed Multiple Myeloma	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	0	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2016-0482	October 2017	October 2020	October 2020	September 14, 2017	null	September 20, 2017			https://ClinicalTrials.gov/show/NCT03283046
112	NCT03461952	Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)	NIMBLe	Recruiting	No Results Available	Advanced Solid Tumors	Drug: Nivolumab|Drug: Ipilimumab	Objective Response Rate by RECIST 1.1|Efficacy as measured by objective response rate|Duration of response|Number and severity of adverse events using CTCAE 5.0|Correlation between POLE or POLD1 mutations in tumor and POLE or POLD1 mutations in blood|To evaluate response by iRECIST	Canadian Cancer Trials Group|Cancer Research Institute, New York City|Bristol-Myers Squibb|Personal Genome Diagnostics	All	18 Years and older   (Adult, Older Adult)	Phase 2	100	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	I235|0001	August 28, 2018	May 2021	July 2022	March 12, 2018	null	November 14, 2018	Tom Baker Cancer Centre, Calgary, Alberta, Canada		https://ClinicalTrials.gov/show/NCT03461952
113	NCT02553642	Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260)		Recruiting	No Results Available	Bladder Cancer|Melanoma	Drug: Nivolumab|Drug: Nivolumab plus Ipilimumab	response rate|PD-L1 expression	Memorial Sloan Kettering Cancer Center|UConn Health|Bristol-Myers Squibb|Adaptive Biotechnologies|MedGenome	All	18 Years and older   (Adult, Older Adult)	Phase 2	70	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	15-126	September 14, 2015	September 2019	September 2019	September 17, 2015	null	August 16, 2018	University of Connecticut Health Center, Farmington, Connecticut, United States|Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02553642
114	NCT03442569	PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC		Recruiting	No Results Available	Colon Cancer	Drug: Panitumumab|Drug: Nivolumab|Drug: Ipilimumab	Overall Response Rate|Overall Response Rate per irRECIST|Length of Progression Free Survival|Length of Overall Survival|Duration of Response|Toxicity of Treatment	UNC Lineberger Comprehensive Cancer Center|Amgen|Bristol-Myers Squibb	All	18 Years to 120 Years   (Adult, Older Adult)	Phase 2	56	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LCCC1632	March 9, 2018	December 14, 2020	December 14, 2023	February 22, 2018	null	November 9, 2018	Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States|University of North Carolina at Chapel Hill Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03442569
115	NCT00362713	Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection		Completed	No Results Available	Urothelial Carcinoma	Drug: Ipilimumab	Safety of two dose levels of ipilimumab, given prior to surgery, in this patient population.|To evaluate anti-cancer immunological activity in blood and tissue samples compared to pre-treatment or control samples.	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	12	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-027	March 2007	October 2009	October 2009	August 10, 2006	null	September 30, 2016	The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00362713
116	NCT02350764	Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs		Recruiting	No Results Available	Advanced Stage Non-small Cell Lung Cancer	Drug: nivolumab|Drug: pilimumab	Best overall response rate (confirmed partial + complete response) will be assessed as part of this study. Tumor response will be assessed using RECIST 1.1)	Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	35	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	14-137	January 2015	January 2019	January 2019	January 30, 2015	null	January 30, 2018	Memorial Sloan Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02350764
117	NCT03409848	Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric Adenocarcinoma	INTEGA	Recruiting	No Results Available	Gastric Cancer|Esophageal Cancer|Adenocarcinoma Gastric|HER2 Positive Gastric Cancer|Metastatic Gastric Cancer|GastroEsophageal Cancer	Drug: Nivolumab|Drug: Ipilimumab	Overall Survival|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Progression Free Survival|Response Rate|Health related Quality of Life|Translational research tumor block|Translational research blood - immunoprofiling|Translational research blood - circulating Tumor cells (CTC)|Translational research blood - circulating Tumor DNA (ctDNA)|Central Imaging Review - ORR|Central Imaging Review - PFS	AIO-Studien-gGmbH|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	97	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AIO-STO-0217|2017-000624-10|CA209-99R	March 1, 2018	October 2021	January 2022	January 24, 2018	null	March 23, 2018	Universitätsklinikum Hamburg-Eppendorf Hubertus Wald Tumorzentrum - UCCH II. Medizinische Klinik und Poliklinik (Onkologie, Hämatologie, KMT mit Sektion Pneumologie), Hamburg, Germany		https://ClinicalTrials.gov/show/NCT03409848
118	NCT01592370	An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma		Recruiting	No Results Available	Non-Hodgkin's Lymphoma|Hodgkin Lymphoma|Multiple Myeloma	Biological: Nivolumab|Biological: Ipilimumab|Biological: Lirilumab|Biological: Daratumumab|Drug: Pomalidomide|Drug: Dexamethasone	Safety and tolerability of Nivolumab alone and in combination as measured by incidence of drug related adverse events (AEs), serious drug related AEs, dose-limiting toxicities, and laboratory test abnormalities|Maximum observed serum concentration (Cmax)|Serum concentration achieved at the end of dosing interval (trough concentration, all participants) [Cmin]|Time of maximum observed serum concentration (Tmax)|Area under the plasma concentration-time curve from time zero to the last time of the last quantifiable concentration [AUC(0-T)]|Area under the concentration-time curve in one dosing interval [AUC(TAU)]|Serum concentration achieved at the end of study drug infusion (Ceoinf)|Best Overall Response (BOR)|Objective Response Rate (ORR)|Duration of Objective Response|Progression Free Survival Rate (PFSR)|Modified Severity Weighted Assessment Tool (mSWAT) for patients with cutaneous T cell lymphoma|Immunogenicity as measured by the anti-drug antibody (ADA) status both at sample level and at patient level|Minimal Residual Disease (MRD) in patients with multiple myeloma receiving nivolumab in combination with daratumumab|PD-L1 expression	Bristol-Myers Squibb|Janssen, LP	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	375	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-039|2018-001030-17	June 27, 2012	June 14, 2020	June 15, 2020	May 7, 2012	null	November 20, 2018	Local Institution, Little Rock, Arkansas, United States|Local Institution, Fresno, California, United States|Local Institution, Long Beach, California, United States|Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States|University of Colorado Denver, Aurora, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Local Institution, Gainesville, Florida, United States|Local Institution, Miami, Florida, United States|Cancer Institute Of Florida, Orlando, Florida, United States|Local Institution, Tampa, Florida, United States|Local Institution, Atlanta, Georgia, United States|Local Institution, Skokie, Illinois, United States|Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States|Local Institution, Lafayette, Indiana, United States|University Of Kansas Medical Center, Kansas City, Kansas, United States|The Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Local Institution, Saint Louis, Missouri, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|John Theurer Cancer Center, Hackensack, New Jersey, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Local Institution, Cleveland, Ohio, United States|Local Institution, Columbus, Ohio, United States|Local Institution, Oklahoma City, Oklahoma, United States|OHSU Center for Hematologic Malignancies, Portland, Oregon, United States|Abramson Cancer Center, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Local Institution, Knoxville, Tennessee, United States|Local Institution, Murray, Utah, United States|Local Institution, Saint George, Utah, United States|Huntsman Cancer Institute At The Univ. Of Utah, Salt Lake City, Utah, United States|Local Institution, Salt Lake City, Utah, United States|Local Institution, Milwaukee, Wisconsin, United States|Local Institution, Impact Migration, Belgium|Local Institution, Sint-Niklaas, Belgium|Local Institution, Yvoir, Belgium|Local Institution, Nantes Cedex 1, France|Local Institution, Poitiers, France|Local Institution, Athens, Greece|Local Institution, Chorzow, Poland|Local Institution, Poznan, Poland|Local Institution, Warszawa, Poland|Local Institution, Wroclaw, Poland		https://ClinicalTrials.gov/show/NCT01592370
119	NCT03507699	Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer		Not yet recruiting	No Results Available	Colorectal Neoplasms Malignant|Liver Metastases	Radiation: Liver radiation therapy|Drug: Nivolumab Injection [Opdivo]|Drug: Ipilimumab Injection [Yervoy]|Drug: CMP-001	Number of participants with serious dose-limiting treatment-related adverse events as assessed by CTCAE v5.0|Response rate as assessed by RECIST v1.1|Progression free survival	Sheba Medical Center|Checkmate Pharmaceuticals|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	19	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	4465-17-SMC|CA209-991	July 1, 2018	May 31, 2020	May 31, 2021	April 25, 2018	null	April 25, 2018	Sheba Medical Center, Ramat Gan, Israel		https://ClinicalTrials.gov/show/NCT03507699
120	NCT01524991	First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma		Active, not recruiting	No Results Available	Urothelial Carcinoma	Drug: Gemcitabine|Drug: Cisplatin|Drug: Ipilimumab	One-Year Overall Survival|Progression-Free Survival|Best Overall Response Rate|Number of Adverse Events Experienced by Patients	Hoosier Cancer Research Network|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	36	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GU10-148	January 2012	July 15, 2017	December 2018	February 2, 2012	null	July 13, 2018	City of Hope: Duarte, Duarte, California, United States|IU Health Goshen Hospital, Goshen, Indiana, United States|Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana, United States|IU Health Central Indiana Cancer Centers, Indianapolis, Indiana, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States|Tisch Cancer Institute at Mount Sinai Medical Center, New York, New York, United States|Texas Oncology, PA, Dallas, Texas, United States|Virginia Oncology Associates, Norfolk, Virginia, United States		https://ClinicalTrials.gov/show/NCT01524991
121	NCT02107755	Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma		Active, not recruiting	No Results Available	Liver Metastases|Lung Metastases|Recurrent Melanoma|Stage IV Melanoma|Tumors Metastatic to Brain	Biological: ipilimumab|Radiation: stereotactic radiosurgery|Other: laboratory biomarker analysis	Rate of progression-free survival by mWHO criteria|Rate of progression-free survival by irRC criteria|Frequency of grade 3 and grade 4 toxicities according to Common Toxicity Criteria for Adverse Events (CTCAE) version 4|Frequency of objective response rate, defined as complete response + partial response, measured by computed tomography (CT) using mWHO criteria|Frequency of objective response rate, defined using irRC|Rate of local failure|Rate of overall survival	Allison Quick|Bristol-Myers Squibb|Ohio State University Comprehensive Cancer Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	8	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	OSU-12182|NCI-2014-00381	July 2014	June 2018	June 2018	April 8, 2014	null	November 22, 2017	Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States		https://ClinicalTrials.gov/show/NCT02107755
122	NCT02703623	A Dynamic Allocation Modular Sequential Trial of Approved and Promising Therapies in Men With Metastatic Castrate Resistant Prostate Cancer (DynaMO)		Recruiting	No Results Available	Prostate Cancer	Drug: Abiraterone acetate|Drug: Prednisone|Drug: ARN509|Drug: Ipilimumab|Drug: Cabazitaxel|Drug: Carboplatin	Overall Survival (OS) of Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) to the Bone Who Have a Satisfactory Decline in Serum Markers|Overall Survival (OS) of Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) to the Bone Who Have a Unsatisfactory Decline in Serum Markers|Toxicity Profile of Study Drug Combinations|Time to Treatment Failure (TTF) of Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) to the Bone Who Have a Satisfactory Decline in Serum Markers|Time to Treatment Failure (TTF) of Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) to the Bone Who Have a Unsatisfactory Decline in Serum Markers	M.D. Anderson Cancer Center|Bristol-Myers Squibb|Janssen, LP|Sanofi	Male	18 Years and older   (Adult, Older Adult)	Phase 2	265	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2014-0386|NCI-2016-00670	May 2016	May 2020	May 2020	March 9, 2016	null	November 26, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02703623
123	NCT02046733	Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease	STIMULI	Recruiting	No Results Available	Limited Stage Small Cell Lung Cancer|Small Cell Lung Cancer	Drug: Ipilimumab|Drug: Nivolumab	Overall survival|Progression-free survival determined by RECIST 1.1|Objective response|Time to treatment failure|Toxicity	European Thoracic Oncology Platform|Intergroupe Francophone de Cancerologie Thoracique|Ludwig Center for Cancer Research of Lausanne|Frontier Science Foundation, Hellas|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	260	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ETOP/IFCT 4-12|2013-002609-78|CA184-310|SNCTP000000166	July 28, 2014	October 2019	January 2022	January 28, 2014	null	February 20, 2018	University Hospital Gasthuisberg, KU Leuven, Leuven, Belgium|Avignon - Institut Sainte-Catherine, Avignon, France|Caen - Centre François Baclesse, Caen, France|CHU, Caen, France|Percy/Armées, Clamart, France|Clermont-Ferrand, Clermont-Ferrand, France|Créteil - CHI, Creteil, France|CHU, Grenoble, France|Centre Hospitalier Général, Le Mans, France|Hôpital Louis Pradel, Lyon, France|Lyon - Sud, Lyon, France|AP-HM, Marseille, France|Centre Hospitalier Universitaire de Montpellier, Montpellier, France|CH, Mulhouse, France|CRLCC, Nantes, France|Nice - CRLCC, Nice, France|Orléans - CH, Orléans, France|Paris - Bichat, Paris, France|Paris - Saint-Louis, Paris, France|Paris - Tenon, Paris, France|CHU, Rennes, France|Nouvel Hôpital Civil, Strasbourg, France|Suresnes, Suresnes, France|CHI, Toulon, France|CHU, Toulouse, France|CHU, Tours, France|Institut Gustave Roussy, Villejuif, France|Klinikum Esslingen, Esslingen, Germany|LungenClinic Grosshansdorf GmbH, Grosshansdorf, Germany|Klinikum München-Bogenhausen, München, Germany|Thoracic Oncology Centre Munich, München, Germany|Pius-Hospital Oldenburg, Oldenburg, Germany|Krankenhaus der Barmherzigen Brüder, Trier, Germany|Universitätsklinikum Tübingen, Tübingen, Germany|VUMC, Amsterdam, Netherlands|Maastro Clinic, Maastricht, Netherlands|Hospital General Universitario Alicante, Alicante, Spain|Hospital Universitario Cruces, Barakaldo, Spain|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|Clinico San Carlos, Madrid, Spain|Hospital Puerta de Hierro, Madrid, Spain|Hospital Universitario 12 Octubre, Madrid, Spain|Hospital Universitario Fundacion Jimenez Díaz, Madrid, Spain|Hospital Universitario Central De Asturias, Oviedo, Spain|Hospital Virgen De La Salud, Toledo, Spain|Hospital Clínico Universitario De Valencia, Valencia, Spain|Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland|University Hospital Zürich, Zürich, Switzerland|St James' University Hospital, Leeds, United Kingdom|Royal Marsden, London, United Kingdom|The Christie NHS Foundation Trust, Manchester, United Kingdom		https://ClinicalTrials.gov/show/NCT02046733
124	NCT03335540	An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment	ADVISE	Recruiting	No Results Available	Advanced Cancer	Biological: Nivolumab|Biological: Relatlimab|Biological: Cabiralizumab|Biological: Ipilimumab|Biological: anti-GITR|Drug: IDO1 Inhibitor|Biological: Lirilumab|Radiation: Radiation Therapy	Number of participants with qualified tumor biopsy specimen at baseline|Percent of change from baseline in histopathologic features|Percent of change from baseline in biomarker expression patterns|Number of Adverse Events (AEs)|Number of Serious Adverse Events (SAEs)|Number of Laboratory Abnormalities	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	50	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA028-001	March 13, 2018	January 30, 2020	January 31, 2022	November 7, 2017	null	October 4, 2018	The University of Chicago Medicine, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Local Institution, Baltimore, Maryland, United States		https://ClinicalTrials.gov/show/NCT03335540
125	NCT03138161	SAINT:Trabectedin, Ipilimumab and Nivolumab as First Line Treatment for Advanced Soft Tissue Sarcoma		Recruiting	No Results Available	Advanced Soft Tissue Sarcoma|Metastatic Soft Tissue Sarcoma	Drug: Trabectedin|Drug: Ipilimumab|Drug: Nivolumab	Maximum tolerated dose|Objective response rate (ORR), disease control rate (DCR)|Progression free survival (PFS), 6 month PFS rate|Overall survival (OS), 6 month OS rate	Sarcoma Oncology Research Center, LLC|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	45	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	SOC-1702	April 13, 2017	June 30, 2020	August 31, 2020	May 3, 2017	null	September 6, 2018	Sarcoma Oncology Research Center, Santa Monica, California, United States		https://ClinicalTrials.gov/show/NCT03138161
126	NCT01703507	Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma		Active, not recruiting	No Results Available	Recurrent Melanoma|Stage IV Melanoma|Tumors Metastatic to Brain	Drug: Ipilimumab|Radiation: Whole-Brain Radiation Therapy (WBRT)|Radiation: Stereotactic Radiosurgery (SRS)	Maximum tolerated dose (MTD) of ipilimumab|Rate of developing new brain metastases in each arm|Response of extracranial disease|Overall survival (OS) rate|Progression free survival (PFS) rate|Safety and tolerability in terms of adverse events and serious adverse events	Sidney Kimmel Cancer Center at Thomas Jefferson University|Bristol-Myers Squibb|Thomas Jefferson University	All	18 Years and older   (Adult, Older Adult)	Phase 1	24	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	12P.314|2012-43	November 9, 2012	May 20, 2015	November 2019	October 10, 2012	null	December 11, 2017	Ohio State University, Columbus, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT01703507
127	NCT03404960	Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy	Parpvax	Recruiting	No Results Available	Pancreatic Adenocarcinoma	Drug: Niraparib + Nivolumab|Drug: Niraparib + Ipilimumab	Progression-free survival|Proportion of tumors with homologous recombination deficits (HRD), in patients with stability or response to platinum therapy|Objective response rate (ORR) in those with measurable disease|Duration of response (DOR)|Overall survival (OS)|Safety and tolerability of this combination. Number of participants with treatment-related adverse events as assessed by CTCAE version 4.03|Correlation of HRDs with response to treatment with niraparib plus immune checkpoint blockade|Immune activation prior to treatment|Immune activation prior during treatment	University of Pennsylvania|Bristol-Myers Squibb|Tesaro, Inc.	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	84	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	828516	January 31, 2018	January 2021	June 2021	January 19, 2018	null	February 21, 2018	University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT03404960
128	NCT00732186	Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia		Withdrawn	No Results Available	Leukemia, Myeloid, Chronic	Biological: Ipilimumab	To evaluate the safety of ipilimumab in combination with dasatinib in CML patients with a loss of previously achieved major molecular response or a loss of previously achieved cytogenetic response to dasatinib|To evaluate the frequency of molecular response, complete cytogenetic response and an overall efficacy signal response rate|To explore the immunologic responses to combination therapy with ipilimumab and dasatinib|To explore whether molecular responses to combination therapy with ipilimumab and dasatinib correlate with immunologic responses	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	0	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-033	August 2009	February 2011	February 2011	August 11, 2008	null	February 17, 2016	The University Of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT00732186
129	NCT01913691	Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma		Withdrawn	No Results Available	Merkel Cell Carcinoma	Drug: Ipilimumab	Overall survival at 12 months with ipilimumab treatment.|Determine the best overall response rate, median survival, disease-specific survival, and progression free survival.|Determine median survival, disease-specific survival, and progressionfree survival	National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC)	All	18 Years to 100 Years   (Adult, Older Adult)	Phase 2	0	NIH	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	130173|13-C-0173	July 9, 2013	February 3, 2014	February 3, 2014	August 1, 2013	null	November 22, 2018			https://ClinicalTrials.gov/show/NCT01913691
130	NCT02626962	Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma	GEM1402	Active, not recruiting	No Results Available	Uveal Melanoma	Drug: ipilimumab|Drug: Nivolumab	Overall Survival at 12 months|Overall survival at 24 months.|Progression Free Survival (PFS)|Global PFS according to RECIST 1.1 criteria.|Objective Response Rate (ORR)|Disease Control Rate|Duration of response	Grupo Español Multidisciplinar de Melanoma|Bristol-Myers Squibb	All	18 Years to 99 Years   (Adult, Older Adult)	Phase 2	48	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GEM-1402|2015-004429-15	April 2016	February 2020	February 2020	December 10, 2015	null	November 27, 2018	Hospital Son Espases, Palma De Mallorca, Baleares, Spain|ICO Hospitalet, L'Hospitalet de Llobregat, Spain|H. Insular de Canarias, Las Palmas de Gran Canaria, Spain|Hospital La Paz, Madrid, Spain|H. U. Virgen de la Victoria, Malaga, Spain|Clínica Universidad de Navarra, Pamplona, Spain|H. U. Clínico de Santiago, Santiago, Spain|H.U. Virgen Macarena, Sevilla, Spain|Hospital General Universitario de Valencia, Valencia, Spain|H. C. U. de Valladolid, Valladolid, Spain		https://ClinicalTrials.gov/show/NCT02626962
131	NCT02899299	Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients	CheckMate743	Active, not recruiting	No Results Available	Mesothelioma	Biological: Nivolumab|Biological: Ipilimumab|Drug: Pemetrexed|Drug: Cisplatin|Drug: Carboplatin	Overall Survival (OS)|Progression Free Survival (PFS)|Objective Response Rate (ORR)|Disease Control Rate (DCR)|Composite correlation of PD-L1 expression level and efficacy	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	600	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-743|2016-001859-43	October 25, 2016	October 4, 2020	September 28, 2021	September 14, 2016	null	November 20, 2018	Ucsf, San Francisco, California, United States|Yale University, New Haven, Connecticut, United States|H. Lee Moffitt Cancer Center & Research Inst, Inc, Tampa, Florida, United States|University Of Chicago, Chicago, Illinois, United States|Univ Of Maryland Greenbaum Cancer Center, Baltimore, Maryland, United States|Barbara Ann Karmanos Cancer Center, Detroit, Michigan, United States|Cancer & Hematology Centers Of Western Michigan, Grand Rapids, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Allegheny Cancer Center, Jefferson Hills, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|West Virginia University, Morgantown, West Virginia, United States|Concord Repatriation General Hospital, Sydney, New South Wales, Australia|Local Institution, Birtinya, Queensland, Australia|Monash Medical Centre Clayton, Clayton, Victoria, Australia|Cabrini Hospital, Malvern, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Brussels, Belgium|Local Institution, Edegem, Belgium|Local Institution, Liege, Belgium|Local Institution, Sint-Niklaas, Belgium|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Local Institution, Beijing, Beijing, China|Local Institution, Haerbin, Heilongjiang, China|Local Institution, Changchun, Jilin, China|Local Institution, Shenyang, Liaoning, China|Local Institution, Hanghzou, Zhejiang, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Kunming, China|Local Institution, Shanghai, China|Administradora Del Country S.A. - Clinica Del Country, Bogota, Colombia|Hospital Universitario San Ignacio, Bogota, Colombia|Local Institution, Caen, France|Local Institution, Creteil, France|Local Institution, La Tronche, France|Local Institution, Lille Cedex, France|Local Institution, Marseille Cedex 20, France|Local Institution, Paris, France|Local Institution, Saint Herblain, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulon Cedex, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Coswig, Germany|Local Institution, Essen, Germany|Local Institution, Gottingen, Germany|Local Institution, Grosshansdorf, Germany|Local Institution, Hamburg, Germany|Local Institution, Heidelberg, Germany|Local Institution, Homburg an d. Saar, Germany|Local Institution, Immenhausen, Germany|Local Institution, Koeln, Germany|Local Institution, Moers, Germany|Sotiria General Hospital, Athens, Greece|Interbalkan European Medical Center, Thessaloniki, Greece|Centro Di Riferimento Oncologico, Aviano, Italy|Istituto Tumori Giovanni Paolo II, Bari, Italy|Aou Policlinico V. Emanuele Di Catania, Catania, Italy|Ospedale Policlinico San Martino, Genova, Italy|Aorn Dei Colli, Napoli, Italy|Ospedale S. Maria Delle Croci, Ravenna, Italy|Istituto Clinico Humanitas, Rozzano, Italy|Azienda Ospedaliera Universitaria Senese, Siena, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Fukuyama-shi, Hiroshima, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Amagasaki-shi, Hyogo, Japan|Local Institution, Nishinomiya-shi, Hyogo, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Natori-shi, Miyagi, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Kitaadachi-gun, Saitama, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Ube-shi, Yamaguchi, Japan|Local Institution, Osakasayama-city, Japan|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Mexico, Distrito Federal, Mexico|Medica Sur, Mexico, Distrito Federal, Mexico|Local Institution, Guadalajara, Jalisco, Mexico|Centro Estatal de Cancerologia, Chihuahua, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Bytom, Poland|Local Institution, Krakow, Poland|Local Institution, Warszawa, Poland|Local Institution, Bucharest, Romania|Local Institution, Bucuresti, Romania|Local Institution, Craiova, Romania|Local Institution, Romania, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, St.petersburg, Russian Federation|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Parktown, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Bern, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, Zurich, Switzerland|Local Institution, Diyarbak?r, Turkey|Local Institution, Istanbul, Turkey|Local Institution, Seyhan, Turkey|Local Institution, Truro, Cornwall, United Kingdom|Edinburgh Cancer Centre, Edinburgh, Midlothian, United Kingdom|Local Institution, Leicester, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Southampton, United Kingdom		https://ClinicalTrials.gov/show/NCT02899299
132	NCT02460068	A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis	NIBIT-M2	Recruiting	No Results Available	Brain Metastases	Drug: Fotemustine|Drug: Fotemustine and Ipilimumab|Drug: Ipilimumab and nivolumab	Overall Survival (OS)|safety (adverse events)|m-WHO and immune-related Disease Control Rate (DCR) in and outside the brain|Immune-related Progression-free Survival (irPFS)|m-WHO Progression-free Survival (irPFS)|Objective Response Rate (ORR)|Immune-related Objective Response Rate (irORR)|Time to Response (TTR)|Immune-related Time to Response (irTTR)|Duration of Response (DoR)|Immune-related Duration of Response (irDoR)|Brain progression-free survival (Brain-PFS)	Italian Network for Tumor Biotherapy Foundation|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	168	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NIBIT-M2	December 2012	January 2018	January 2020	June 2, 2015	null	June 2, 2015	Medical Oncology, Cancer Institute "Giovanni Paolo II", Bari, Italy|Medical Oncology, Pope Giovanni XXIII Hospital, Bergamo, Italy|National Institute for Cancer Research, Genoa, Italy|Immunotherapy and Somatic Cell Therapy Unit, Scientific Institute of Romagna, Meldola, Italy|Surgical Oncology, National Cancer Institute, Milan, Italy|European Institute of Oncology, Milan, Italy|Medical Oncology and Innovative Therapy, National Cancer Institute, Naples, Italy|esophageal and melanoma oncology, Istituto Oncologico Veneto, Padua, Italy|Medical Oncology, National Cancer Institute "Regina Elena", Rome, Italy|Medical Oncology and Immunotherapy Unit, University Hospital of Siena, Siena, Italy|S C Dermatology, A.O.U. City of Health and Science of Turin, Turin, Italy		https://ClinicalTrials.gov/show/NCT02460068
133	NCT02115139	GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases	GRAY-B	Completed	No Results Available	Melanoma|Brain Metastases	Drug: Ipilimumab	1-year survival rate|Progression-Free survival (PFS)|Intracranial PFS|Extracranial PFS|Overall survival|Response rate|Adverse Event rates|Rate of dose delays/reductions and treatment exposure.	Grupo Español Multidisciplinar de Melanoma|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	58	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GEM 1202|2013-001132-22	April 4, 2014	December 31, 2016	July 31, 2018	April 15, 2014	null	November 27, 2018	ICO Badalona, Badalona, Spain|H. Clinic de Barcelona, Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain|H. Insular de Canarias, Las Palmas de Gran Canaria, Spain|H. U. Gregorio Marañón, Madrid, Spain|Hospital Universitario 12 de Octubre, Madrid, Spain|Clínica Universidad de Navarra, Pamplona, Spain|H. Clínico de Santiago, Santiago de Compostela, Spain|H.U. Virgen Macarena, Sevilla, Spain|H. Virgen de la Salud, Toledo, Spain|H. General de Valencia, Valencia, Spain|Instituto Valenciano de Oncología, Valencia, Spain		https://ClinicalTrials.gov/show/NCT02115139
134	NCT03430791	Trial of Combination TTF(Optune), Nivolumab Plus/Minus Ipilimumab for Bevacizumab-naïve, Recurrent Glioblastoma		Recruiting	No Results Available	Recurrent Glioblastoma	Drug: Nivolumab 240 mg IV|Drug: Nivolumab 3 mg/kg|Drug: Ipilimumab 1 mg/kg|Device: NovoTTF200A (Optune)	Objective response rate according to modified iRANO criteria	Baptist Health South Florida|Bristol-Myers Squibb|NovoCure Ltd.	All	18 Years and older   (Adult, Older Adult)	Phase 2	60	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-ODI-002	November 5, 2018	August 2020	August 2021	February 13, 2018	null	November 15, 2018	Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States		https://ClinicalTrials.gov/show/NCT03430791
135	NCT02662725	Ipilimumab Combined With a Stereotactic Radiosurgery in Melanoma Patients With Brain Metastases	IPI+RTS	Completed	No Results Available	Melanoma|Brain Metastasis	Drug: IPILIMUMAB|Radiation: Stereotactic radiosurgery	Overall survival rate|All adverse events ≥ Grade 3 according to CTCAE, Version 4.0 criteria,|Overall response rate in brain|Global overall response rate|Disease control rate in brain|Global disease control rate|Progression free survival	University Hospital, Lille|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	73	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2011_48|2012-000852-32	September 2012	December 2015	December 2015	January 25, 2016	null	January 25, 2016	CHU de Bordeaux, Bordeaux, France|CHU de Caen, Caen, France|Hôpital Trousseau - CHRU de Tours, Chambray-lès-Tours, France|CHU - Hôpital d'Estaing, Clermont - Ferrand, France|Hôpital A. Michallon, La Tronche, France|CHRU, Hôpital Claude Huriez, Lille, France|AP-HM Hôpital de la Timone, Marseille, France|Hôpital Saint Eloi, Montpellier, France|CHU Nantes - Place Alexis Ricordeau, Nantes, France|Hôpital Archet 2, Nice, France|AP-HP, Hôpital Ambroise Paré, Paris, France|AP-HP, Hôpital Saint-Louis, Paris, France|CHU de Bordeaux, Pessac, France|Centre hospitalier Lyon Sud, Pierre-benite, France|Centre Régional de Lutte Contre le Cancer Eugène Marquis, Rennes, France|CHU de Toulouse - Larrey, Toulouse, France|Hôpitaux de Brabois, Vandoeuvre Les Nancy, France|Institut Gustave Roussy, Villejuif, France		https://ClinicalTrials.gov/show/NCT02662725
136	NCT01709162	Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma		Terminated	Has Results	Melanoma	Biological: Ipilimumab|Drug: Chemotherapy	Overall Survival|Disease Control Rate (DCR)|Best Overall Response Rate (BORR)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	31	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-243|2012-003291-38	March 2013	July 2014	July 2014	October 18, 2012	November 30, 2015	November 30, 2015	Birmingham Hematology & Oncology Associates Llc, Birmingham, Alabama, United States|Rocky Mountain Cancer Centers, Aurora, Colorado, United States|Investigative Clinical Research Of Indiana, Llc, Indianapolis, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Comprehensive Cancer Center Of Nevada, Las Vegas, Nevada, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Texas Oncology Sammons Cancer Center, Dallas, Texas, United States|Local Institution, Wien, Austria|Local Institution, Bordeaux, France|Local Institution, Nantes Cedex 1, France|Local Institution, Paris, France|Local Institution, Erfurt, Germany|Local Institution, Goettingen, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kiel, Germany|Local Institution, Koln, Germany|Local Institution, Siena, Italy		https://ClinicalTrials.gov/show/NCT01709162
137	NCT02939300	Ipilimumab and Nivolumab in Leptomeningeal Metastases		Recruiting	No Results Available	Leptomeningeal Carcinomatosis	Drug: Nivolumab|Drug: Ipilimumab	Overall Survival Rate|Intracranial Response Rate|Extracranial Response Rate|Leptomeningeal Disease Response Rate|Time To The First Occurrence Of Extracranial Disease Progression, Or Death From Any Cause|Time To The First Occurrence Of Intracranial Disease Progression, Or Death From Any Cause|Toxicity by CTCAE Criteria	Massachusetts General Hospital|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	18	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-136	January 2017	January 2020	January 2024	October 20, 2016	null	September 18, 2018	Massachusetts general Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT02939300
138	NCT01585194	Phase II Study of Nivolumab in Combination With Ipilimumab for Uveal Melanoma		Active, not recruiting	No Results Available	Melanoma|Uveal Melanoma	Drug: Nivolumab|Drug: Ipilimumab	Overall Response Rate|Progression-Free Survival	M.D. Anderson Cancer Center|Bristol-Myers Squibb|National Cancer Institute (NCI)	All	18 Years and older   (Adult, Older Adult)	Phase 2	67	Other|Industry|NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2011-0919|NCI-2012-00665|1R21CA208609-01	November 29, 2012	November 2019	November 2019	April 25, 2012	null	November 5, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT01585194
139	NCT03387761	Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy	NABUCCO	Recruiting	No Results Available	Urothelial Carcinoma	Drug: Ipilimumab|Drug: Nivolumab	Number of patients that have surgical resection <12 weeks after study start|Efficacy of immunotherapy, assessed by by the percentage of pathological complete response rate (pCR) at cystectomy|Differences in immune infiltrates in responders vs nonresponders|T-cell (dys)functionality as measured by comparing the transcriptome of tumor-specific T cells in intra-patient pre- and post therapy tissue|Explore whether radiomics-based predictive models can be established for immunotherapy responders vs non-responders	The Netherlands Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	24	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	N17NAB	January 15, 2018	June 1, 2020	December 1, 2020	January 2, 2018	null	November 14, 2018	Antoni van Leeuwenhoek ziekenhuis, Amsterdam, NH, Netherlands		https://ClinicalTrials.gov/show/NCT03387761
140	NCT00261365	Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)		Completed	No Results Available	Unresectable Stage III or IV Malignant Melanoma	Drug: Ipilimumab	Purpose - to identify candidate markers predictive of response and/or serious toxicity to MDX-101 (BMS-734016)|Safety & tumor response are important secondary objectives. Safety evaluated|Tumor response measured	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	80	Industry	Interventional	Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA184-004	November 2005	October 2007	October 2007	December 5, 2005	null	September 29, 2016	Comprehensive Cancer Center, Palm Springs, California, United States|The Angeles Clinic And Research Institution, Santa Monica, California, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Local Institution, Aarhus C, Denmark|Local Institution, Odense C, Denmark|Local Institution, Jerusalem, Israel|Local Institution, Bari, Italy|Local Institution, Forli', Italy|Local Institution, Ravenna, Italy|Local Institution, Rimini, Italy|Local Institution, Oslo, Norway|Local Institution, Lima, Peru|Local Institution, Lima, Peru|Local Institution, Gothenberg, Sweden|Local Institution, Stockholm, Sweden		https://ClinicalTrials.gov/show/NCT00261365
141	NCT00289627	A Single Arm Study of Ipilimumab Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma		Completed	No Results Available	Melanoma	Drug: ipilimumab (MDX-010, BMS-734016)	Evaluate BORR in patients with previously treated Stage III (unresectable) or Stage IV melanoma receiving ipilimumab.|estimate disease control rate|estimate progression free survival rate at Week 12|estimate PFS|estimate overall survival|estimate survival rate at one year|estimate duration of BOR|evaluate proportion of patients whose duration of response is >=24 weeks|estimate time to BOR|evaluate safety profile of ipilimumab during the induction and maintenance phases|evaluate health-related quality of life|obtain PK sample for population PK analysis	Bristol-Myers Squibb|Medarex	All	18 Years and older   (Adult, Older Adult)	Phase 2	155	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-008	April 2006	July 2007	July 2007	February 10, 2006	null	September 28, 2016	Little Rock, Arkansas, United States|San Francisco, California, United States|Santa Monica, California, United States|Chicago, Illinois, United States|Park Ridge, Illinois, United States|Goshen, Indiana, United States|Hazard, Kentucky, United States|Alburquerque, New Mexico, United States|New York, New York, United States|Portland, Oregon, United States|Greenville, South Carolina, United States|Knoxville, Tennessee, United States|Dallas, Texas, United States|Charlottesvillle, Virginia, United States|Local Institution, Salzburg, Austria|Local Institution, Wels, Austria|Local Institution, Wien, Austria|Local Institution, Turku, Finland|Local Institution, Genova, Italy|Local Institution, Meldola, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Siena, Italy|Local Institution, Torino, Italy|Local Institution, Oslo, Norway|Local Institution, Lodz, Poland|Local Institution, Poznan, Poland|Local Institution, Wroclaw, Poland|Local Institution, Barnaul, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Murmansk, Russian Federation|Local Institution, Ryazan, Russian Federation|Local Institution, Samara, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Stavropol, Russian Federation|Local Institution, Velikiy Novgorod, Russian Federation|Local Institution, Voronezh, Russian Federation|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Tenerife, Spain|Local Institution, Valencia, Spain|Local Institution, Goteborg, Sweden|Local Institution, Lund, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Uppsala, Sweden|Local Institution, Cherkassy, Ukraine|Local Institution, Dnipropetrovsk, Ukraine|Local Institution, Kiev, Ukraine|Local Institution, Lvov, Ukraine|Local Institution, Sumy, Ukraine|Local Institution, Uzhgorod, Ukraine		https://ClinicalTrials.gov/show/NCT00289627
142	NCT01701674	Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts		Active, not recruiting	Has Results	Metastatic Melanoma	Drug: Ipilimumab|Procedure: Tumor Infiltrating Lymphocytes (TIL)|Drug: Administration of Lymphodepletion|Drug: Cyclophosphamide as Part of Lymphodepletion|Drug: Fludarabine as Part of Lymphodepletion|Drug: High Dose IL-2|Biological: Adoptive Cell Therapy with TIL	Occurrence of Dose Limiting Toxicity (DLT) Events|Rate of Meeting Feasibility Requirements|Overall Response Rate (ORR)|Progression Free Survival (PFS)	H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb|Iovance Biotherapeutics, Inc.	All	18 Years and older   (Adult, Older Adult)	Not Applicable	13	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-17057|CA184-213	October 3, 2012	April 21, 2016	February 2019	October 5, 2012	May 2, 2017	September 17, 2018	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT01701674
143	NCT03620123	A Randomized Phase II Study on the Optimization of Immunotherapy in Squamous Carcinoma of the Head and Neck	OPTIM	Recruiting	No Results Available	Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck|Carcinoma, Squamous Cell of Head and Neck	Drug: Nivolumab and Ipilimumab|Drug: Docetaxel	objective response rate in all randomized subjects|overall survival [OS]|Progression-free survival [PFS]|Best overall response [BOR]|Duration of Response [DOR]|Health related quality of life|Health related quality of life: EORTC QLQ-H&N35|Health related quality of life: EQ-5D-5L|Toxicity/Safety according to CTC-AE-criteria	AIO-Studien-gGmbH|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	280	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	AIO-KHT-0117|2017-003349-14|CA209-998	July 16, 2018	July 2022	July 2023	August 8, 2018	null	August 8, 2018	Medical School Hannover (MHH) Dept. of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover, Germany		https://ClinicalTrials.gov/show/NCT03620123
144	NCT01696045	Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma		Terminated	Has Results	Malignant Melanoma	Biological: Ipilimumab	Overall Survival (OS) Rate at 1 Year|Percentage of Participants With Severe Immune-Mediated Adverse Reactions (imARs)|Disease Control Rate (DCR)|Progression Free Survival|Best Overall Response Rate (BORR)|Overall Survival Time	Bristol-Myers Squibb	All	12 Years to 17 Years   (Child)	Phase 2	14	Industry	Interventional	Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-178|2012-002249-39	November 12, 2012	July 31, 2016	July 31, 2016	September 28, 2012	August 1, 2017	August 29, 2017	Phoenix Children'S Hospital, Phoenix, Arizona, United States|Childrens Hospital Of La, Los Angeles, California, United States|Children'S Hospital Of Orange County, Orange, California, United States|Children'S Hospital Colorado, Aurora, Colorado, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|James Whitcomb Riley Hospital For Children, Indianapolis, Indiana, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University Of Pittsburgh Medical Center Cancer Center, Pittsburgh, Pennsylvania, United States|St. Jude Children'S Research Hospital, Memphis, Tennessee, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|Primary Children'S Medical Center, Salt Lake City, Utah, United States|University Of Utah, Salt Lake City, Utah, United States|Local Institution, Gent, Belgium|Local Institution, Copenhagen, Denmark|Local Institution, Lyon, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex 1, France|Local Institution, Villejuif Cedex, France|Local Institution, Dortmund, Germany|Local Institution, Erlangen, Germany|Local Institution, Hamburg, Germany|Local Institution, M?nster, Germany|Local Institution, Munster, Germany|Local Institution, Mexico, D.F, Mexico|Local Institution, Df, Distrito Federal, Mexico|Local Institution, Leon, Guanajato, Guanajuato, Mexico|Local Institution, Esplugues de Llobregat- Barcelona, Spain|Local Institution, Bristol, Avon, United Kingdom|Local Institution, Newcastle, Northumberland, United Kingdom|Local Institution, Sutton, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT01696045
145	NCT01515189	Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab		Completed	Has Results	Melanoma	Biological: Ipilimumab	Overall Survival (OS)|Progression Free Survival (PFS) by mWHO Criteria|Best Overall Response Rate (BORR) by mWHO Criteria|Disease Control Rate (DCR) by mWHO Criteria|Duration of Response (DOR) by mWHO Criteria|Duration of Stable Disease by mWHO Criteria|Rate of Overall Survival|Overall Survival of Participants With Brain Metastases at Baseline	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	831	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA184-169|2011-004029-28	February 17, 2012	February 6, 2016	August 17, 2017	January 24, 2012	March 24, 2017	September 13, 2018	The Angeles Clinic And Research Institute, Los Angeles, California, United States|University Of California Los Angeles, Los Angeles, California, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|Oncology Specialists, S.C., Park Ridge, Illinois, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Providence Portland Medical Center, Portland, Oregon, United States|St. Luke's Cancer Center - Anderson Campus, Easton, Pennsylvania, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, San Miguel De Tucuman, Tucuman, Argentina|Fundacion Cidea, Buenos Aires, Argentina|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Coffs Harbour, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Linz, Austria|Local Institution, Vienna, Austria|Local Institution, Bruxelles, Belgium|Local Institution, Leuven, Belgium|Local Institution, Edmonton, Alberta, Canada|Local Institution, Halfax, Nova Scotia, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Brno, Czechia|Local Institution, Olomouc, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Aarhus, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense, Denmark|Local Institution, Bordeaux, France|Local Institution, Dijon Cedex, France|Local Institution, Grenoble, France|Local Institution, Lille, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex 1, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Reims Cedex, France|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Local Institution, Buxtehude, Germany|Local Institution, Essen, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kiel, Germany|Local Institution, Mainz, Germany|Local Institution, Munich, Germany|Local Institution, Tubingen, Germany|Local Institution, Budapest, Hungary|Local Institution, Kaposvar, Hungary|Local Institution, Szeged, Hungary|Local Institution, Jerusalem, Israel|Local Institution, Meldola (fc), Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Leon, Guanajato, Guanajuato, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Leiden, Netherlands|Local Institution, Bergen, Norway|Local Institution, Oslo, Norway|Local Institution, Gdansk, Poland|Local Institution, Poznan, Poland|Local Institution, Warszawa, Poland|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, George, Western CAPE, South Africa|Local Institution, Rondebosch, Western CAPE, South Africa|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Navarra, Spain|Instituto Valenciano De Oncologia, Valencia, Spain|Local Institution, Valencia, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Lund, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Umea, Sweden|Local Institution, Lausanne, Switzerland|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Glasgow, Scotland, Strathclyde, United Kingdom|Local Institution, London, Surrey, United Kingdom|Local Institution, Swansea, United Kingdom		https://ClinicalTrials.gov/show/NCT01515189
146	NCT02320058	An Investigational Immuno-therapy Study to Evaluate Safety and Effectiveness in Patients With Melanoma That Has Spread to the Brain, Treated With Nivolumab in Combination With Ipilimumab, Followed by Nivolumab by Itself	CheckMate204	Active, not recruiting	No Results Available	Melanoma	Drug: Ipilimumab|Drug: Nivolumab	Intracranial Clinical Benefit Rate (CBR)|Extracranial Clinical Benefit Rate|Overall Survival (OS)|Number of adverse events (AEs)|Number of serious adverse events (SAEs)|Number AEs leading to death|Number of clinically significant abnormalities in general laboratory tests in combination with Ipilimumab and Nivolumab|Objective response rate (ORR)|Progression free survival (PFS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	119	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-204	January 5, 2015	November 3, 2022	November 4, 2022	December 19, 2014	null	May 22, 2018	City of Hope, Duarte, California, United States|Angeles Clinic and Research Institute, Los Angeles, California, United States|UCLA Medical Hematology and Oncology, Los Angeles, California, United States|Stanford University, Palo Alto, California, United States|The California Pacific Medical Research Institute, San Francisco, California, United States|UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|University of Colorado Cancer Center, Aurora, Colorado, United States|Washington Cancer Inst at MedStar Washington Hospital Ctr, Washington, District of Columbia, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Mount Sinai Medical Center, Aventura, Florida, United States|H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States|Winship Cancer Institute, Emory University, Atlanta, Georgia, United States|Loyola University Medical Center, Chicago, Illinois, United States|University of Chicago, Chicago, Illinois, United States|Weinberg Cancer Institute At Franklin Square, Baltimore, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Faber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|NYU Langone Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Case School of Medicineuniversity Hospitals of Cleveland, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|St Luke's Health Network, Easton, Pennsylvania, United States|Abramson Cancer Center of The University of Pennsylvania, Philadelphia, Pennsylvania, United States|University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah, United States|Inova Melanoma and Skin Cancer Center, Fairfax, Virginia, United States		https://ClinicalTrials.gov/show/NCT02320058
147	NCT01990859	Phase 2 Study of Ipilimumab in Japanese Advanced Melanoma Patients		Completed	Has Results	Melanoma	Biological: Ipilimumab	Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation of Study Drug, Related AEs, Immune-related AEs (IrAEs) at Primary Endpoint - All Treated Participants|Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation of Study Drug, Related AEs, Immune-related AEs (IrAEs) - All Treated Participants|Number of Participants Who Died - All Treated Participants|Number of Participants With Hematology Laboratory Abnormalities|Number of Participants With Liver Function Laboratory Abnormalities|Number of Participants With Renal Laboratory Abnormalities|Number of Participants With Complete Response, Partial Response, Stable Disease, or Progressive Disease as the Best Overall Response|Percent of Participants With Best Overall Response (BOR) of Complete Response or Partial Response	Bristol-Myers Squibb	All	20 Years and older   (Adult, Older Adult)	Phase 2	20	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-396	December 2013	May 2014	February 2015	November 25, 2013	May 21, 2015	March 14, 2016	Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Matsumoto-shi, Nagano, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Chuo-shi, Yamanashi, Japan		https://ClinicalTrials.gov/show/NCT01990859
148	NCT00920907	Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma		Completed	Has Results	Advanced Melanoma	Biological: Ipilimumab	Maximum Observed Serum Concentration (Cmax) of Ipilimumab Manufactured by Process C Relative to the Cmax of Ipilimumab Manufactured by Process B - Evaluable Pharmacokinetic Population|Area Under the Serum Concentration-time Curve (AUC) From Time Zero to Day 21, AUC(0-21d), of Ipilimumab Manufactured by Process C Relative to the AUC(0-21d) of Ipilimumab Manufactured by Process B - Evaluable Pharmacokinetic Population|Time of Maximum Observed Serum Concentration (Tmax) of Ipilimumab Manufactured by Process C Relative to the Tmax of Ipilimumab Manufactured by Process B - Evaluable Pharmacokinetic Population|Terminal Elimination Half Life (T-HALF) of Ipilimumab Manufactured by Process C Relative to the T-HALF of Ipilimumab Manufactured by Process B - Evaluable Pharmacokinetic Population|Clearance (CLT) of Ipilimumab Manufactured by Process C Relative to the CLT of Ipilimumab Manufactured by Process B - Evaluable Pharmacokinetic Population|Volume of Distribution at Steady State (Vss) of Ipilimumab Manufactured by Process C Relative to the Vss of Ipilimumab Manufactured by Process B - Evaluable Pharmacokinetic Population|Best Overall Tumor Response Per Investigator Based on Modified World Health Organization (mWHO) Criteria - All Randomized Participants|Best Overall Tumor Response Per Investigator Based on Immune-related (ir) Response Criteria (RC) - All Randomized Participants|Median Overall Survival Following First Ipilimumab Dose - All Treated Participants|Model Estimates of Mean Absolute Lymphocyte Count at Each Nominal Ipilimumab Induction Dose and at End of the Induction Dosing Period|Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, and AEs Leading to Discontinuation|Number of Participants Who Developed Antibodies and Neutralizing Antibodies|Mean Change From Baseline in Sitting Systolic and Diastolic Blood Pressure - All Treated Participants up to Data Cutoff|Mean Change From Baseline in Sitting Pulse Rate - All Treated Participants up to Data Cutoff|Number of Participants With 2-Grade or Greater Shift From Baseline (Worsening) in Hematology Laboratory Safety Tests - All Treated Participants|Number of Participants With 2-Grade or Greater Shift From Baseline (Worsening) in Chemistry Laboratory Safety Tests (Non-electrolyte) - All Treated Participants|Number of Participants With 2-Grade or Greater Shift From Baseline (Worsening) in Electrolyte Laboratory Safety Tests - All Treated Participants	Bristol-Myers Squibb|Medarex	All	18 Years and older   (Adult, Older Adult)	Phase 1	99	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-087	August 2009	April 2010	October 2012	June 15, 2009	March 6, 2014	June 20, 2014	The Angeles Clinic & Research Inst., Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|H Lee Moffitt Cancer Center, Tampa, Florida, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Carolinas Medical Center, Charlotte, North Carolina, United States|St Luke'S Hospital And Health Network, Bethlehem, Pennsylvania, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT00920907
149	NCT01783938	Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)		Active, not recruiting	Has Results	Advanced or Metastatic Melanoma	Biological: Nivolumab|Biological: Ipilimumab	Percentage of Participants With Treatment-related Grade 3-5 Adverse Events (AEs) During the Induction Periods|Investigator-assessed Response Rate at Week 25|Investigator-assessed Duration of Response (DOR)|Investigator-assessed Rate of Progression	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	177	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-064	April 17, 2013	April 3, 2015	October 18, 2019	February 5, 2013	April 11, 2016	August 2, 2018	H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, Indiana, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|University Of Pennsylvania, Philadelphia, Pennsylvania, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|University Of Virginia Health System, Charlottesville, Virginia, United States		https://ClinicalTrials.gov/show/NCT01783938
150	NCT01673854	Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma		Completed	Has Results	Melanoma	Drug: Ipilimumab|Biological: Vemurafenib	Percentage of Participants Who Received Ipilimumab and Who Had Grade 3-4 Drug-related Skin Adverse Events (AEs)|Percentage of Participants Who Received Ipilimumab and Who Had Grade 3-4 Drug-related Gastrointestinal Adverse Events (AEs)|Percentage of Participants Who Received Ipilimumab and Who Had Grade 3-4 Drug-related Hepatobiliary Adverse Events	Bristol-Myers Squibb	All	Child, Adult, Older Adult	Phase 2	70	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-240|2012‐002054‐24	September 13, 2012	July 25, 2014	May 12, 2015	August 28, 2012	October 19, 2015	July 24, 2018	Beverly Hills Cancer Center, Beverly Hills, California, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|University Of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Mount Sinai School Of Medicine, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Dumc, Durham, North Carolina, United States|University Hospitals Of Cleveland, Cleveland, Ohio, United States|University Hospitals, Cleveland, Ohio, United States		https://ClinicalTrials.gov/show/NCT01673854
151	NCT02545075	A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine		Active, not recruiting	No Results Available	Melanoma	Drug: Ipilimumab|Drug: Dacarbazine	Overall survival|Survival Rates|Progression Free Survival|Duration of response|Disease control rate|Best Overall Response rate|Duration of stable disease	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	180	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-248	October 31, 2015	December 31, 2018	November 5, 2019	September 9, 2015	null	February 19, 2018	Local Institution, Nanjing, Jiangsu, China|Local Institution, Changchun, Jilin, China|Local Institution, Xi'an, Shanxi, China|Local Institution, Tianjing, Tianjin, China|Local Institution, Hanghzou, Zhejiang, China|Local Institution, Beijing, China|Local Institution, Kunming, China|Local Institution, Shanghai, China		https://ClinicalTrials.gov/show/NCT02545075
152	NCT00729950	Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma		Completed	No Results Available	Malignant Melanoma	Biological: MDX-010	To determine the safety and pharmacokinetic profile of single and multiple doses of MDX-010.|Determine the clinical activity profile of single and multiple doses of MDX-010	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	92	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MDX010-15|CA184-001	July 2003	October 2005	June 2007	August 8, 2008	null	April 26, 2010	Arizona Cancer Center, Tucson, Arizona, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Piedmont Oncology Specialists, Charlotte, North Carolina, United States|Providence Portland Medical Center, Portland, Oregon, United States		https://ClinicalTrials.gov/show/NCT00729950
153	NCT01927419	Study of Nivolumab (BMS-936558) Plus Ipilimumab Compared With Ipilimumab Alone in the Treatment of Previously Untreated, Unresectable, or Metastatic Melanoma	CheckMate 069	Active, not recruiting	Has Results	Unresectable Melanoma|Metastatic Melanoma	Drug: Nivolumab|Drug: Ipilimumab|Drug: Placebo	Percentage of Participants With Investigator-assessed Objective Response in the Randomized, BRAF Wild-type Population|Percentage of Participants With Investigator-assessed Objective Response in the Randomized Population|Investigator-assessed Progression-free Survival (PFS) in All Populations|Percentage of BRAF Mutation-positive Participants With Investigator-assessed Objective Response|Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Overall Quality of Life (QOL) Score	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	179	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA209-069|2013-002018-11	August 21, 2013	July 24, 2014	February 6, 2019	August 22, 2013	February 8, 2016	April 9, 2018	San Francisco Oncology Associates, San Francisco, California, United States|Orlando Health Inc, Orlando, Florida, United States|University Of Louisville Medical Center, Inc., Dba, Louisville, Kentucky, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|University Of New Mexico Cancer Center, Albuquerque, New Mexico, United States|NYU Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Duke University Medical Center, Durham, North Carolina, United States|The Christ Hospital, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|St. Luke's Hospital, Easton, Pennsylvania, United States|GHS Cancer Institute, Greenville, South Carolina, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University Of Wisconsin Paul P Carbone Comprehensive Ca Ctr, Madison, Wisconsin, United States|Local Institution, Toulouse, France|Local Institution, Villejuif, France		https://ClinicalTrials.gov/show/NCT01927419
154	NCT01400451	Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)		Terminated	Has Results	Melanoma	Drug: Ipilimumab (BMS-734016)|Drug: Vemurafenib	During the Lead In Period: Number of Participants With Adverse Events (AEs), AEs Leading to Drug Discontinuation, Serious Adverse Events (SAEs), and Deaths in Participants Treated With Vemurafenib Alone|During the Combination Treatment Period: Number of Participants With Adverse Events (AEs), AEs Leading to Drug Discontinuation, Serious Adverse Events (SAEs), and Deaths in Participants Treated With Concurrent Ipilimumab and Vemurafenib|Number of Participants With Hepatic Dose Limiting Toxicities (DLT) in Participants Treated With Concurrent Ipilimumab and Vemurafenib	Bristol-Myers Squibb|Roche-Genentech	All	18 Years and older   (Adult, Older Adult)	Phase 1	18	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-161 ST|2011-000906-22	November 2011	April 2013	December 2013	July 22, 2011	May 19, 2014	January 1, 2015	University Of California Los Angeles, Los Angeles, California, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Dana Farber Cancer Inst, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT01400451
155	NCT00324155	Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma		Completed	Has Results	Melanoma	Drug: Ipilimumab|Drug: Placebo|Drug: Dacarbazine	Overall Survival (OS)|Survival Rate at 1 Year, 18 Months, 2 Years, and 3 Years|Disease Control Rate (DCR)|Median Number of Months of Progression-free Survival (PFS)|Progression-free Survival (PFS) Rate Truncated at Week 12|Best Overall Response Rate (BORR)|Duration of Response (DOR): Randomized Participants With Response of Complete Response (CR) or Partial Response (PR)|Time to Response: All Randomized Participants With Response to Treatment|Duration of Stable Disease (SD): Randomized Participants With Stable Disease|Percentage of Participants With Brain Metastasis-Free Survival at Time of Data Cutoff|Number of Participants With Adverse Events (AEs), Drug-related AEs, AEs Leading to Discontinuation, Serious Adverse Events (SAEs), Drug-related SAEs, Drug-related Hypersensitivity, Immune-related AEs/SAEs, and Inflammatory AEs/SAEs|Number of Participants With Grade 2-3 and Grade 3-4 Immune-related Adverse Events (irAEs) With Resolution Resolved|Time to Resolution of Grade 2-3, Grade 3-4 Immune-related Adverse Events (irAEs)	Bristol-Myers Squibb|Medarex	All	18 Years and older   (Adult, Older Adult)	Phase 3	681	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA184-024	August 2006	January 2011	October 2013	May 10, 2006	March 10, 2014	November 3, 2014	Pacific Cancer Medical Center, Anaheim, California, United States|Wilshire Oncology Medical Group Inc, La Verne, California, United States|The Angeles Clinic And Research Institute, Los Angeles, California, United States|Comprehensive Cancer Center, Palm Springs, California, United States|Sharp Clinical Oncology Research, San Diego, California, United States|Saint Francis Hospital And Medical Center, Hartford, Connecticut, United States|Hematology Oncology, P.C., Stamford, Connecticut, United States|Cancer Specialists Of North Florida Beaches, Jacksonville, Florida, United States|Orlando Health, Inc. M.D. Anderson Cancer Center Orlando, Orlando, Florida, United States|Hematology Oncology Associates Of The Treasure Coast, Port Saint Lucie, Florida, United States|University Of Chicago, Chicago, Illinois, United States|Mid-Illinois Hematology/Oncology Associates, Ltd., Normal, Illinois, United States|Oncology Specialists, Sc, Park Ridge, Illinois, United States|Central Indiana Cancer Centers, Fishers, Indiana, United States|Indiana University Cancer Center, Indianapolis, Indiana, United States|Hutchinson Clinic, Pa, Hutchinson, Kansas, United States|Kentucky Cancer Clinic, Hazard, Kentucky, United States|Greater Baltimore Medical Center, Baltimore, Maryland, United States|Sinai Hospital Of Baltimore, Baltimore, Maryland, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Ellis Fischel Cancer Center, Columbia, Missouri, United States|St Joseph Oncology Inc, Saint Joseph, Missouri, United States|University Of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Blumenthal Cancer Center, Charlotte, North Carolina, United States|Providence Portland Medical Center, Portland, Oregon, United States|St. Luke'S Hospital & Health Network, Bethlehem, Pennsylvania, United States|Lowcountry Hematology & Oncology, Pa, Mount Pleasant, South Carolina, United States|Thompson Cancer Survival Center, Knoxville, Tennessee, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States|Joe Arrington Cancer Research And Treatment Center, Lubbock, Texas, United States|Virginia Cancer Institute, Richmond, Virginia, United States|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Buenos Aires, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Santa Fe, Argentina|Local Institution, Coffs Harbour, New South Wales, Australia|Local Institution, Newcastle, New South Wales, Australia|Local Institution, Port Macquarie, New South Wales, Australia|Local Institution, South Brisbane, Queensland, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Vienna, Austria|Local Institution, Brasschaat, Belgium|Local Institution, Brussels, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Fortaleza, Ceara, Brazil|Local Institution, Porto Alegre, Rs, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Saskatoon, Saskatchewan, Canada|Local Institution, Santiago, Chile|Local Institution, Olomouc, Czech Republic|Local Institution, Praha, Czech Republic|Local Institution, Nantes, Cedex 1, France|Local Institution, Saint Etienne, Cedex 2, France|Local Institution, Brest, Cedex, France|Local Institution, Bordeaux, France|Local Institution, Marseille, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Heidelberg, Germany|Local Institution, Jena, Germany|Local Institution, Kiel, Germany|Local Institution, Mannheim, Germany|Local Institution, Muenchen, Germany|Local Institution, Tubingen, Germany|Local Institution, Kaposyar, Hungary|Local Institution, Dublin, Dublin 4, Ireland|Local Institution, Cork, Ireland|Local Institution, Galway, Ireland|Local Institution, Jerusalem, Israel|Local Institution, Tel Aviv, Israel|Local Institution, Genova, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Ragusa, Italy|Local Institution, Rome, Italy|Local Institution, Siena, Italy|Local Institution, Eindhoven, Netherlands|Local Institution, Hv Amsterdam, Netherlands|Local Institution, Wurzburg, Netherlands|Local Institution, Montebello, Oslo, Norway|Local Institution, Gdansk, Poland|Local Institution, Lodz, Poland|Local Institution, Lublin, Poland|Local Institution, Poznan, Poland|Local Institution, Wroclaw, Poland|Local Institution, Lisboa, Portugal|Local Institution, Pyatigorsk, Stavropol, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Murmansk, Russian Federation|Local Institution, Ryazan, Russian Federation|Local Institution, Samara, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, St.-Petersburg, Russian Federation|Local Institution, Stavropol, Russian Federation|Local Institution, Port Elizabeth, Eastern Cape, South Africa|Local Institution, Groenkloof, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Saxonworld, Gauteng, South Africa|Local Institution, Cape Town, Western Cape, South Africa|Local Institution, Johannesburg, South Africa|Local Institution, Barcelona, Spain|Local Institution, Canarias, Spain|Local Institution, Valencia, Spain|Local Institution, Zaragoza, Spain|Local Institution, Basel, Switzerland|Local Institution, Geneva, Switzerland|Local Institution, Cherkassy, Ukraine|Local Institution, Dnepropetrovsk, Ukraine|Local Institution, Lviv, Ukraine|Local Institution, Uzhgorod, Ukraine|Local Institution, Bristol, Avon, United Kingdom|Local Institution, Poole, Dorset, United Kingdom|Local Institution, Chelmsford, Essex, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Wirral, Merseyside, United Kingdom|Local Institution, Guildford, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT00324155
156	NCT01681212	Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma		Completed	Has Results	Melanoma	Drug: Ipilimumab|Drug: Dacarbazine	Percentage of Participants Surviving at 1 Year|Number of Participants With Grade 3-4 Immune-related Adverse Events (irAEs)|Number of Patients Who Died and Who Had Serious Adverse Events (SAEs), Treatment-related SAEs, Adverse Events (AEs) Leading to Discontinuation, Related AEs Leading to Discontinuation, Related AEs, Grade 3-4 AEs, and Related Grade 3-4 AEs	Bristol-Myers Squibb	All	20 Years and older   (Adult, Older Adult)	Phase 2	21	Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-202	October 2012	May 2014	May 2014	September 7, 2012	June 11, 2015	June 11, 2015	Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Matsumoto-shi, Nagano, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Chuo-shi, Yamanashi, Japan		https://ClinicalTrials.gov/show/NCT01681212
157	NCT03029780	An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma	CheckMate 800	Active, not recruiting	No Results Available	Renal Cell Carcinoma	Biological: Opdivo|Biological: Yervoy	Incidence of adverse events (AEs) in anaphylactic reaction SMQ (Standardized Medical Dictionary for Regulatory Activities Queries)|Incidence of AEs in anaphylactic reaction SMQ (Standardized Medical Dictionary for Regulatory Activities Queries)|Incidence of grade 3-5 AEs|Nivolumab as measured using serum concentration- time data|Ipilimumab as measured using serum concentration- time data|Anti-nivolumab antibody|Anti-ipilimumab antibody|Maximum observed serum concentration (Cmax)|Objective Response Rate (ORR)|Progression Free Survival (PFS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	118	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-800	February 9, 2017	November 27, 2017	February 21, 2021	January 24, 2017	null	April 30, 2018	Cancer Specialists of North FL, Jacksonville, Florida, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Local Institution, Pittsburgh, Pennsylvania, United States|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, Elizabeth Vale, South Australia, Australia|Local Institution, Malvern, Victoria, Australia|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile		https://ClinicalTrials.gov/show/NCT03029780
158	NCT03068455	An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma	CheckMate 915	Active, not recruiting	No Results Available	Melanoma	Biological: nivolumab|Biological: ipilimumab	Recurrence-free survival (RFS)|Overall Survival (OS)|PD-L1 expression	Bristol-Myers Squibb	All	12 Years and older   (Child, Adult, Older Adult)	Phase 3	2000	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA209-915|2016-003729-41	April 7, 2017	November 8, 2020	February 17, 2023	March 1, 2017	null	October 9, 2018	University of Arizona Cancer Center, Tucson, Arizona, United States|The Angeles Clinic & Research Institute, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|University Of Colorado, Aurora, Colorado, United States|Georgetown University Med Ctr, Washington, District of Columbia, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|UF Health Cancer Center at Orlando Health, Orlando, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|University Of Chicago, Chicago, Illinois, United States|Oncology Specialists, S.C., Park Ridge, Illinois, United States|Mass General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Virginia Piper Cancer Institute, Minneapolis, Minnesota, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|NYU Langone Medical Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Carolinas Med Ctr, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Providence Cancer Center Oncology And Hematology Care, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|St. Luke's University Health Network, Bethlehem, Pennsylvania, United States|Local Institution, Nashville, Tennessee, United States|Texas Oncology Sammons Cancer Center, Dallas, Texas, United States|Md Anderson Can Cnt, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|Inova Melanoma and Skin Cancer Center, Fairfax, Virginia, United States|University Of Washington Cancer Care Alliance, Seattle, Washington, United States|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Subiaco, Western Australia, Australia|Local Institution, Graz, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Liege, Belgium|Local Institution, Salvador, Bahia, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Florianopolis, Santa Catarina, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Sao Jose do Rio Preto, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Ottawa, Ontario, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Montreal, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Klinika komplexni onkologicke pece, Brno, Czechia|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Dermatovenerologicka klinika 3. LF UK a FNKV, Praha 10, Czechia|Dermatovenerologicka klinika VFN a 1. LF UK, Praha 2, Czechia|Centre Hospitalier Universitaire Dijon Bocage, Dijon, France|Hopital Claude Huriez, LILLE Cedex, France|Hopital De La Timone, Marseille Cedex 5, France|Chu Nantes, Nantes, France|Hopital Saint Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite Cedex, France|Institut Claudius Regaud, Toulouse Cedex 9, France|Institut Gustave Roussy, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Buxtehude, Germany|Local Institution, Essen, Germany|Local Institution, Gera, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Luebeck, Germany|Local Institution, Muenchen, Germany|Local Institution, Tuebingen, Germany|Local Institution, Athens, Greece|Metropolitan Hospital, Athens, Greece|Local Institution, Haifa, Israel|Local Institution, Jerusalem, Israel|Local Institution, Tel Hashomer, Israel|Local Institution, Bergamo, Italy|Ospedale Policlinico San Martino, Genova, Italy|IRCCS Istituto Nazionale Tumori Milano, Milano, Italy|Istituto Nazionale Tumori Fondazione Pascale, Napoli, Italy|Istituto Oncologico Veneto IOV, Padova, Italy|Azienda Ospedaliera Universitaria Senese, Siena, Italy|Local Institution, Tauranga, BAY OF Plenty, New Zealand|Local Institution, Christchurch, New Zealand|Local Institution, Dunedin, New Zealand|Klinika Nowotworow Ukladowych i Uogolnionych, Krakow, Poland|Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow, Warszawa, Poland|Institute Of Oncology "Prof.Dr.Alexandru Trestioreanu" Bucha, Bucharest, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Local Institution, Krasnodar, Russian Federation|Local Institution, Krasnoyarsk, Russian Federation|Local Institution, Moscow, Russian Federation|Hospital Universitari Germans Trias I Pujol, Badalona-barcelona, Spain|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Clinic I Provincial, Barcelona, Spain|Hospital Gral. Univ. Gregorio Maranon, Madrid, Spain|Hospital Regional Universitario De Malaga, Malaga, Spain|Hosp Univ Virgen Macarena, Sevilla, Spain|Hospital Universitario Y Politecnico La Fe, Valencia, Spain|Local Institution, Lausanne, Switzerland|Local Institution, Zurich, Switzerland|The Beatson West Of Scotland Cancer Centre, Glasgow, Dumfries & Galloway, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|The Royal Marsden Hospital, London, United Kingdom|Christie Hospital Nhs Trust, Manchester, United Kingdom|Royal Marsden Hospital - Surrey, Sutton., United Kingdom		https://ClinicalTrials.gov/show/NCT03068455
159	NCT02231749	Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)		Active, not recruiting	Has Results	Advanced Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma	Biological: Nivolumab|Biological: Ipilimumab|Drug: Sunitinib	Investigator-assessed Objective Response Rate(ORR) in Intermediate/Poor Risk Participants Per IRRC Using RECIST v1.1|Overall Survival (OS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)|Progression-Free Survival (PFS) in Intermediate/Poor-Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)|Investigator-assessed Objective Response Rate(ORR) in Any Risk Participants Per IRRC Using RECIST v1.1|Overall Survival (OS) in Any Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)|Progression-Free Survival (PFS) in Any Risk Participants With Previously Untreated Metastatic Renal Cell Carcinoma (mRCC)	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	1390	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-214|2014-001750-42	October 13, 2014	June 26, 2017	September 30, 2019	September 4, 2014	October 16, 2018	October 16, 2018	City Of Hope, Duarte, California, United States|UCSD Moores Cancer Center, La Jolla, California, United States|Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|Stanford Cancer Center, Stanford, California, United States|Smilow Cancer Hospital. At Yale New Haven, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, Indiana, United States|University Of Iowa Hospitals And Clinics, Iowa City, Iowa, United States|University Of Kansas Cancer Center, Fairway, Kansas, United States|Uof Md,Greenebaum Cancer Ctr., Baltimore, Maryland, United States|Johns Hopkins University, Baltimore, Maryland, United States|Tufts Medical Center, Boston, Massachusetts, United States|Beth Isr. Deacon. Med Cnt, Boston, Massachusetts, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Karmanos Cancer Institute, Detroit, Michigan, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke University Medical Center, Durham, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Ohio State University, Columbus, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Pittsburgh Cancer Institute Cancer Services, Pittsburgh, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology, P.A., Dallas, Texas, United States|UT Southwestern Medical Center, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|COIBA, Berazategui, Buenos Aires, Argentina|Local Institution, Capital Federal, Buenos Aires, Argentina|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Centro Medico San Roque, San Miguel de Tucuman, Tucuman, Argentina|Centro Para La Atencion Integral Del Paciente Oncologico, San Miguel De Tucuman, Tucuman, Argentina|Instituto Medico Especialazado Alexander Fleming, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Local Institution, Kogarah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Herston, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Clayton, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Elizabeth Vale, Australia|Local Institution, Murdoch, Australia|Local Institution, Linz, Austria|Local Institution, Vienna, Austria|Local Institution, Wels, Austria|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Calgary, Alberta, Canada|Local Institution, Edmonton, Alberta, Canada|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Moncton, New Brunswick, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Centro De Cancer, Pontificia Universidad Catolica, Santiago, Metropolitana, Chile|Fundacion Arturo Lopez Perez, Santiago, Metropolitana, Chile|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Instituto Oncologico, Vina del Mar, Chile|Local Institution, Bogota, Colombia|Hospital Pablo Tobon Uribe, Medellin, Colombia|Instituto de Cancerologia SA, Medellin, Colombia|Local Institution, Brno, Czechia|Local Institution, Hradec Kralove, Czechia|Local Institution, Liberec, Czechia|Local Institution, Olomouc, Czechia|Aarhus University Hospital, Aarhus C, Denmark|Herlev University Hospital, Herlev, Denmark|Local Institution, Odense, Denmark|Helsinki University Hospital, Helsinki, Finland|Tampere University Hospital, Tampere, Finland|Local Institution, Besancon, France|Local Institution, Bordeaux, France|Local Institution, La Roche sur Yon, France|Local Institution, Marseille Cedex 9, France|Local Institution, Paris, France|Local Institution, Saint Herblain, France|Local Institution, Strasbourg, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Villejuif, France|Local Institution, Aachen, Germany|Local Institution, Erlangen, Germany|Local Institution, Frankfurt, Germany|Local Institution, Hamburg, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Homburg, Germany|Local Institution, Jena, Germany|Local Institution, Magdeburg, Germany|Local Institution, Muenchen, Germany|Local Institution, Muenster, Germany|Local Institution, Ulm, Germany|Local Institution, Budapest, Hungary|Local Institution, Debrecen, Hungary|Local Institution, Gyula, Hungary|Local Institution, Pecs, Hungary|Local Institution, Wilton, Cork, Ireland|Local Institution, Dublin 7, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Beer Jacob, Israel|Local Institution, Haifa, Israel|Local Institution, Kfar Saba, Israel|Local Institution, Petach Tikva, Israel|Local Institution, Ramat-gan, Israel|Ospedal S. Donato Usl 8, Arezzo, Italy|Ist.Scient. Romagnolo Per Lo Studio E Cura Tumori, Meldola (fc), Italy|Local Institution, Milano, Italy|Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Napoli, Italy|Istituto Oncologico Veneto IOV, Padova, Italy|Local Institution, Pavia, Italy|Local Institution, Roma, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Sapporo-shi, Hokai-do, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Hamamatsu-shi, Shizuoka, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Koto-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Tokyo, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Mexico D.f., Distrito Federal, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Santiago de Queretaro, Queretaro, Mexico|Local Institution, Oaxaca, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Krakow, Poland|Local Institution, Olsztyn, Poland|Local Institution, Poznan, Poland|Local Institution, Wroclaw, Poland|Hospital De La Santa Creu I Sant Pau, Barcelona, Spain|H. Univ. Vall dHebron, Barcelona, Spain|Hospital Ramon Y Cajal, Madrid, Spain|Hospital Clinico San Carlos, Madrid, Spain|Hosp Univer 12 De Octubre, Madrid, Spain|Hospital General De Asturias, Oviedo, Spain|Hospital General Universitario Virgen Del Rocio, Sevilla, Spain|Karolinska University Hospital, Solna, Sweden|Local Institution, Taipei, Taiwan|Local Institution, Taipei, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Istanbul, Turkey|Local Institution, London, Greater London, United Kingdom|Local Institution, Glasgow, Lanarkshire, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Northwood, United Kingdom|Local Institution, Swansea, United Kingdom	"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02231749/SAP_000.pdf|"Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/49/NCT02231749/Prot_001.pdf	https://ClinicalTrials.gov/show/NCT02231749
160	NCT02599402	Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma	CheckMate 401	Active, not recruiting	No Results Available	Melanoma	Drug: Nivolumab|Drug: Ipilimumab	Rate and frequency for high-grade (CTCAE v4.0 Grade 3-5) treatment-related, select adverse events in study subjects|Incidence of all high-grade (Grades 3-5), select adverse events|Median time to onset (Grades 3-4) of select adverse events|Median time to resolution (Grades 3-4) of select adverse events|Resolution of an Adverse Event (AE)|Overall survival time from first dosing date to the date of death.|Safety will be measured by the incidence of all AEs, treatment-related AEs, serious AEs, deaths, laboratory abnormalities, and select AEs|Tolerability will be measured by the incidence of all AEs, treatment-related AEs, serious AEs, deaths, laboratory abnormalities, and select AEs|ORR|Investigator-assessed Progression free survival (PFS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	615	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-401|2015-001274-17	December 8, 2015	December 19, 2021	December 20, 2021	November 6, 2015	null	August 1, 2018	Local Institution, Garran, Australian Capital Territory, Australia|Local Institution, Coffs Harbour, New South Wales, Australia|Local Institution, Gateshead, New South Wales, Australia|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Tiwi, Northern Territory, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Cairns, Queensland, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Bedford Park, South Australia, Australia|Local Institution, Hobart, Tasmania, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Melbourne, Victoria, Australia|Local Institution, Murdoch, Western Australia, Australia|Local Institution, Perth, Western Australia, Australia|Local Institution, Camperdown, Australia|Local Institution, Nedlands, Australia|Local Institution, Graz, Austria|Local Institution, Innsbruck, Austria|Local Institution, Salzburg, Austria|Local Institution, Vienna, Austria|Local Institution, Brussel, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Helsinki, Finland|Local Institution, Oulu, Finland|Local Institution, Tampere, Finland|Local Institution, Turku, Finland|Local Institution, Angers, France|Local Institution, Bordeaux, France|Local Institution, Boulogne Billancourt, France|Local Institution, Cedex, France|Local Institution, Clermont-Ferrand, France|Local Institution, Dijon, France|Local Institution, Le Mans, France|Local Institution, Lille, France|Local Institution, Marseille, France|Local Institution, Montpellier, France|Local Institution, Nantes, France|Local Institution, Nice, France|Local Institution, Paris, France|Local Institution, Pierre Benite Cedex, France|Local Institution, Rennes, France|Local Institution, Rouen, France|Local Institution, TOULOUSE Cedex 9, France|Local Institution, Vandoeuvre les Nancy, France|Local Institution, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Dresden, Germany|Local Institution, Erfurt, Germany|Local Institution, Erlangen, Germany|Local Institution, Frankfurt, Germany|Local Institution, Freiburg im Breisgau, Germany|Local Institution, Gottingen, Germany|Local Institution, Hannover, Germany|Local Institution, Leipzig, Germany|Local Institution, Ludwigshafen, Germany|Local Institution, Luebeck, Germany|Local Institution, Mainz, Germany|Local Institution, Mannheim, Germany|Local Institution, Regensburg, Germany|Local Institution, Schwerin, Germany|Local Institution, Stade, Germany|Local Institution, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Bari, Italy|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Meldola, Italy|Local Institution, Milano, Italy|Local Institution, Milan, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Pisa, Italy|Local Institution, Roma, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Terni, Italy|Local Institution, Torino, Italy|Local Institution, Oslo, Norway|Local Institution, Stavanger, Norway|Local Institution, Eskilstuna, Sweden|Local Institution, Gavle, Sweden|Local Institution, Karlskrona, Sweden|Local Institution, Karlstad, Sweden|Local Institution, Linkoping, Sweden|Local Institution, Solna, Sweden|Local Institution, Sundsvall, Sweden|Local Institution, Vaxjo, Sweden|Local Institution, Basel, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, Sheffield, Yorkshire, United Kingdom|Local Institution, Cambridge, United Kingdom|Local Institution, Cottingham, United Kingdom|Local Institution, Glasgow, United Kingdom|Local Institution, Headington, United Kingdom|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Newcastle Upon Tyne, United Kingdom|Mount Vernon Cancer Centre, Northwood, United Kingdom|Local Institution, Nottingham, United Kingdom|Local Institution, Preston, United Kingdom|Local Institution, Southampton, United Kingdom|Local Institution, Sutton., United Kingdom|Local Institution, Swansea, United Kingdom|Local Institution, Truro, United Kingdom		https://ClinicalTrials.gov/show/NCT02599402
161	NCT03138512	A Study Comparing the Combination of Nivolumab and Ipilimumab Versus Placebo in Participants With Localized Renal Cell Carcinoma	CheckMate 914	Recruiting	No Results Available	Renal Cell Carcinoma	Biological: Nivolumab|Biological: Ipilimumab|Drug: Placebo	Disease-free survival (DFS)|Overall Survival (OS)|Common Terminology Criteria for Adverse Events (CTCAE) version 4.0	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	800	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA209-914|2016-004502-34	July 5, 2017	September 5, 2022	July 7, 2023	May 3, 2017	null	November 20, 2018	Alabama Oncology, Birmingham, Alabama, United States|Highland Oncology Group, Fayetteville, Arkansas, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|Local Institution, New Haven, Connecticut, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Local Institution, Atlanta, Georgia, United States|Northwestern University, Chicago, Illinois, United States|Local Institution, Evansville, Indiana, United States|Washington University, Saint Louis, Missouri, United States|Meridan Health System-Jersey Shore Medical Center, Neptune, New Jersey, United States|Local Institution, Albany, New York, United States|Roswell Park Cancer Institute, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Ohio State University, Columbus, Ohio, United States|Providence Newburg Medical Center, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|Bon Secours-St Francis Hosp, Greenville, South Carolina, United States|Erlanger Oncology & Hematology - Univ. of TN, Chattanooga, Tennessee, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States|Local Institution, Seattle, Washington, United States|Local Institution, Ciudad Autonoma Beunos Aires, Buenos Aires, Argentina|Hospital Privado De Comunidad, Mar Del Plata, Buenos Aires, Argentina|Instituto Medico Rio Cuarto S.A., Rio Cuarto, Cordoba, Argentina|Hospital Italiano De Buenos Aires, Caba, Argentina|Local Institution, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Clinica Privada Universitaria Reina Fabiola, Cordoba, Argentina|Centro Polivalente de Asistencia e Investigacion Clinica CER San Juan, San Juan, Argentina|Centro Medico San Roque, Tucuman, Argentina|Local Institution, Randwick, New South Wales, Australia|Royal North Shore Hospital, Sydney, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|ICON Cancer Center, Chermside, Queensland, Australia|Local Institution, Malvern, Victoria, Australia|St John of God Murdoch Hospital, Perth, Western Australia, Australia|Lyell McEwin Hospital, Elizabeth Vale, Australia|Krankenhaus Der Barmherzigen Schwestern, Linz, Austria|Local Institution, Wien, Austria|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Hasselt, Belgium|Local Institution, Liege, Belgium|Local Institution, Brasilia, Distrito Federal, Brazil|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio de Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Vancouver, British Columbia, Canada|Local Institution, Saint John, New Brunswick, Canada|Local Institution, Toronto, Ontario, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Rimouski, Quebec, Canada|Local Institution, Oshawa, Canada|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Beijing, Beijing, China|Local Institution, Fuzhou, Fujian, China|Local Institution, Guangzhou, Guangdong, China|Local Institution, Wuhan, Hubei, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanjing, Jiangsu, China|Local Institution, Nanchang, Jiangxi, China|Local Institution, Changchun, Jilin, China|Local Institution, Yantai, Shandong, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Shanghai, Shanghai, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Chengdu, Sichuan, China|Local Institution, Tianjin, Tianjin, China|Local Institution, Hangzhou, Zhejiang, China|Local Institution, Guangzhou, China|Local Institution, Hangzhou, China|Local Institution, Shanghai, China|Local Institution, Shanghai, China|Local Institution, Xi?an, China|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Local Institution, Besancon, France|Local Institution, La Roche sur Yon, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Strasbourg, France|Local Institution, Tours Cedex, France|Local Institution, Vandoeuvre Les Nancy, France|Local Institution, Villejuif, France|Universitaetsklinikum Aachen, Aachen, Germany|Universitaetsklinikum Essen, Essen, Germany|Asklepios Klinik Altona, Hamburg, Germany|Medizinische Hochschule Hannover, Hannover, Germany|Universitaetsklinikum Jena, Jena, Germany|Klinikum Grosshadern, Munich, Germany|Klinikum Nuernberg Nord, Urologische Klinik, Nuernberg, Germany|Universitaetsklinikum Rostock, Rostock, Germany|Univ. Klinikum Wuerzburg, Wuerzburg, Germany|Local Institution, Arezzo, Italy|A.O. Istituti Ospitalieri Di Cremona, Cremona, Italy|Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Napoli, Italy|Azienda Ospedaliera Di Parma, Parma, Italy|Fondazione Policlinico Universitario A. Gemelli, Roma, Italy|Policlinico G. Rossi, Verona, Italy|Local Institution, Toyoake Shi, Aichi, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Hiroshima-Shi, Hiroshima, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Kobe-shi, Hyogo, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Kyoto-shi, Kyoto, Japan|Local Institution, Nagasaki-shi, Nagasaki, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Osaka-sayama, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Tokushima-shi, Tokushima, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Ube, Yamaguchi, Japan|Local Institution, Mexico, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Local Institution, Zapopan, Jalisco, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Local Institution, Mazatlan, Sinaloa, Mexico|Local Institution, Chihuahua, Mexico|Local Institution, San Luis Potosi, Mexico|Local Institution, San Luis Potosi, Mexico|Local Institution, Amsterdam, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Zwolle, Netherlands|Local Institution, Biala Podlaska, Poland|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Local Institution, Lublin, Poland|Local Institution, Warsaw, Poland|Oddzial Onkologii Klinicznej, Wroclaw, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Nizhniy Novgorod, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, Singapore, Singapore|Local Institution, Singapore, Singapore|Hospital San Pedro De Alcantara, Caceres, Spain|H. Lucus Augusti, Lugo, Spain|Local Institution, Madrid, Spain|Hospital Parc Tauli, Sabadell, Spain|Hospital General Universitario Virgen Del Rocio, Sevilla, Spain|Local Institution, Sevilla, Spain|Local Institution, Glasgow, Dumfries & Galloway, United Kingdom|Local Institution, Swansea, Glamorgan, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Preston, United Kingdom		https://ClinicalTrials.gov/show/NCT03138512
162	NCT01844505	Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)		Active, not recruiting	Has Results	Unresectable or Metastatic Melanoma	Biological: Nivolumab|Biological: Ipilimumab|Biological: Placebo for Nivolumab|Biological: Placebo for Ipilimumab	Progression Free Survival (PFS)|Overall Survival (OS)|Rate of Overall Survival|Rate of Progression-Free Survival|Objective Response Rate (ORR) Per Investigator Assessment|Progression-Free Survival Based on PD-L1 Expression Level|Overall Survival Based on PD-L1 Expression Level|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Social Functioning|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Cognitive Functioning|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Emotional Functioning|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Role Functioning|Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Physical Functioning	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	1296	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA209-067|2012-005371-13	May 23, 2013	August 1, 2016	March 31, 2019	May 1, 2013	September 26, 2017	March 16, 2018	Banner-MD Anderson Cancer Center, Gilbert, Arizona, United States|University Of Arizona Cancer Center, Tucson, Arizona, United States|UC San Diego Moores Cancer Ctr, La Jolla, California, United States|The Angeles Clinic And Research Institute., Los Angeles, California, United States|University Of California - Los Angeles, Los Angeles, California, United States|Comprehensive Cancer Center At Desert Regional Medical Ctr, Palm Springs, California, United States|Desert Hematology Oncology Medical Group, Rancho Mirage, California, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|Ucsf Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States|University Of Colorado Cancer Center, Aurora, Colorado, United States|Yale University, New Haven, Connecticut, United States|Georgetown University Medical Center, Washington, District of Columbia, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|Baptist MD Anderson Cancer Center, Jacksonville, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Maine Center For Cancer Medicine, Scarborough, Maine, United States|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Lutherville, Maryland, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Beth Israel Deaconness Medical Center, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Allina Health, Minneapolis, Minnesota, United States|University Of Mississippi Medical Center, Jackson, Mississippi, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers Of Nevada, Las Vegas, Nevada, United States|Atlantic Melanoma Center, Morristown, New Jersey, United States|University Of New Mexico Cancer Center, Albuquerque, New Mexico, United States|New York Oncology Hematology, Pc, Clifton Park, New York, United States|NYU Clinical Cancer Center, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Duke Cancer Institute, Durham, North Carolina, United States|University Hospitals, Cleveland, Ohio, United States|Providence Cancer Center Oncology and Hematology Care- Eastside, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|St. Luke's Cancer Center - Anderson Campus, Easton, Pennsylvania, United States|Hillman Cancer Center, Pittsburgh, Pennsylvania, United States|Greenville Health System, Greenville, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States|Texas Oncology, Dallas, Texas, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States|University of Washington, Seattle, Washington, United States|Local Institution, Camperdown, New South Wales, Australia|Local Institution, Coffs Harbour, New South Wales, Australia|Local Institution, Gateshead, New South Wales, Australia|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Kurralta Park, South Australia, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Melbourne, Australia|Local Institution, Salzburg, Austria|Local Institution, Wien, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Edegem, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|London Regional Cancer Program, London, Ontario, Canada|The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada|Princess Margaret Hospital, Toronto, Ontario, Canada|CHUM, Montreal, Quebec, Canada|CHU de Quebec, Quebec, Canada|Local Institution, Brno, Czechia|Local Institution, Hradec Kralove, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Praha 8, Czechia|Aarhus University Hospital, Aarhus C, Denmark|Herlev University Hospital, Herlev, Denmark|Odense University Hospital, Odense, Denmark|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Boulogne Billancourt, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex, France|Local Institution, Paris Cedex 10, France|Local Institution, Pierre Benite, France|Local Institution, Rennes, France|Local Institution, Villejuif, France|Local Institution, Buxtehude, Germany|Local Institution, Erfurt, Germany|Local Institution, Erlangen, Germany|Local Institution, Essen, Germany|Local Institution, Hannover, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kiel, Germany|Local Institution, Leipzig, Germany|Local Institution, Munich, Germany|Local Institution, Tubingen, Germany|Local Institution, Cork, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Jerusalem, Israel|Local Institution, Tel Hashomer, Israel|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Meldola (FC), Italy|Local Institution, Milano, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Leiden, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Auckland, New Zealand|Local Institution, Oslo, Norway|Local Institution, Bydgoszcz, Poland|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Lodz, Poland|Local Institution, Warsaw, Poland|Local Institution, Badalona-Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Malaga, Spain|Local Institution, Pamplona-Navarra, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Stockholm, Sweden|Local Institution, Geneva, Switzerland|Local Institution, Lausanne, Switzerland|Local Institution, St. Gallen, Switzerland|Local Institution, Zürich, Switzerland|Local Institution, Cambridge, Cambridgeshire, United Kingdom|Local Institution, Swansea, Carmarthenshire, United Kingdom|Local Institution, Glasgow, Dumfries & Galloway, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Northwood, Middlesex, United Kingdom|Local Institution, Nottingham, Nottinghamshire, United Kingdom		https://ClinicalTrials.gov/show/NCT01844505
163	NCT01621490	PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma	PD-1	Active, not recruiting	No Results Available	Advanced Melanoma|Metastatic Melanoma	Biological: Nivolumab|Drug: Ipilimumab	Immunomodulatory effects of Nivolumab and Nivolumab in combination with Ipilimumab as measured by changes from baseline in activated and memory T cells, interferon, interferon inducible factors, and CD4 and CD8 T cell infiltration|Safety and tolerability of Nivolumab, Ipilimumab and Nivolumab in combination with Ipilimumab as measured by the incidence of adverse events (AEs), serious AEs, death, and changes in vital signs|Safety and tolerability of Nivolumab, Ipilimumab and Nivolumab in combination with Ipilimumab as measured by laboratory test abnormalities|Antitumor Activity of Nivolumab and Nivolumab in combination with Ipilimumab as measured by the objective response rate (ORR), duration of response, and progression free survival (PFS)|Immunogenicity of Nivolumab and Nivolumab in combination with Ipilimumab as measured by the frequency of baseline positive subjects and the frequency of ADA positive subjects|Association between Programmed cell death ligand 1 (PD-L1) and clinical efficacy will be measured by PDL1 expression levels clinical activity (ORR, PFS)	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	237	Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science	CA209-038|2012-001840-23	September 27, 2012	September 12, 2017	December 2, 2018	June 18, 2012	null	August 1, 2018	Ucla, Los Angeles, California, United States|University Of Chicago, Chicago, Illinois, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Lutherville, Maryland, United States|Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Memorial Sloan-Kettering Cancer Center, New York, New York, United States|Providence Portland Medical Center, Portland, Oregon, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States|The University Of Texas MD Anderson Cancer Center, Houston, Texas, United States|University Of Virginia, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Amsterdam, Netherlands|Local Institution, Pamplona, Spain		https://ClinicalTrials.gov/show/NCT01621490
164	NCT02905266	A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma		Active, not recruiting	No Results Available	Melanoma	Biological: Nivolumab|Biological: Ipilimumab	Incidence of adverse events in anaphylactic reaction SMQ (Standardized Medical Dictionary for Regulatory Activities Queries)|Incidence of events within the hypersensitivity/infusion reaction select Adverse Events (AEs)category|Incidence of grade 3-5 AEs|Objective Response Rate (ORR)|Progression Free Survival (PFS)|Pharmacokinetics (PK) as measured using serum concentration-time data.	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	139	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-742|2016-001941-26	October 27, 2016	October 23, 2017	November 17, 2020	September 19, 2016	null	December 13, 2017	Local Institution, North Sydney, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Cabrini Hospital, Malvern, Victoria, Australia|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex 1, France|Local Institution, Paris Cedex 14, France|Local Institution, Paris, France|Local Institution, Tours, France|Istituto Nazionale Per La Ricerca Sul Cancro - Oncologia Med, Genova, Italy|Istituto Scientifico Romagnolo Per Lo Studio E Cura Tumori, Meldola (FC), Italy|Istituto Europeo Di Oncologia, Milan, Italy|Azienda Ospedaliera Citta della Salute e della Scienza, Torino, Italy|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Sevilla, Spain		https://ClinicalTrials.gov/show/NCT02905266
165	NCT02388906	Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)		Active, not recruiting	No Results Available	Melanoma	Drug: Ipilimumab|Drug: Nivolumab|Other: Placebo matching Ipilimumab|Other: Placebo matching Nivolumab	Recurrence -free-survival|Overall survival	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	15 Years and older   (Child, Adult, Older Adult)	Phase 3	800	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA209-238|2014-002351-26	March 12, 2015	November 29, 2018	November 26, 2019	March 17, 2015	null	July 3, 2018	University Of Arkansas For Medical Sciences, Little Rock, Arkansas, United States|UC San Diego Moores Cancer Ctr, La Jolla, California, United States|The Angeles Clinic & Research Institute, Los Angeles, California, United States|California Pacific Medical Center Research Institute, San Francisco, California, United States|Ucsf-Comprehensive Cancer Center, San Francisco, California, United States|University Of Colorado Cancer Center, Aurora, Colorado, United States|Medstar Washington Hospital Center, Washington, District of Columbia, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Orlando Health, Inc, Orlando, Florida, United States|H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Winship Cancer Institute., Atlanta, Georgia, United States|University of Chicago, Chicago, Illinois, United States|Beth Israel Deaconess Medical Center (BIDMC), Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University Of Michigan Health System, Ann Arbor, Michigan, United States|Allina Health, Fridley, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|The Cancer Center At Hackensack University Medical Center, Hackensack, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|Nyu Clinical Cancer Institute, New York, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Carolinas Healthcare System / Carolinas Medical Center, Charlotte, North Carolina, United States|Duke Cancer Center, Durham, North Carolina, United States|The Ohio State University, Columbus, Ohio, United States|Providence Cancer Center Oncology And Hematology Care, Portland, Oregon, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Hospital, Allentown, Pennsylvania, United States|St. Luke's Cancer Center - Anderson Campus, Easton, Pennsylvania, United States|Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina, United States|Sarah Cannon Research Institute, Nashville, Tennessee, United States|Texas Oncology Sammons Cancer Center, Dallas, Texas, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|University Of Washington Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Capital Federal, Buenos Aires, Argentina|Local Institution, San Miguel de Tucuman, Tucuman, Argentina|Local Institution, Cordoba, Argentina|Local Institution, Gateshead, New South Wales, Australia|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Southport, Queensland, Australia|Local Institution, Adelaide, South Australia, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Prahran, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Camperdown, Australia|Local Institution, Graz, Austria|Local Institution, Salzburg, Austria|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Cross Cancer Institute, Edmonton, Alberta, Canada|BC Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|Mcgill University Dept Of Oncology, Montreal, Quebec, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Local Institution, Hradec Kralove, Czechia|Local Institution, Ostrava-Poruba, Czechia|Local Institution, Praha 10, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Helsinki, Finland|Local Institution, Tampere, Finland|Local Institution, Lille, France|Local Institution, Marseille Cedex 5, France|Local Institution, Nantes Cedex 1, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Toulouse Cedex 9, France|Local Institution, Athens, Greece|Local Institution, Neo Faliro, Greece|Local Institution, Budapest, Hungary|Local Institution, Dublin 7, Ireland|Local Institution, Dublin, Ireland|Local Institution, Dublin, Ireland|Local Institution, Galway, Ireland|Local Institution, Bergamo, Italy|Local Institution, Genova, Italy|Local Institution, Meldola (FC), Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Nagoya-shi, Aichi, Japan|Local Institution, Fukuoka-shi, Fukuoka, Japan|Local Institution, Tsukuba-shi, Ibaraki, Japan|Local Institution, Kumamoto-shi, Kumamoto, Japan|Local Institution, Matsumoto-shi, Nagano, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Sunto-gun, Shizuoka, Japan|Local Institution, Chuo-ku, Tokyo, Japan|Local Institution, Chuo-shi, Yamanashi, Japan|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Seoul, Korea, Republic of|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Veldhoven, Netherlands|Local Institution, Bergen, Norway|Local Institution, Oslo, Norway|Local Institution, Gdansk, Poland|Local Institution, Krakow, Poland|Local Institution, Warszawa, Poland|Local Institution, Craiova, Romania|Local Institution, Romania, Romania|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Saxonwold, Johannesburg, Gauteng, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Local Institution, Cape Town, Western CAPE, South Africa|Hospital Clinic I Provincial, Barcelona, Spain|Hospital General Universitario Gregorio Maranon, Madrid, Spain|Hosp Univ Virgen Macarena, Sevilla, Spain|Hospital General Univ De Valencia, Valencia, Spain|Local Institution, Gothenberg, Sweden|Local Institution, Lund, Sweden|Local Institution, Zurich, Switzerland|Local Institution, Kaohsiung, Taiwan|Local Institution, Taichung, Taiwan|Local Institution, Taoyuan, Taiwan|Local Institution, Bristol, Avon, United Kingdom|Local Institution, Swansea, Carmarthenshire, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Northwood, Middlesex, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|Local Institution, Newcastle Upon Tyne, Tyne and Wear, United Kingdom|Local Institution, Leicester, United Kingdom|Local Institution, Surrey, United Kingdom		https://ClinicalTrials.gov/show/NCT02388906
166	NCT02017717	A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients	CheckMate 143	Active, not recruiting	No Results Available	Recurrent Glioblastoma	Biological: Nivolumab|Biological: Bevacizumab|Biological: Ipilimumab	Cohorts 1,1b, 1c and 1d : Safety and tolerability based on drug related events leading to permanent discontinuation prior to completing 4 doses|Cohort 2: Overall Survival (OS)|Cohort 2: Overall Survival rate (OS)|Cohort 2: Progression Free Survival (PFS)|Cohort 2: Objective Response Rate(ORR)	Bristol-Myers Squibb	All	Child, Adult, Older Adult	Phase 3	626	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-143|2013-003738-34	January 27, 2014	January 10, 2017	October 26, 2018	December 23, 2013	null	March 16, 2018	University of Alabama at Birmingham, Birmingham, Alabama, United States|Cedars Sinai Medical Center, Los Angeles, California, United States|UCLA Neuro-Oncology Program, Los Angeles, California, United States|The Regents of the University of California, San Francisco, San Francisco, California, United States|Anschutz Cancer Pavilion, Aurora, Colorado, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Georgetown University, Washington, District of Columbia, United States|Moffitt Cancer Center, Tampa, Florida, United States|Winship Cancer Institute, Atlanta, Georgia, United States|Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States|Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Henry Ford Health System, Detroit, Michigan, United States|Mayo Clinic, Rochester, Minnesota, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Preston Robert Tisch Brain Tumor Center at Duke University, Durham, North Carolina, United States|University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Thomas Jefferson University, Philadelphia, Pennsylvania, United States|Medical University Of South Carolina, Charleston, South Carolina, United States|Vanderbilt University Medical Center, Nashville, Tennessee, United States|University Of Texas Md Anderson Cancer Ctr, Houston, Texas, United States|University of Virginia Health System, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Swedish Neuroscience Institute, Seattle, Washington, United States|Local Institution, Liverpool, New South Wales, Australia|Local Institution, East Bentleigh, Victoria, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Aarhus University Hospital, Aarhus C, Denmark|Odense University Hospital, Odense C, Denmark|Local Institution, Bron cedex, France|Local Institution, Marseille Cedex 5, France|Local Institution, Paris cedex 13, France|Local Institution, Paris, France|Universitaetsklinikum Bonn, Bonn, Germany|Klinikum Der J. W. Goethe-Universitaet Frankfurt/Main, Frankfurt Am Main, Germany|Local Institution, Heidelberg, Germany|Universitaetsklinikum Muenster, Muenster, Germany|Local Institution, Bologna, Italy|Local Institution, Milano, Italy|Local Institution, Siena, Italy|Local Institution, Torino, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Groningen, Netherlands|Local Institution, Gdansk, Poland|Local Institution, Warszawa, Poland|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Pamplona, Spain|Centre hospitalier universitaire Vaudois (CHUV), Lausanne, Switzerland|UniversitaetsSpital Zurich, Zuerich, Switzerland|Local Institution, London, Greater London, United Kingdom|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Wirral, Merseyside, United Kingdom		https://ClinicalTrials.gov/show/NCT02017717
167	NCT00636168	Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma		Active, not recruiting	Has Results	High Risk Stage III Melanoma	Drug: ipilimumab|Drug: Placebo	Recurrence Free Survival (RFS) Per Independent Review Committee (IRC) in the Intent to Treat (ITT) Population|Number of Patients With Recurrence or Death as Per Independent Review Committee (IRC) in the Intent to Treat (ITT) Population|Recurrence-Free Survival (RFS) Rates Per IRC at 1 Year, 2 Years, and 3 Years in the ITT Population|Number of Patients With Distant Metastasis or Death as Per Independent Review Committee (IRC) in the Intent to Treat (ITT) Population|Rate of Overall Survival (OS)|Number of Patients With Adverse Events (AEs) Leading to Discontinuation of Treatment, Serious AEs (SAEs), Drug-Related SAEs, Immune-related AEs (irAEs), Immune-mediated Adverse Reactions (imARs), Deaths in Treated Population|Exposure Adjusted Incidence Rate of Adverse Events Including Multiple Occurrences of Unique Events|Mean Change From Baseline in Global Health Status Scores at Each Assessment Timepoint	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	1211	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA184-029|EORTC 18071	June 30, 2008	July 26, 2013	December 31, 2018	March 14, 2008	August 19, 2014	November 6, 2017	The Angeles Clinic & Research Institute, Los Angeles, California, United States|Sharp Memorial Hospital, San Diego, California, United States|California Pacific Medical Center, San Francisco, California, United States|North. Cal. Melanoma Center-St. Mary's Medical Center, San Francisco, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Boca Raton Comprehensive Cancer Center, Boca Raton, Florida, United States|H Lee Moffitt Cancer Cnt And Res Inst, Tampa, Florida, United States|Oncology Specialists, S.C., Park Ridge, Illinois, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Nevada Cancer Center, Las Vegas, Nevada, United States|Atlantic Melanoma Center, Morristown, New Jersey, United States|University Of New Mexico Cancer Center, Albuquerque, New Mexico, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|St Lukes Hospital And Health Network, Bethlehem, Pennsylvania, United States|Vanderbilt-Ingram Cancer Ctr, Nashville, Tennessee, United States|Center For Oncology Research & Treatment, P.A., Dallas, Texas, United States|Huntsman Cancer Institute At The Univ. Of Utah, Salt Lake City, Utah, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, Waratah, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Woolloongabba, Queensland, Australia|Local Institution, Box Hill, Victoria, Australia|Local Institution, Malvern, Victoria, Australia|Local Institution, Nedlands, Western Australia, Australia|Local Institution, Graz, Austria|Local Institution, Wien, Austria|Local Institution, Gent, Belgium|Local Institution, Leuven, Belgium|Local Institution, Calgary, Alberta, Canada|Local Institution, Edmonton, Alberta, Canada|Local Institution, Montreal, Quebec, Canada|Local Institution, Praha 2, Czechia|Local Institution, Praha 2, Czechia|Local Institution, Aarhus C, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense C, Denmark|Local Institution, Helsinki, Finland|Local Institution, Turku, Finland|Local Institution, Lillie, Cedex, France|Local Institution, Boulogne-billancourt, France|Local Institution, Marseille Cedex 5, France|Local Institution, Paris, France|Local Institution, Paris, France|Local Institution, Pierre Benite, France|Local Institution, Vandoeuvre Les Nancy, France|Local Institution, Villejuif, France|Local Institution, Berlin, Germany|Local Institution, Essen, Germany|Local Institution, Gottingen, Germany|Local Institution, Heidelberg, Germany|Local Institution, Kiel, Germany|Local Institution, Koln, Germany|Local Institution, Luebeck, Germany|Local Institution, Mannheim, Germany|Local Institution, Tubingen, Germany|Local Institution, Wurzburg, Germany|Local Institution, Genova, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Roma, Italy|Local Institution, Siena, Italy|Local Institution, Amsterdam, Netherlands|Local Institution, Amsterdam, Netherlands|Local Institution, Leiden, Netherlands|Local Institution, Nijmegen, Netherlands|Local Institution, Rotterdam, Netherlands|Local Institution, Oslo, Norway|Local Institution, Poznan, Poland|Local Institution, Warszawa, Poland|Local Institution, Pyatigorsk, Stavropol Region, Russian Federation|Local Institution, Ivanovo, Russian Federation|Local Institution, Izhevsk, Russian Federation|Local Institution, Krasnodar, Russian Federation|Local Institution, Krasnoyarsk, Russian Federation|Local Institution, Lipetsk, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Petrozavodsk, Russian Federation|Local Institution, Saratov, Russian Federation|Local Institution, St Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, St. Petersburg, Russian Federation|Local Institution, Tomsk, Russian Federation|Local Institution, Ufa, Russian Federation|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Zaragoza, Spain|Local Institution, Stockholm, Sweden|Local Institution, Zurich, Switzerland|Local Institution, Chelmsford, Essex, United Kingdom|Local Institution, London, Greater London, United Kingdom|Local Institution, Southampton, Hampshire, United Kingdom|Local Institution, Nottingham, Nottinghamshire, United Kingdom|Local Institution, Leeds, Yorkshire, United Kingdom		https://ClinicalTrials.gov/show/NCT00636168
168	NCT02374242	Anti‐PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases	ABC	Active, not recruiting	No Results Available	Melanoma|Brain Metastases	Drug: Nivolumab|Drug: Ipilimumab	Intracranial response rate|Extracranial response rate|Overall response rate|Progression free survival in intracranial disease|Progression free survival in extracranial disease|Overall progression free survival|Overall survival|Safety and tolerability of nivolumab and nivolumab + ipilimumab (verse events by type, frequency and severity using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.)|Patient rated quality of life|Clinical response using immune related response criteria (irRC)|Tissue and blood biomarkers of response and progression|FET‐PET response in the brain at 6 and 12 weeks on therapy (Proportion of patients with a lower standardised uptake value from baseline in intracranial metastases, following at least ONE dose of study treatment)	Melanoma Institute Australia|Australia and New Zealand Melanoma Trials Group|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	76	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209‐170|ACTRN12614001315606|ANZMTG 01.14	November 4, 2014	September 4, 2017	December 2022	February 27, 2015	null	April 11, 2018	Melanoma Institute Australia, North Sydney, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia		https://ClinicalTrials.gov/show/NCT02374242
169	NCT01024231	Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma		Active, not recruiting	No Results Available	Malignant Melanoma	Drug: BMS-936558 (MDX1106-04)|Drug: Ipilimumab	Safety assessments will be based on adverse event reports and the results of clinical laboratory tests, immune safety tests, physical examinations, vital sign measurements, ECOG performance status, and ECG evaluations|Pharmacokinetic peak and trough concentration of each study drug when given in combination together or in a sequenced regimen|Blood samples to test immunogenicity|Tumor response evaluations	Bristol-Myers Squibb|Medarex|Ono Pharma USA Inc	All	18 Years and older   (Adult, Older Adult)	Phase 1	136	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-004|(MDX1106-04)	December 14, 2009	April 7, 2019	December 30, 2019	December 2, 2009	null	December 13, 2017	Yale University School Of Medicine, New Haven, Connecticut, United States|Medstar Georgetown-Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Hillman Cancer Research Pavilion, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT01024231
170	NCT00050102	Comparison Study of MDX-010 (CTLA-4) Alone and Combined With DTIC in the Treatment of Metastatic Melanoma		Completed	No Results Available	Melanoma	Drug: MDX-010 (CTLA-4)		Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	null	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MDX010-08|CA184-013	October 2002	February 2004	February 2004	November 22, 2002	null	January 28, 2011	Arizona Cancer Center, Tucson, Arizona, United States|Pacific Shores Medical Group, Long Beach, California, United States|USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States|Northern California Melanoma Center, San Francisco, California, United States|Cancer Institute Medical Group, Santa Monica, California, United States|Indiana Oncology/ Hematology Consultants, Indianapolis, Indiana, United States|Piedmont Oncology Specialists, Charlotte, North Carolina, United States|Joe Arrington Cancer. Research & Treatment Center, Lubbock, Texas, United States|Huntsman Cancer Institute, Salt Lake City, Utah, United States		https://ClinicalTrials.gov/show/NCT00050102
171	NCT03355976	BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas		Recruiting	No Results Available	Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|Extra Renal Origin|Clear Cell Adenocarcinoma	Drug: Nivolumab|Drug: Ipilimumab	Proportion of patients who have objective tumor response (complete or partial) by modified RECIST 1.1 in patients with clear cell carcinomas treated with nivolumab or the combination of nivolumab and ipilimumab|Compare median PFS for patients treated with nivolumab (Arm 1) and the combination of nivolumab and ipilimumab (Arm 2)	Don Dizon|Bristol-Myers Squibb|Rhode Island Hospital|The Miriam Hospital|Brown University	All	18 Years and older   (Adult, Older Adult)	Phase 2	62	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	BrUOG 354	April 30, 2018	February 2020	February 2022	November 29, 2017	null	July 26, 2018	Rhode Island Hospital, Providence, Rhode Island, United States|The Miriam Hospital, Providence, Rhode Island, United States		https://ClinicalTrials.gov/show/NCT03355976
172	NCT01245556	Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma		Completed	No Results Available	Melanoma	Drug: BMS-908662|Drug: Ipilimumab	Toxicity will be evaluated according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 3|Efficacy as determined by estimates of objective response rates and response duration|PK for BMS-908662 as determined by minimum and maximum observed concentrations, time of maximum observed concentration, area under the concentration curve for one dosing interval and the accumulation index|PD will be assessed by evaluating markers of RAS/RAF pathway activity	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	8	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA206-005	January 2011	November 2012	November 2012	November 22, 2010	null	June 12, 2013	H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States|Jedd D. Wolchok, Md,Phd, New York, New York, United States		https://ClinicalTrials.gov/show/NCT01245556
173	NCT01472081	Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)		Active, not recruiting	No Results Available	Renal Cell Carcinoma|Clear-cell Metastatic Renal Cell Carcinoma	Biological: Nivolumab|Biological: Pazopanib|Drug: Sunitinib|Biological: Ipilimumab	Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of Adverse event (AE)|Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of Serious adverse event (SAE)|Safety and tolerability of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by incidence of lab abnormality|Antitumor activity of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by Objective Response Rate (ORR)|Antitumor activity of Nivolumab plus Sunitinib, Pazopanib, or Ipilimumab measured by duration of response according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1	Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 1	175	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-016	January 2012	February 2016	June 2018	November 16, 2011	null	April 19, 2017	City Of Hope, Duarte, California, United States|Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States|Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Cleveland Clinic, Cleveland, Ohio, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Tennessee Oncology, Pllc, Nashville, Tennessee, United States|The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Cross Cancer Institute, Edmonton, Alberta, Canada|Bc Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada|Princess Margaret Hospital-Uhn, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT01472081
174	NCT01489059	Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma		Completed	No Results Available	Melanoma	Biological: BMS-982470 (recombinant interleukin-21)|Biological: Ipilimumab	Part1 (Dose Escalation): The Maximum tolerated dose (MTD) of BMS-982470 using 2 distinct schedules when administered in combination with Ipilimumab|Part 2 (Cohort Escalation): Safety and tolerability of the MTD dose for each of the schedules|Efficacy of BMS-982470 in combination with Ipilimumab as measured by objective response|Area under the serum concentration-time curve from time zero to the last quantifiable concentration [AUC(0-T)] of BMS-982470 and Ipilimumab|Area under the serum concentration-time curve in one dosing interval [AUC(TAU)] of BMS-982470 and Ipilimumab|Area under the serum concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of BMS-982470 and Ipilimumab|The maximum observed serum concentration (Cmax) of BMS-982470 and Ipilimumab|Trough observed serum concentration (Cmin) of BMS-982470 and Ipilimumab|The time of maximum observed serum concentration (Tmax) of BMS-982470 and Ipilimumab|Serum half-life (T-HALF) of BMS-982470 and Ipilimumab|Apparent total body clearance (CLT) of BMS-982470 and Ipilimumab|Apparent volume of distribution at steady state (Vss) of BMS-982470 and Ipilimumab|Incidence of BMS-984270 and Ipilimumab Anti-Drug Antibodies	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	42	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA220-007	December 2011	June 2014	June 2014	December 9, 2011	null	August 29, 2014	Oncology Research Associates, Pllc D/B/A, Scottsdale, Arizona, United States|Ucla Hematology/Oncology., Los Angeles, California, United States|H. Lee Moffitt Cancer Center & Research Inst, Inc, Tampa, Florida, United States|Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, Indiana, United States|University Of Louisville Medical Center, Inc., Dba, Louisville, Kentucky, United States|Portland Providence Medical Center, Portland, Oregon, United States|Md Anderson Can Cnt, Houston, Texas, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, San Juan, Puerto Rico		https://ClinicalTrials.gov/show/NCT01489059
175	NCT00803374	Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma		Withdrawn	No Results Available	Melanoma	Drug: AntiCD137|Drug: Ipilimumab	Evidence of safety and tolerability as determined by analysis of adverse event reports and results of vital sign measurements, physical examinations, and clinical laboratory tests|Evidence of clinical improvement in tumor burden confirmed by CT or MRI	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	0	Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA186-007	November 2010	July 2012	January 2013	December 5, 2008	null	November 21, 2011	Local Institution, Los Angeles, California, United States|Local Institution, New Haven, Connecticut, United States|Local Institution, Tampa, Florida, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|Local Institution, New York, New York, United States		https://ClinicalTrials.gov/show/NCT00803374
176	NCT02714218	A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma		Active, not recruiting	No Results Available	Melanoma	Biological: Nivolumab 3 mg/kg IV|Biological: Ipilimumab 1 mg/kg IV|Biological: Nivolumab 1 mg/kg IV|Biological: Ipilimumab 3 mg/kg IV|Biological: Nivolumab 6 mg/kg IV	Incidence of drug-related Grade 3 - 5 Adverse Events (AEs)|Objective I Response Rate (ORR)|Overall survival (OS)|Mean changes from baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-30) global health status/quality of life (Qol) composite scale|Progression Free Survival (PFS) in all treated subjects	Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	483	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment	CA209-511	March 24, 2016	April 20, 2017	April 15, 2022	March 21, 2016	null	April 27, 2018	University Of Colorado Cancer Center, Aurora, Colorado, United States|H. Lee Moffitt Cancer Center, Tampa, Florida, United States|Allina Health, Fridley, Minnesota, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States|John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States|Levine Cancer Institute, Charlotte, North Carolina, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|University Of Virginia Health System, Charlottesville, Virginia, United States|Seattle Cancer Care Alliance, Seattle, Washington, United States|Local Institution, North Sydney, New South Wales, Australia|Local Institution, Waratah, New South Wales, Australia|Local Institution, Greenslopes, Queensland, Australia|Local Institution, Melbourne, Victoria, Australia|Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Cancer Centre, Toronto, Ontario, Canada|CHU de Quebec - Universite Laval, Quebec, Canada|Local Institution, Aarhus, Denmark|Local Institution, Herlev, Denmark|Local Institution, Odense, Denmark|Hopital Saint Andre, Bordeaux, France|Chru De Lille, Lille, France|Hopital De La Timone, Marseille Cedex 5, France|Hopital Hotel Dieu, Nantes Cedex, France|Hopital Saint Louis, Paris, France|Centre Hospitalier Lyon Sud, Pierre Benite, France|Institut Claudius Regaud, Toulouse Cedex 9, France|Institut Gustave Roussy, Villejuif, France|Universitaetsklinikum Essen, Essen, Germany|Universitaetsklinikum Heidelberg, Heidelberg, Germany|Ludwig-Maximilians-Universitaet, Muenchen, Germany|Universitaetsklinikum Tuebingen, Tuebingen, Germany|Local Institution, Ramat Gan, Israel|Local Institution, Bergamo, Italy|Local Institution, Milano, Italy|Local Institution, Napoli, Italy|Local Institution, Padova, Italy|Local Institution, Siena, Italy|Local Institution, Taormina, Italy|Netherland Cancer Institute, Amsterdam, Netherlands|Local Institution, Amsterdam, Netherlands|University Medical Center Groningen (Umcg), Groningen, Netherlands|Uniwersyteckie Centrum Kliniczne Klinika Onkologii I Radiote, Gdansk, Poland|Klinika Nowotworow Ukladowych i Uogolnionych, Krakow, Poland|Klinika Nowotworow Tkanek Miekkich, Kosci i Czerniakow, Warszawa, Poland|Local Institution, Moscow, Russian Federation|Local Institution, Badalona-barcelona, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, San Sabastian Gipuzkoa, Spain|Local Institution, Valencia, Spain|Local Institution, Manchester, Greater Manchester, United Kingdom|Local Institution, Oxford, Oxfordshire, United Kingdom|Local Institution, Guildford, Surrey, United Kingdom|Local Institution, London, United Kingdom		https://ClinicalTrials.gov/show/NCT02714218
177	NCT03177239	Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)	UNISoN	Recruiting	No Results Available	Renal Cell Carcinoma|Papillary Renal Cell Carcinoma Type 1|Papillary Renal Cell Carcinoma Type 2|Chromophobe Renal Cell Carcinoma|Sarcomatoid Renal Cell Carcinoma|Xp11 Translocation Carcinoma	Drug: Nivolumab|Drug: Ipilimumab	The objective tumour response rate, as assessed by RECIST1.1|Duration of objective tumour response, as assessed by RECIST1.1|Progression-free survival (PFS), as assessed by RECIST1.1|Immune-related tumour response rate, as assessed by irRECIST.|Immune-related disease control rate (irDCR6), as assessed by irRECIST.|The number of patients alive at the end of the study, as assessed by date of death.|The number of patients with adverse events, particularly immune-related adverse events, that are related to study drug, as assessed and graded according to CTCAE v4.03.|The number of participants with permanent discontinuation of treatment or delays due to toxicity, as assessed and graded according to CTCAE v4.03.	Australian and New Zealand Urogenital and Prostate Cancer Trials Group|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	85	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ANZUP 1602	October 19, 2017	December 2021	December 2022	June 6, 2017	null	June 29, 2018	Border Medical Oncology, Albury, New South Wales, Australia|Campbelltown Hospital, Campbelltown, New South Wales, Australia|Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia|St Vincents Hospital, Darlinghurst, New South Wales, Australia|Northern Cancer Institute, French Forest, New South Wales, Australia|St. George Hospital, Kogarah, New South Wales, Australia|Calvary Mater Newcastle, Newcastle, New South Wales, Australia|Port Macquarie Base Hospital, Port Macquarie, New South Wales, Australia|Prince of Wales Hospital, Randwick, New South Wales, Australia|Tamworth Hospital - North West Cancer Centre, Tamworth, New South Wales, Australia|Westmead Hospital, Westmead, New South Wales, Australia|Sunshine Coast University Hospital, Birtinya, Queensland, Australia|Royal Brisbane & Women's Hospital, Brisbane, Queensland, Australia|Flinders Medical Centre, Adelaide, South Australia, Australia|Ashford Cancer Centre, Adelaide, South Australia, Australia|Ballarat Oncology & Haematology Services, Ballarat, Victoria, Australia|Box Hill Hospital - Eastern Health, Box Hill, Victoria, Australia|Monash Medical Centre, Clayton, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia		https://ClinicalTrials.gov/show/NCT03177239
178	NCT03274258	Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma		Recruiting	No Results Available	Renal Medullary Carcinoma|Other Disorders of Kidney and Ureter	Drug: Nivolumab|Drug: Ipilimumab	Overall Response Rate (ORR) of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma|Progression-Free Survival (PFS) of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma|Safety of Nivolumab Plus Ipilimumab in Patients With Renal Medullary Carcinoma by CTCAE v4.03	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	35	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-0201|NCI-2018-01066	December 13, 2017	July 2020	July 2020	September 6, 2017	null	September 14, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03274258
179	NCT00289640	Study of Ipilimumab (MDX-010) Monotherapy in Patients With Previously Treated Unresectable Stage III or IV Melanoma		Completed	No Results Available	Melanoma	Drug: ipilimumab (MDX-010, BMS-734016)|Drug: Ipilimumab	estimate BORR in patients with previously treated, therapy-refractory or -intolerant, Stage III (unresectable) or Stage IV melanoma receiving ipilimumab doses of 0.3, 3, and 10 mg/kg.|estimate progression free survival rate at Week 12 assessment and other timepoints|estimate disease control rate at various time points|estimate overall survival|estimate survival rate at one year|evaluate health-related quality of life|obtain pharmacokinetic samples for population PK analysis	Bristol-Myers Squibb|Medarex	All	16 Years and older   (Child, Adult, Older Adult)	Phase 2	210	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA184-022	April 2006	July 2007	July 2007	February 10, 2006	null	March 2, 2010	Arizona Cancer Center, Tucson, Arizona, United States|Wilshire Oncology Medical Group Inc, Laverne, California, United States|Scripps Cancer Center, San Diego, California, United States|The Angeles Clinic And Research Institution, Santa Monica, California, United States|Yale University School Of Medicine, New Haven, Connecticut, United States|Baptist Cancer Institute, Jacksonville, Florida, United States|Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States|Md Anderson Cancer Center Orlando, Orlando, Florida, United States|Palm Beach Cancer Institute, West Palm Beach, Florida, United States|Oncology Specialists, Sc, Park Ridge, Illinois, United States|American Health Network, Indianapolis, Indiana, United States|University Of Louisville, Louisville, Kentucky, United States|Harry And Jeanette Weinberg Cancer Inst At Franklin Square, Baltimore, Maryland, United States|Hubert H. Humphrey Cancer Center, Robbinsdale, Minnesota, United States|Ellis Fischel Cancer Center, Columbia, Missouri, United States|St Joseph Oncology Inc, St Joseph, Missouri, United States|Washington University School Of Medicine, St. Louis, Missouri, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Presbyterian Hospital, Charlotte, North Carolina, United States|The Christ Hospital Cancer Center Research, Cincinnati, Ohio, United States|Cleveland Clinic, Cleveland, Ohio, United States|Providence Portland Medical Center, Portland, Oregon, United States|Cancer Centers Of The Carolinas, Greenville, South Carolina, United States|Center For Oncology Research & Treatment, P.A., Dallas, Texas, United States|Mary Crowley Medical Research Center, Dallas, Texas, United States|Local Institution, Newcastle, New South Wales, Australia|Local Institution, Brisbane, Queensland, Australia|Local Institution, Heidelberg, Victoria, Australia|Local Institution, Wodonga, Victoria, Australia|Local Institution, Brussels, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Bruxelles, Belgium|Local Institution, Centro-Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Porto Alegre, Rio Grande Do Sul, Brazil|Local Institution, Jau, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Calgary, Alberta, Canada|Local Institution, Edmonton, Alberta, Canada|Local Institution, Kingston, Ontario, Canada|Local Institution, Olomouc, Czech Republic|Local Institution, Praha, Czech Republic|Local Institution, Brest, Cedex, France|Local Institution, Clermont Ferrand, France|Local Institution, Lyon Cedex 08, France|Local Institution, Lyon, France|Local Institution, Marseille Cedex 09, France|Local Institution, Paris, France|Local Institution, Rennes, France|Local Institution, Toulouse, France|Local Institution, Vandoeuvre Les Nancy, France|Local Institution, Berlin, Germany|Local Institution, Essen, Germany|Local Institution, Heidelberg, Germany|Local Institution, Jena, Germany|Local Institution, Kiel, Germany|Local Institution, Mannheim, Germany|Local Institution, Wurzburg, Germany|Local Institution, Pécs, Hungary|Local Institution, Johannesburg, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Pretoria, Gauteng, South Africa|Local Institution, Cape Town, Western Cape, South Africa		https://ClinicalTrials.gov/show/NCT00289640
180	NCT01838200	A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumab Therapy in Patients With Advanced Metastatic Melanoma		Terminated	No Results Available	Metastatic Melanoma	Biological: Bacillus Calmette-Guérin (BCG) vaccine|Drug: Ipilimumab	Safety|Clinical Efficacy as measured by tumor response|Immunogenicity: Humoral Immunity|Immunogenicity: Cellular Immunity|Immunogenicity; In situ Immunity	Ludwig Institute for Cancer Research|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	6	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LUD2012-003	April 2013	October 31, 2016	June 14, 2017	April 23, 2013	null	March 8, 2018	Austin Health, LICR Melbourne Austin Branch, Heidelberg, Victoria, Australia		https://ClinicalTrials.gov/show/NCT01838200
181	NCT00796991	Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine		Completed	Has Results	Advanced Melanoma	Drug: Ipilimumab|Drug: Carboplatin|Drug: Paclitaxel|Drug: Dacarbazine	Pharmacokinetic Parameter Maximum Observed Serum Concentration (Cmax) for Ipilimumab, Paclitaxel, Dacarbazine and the Active Metabolite for Dacarbazine, 5-aminoimidazole-4carboxamide (AIC)- Pharmacokinetic Analysis Population|Area Under the Concentration Time Curve (AUC) From Time Zero to 21 Days [AUC(0-21d)] for Ipilimumab and AUC Time Zero Extrapolated to Infinity [AUC(INF)] for Paclitaxel, Dacarbazine and the Active Metabolite AIC - Pharmacokinetic Analysis Population|Pharmacokinetic Parameter of Time of Maximum Observed Concentration (Tmax) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population|Pharmacokinetic Parameter of Terminal Elimination Half Life (T-HALF) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population|Pharmacokinetic Parameter of Clearance (CLT) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population|Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population|Number of Participants in Best Overall Response Categories Based on Modified World Health Organization (mWHO) Criteria - All Treated Participants|Number of Participants in Best Overall Response Categories Based on Immune Related (ir) Response Criteria (RC) - All Treated Participants|Number of Participants With Objective Response to Treatment and Disease Control Using mWHO Criteria - All Randomized Participants|Number of Participants With Adverse Events, Serious Adverse Events, Deaths, and Discontinuation Due to Adverse Events From Day 1 to Week 48 - All Treated Population|Mean Absolute Lymphocyte Count (ALC) at Each Nominal Ipilimumab Induction Dose and at End of the Induction Period - Pharmacodynamic Population|Mean Change From Baseline at Weeks 16 and 48 in Diastolic and Systolic Blood Pressure - All Treated Population|Mean Change From Baseline in Pulse Rate at Weeks 16 and 48 - All Treated Population|Mean Change From Baseline in Respiration Rate at Weeks 16 and 48 - All Treated Population|Mean Baseline Change in Body Temperature at Weeks 16 and 48 - All Treated Population|Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Hemoglobin - All Treated Population|Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Leukocytes - All Treated Population|Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Lymphocytes - All Treated Population|Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Neutrophils - All Treated Population|Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Neutrophils Plus Bands - All Treated Population|Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Platelet Count - All Treated Population|Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Alanine Aminotransferase (ALT) - All Treated Population|Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Aspartate Aminotransferase (AST) - All Treated Population|Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Albumin - All Treated Population|Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Alkaline Phosphatase - All Treated Population|Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Bilirubin - All Treated Population|Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Serum Potassium (High) - All Treated Population|Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Amylase - All Treated Population|Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Calcium (High) - All Treated Population|Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Lipase - All Treated Population|Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Uric Acid - All Treated Population	Bristol-Myers Squibb|Medarex	All	18 Years and older   (Adult, Older Adult)	Phase 1	72	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-078	February 2009	November 2009	October 2012	November 24, 2008	January 6, 2014	January 6, 2014	The Angeles Clinic & Research Inst., Los Angeles, California, United States|H Lee Moffit Cancer Cnt And Res Inst, Tampa, Florida, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Blumenthal Cancer Center, Carolinas Medical Center, Charlotte, North Carolina, United States		https://ClinicalTrials.gov/show/NCT00796991
182	NCT03445533	A Study of IMO-2125 in Combination With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)	ILLUMINATE-301	Recruiting	No Results Available	Metastatic Melanoma	Drug: Ipilimumab|Drug: IMO-2125	Compare the efficacy of IMO-2125 in combination with ipilimumab versus ipilimumab alone	Idera Pharmaceuticals, Inc.|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 3	308	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2125-MEL-301	May 30, 2018	November 2021	June 2022	February 26, 2018	null	November 28, 2018	University of Alabama at Birmingham (UAB), Birmingham, Alabama, United States|Banner MD Anderson Cancer Center, Gilbert, Arizona, United States|Cancer Treatment Centers of America (CTCA) - Western Regional Medical Center, Scottsdale, Arizona, United States|University of Southern California, Los Angeles, California, United States|University of California, Los Angeles (UCLA), Los Angeles, California, United States|Sutter Health Sacramento, Sacramento, California, United States|University of California, San Diego (UCSD) - Moores Cancer Center, San Diego, California, United States|Stanford Cancer Center, Stanford, California, United States|Mount Sinai Medical Center of Florida, Inc., Miami Beach, Florida, United States|University of Florida Health Cancer Center - Orlando Health, Orlando, Florida, United States|The Winship Cancer Institute Emory University, Atlanta, Georgia, United States|Rush University Medical Center, Chicago, Illinois, United States|Community Health Network, Indianapolis, Indiana, United States|Norton Cancer Institute, Louisville, Kentucky, United States|Greater Baltimore Medical Center (GBMC), Baltimore, Maryland, United States|Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States|The Valley Hospital, Ridgewood, New Jersey, United States|The Christ Hospital, Cincinnati, Ohio, United States|University of Cincinnati Health, Cincinnati, Ohio, United States|The Cleveland Clinic Foundation, Cleveland, Ohio, United States|The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solovev Research Institute (OSUCCC - James), Columbus, Ohio, United States|St. Luke's Hospital - Anderson Campus, Easton, Pennsylvania, United States|Virginia Mason Medical Center, Seattle, Washington, United States|West Virginia University Cancer Institute, Morgantown, West Virginia, United States|Greenslopes Private Hospital, Greenslopes, Queensland, Australia|Icon Cancer Center, South Brisbane, Queensland, Australia|Gold Coast University Hospital, Southport, Queensland, Australia|Queen Elizabeth Hospital, Woodville South, South Australia, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|University Hospital Geelong, Geelong, Victoria, Australia|Fiona Stanley Hospital, Murdoch, Western Australia, Australia|Tom Baker Cancer Centre, Calgary, Alberta, Canada|Alberta Health Services Cross Cancer Institute, Edmonton, Alberta, Canada|Princess Margaret Hopsital, Toronto, Ontario, Canada|Fakultni nemocnice Olomouc - Oncology clinic, Olomouc, Czechia|Dermatovenerologika Klinika, Praha, Czechia|Vseobecna fakultni nemocnice v Praze, Praha, Czechia|CHU - Clermont Ferrand, Clermont-Ferrand, Cedex, France|CHRU Besançon - Jean Minjoz, Rouen, Cedex, France|CHU Amiens Picardie - Hopital Sud, Amiens, France|CHRU de Brest - Hopital Augustin Morvan, Brest, France|CHU Dijon - Hôpital Mitterrand, Dijon, France|CHU de Grenoble, La Tronche, France|Centre Leon Berard, Lyon Cedex 08, France|CHU de Marseille - Hopital de la Timone, Marseille, France|Hopital Saint Louis, Paris, France|CHU Hopitaux de Rouen, Rouen, France|Institut Gustave Roussy, Villejuif, France|Universitaetsklinikum Heidelberg Universitaets-Hautklinik, Heidelberg, Germany|Istituto Tumori Giovanni Paolo II IRCCS Ospedale Oncologico Bari, Bari, Italy|ASST degli Spedali Civili di Brescia, Brescia, Italy|Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy|Azienda Ospedaliero Universitaria Senese, Siena, Italy|Universita di Torino, Torino, Italy|Universitair Medisch Centrum Utrecht, Utrecht, Netherlands|Skånes Universitetssjukhus i Lund, Lund, Sweden|Karolinska Universitetssjukhuset, Solna, Sweden|Centrallasarettet i Växjö, Växjö, Sweden		https://ClinicalTrials.gov/show/NCT03445533
183	NCT02846376	Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant	CPIT-002	Recruiting	No Results Available	Acute Myeloid Leukemia and Myelodysplastic Syndrome	Drug: Nivolumab|Drug: Ipilimumab	Safety: The occurrence of at least one treatment-related limiting toxicity defined as a ≥ grade 4 non-hematologic toxicity as specified by the CTCAE 4.0.|Toxicities: Common Terminology Criteria for Adverse Events (CTCAE) will be used for the assessment and grading of all toxicities experienced by patients enrolled into this study.|Assessment of blood immune reconstitution by sequencing to determine diversity and highest frequency clonal specificities|Tumor site immune phenotyping|Assessment of complete response (CR) rate|Assessment of blood phenotype|Assessment of blood TCR repertoire via TCR Immunoseq Assay Profiling|Assess tumor site TCR repertoire using Poisson regression analysis with generalized estimating equations (GEE)|Assess tumor site PD-L1/2 expression|Efficacy as assessed by progression free survival (PFS)	Hackensack Meridian Health	All	18 Years to 70 Years   (Adult, Older Adult)	Phase 1	21	Other	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro2016-0526	October 2018	July 2019	July 2023	July 27, 2016	null	October 2, 2018	John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States		https://ClinicalTrials.gov/show/NCT02846376
184	NCT02304458	Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas		Recruiting	No Results Available	Metastatic Melanoma|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Recurrent Hodgkin Lymphoma|Recurrent Malignant Solid Neoplasm|Recurrent Melanoma|Recurrent Neuroblastoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Osteosarcoma|Recurrent Rhabdomyosarcoma|Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor|Refractory Hodgkin Lymphoma|Refractory Malignant Solid Neoplasm|Refractory Melanoma|Refractory Neuroblastoma|Refractory Non-Hodgkin Lymphoma|Refractory Osteosarcoma|Refractory Rhabdomyosarcoma|Stage III Cutaneous Melanoma AJCC v7|Stage IIIA Cutaneous Melanoma AJCC v7|Stage IIIB Cutaneous Melanoma AJCC v7|Stage IIIC Cutaneous Melanoma AJCC v7|Stage IV Cutaneous Melanoma AJCC v6 and v7	Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Pharmacological Study	Maximum tolerated dose of nivolumab (Phase I)|Response rate of nivolumab, defined as either complete response, partial response, stable disease, or progressive disease, according to the Response Evaluation Criteria in Solid Tumors (Part B)|Response rate of nivolumab in expanded cohorts of patients with neuroblastoma, osteosarcoma, rhabdomyosarcoma, Ewing sarcoma, Hodgkin lymphoma, and non-Hodgkin lymphoma (Part B)|Recommended phase 2 dose of nivolumab plus ipilimumab (Part C)|Response rate of nivolumab combined with ipilimumab, defined as either complete response, partial response, stable disease, or progressive disease, according to the Response Evaluation Criteria in Solid Tumors (Part D)|Response rate of nivolumab combined with ipilimumab in expanded cohorts of patients with neuroblastoma, osteosarcoma, rhabdomyosarcomas, Ewing sarcoma, Hodgkin lymphoma, and non-Hodgkin lymphoma (Part D)|Response rate assessed according to Response Evaluation Criteria in Solid Tumors (Part E)	National Cancer Institute (NCI)	All	12 Months to 30 Years   (Child, Adult)	Phase 1|Phase 2	484	NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NCI-2014-01222|ADVL1412|UM1CA097452	February 2, 2015	October 31, 2020	null	December 2, 2014	null	November 26, 2018	Children's Hospital of Alabama, Birmingham, Alabama, United States|Children's Hospital Los Angeles, Los Angeles, California, United States|Children's Hospital of Orange County, Orange, California, United States|Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States|UCSF Medical Center-Mission Bay, San Francisco, California, United States|Children's Hospital Colorado, Aurora, Colorado, United States|Children's National Medical Center, Washington, District of Columbia, United States|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States|Lurie Children's Hospital-Chicago, Chicago, Illinois, United States|Riley Hospital for Children, Indianapolis, Indiana, United States|National Institutes of Health Clinical Center, Bethesda, Maryland, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|C S Mott Children's Hospital, Ann Arbor, Michigan, United States|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States|Washington University School of Medicine, Saint Louis, Missouri, United States|Columbia University/Herbert Irving Cancer Center, New York, New York, United States|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States|Oregon Health and Science University, Portland, Oregon, United States|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States|St. Jude Children's Research Hospital, Memphis, Tennessee, United States|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States|Seattle Children's Hospital, Seattle, Washington, United States|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States|Hospital for Sick Children, Toronto, Ontario, Canada		https://ClinicalTrials.gov/show/NCT02304458
185	NCT03141177	A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma	CheckMate 9ER	Recruiting	No Results Available	Renal Cell Carcinoma	Biological: Nivolumab|Drug: Cabozantinib|Drug: Sunitinib|Biological: Ipilimumab	Progression Free Survival (PFS) per blinded independent central review (BICR)|Overall Survival (OS)|Objective Response Rate (ORR)|Incidence of adverse events (AEs)|Incidence of Serious Adverse Events (SAEs)	Bristol-Myers Squibb|Exelixis|Ono Pharmaceutical Co. Ltd	All	18 Years and older   (Adult, Older Adult)	Phase 3	630	Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-9ER|2017-000759-20	July 11, 2017	September 22, 2019	April 22, 2023	May 4, 2017	null	November 20, 2018	Southern Cancer Center, Inc., Daphne, Alabama, United States|Cancer Treatment Centers of America-Western, Goodyear, Arizona, United States|University of Arizona Cancer Center, Tucson, Arizona, United States|CBCC Global Research, Inc., Bakersfield, California, United States|Local Institution, Los Angeles, California, United States|UCLA Hematology Oncology, Los Angeles, California, United States|Cancer Care Associates Medical Group, Inc., Redondo Beach, California, United States|Coastal Integrative Cancer Care, San Luis Obispo, California, United States|Central Coast Med Oncology, Santa Maria, California, United States|University Of Colorado Cancer Center, Aurora, Colorado, United States|University Cancer Blood Ctr, Athens, Georgia, United States|Southeastern Regional Medical Center - CTCA, Newnan, Georgia, United States|Rush University Med Ctr, Chicago, Illinois, United States|Midwestern Regional Medical Center, Zion, Illinois, United States|Ft. Wayne Med Onco-Hema Inc, Fort Wayne, Indiana, United States|Cancer Center Of Kansas, Wichita, Kansas, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|Dana Farber Cancer Institute, Boston, Massachusetts, United States|Local Institution, Boston, Massachusetts, United States|University Of Michigan, Ann Arbor, Michigan, United States|HCA Midwest Division, Kansas City, Missouri, United States|Washington University School Of Medicine, Saint Louis, Missouri, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, United States|Local Institution, Buffalo, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Local Institution, Cincinnati, Ohio, United States|Oregon Health & Science University, Portland, Oregon, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|Tennessee Oncology, PLLC, Nashville, Tennessee, United States|Texas Oncology, Austin, Texas, United States|Baylor Sammons Cancer Center, Dallas, Texas, United States|MD Anderson Cancer Center, Houston, Texas, United States|Local Institution, Midland, Texas, United States|Local Institution, Plano, Texas, United States|Texas Cancer Center - Sherman, Sherman, Texas, United States|Local Institution, Salt Lake City, Utah, United States|Virginia Oncology Associates, Norfolk, Virginia, United States|Local Institution, Seattle, Washington, United States|Hospital Italiano De Buenos Aires, Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina|Local Institution, Córdoba, Cordoba, Argentina|Clinica Viedma S.A., Viedma, RIO Negro, Argentina|Centro Medico San Roque, San Miguel De Tucuman, Tucuman, Argentina|Centro De Diagnostico Urologico S.R.L., Buenos Aires, Argentina|Local Institution, Caba, Argentina|Instituto Oncologico De Cordoba, Cordoba, Argentina|Clinica Privada Universitaria Reina Fabiola, Cordoba, Argentina|The Kinghorn Cancer Centre, Darlinghurst, New South Wales, Australia|Macquarie University, North Ryde, New South Wales, Australia|Local Institution, Sydney, New South Wales, Australia|Local Institution, Westmead, New South Wales, Australia|Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Local Institution, South Brisbane, Queensland, Australia|Tasman Oncology Research Pty Ltd, Southport, Queensland, Australia|Cabrini Hospital, Malvern, Victoria, Australia|Affinity Clinical Research Services Pty Ltd, Doubleview, Western Australia, Australia|Local Institution, Elizabeth Vale, Australia|Local Institution, Belo Horizonte, Minas Gerais, Brazil|Local Institution, Ijui, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Porto Alegre, RIO Grande DO SUL, Brazil|Local Institution, Barretos, SAO Paulo, Brazil|Local Institution, Rio De Janeiro, Brazil|Local Institution, Sao Paulo, Brazil|Local Institution, Sao Paulo, Brazil|Centro Internacional de Estudios Clinicos, Recoleta, Santiago DE Chile, Chile|Klinika onkologie a radioterapie, Hradec Kralove, Czechia|Onkologicka klinika, Olomouc, Czechia|Local Institution, Bordeaux, France|Local Institution, Caen, France|Local Institution, Lyon Cedex 08, France|Local Institution, Marseille Cedex 9, France|Local Institution, Montpellier Cedex, France|Local Institution, Nantes, France|Local Institution, Paris, France|Local Institution, Strasbourg Cedex, France|Local Institution, Toulouse, France|Local Institution, Villejuif, France|Universitaetsklinikum Aachen, Aachen, Germany|Universitaetsklinikum Bonn, Bonn, Germany|Klinik Essen-Mitte, Essen, Germany|Universitaetsklinikum Jena, Jena, Germany|Klinikum Rechts Der Isar Der Tum, Muenchen, Germany|Klinikum Nuernberg Nord, Urologische Klinik, Nuernberg, Germany|Uniklinik Tuebingen, Tuebingen, Germany|Alexandra General Hospital, Athens, Greece|Local Institution, Thessaloniki, Greece|Local Institution, Haifa, Israel|Local Institution, Kfar Saba, Israel|Local Institution, Petah Tikva, Israel|Local Institution, Ramat Gan, Israel|Ospedale S. Donato - Usl 8, Arezzo, Italy|Ospedale San Raffaele, Milano, Italy|Azienda Ospedaliera Di Rilievo Nazionale A. Cardarelli, Napoli, Italy|I.O.V. Istituto Oncologico Veneto Ircss, Padova, Italy|IRCCS Istituti Clinici Scientifici Maugeri, Pavia, Italy|Local Institution, Pavia, Italy|Local Institution, Akita-shi, Akita, Japan|Local Institution, Hirosaki-shi, Aomori, Japan|Local Institution, Chiba-shi, Chiba, Japan|Local Institution, Sapporo-shi, Hokkaido, Japan|Local Institution, Sapporo, Hokkaido, Japan|Local Institution, Kobe, Hyogo, Japan|Local Institution, Morioka-shi, Iwate, Japan|Local Institution, Yokohama-shi, Kanagawa, Japan|Local Institution, Yokohama, Kanagawa, Japan|Local Institution, Nagasaki-shi, Nagasaki, Japan|Local Institution, Niigata-shi, Niigata, Japan|Local Institution, Okayama-shi, Okayama, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osaka-shi, Osaka, Japan|Local Institution, Osakasayama-shi, Osaka, Japan|Local Institution, Suita-shi, Osaka, Japan|Local Institution, Hidaka-shi, Saitama, Japan|Local Institution, Tokushima-shi, Tokushima, Japan|Local Institution, Arakawa-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Bunkyo-ku, Tokyo, Japan|Local Institution, Minato-ku, Tokyo, Japan|Local Institution, Shinjuku-Ku, Tokyo, Japan|Local Institution, Yamagata-shi, Yamagata, Japan|Local Institution, Fukuoka, Japan|Comite Mexicano para la Prevenion de la Osteoporosis A.C., Ciudad de Mexico, Distrito Federal, Mexico|Instituto Nacional De Ciencias Medicas Y Nutricion S.Z., Mexico, Distrito Federal, Mexico|Local Institution, Tlalpan, Distrito Federal, Mexico|Investigacion Biomedica para el desarrollo de Farmacos, S.A. de C.V., Zapopan, Jalisco, Mexico|Local Institution, Monterrey, Nuevo LEON, Mexico|Hospital Universitario Dr. Jose Eleuterio Gonzalez, Monterrey, Nuevo LEON, Mexico|Merida Investigacion Clincia, Merida, Yucatan, Mexico|Local Institution, Monterrey, NL, Mexico|Hospital Medica Tec 100, Queretaro, Mexico|WSS w Bialej Podlaskiej, Biala Podlaska, Poland|Ambulatorium Chemioterapii, Bydgoszcz, Poland|Wojewodzkie Centrum Onkologii, Gdansk, Poland|Prof. Dr. Ion Chiricuta Institute Of Oncology Day Care Depar, Cluj-napoca, Romania|Sf. Nectarie Oncology Center, Craiova, Romania|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Moscow, Russian Federation|Local Institution, Nizhniy Novgorod, Russian Federation|Local Institution, Saint-Petersburg, Russian Federation|Local Institution, A Coru?a, Spain|Local Institution, Barcelona, Spain|Local Institution, Madrid, Spain|Local Institution, Madrid, Spain|Local Institution, Santander, Spain|Local Institution, Sevilla, Spain|Local Institution, Valencia, Spain|Local Institution, Ankara, Turkey|Local Institution, Ankara, Turkey|Local Institution, Ankara, Turkey|Local Institution, Antalya, Turkey|Local Institution, Denizli, Turkey|Local Institution, Edirne, Turkey|Local Institution, Istanbul, Turkey|Local Institution, London, United Kingdom|Local Institution, Manchester, United Kingdom|Local Institution, Newcastle Upon Tyne, United Kingdom|Local Institution, Truro, United Kingdom		https://ClinicalTrials.gov/show/NCT03141177
186	NCT03048474	Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma	INITIATE	Active, not recruiting	No Results Available	Malignant Pleural Mesothelioma	Drug: nivolumab and ipilimumab	Disease Controle Rate (DCR) at 12 weeks|Safety: the incidence of adverse events, serious adverse events, deaths and laboratory abnormalities.|Disease Controle Rate (DCR) at 6 months|Progression Free Survival (PFS)|Overall Survival (OS)|Overall Response Rate (ORR)	The Netherlands Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	36	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	N16INM	September 2016	December 2017	December 2019	February 9, 2017	null	November 1, 2018	Netherlands Cancer Institute-Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, North-Holland, Netherlands		https://ClinicalTrials.gov/show/NCT03048474
187	NCT00135408	A Study of MDX-010 (BMS-734016) Administered With or Without Prophylactic Oral Budesonide		Completed	No Results Available	Malignant Melanoma	Drug: Ipilimumab+ Placebo|Drug: Ipilimumab+ Budesonide	Rate of Grade 2,3,4 Diarrhea - patients on study drug.|Safety monitored w/follow-up period. Assess Best Objective response, Disease control rate, progression free survival, overall survival, duration/best objective response, Time/best objective response. PK, immunogenicity & pharmacodynamic analysis	Bristol-Myers Squibb|Medarex	All	18 Years and older   (Adult, Older Adult)	Phase 2	115	Industry	Interventional	Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment	CA184-007	December 2005	July 2007	July 2007	August 26, 2005	null	September 28, 2016	Los Angeles, California, United States|San Francisco, California, United States|Charlotte, North Carolina, United States|Seattle, Washington, United States|Local Institution, Kitchener, Canada|Local Institution, Moncton, Canada|Local Institution, Tel Aviv, Israel|Local Institution, Forli, Italy|Local Institution, Lima, Peru|Local Institution, Hull, United Kingdom		https://ClinicalTrials.gov/show/NCT00135408
188	NCT00357461	Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma		Withdrawn	No Results Available	Melanoma (Skin)	Biological: gp100:209-217(210M) peptide vaccine|Biological: gp100:280-288(288V) peptide vaccine|Biological: incomplete Freund's adjuvant|Biological: ipilimumab	Clinical response|Safety and toxicity|Immunologic response|Response rate|Overall survival	Bristol-Myers Squibb|National Cancer Institute (NCI)	All	16 Years and older   (Child, Adult, Older Adult)	Phase 2	0	Industry|NIH	Interventional	Allocation: Randomized|Masking: None (Open Label)|Primary Purpose: Treatment	CDR0000486705|NCI-06-C-0159|NCI-P6951|MDX-NCI-06-C-0159	May 2006	null	null	July 27, 2006	null	May 15, 2013			https://ClinicalTrials.gov/show/NCT00357461
189	NCT01654692	A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma	NIBIT-M1	Completed	No Results Available	Metastatic Malignant Melanoma	Drug: Ipilimumab and Fotemustine	The immune response disease control rate (irDCR) using the immune-related (ir) tumor response criteria of the combination of ipilimumab and fotemustine in patients with unresectable locally advanced or metastatic melanoma.|safety and feasibility of the combination of ipilimumab and fotemustine|Immune-related Major Durable Disease Control Rate (irMDDCR)|Immune-related Objective Response Rate (irORR)|Immune-related Time to Response (irTTR)|Immune-related Progression-Free Survival (irPFS)|Brain Progression-free Survival (Brain-PFS)|Overall Survival (OS)	Italian Network for Tumor Biotherapy|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	86	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	NIBIT-M1|2010-019356-50	June 2010	May 2012	September 2014	August 1, 2012	null	May 13, 2015	National Institute for Cancer Research, Genoa, Italy|Immunotherapy and Somatic Cell Therapy Unit, Scientific Institute of Romagna, Meldola, Italy|European Institute of Oncology, Milan, Italy|Melanoma Unit, San Raffaele Hospital, Milan, Italy|Surgical Oncology, National Cancer Institute, Milan, Italy|Medical Oncology and Innovative Therapy, National Cancer Institute, Naples, Italy|Medical Oncology and Immunotherapy-University Hospital of Siena, Siena, Italy		https://ClinicalTrials.gov/show/NCT01654692
190	NCT03313323	Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic Melanoma	Zirconipi	Recruiting	No Results Available	Melanoma	Biological: 89Zirconium-labeled ipilimumab	The detection of 89Zr-ipilimumab in tumor lesions|The visual detection of 89Zr-ipilimumab in normal tissue|The quantitative detection of 89Zr-ipilimumab in normal tissue|Comparison between uptake of 89Zr-ipilimumab|Clinical outcome (response)|Clinical outcome (survival)|Side effects|Pharmacokinetics of 89Zr-ipilimumab|CTLA-4+CD4+ expression of PBMCs|Immunohistochemical analysis	VU University Medical Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	29	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic	2015.300	February 16, 2017	February 16, 2019	February 15, 2020	October 18, 2017	null	October 18, 2017	VU Medical Center, Amsterdam, Noord-Holland, Netherlands		https://ClinicalTrials.gov/show/NCT03313323
191	NCT00972933	Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma		Completed	No Results Available	Melanoma	Drug: ipilimumab	To study the effects of ipilimumab upon the host immune response in nodal metastatic melanoma and in the peripheral blood comparing pre-treatment with post-treatment (baseline, 6 weeks) immunologic features.|To study the effects of ipilimumab upon the host immune response.|To collect pilot data comparing pre-treatment with post-treatment proteomic and genetic features.|To evaluate the clinical efficacy of preoperative neoadjuvant therapy with ipilimumab in high risk clinically and pathologically node-positive melanoma patients (AJCC stage IIIB-C).|To collect safety data and evaluate the safety of neoadjuvant therapy with ipilimumab in high risk clinically and pathologically node-positive melanoma patients (AJCC stage IIIB-C).	Diwakar Davar|Bristol-Myers Squibb|University of Pittsburgh	All	18 Years and older   (Adult, Older Adult)	Early Phase 1	59	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	08-144	December 2009	July 17, 2013	September 26, 2017	September 9, 2009	null	December 7, 2017	University of Pittsburgh Medical Center/University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT00972933
192	NCT03528408	Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma		Recruiting	No Results Available	Melanoma	Drug: Nivolumab|Drug: Ipilimumab	3 year Relapse Free Survival (RFS)|Median RFS|Overall Survival (OS)|3 year OS|Assess Adverse Events	Suthee Rapisuwon|Bristol-Myers Squibb|Hoosier Cancer Research Network	All	18 Years and older   (Adult, Older Adult)	Phase 2	50	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCRN-MEL17-309	July 26, 2018	July 2020	June 2023	May 17, 2018	null	September 21, 2018	Georgetown University, Washington, District of Columbia, United States		https://ClinicalTrials.gov/show/NCT03528408
193	NCT02731729	Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy		Active, not recruiting	No Results Available	Melanoma	Drug: ipilimumab|Drug: nivolumab	objective response as defined by RECIST v1.1 criteria	Parker Institute for Cancer Immunotherapy|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	70	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PICI0001|16-043	April 2016	August 2018	January 1, 2021	April 7, 2016	null	July 9, 2018	University of California, Los Angeles, Los Angeles, California, United States|University of California, San Francisco, San Francisco, California, United States|Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States|Memorial Sloan Kettering Westchester, Harrison, New York, United States|Memorial Sloan Kettering Cancer Center, New York, New York, United States|Lehigh Valley Health Network, Allentown, Pennsylvania, United States|University of Pennsylvania, Philadelphia, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02731729
194	NCT02970981	Study of Combination of Ipilimumab and Nivolumab in Patients With Melanoma		Active, not recruiting	No Results Available	Melanoma	Biological: Nivolumab|Biological: Ipilimumab	Safety (adverse events) of the protocol therapy|Immune Response Assessment|Time to relapse	New York University School of Medicine|Bristol-Myers Squibb	All	16 Years and older   (Child, Adult, Older Adult)	Phase 2	16	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	16-00098	November 29, 2016	November 2018	November 2020	November 22, 2016	null	December 18, 2017	Laura and Isaac Perlmutter Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02970981
195	NCT01119508	Ipilimumab + Temozolomide in Metastatic Melanoma		Completed	No Results Available	Metastatic Melanoma	Drug: Ipilimumab|Drug: Temozolomide	6-Month Progression-Free Survival (PFS) Rate	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years to 75 Years   (Adult, Older Adult)	Phase 2	64	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2009-0408|NCI-2011-00565	May 2010	August 2016	August 2016	May 7, 2010	null	August 17, 2016	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT01119508
196	NCT03682276	Safety and Bioactivity of Ipilimumab and Nivolumab Combination Prior to Liver Resection in Hepatocellular Carcinoma	PRIME-HCC	Not yet recruiting	No Results Available	Hepatocellular Carcinoma	Biological: Ipilimumab|Biological: Nivolumab	Delay to surgery|Incidence of treatment-emergent adverse events [Safety and Tolerability]|Objective response rate|Pathologic response rate	Imperial College London|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	32	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	C/36/2017|2018-000987-27|CA209-9LC	December 1, 2018	December 1, 2020	September 1, 2022	September 24, 2018	null	September 24, 2018	Imperial College Healthcare NHS Trust, London, Greater London, United Kingdom		https://ClinicalTrials.gov/show/NCT03682276
197	NCT02917772	Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma	TITAN-RCC	Recruiting	No Results Available	Carcinoma, Renal Cell|Clear-cell Metastatic Renal Cell Carcinoma	Biological: Nivolumab/Ipilimumab	Objective Response Rate (ORR)|General considerations: RR, TTR, DoR, PFS, TIR (Time to Immunotherapy Resistance), OS|Remission Rates during TITAN treatment: RR1, RR2, RR2SD, RR3|Time to Immunotherapy Resistance: TIR|Time-to-Response: TTR|Duration of Response: DOR|Overall survival:OS|Safety: Adverse events assessment|Safety: Frequency of abnormal laboratory parameters|Patient reported outcomes|Exploratory objectives: Immune monitoring	AIO-Studien-gGmbH|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	200	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	0216-ASG	October 2016	October 2018	July 2021	September 28, 2016	null	July 16, 2018	Ordensklinikum Linz Barmherzige Schwestern, Linz, Austria|AKH Wien Universitätsklinik für Innere Medizin I, Wien, Austria|ZNA Middelheim, Antwerpen, Belgium|CHR Verviers, Verviers, Belgium|Fakultní nemocnice Hradec Králové, Hradec Králové, Czechia|Fakultní nemocnice Olomouc, Olomouc, Czechia|FN Motol, Praha, Czechia|Všeobecné fakultní nemocnice, Praha, Czechia|CHD Vendée, La Roche-Sur-Yon, France|Centre Hôpitalier Lyon Sud, Lyon, France|Hôpitaux Universitaires de Strasbourg Hôpital Civil, Strasbourg, France|Institut Claudius Regaud, Toulouse, France|Institut Gustave Roussy, Villejuif, France|Universitätsklinikum Jena und Poliklinik für Urologie, Jena, Thüringen, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|Universitätsklinikum Carl Gustav Carus, Dresden, Germany|Universitätsklinikum Düsseldorf, Düsseldorf, Germany|Universitätsklinikum, Düsseldorf, Germany|Universität des Saarlandes Medizinische Fakultät, Homburg/Saar, Germany|Azienda USL8 Arezzo U.O.C. Oncologia Medica, Arezzo, Italy|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy|IRCCS Fondazione Policlinico San Matteo, Pavia, Italy|Azienda Ospedaliera San Camillo Forlanini, Roma, Italy|Policlinico Universitario A. Gemelli, Roma, Italy|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital 12 de Octubre, Madrid, Spain|Hospital Ramón y Cajal, Madrid, Spain|Hospital Universitario Central de Asturias, Oviedo, Spain|Complejo Hospitalario de Navarra, Pamplona, Spain|Hospital Universitario Marques de Valdecilla, Santander, Spain|Hospital Virgen del Rocio, Sevilla, Spain|Broomfield Hospital, Chelmsford, United Kingdom|Charing Cross Hospital, London, United Kingdom|Kent Oncology Centre, Maidstone, United Kingdom|Royal Preston Hospital, Preston, United Kingdom		https://ClinicalTrials.gov/show/NCT02917772
198	NCT01323517	Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity		Completed	Has Results	Melanoma	Drug: Ipilimumab, Melphalan and Dactinomycin	Progression Free Survival at One Year.|Toxicity of Additional Ipilimumab Will be Evaluated for All Treated Patients Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0|To Determine Response Rates of Combination Therapy. Tumor Assessment Will be Measured by the Immune Related Response Criteria (irRC).|To Define the Immunologic Events and Signatures at the Tumor Site and in the Periphery That Corresponds to Response to Ipilimumab.	Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	26	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	10-101	February 2011	August 14, 2017	August 14, 2017	March 25, 2011	May 15, 2018	May 15, 2018	Memorial Sloan Kettering Cancer Center, New York, New York, United States	"Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/17/NCT01323517/Prot_SAP_000.pdf	https://ClinicalTrials.gov/show/NCT01323517
199	NCT03219671	Nivolumab and Ipilimumab in Classical Kaposi Sarcoma (CKS)		Not yet recruiting	No Results Available	Classic Kaposi Sarcoma	Drug: Nivolumab|Drug: Ipilimumab	ORR|PFS rate|Safety - Incidence of Treatment-Emergent Adverse Events according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events, Version 4.0 (CTCAE v4)|Tolerability - treatment related adverse events (AEs) that caused study drug interruption and discontinuation	Alona Zer|Bristol-Myers Squibb|Rabin Medical Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	20	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA209-937|0095-17-RMC	December 1, 2017	September 1, 2020	September 1, 2022	July 17, 2017	null	September 29, 2017			https://ClinicalTrials.gov/show/NCT03219671
200	NCT02196961	Adjuvant Therapy of Completely Resected Merkel Cell Carcinoma With Immune Checkpoint Blocking Antibodies Versus Observation	ADMEC-O	Recruiting	No Results Available	Merkel Cell Carcinoma	Drug: Ipilimumab|Drug: Nivolumab	Disease-free survival (DFS) at 12 months|Number of adverse events|Overall survival rate at 12 months|DFS rate at 12 months	Prof. Dr. med. Dirk Schadendorf|Bristol-Myers Squibb|University Hospital, Essen	All	18 Years and older   (Adult, Older Adult)	Phase 2	177	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	CA184-205	June 2014	March 2021	March 2021	July 22, 2014	null	August 29, 2017	University Hospital Essen, Dermatology, Essen, NRW, Germany|Charité Universitätsmedizin Berlin, Berlin, Germany|Elbeklinikum Buxtehude, Buxtehude, Germany|University Hospital Dresden, Dermatology, Dresden, Germany|SRH Wald-Klinikum Gera, Gera, Germany|Hannover Medical School, Hannover, Germany|National Centre for Tumour Diseases (NCT), Heidelberg, Germany|University Hospital Schleswig-Holstein, Kiel, Kiel, Germany|University Hospital München (LMU), Munich, Germany|Specialist clinic in Hornheide, Münster, Germany|University Hospital Tübingen, Tübingen, Germany		https://ClinicalTrials.gov/show/NCT02196961
201	NCT03149159	Investigator-Initiated Trial of Combined Ipilimumab, Nivolumab and Stereotactic Radiation in Patients With Metastatic Clear-Cell RCC (ccRCC) Who Have Failed Treatment With Single-Agent Nivolumab		Withdrawn	No Results Available	Clear Cell Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma	Drug: Nivolumab|Drug: Ipilimumab|Radiation: Steriotactic radiation therapy	Number of patients with a partial or complete response|Progression free survival (PFS)	Medical University of South Carolina|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	0	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	102576|CA209-927	April 1, 2018	April 1, 2018	April 1, 2018	May 11, 2017	null	June 18, 2018	Medical University of South Carolina, Charleston, South Carolina, United States		https://ClinicalTrials.gov/show/NCT03149159
202	NCT02736123	Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone		Withdrawn	No Results Available	Melanoma	Drug: Nivolumab - Arm A|Drug: Nivolumab + Ipilimumab - Arm B	Assess the pathologic complete response rate (absence of viable tumor on histologic assessment)|Evaluate preoperative clinical/radiologic response rate|Assess progression free survival|Assess overall survival|Assess biomarkers CD8 T cell, PD-L1 and IDO expression by immunohistochemistry|Assess safety and adverse events	University of Pittsburgh|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	0	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	15-113	October 2016	February 9, 2017	February 9, 2017	April 13, 2016	null	September 20, 2017	UPMC Cancer Center Hillman Cancer Center, Pittsburgh, Pennsylvania, United States		https://ClinicalTrials.gov/show/NCT02736123
203	NCT03724968	Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression		Not yet recruiting	No Results Available	Metastatic Melanoma|Advanced Melanoma|Metastatic Melanoma Stratified by MHC-II Expression	Drug: Nivolumab|Drug: Relatlimab|Drug: Ipilimumab	Change in activated GZMB+ CD8+T-cell density intratumorally, of two immunotherapy regimens|Response rate|Median progression free survival|Median overall survival|Number of participants with treatment-related adverse events as assessed by CTCAE version 5.0	Elizabeth Davis|Bristol-Myers Squibb|Vanderbilt-Ingram Cancer Center	All	18 Years and older   (Adult, Older Adult)	Phase 2	36	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	VICC MEL 18114|NCI-2018-02469	November 2018	November 2022	November 2023	October 30, 2018	null	October 30, 2018	Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States		https://ClinicalTrials.gov/show/NCT03724968
204	NCT03305445	Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL		Recruiting	No Results Available	Relapsed Diffuse Large B-Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma	Drug: Ipilimumab|Drug: Nivolumab	Dose Limiting Toxicities (DLTs)|Completion Remission (CR) Rate|Progression Free Survival (PFS)|Overall Survival (OS)|IgVH level|Delayed CR|Overall Response Rate (ORR)	Icahn School of Medicine at Mount Sinai|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	13	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GCO 17-2164	May 14, 2018	February 1, 2020	April 1, 2020	October 10, 2017	null	May 24, 2018	Icahn School of Medicine at Mount Sinai, New York, New York, United States		https://ClinicalTrials.gov/show/NCT03305445
205	NCT02437279	Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients	OpACIN	Active, not recruiting	No Results Available	Stage III Skin Melanoma	Procedure: Surgery of the tumor|Drug: Infusion with ipilimumab 3 mg/kg q3wks|Drug: Infusion with nivolumab 1 mg/kg q3wks	The alteration in magnitude of the neo-antigen specific T cell response in the time interval pre- to post-adjuvant therapy in peripheral blood|Safety as measured by SUSARs.|The alteration in breadth of the neo-antigen specific T cell response in the time interval pre- to post-adjuvant therapy in peripheral blood|Feasibility as measured adherence to the timelines in the study protocol.|Recurrence Free Survival, as determined according to RECIST 1.1 criteria.|Rate of adverse events and late adverse events|Type of adverse events and late adverse events	The Netherlands Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	20	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	N14OPC|CA209-278|NL51280.031.14	August 12, 2015	December 2017	April 2018	May 7, 2015	null	July 18, 2017	Netherlands Cancer Institute, Amsterdam, NH, Netherlands		https://ClinicalTrials.gov/show/NCT02437279
206	NCT03340129	Anti-PD 1 Brain Collaboration + Radiotherapy: The ABC-X Study		Not yet recruiting	No Results Available	Melanoma Stage Iv	Drug: Ipilimumab|Drug: Nivolumab|Radiation: Stereotactic Radiotherapy|Radiation: Whole Brain Radiotherapy	Intracranial response to immunotherapy|Intracranial progression free survival for patients receiving the addition of radiotherapy|Best extracranial response rate|Overall response rate|Overall progression free survival|Overall survival|Change in neurocognitive function scores|Neurological adverse events requiring an intervention|Description of impaired neurological function and neurological adverse events|Time to neurological deterioration|Duration of neurological deterioration|Patient rated quality of life|Proxy rated quality of life|Functional performance status|Adverse events|Tissue and blood biomarkers of response, progression and neurotoxicity	Melanoma Institute Australia|Bristol-Myers Squibb	All	18 Years to 120 Years   (Adult, Older Adult)	Phase 2	155	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MIA2017/CT	February 2019	August 2020	August 2023	November 13, 2017	null	November 2, 2018	Westmead Hospital, Sydney, New South Wales, Australia|Melanoma Institute Australia, Wollstonecraft, New South Wales, Australia|Princess Alexandra Hospital, Woolloongabba, Queensland, Australia|Royal Adelaide Hospital, Adelaide, South Australia, Australia|Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia		https://ClinicalTrials.gov/show/NCT03340129
207	NCT02659540	A Pilot Study to Evaluate the Safety and Efficacy of Combination Checkpoint Blockade Plus External Beam Radiotherapy in Subjects With Stage IV Melanoma		Active, not recruiting	No Results Available	Melanoma	Drug: Ipilimumab|Drug: Nivolumab|Radiation: Radiotherapy	Assessment of Safety according to to the National Cancer Institute Common Terminology Criteria for Adverse Events.|Overall response rate at weeks 12 and 18.|Disease control rate at weeks 12 and 18.|Progression-Free Survival|Overall Survival|Duration of Response	Ludwig Institute for Cancer Research|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	20	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	LUD2015-006	October 13, 2016	December 2018	December 2021	January 20, 2016	null	September 13, 2018	Research Facility, Palo Alto, California, United States|Research Facility, New York, New York, United States		https://ClinicalTrials.gov/show/NCT02659540
208	NCT02977052	Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab	OpACIN-neo	Recruiting	No Results Available	Malignant Melanoma Stage III	Drug: Ipilimumab|Drug: Nivolumab|Procedure: Surgery|Procedure: Blood for PBMCs|Procedure: Biopsies	Safety as measured by the frequency of grade 3/4 immune-related adverse events, using CTCAE 4.03|Response rate according to RECIST 1.1|Pathological response according to central pathological revision, according to pathological response criteria|Pathologic response rate according to central revision of the marked index lymph node|RFS at 24 months in patients achieving pCR or pnCR in their marked index lymph node and did not undergo CLND. RFS will be calculated from date of resection of the marked lymph node.|RFS at 24 months in patients with pNR and being subsequently treated with adjuvant nivolumab+optional radiotherapy (or dabrafenib/trametinib if BRAFV600E pos. and treatment is approved). RFS will be calculated from day of resection of marked lymph node.|Recurrence Free Survival|Description of late adverse events using CTCAE 4.03|Description of associations of mutational load, RNA tumor signatures, and tumor educated platelet signatures with tumor immune infiltrates and response|Response rate according to RECIST 1.1 at week 6|RFS at 2, 3 and 5 years	The Netherlands Cancer Institute|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	110	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	M16OPN|2016-001984-35|CA209-701	November 2016	June 2020	June 2022	November 30, 2016	null	November 6, 2018	Melanoma Institute Australia, Sydney, New South Wales, Australia|Medical University of Vienna, Vienna, Austria|Netherlands Cancer Institute, Amsterdam, NH, Netherlands|Karolinska Institutet, Stockholm, Sweden		https://ClinicalTrials.gov/show/NCT02977052
209	NCT03241186	Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma		Recruiting	No Results Available	Mucosal Melanoma	Drug: Ipilimumab|Drug: Nivolumab	Assess Recurrence-free survival time (RFS)|Assess the Adverse Events|Overall Survival (OS)	Robert R. McWilliams, MD|Bristol-Myers Squibb|Hoosier Cancer Research Network	All	18 Years and older   (Adult, Older Adult)	Phase 2	36	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MEL16-252	September 12, 2017	April 2019	April 2021	August 7, 2017	null	July 13, 2018	University of Iowa Hospital and Clinics, Iowa City, Iowa, United States|University of Minnesota, Minneapolis, Minnesota, United States|Mayo Clinic Rochester, Rochester, Minnesota, United States|Nebraska Cancer Specialists, Omaha, Nebraska, United States		https://ClinicalTrials.gov/show/NCT03241186
210	NCT03117309	Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma		Recruiting	No Results Available	Advanced Renal Cell Carcinoma	Drug: Nivolumab 240 mg|Drug: Ipilimumab 1mg/kg|Drug: Nivolumab 3mg/kg|Drug: Nivolumab 360mg	Progression Free Survival (PFS) rate|Objective Response Rate (CR/PR)|Response Rate|Clinical Activity (Complete Response (CR), Partial Response (PR) and Stable Disease (SD)|Progression Free Survival (PFS) at one year|Toxicity by calculating the frequency and percentage of adverse event terms (CTCAE v4)	Michael B. Atkins, MD|Bristol-Myers Squibb|Hoosier Cancer Research Network	All	18 Years and older   (Adult, Older Adult)	Phase 2	120	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCRN GU16-260	April 24, 2017	February 2020	February 2021	April 17, 2017	null	November 5, 2018	Georgetown University, Washington, District of Columbia, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, United States|Northwestern University Feinberg Schooll Of Medicine, Chicago, Illinois, United States|University of Illinois Cancer Center, Chicago, Illinois, United States|Beth Isreal Deaconess Medical Center, Boston, Massachusetts, United States|Hackensack University Medical Center, Hackensack, New Jersey, United States|Columbia University, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States|Univeristy of Pennsylvania, Philadelphia, Pennsylvania, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|University of Texas Southwestern Medical Center, Dallas, Texas, United States		https://ClinicalTrials.gov/show/NCT03117309
211	NCT01740401	CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma		Terminated	Has Results	Melanoma	Drug: Cyclophosphamide	The Anti-tumor Activity of the Combination of Low Dose Cyclophosphamide and CTLA-4 Blockade Using Objective Response Rate (ORR)|Progression-free Survival|T Regulatory Cell Profile in Peripheral Blood	Icahn School of Medicine at Mount Sinai|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	10	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	GCO 14-0677|114660	October 2012	December 2013	December 2014	December 4, 2012	April 26, 2017	December 6, 2017	New York University Langone Clinical Cancer Center, New York, New York, United States		https://ClinicalTrials.gov/show/NCT01740401
212	NCT03307616	Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma		Recruiting	No Results Available	Systemic Connective Tissue Disorders	Drug: Nivolumab|Drug: Ipilimumab|Radiation: Radiation Therapy	Pathologic Response|Immunologic Response|Change in Immune Infiltrate in Response to Neoadjuvant Nivolumab Monotherapy and Neoadjuvant Nivolumab and Ipilimumab Combination Therapy|Objective Response Rate (ORR) of Nivolumab Monotherapy and Nivolumab and Ipilimumab Combination Therapy|Recurrence-Free Survival (RFS)|Overall Survival (OS)|Safety of Nivolumab Monotherapy and Combination Ipilimumab and Nivolumab in the Neoadjuvant Setting and Peri-Operatively	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	40	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2017-0143|NCI-2018-01031	October 4, 2017	October 2021	October 2021	October 12, 2017	null	October 12, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT03307616
213	NCT00790010	Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma		Active, not recruiting	No Results Available	Melanoma	Drug: Bevacizumab Plus Ipilimumab Cohort 1|Drug: Bevacizumab Plus Ipilimumab Cohort 2|Drug: Bevacizumab Plus Ipilimumab Cohort 3|Drug: Bevacizumab Plus Ipilimumab Cohort 4	To determine the safety, tolerability and maximum tolerated dosing for the combination of bevacizumab plus ipilimumab in patients with unresectable stage III or stage IV melanoma|To determine the best overall response rate by standard solid tumor response criteria, disease control rate, time to tumor progression, and duration of response for the combination of bevacizumab plus ipilimumab in this patient population|To perform correlative studies investigating the effects of this combination therapy on antitumor immunity and tumor vasculature	Dana-Farber Cancer Institute|Genentech, Inc.|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	46	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	08-142|CA184-058|AVF 4122s	February 26, 2009	June 22, 2018	February 2019	November 13, 2008	null	October 17, 2018	Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States|Dana-Farber Cancer Institute, Boston, Massachusetts, United States|Massachusetts General Hospital, Boston, Massachusetts, United States		https://ClinicalTrials.gov/show/NCT00790010
214	NCT03692338	INTENSE: A Study of a Supervised or Semi-Supervised Exercise InterveNtion or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects Receiving Ipilimumab and Nivolumab for Advanced or Metastatic Renal Cell Carcinoma		Recruiting	No Results Available	Metastatic Renal Cell Carcinoma	Behavioral: Exercise	Change in Cardiopulmonary function,|Patient-reported fatigue as measured by the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale|Patient-reported activity as measured by the Godin Leisure Time Exercise Questionnaire|Patient-reported symptoms as measured by the Functional Assessment of Cancer Therapy-Kidney Symptom Index-19 (FKSI-19)|Patient health outcome as measured by the EQ-5D health questionnaire	Duke University|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Not Applicable	30	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care	Pro00082941	November 19, 2018	August 31, 2020	August 31, 2020	October 2, 2018	null	November 26, 2018	Duke University Medical Center, Durham, North Carolina, United States		https://ClinicalTrials.gov/show/NCT03692338
215	NCT02530463	Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS)		Recruiting	No Results Available	Leukemia|Myelodysplastic Syndrome	Drug: Nivolumab|Drug: Ipilimumab|Drug: 5-azacitidine	Overall Response Rate (ORR) in MDS Participants with Hypomethylating Agent Failure|Overall Response Rate (ORR) in MDS Participants Who Have Not Received Hypomethylating Agents	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 2	120	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2014-0930|NCI-2015-01494	September 8, 2015	September 2021	September 2022	August 21, 2015	null	April 30, 2018	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT02530463
216	NCT01409174	IPI Biochemotherapy for Chemonaive Patients With Metastatic Melanoma		Terminated	No Results Available	Melanoma	Drug: Ipilimumab|Drug: Temozolomide|Drug: Cisplatin|Drug: Interferon Alfa-2b|Drug: Interleukin-2	Tumor Response by Participant using immune-related response criteria (irRC)	M.D. Anderson Cancer Center|Bristol-Myers Squibb	All	18 Years to 65 Years   (Adult, Older Adult)	Phase 1	19	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	2011-0073|NCI-2011-02768	February 2013	May 2016	May 2016	August 4, 2011	null	May 31, 2017	University of Texas MD Anderson Cancer Center, Houston, Texas, United States		https://ClinicalTrials.gov/show/NCT01409174
217	NCT03552380	Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell Carcinoma		Recruiting	No Results Available	Renal Cell Carcinoma	Drug: Entinostat|Drug: Nivolumab|Drug: Ipilimumab	Establish the recommended Phase II dose (RP2D)|Objective Response Rate (ORR) via RECIST 1.1|Assess Adverse Events|ORR via irRC|Progression Free Survival (PFS) via RECIST 1.1|Progression Free Survival (PFS) via irRC|Overall Survival (OS)	Roberto Pili|Bristol-Myers Squibb|Syndax Pharmaceuticals|Indiana University School of Medicine|Hoosier Cancer Research Network	All	18 Years and older   (Adult, Older Adult)	Phase 2	53	Other|Industry	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	HCRN GU17-326	August 31, 2018	August 2019	August 2020	June 11, 2018	null	September 10, 2018	Indiana Univeristy Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States		https://ClinicalTrials.gov/show/NCT03552380
218	NCT03707457	Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma		Not yet recruiting	No Results Available	Glioblastoma|Glioblastoma Multiforme	Drug: Nivolumab|Drug: Anti-GITR Monoclonal Antibody MK-4166|Drug: IDO1 inhibitor INCB024360|Drug: Ipilimumab	Proportion of subjects with dose limiting toxicities evaluated according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1	30	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	J17154	November 2018	November 2021	November 2023	October 16, 2018	null	October 16, 2018			https://ClinicalTrials.gov/show/NCT03707457
219	NCT03493932	Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade		Recruiting	No Results Available	Glioblastoma	Drug: Nivolumab|Drug: BMS-986016	The primary outcome measure is the proportion of patients that have a rise in interferon gamma levels within the tumor microenvironment of 4 pg/ml or higher before the first dose of Nivolumab as compared to after the first dose, the safety of th...|1)change in IFNg in body 2)response of immune environment of brain tumor tissue to Nivolumab 3)To evaluate clinical response of pts 4)the difference in survival between responders and non-responders 5)differences in the immune cells and secreted...	National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)	All	18 Years and older   (Adult, Older Adult)	Phase 1	15	NIH	Interventional	Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other	180077|18-N-0077	September 24, 2018	June 1, 2021	June 1, 2021	April 11, 2018	null	October 26, 2018	National Institutes of Health Clinical Center, Bethesda, Maryland, United States		https://ClinicalTrials.gov/show/NCT03493932
220	NCT02693535	TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer	TAPUR	Recruiting	No Results Available	Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors	Drug: Axitinib|Drug: Bosutinib|Drug: Crizotinib|Drug: Palbociclib|Drug: Sunitinib|Drug: Temsirolimus|Drug: Trastuzumab and Pertuzumab|Drug: Vemurafenib and Cobimetinib|Drug: Cetuximab|Drug: Dasatinib|Drug: Regorafenib|Drug: Olaparib|Drug: Pembrolizumab|Drug: Nivolumab and Ipilimumab	Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria|Overall survival (OS)	American Society of Clinical Oncology|AstraZeneca|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Merck Sharp & Dohme Corp.|Pfizer	All	12 Years and older   (Child, Adult, Older Adult)	Phase 2	1440	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	Pro00014171	March 2016	March 2019	null	February 26, 2016	null	September 11, 2018	University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States|Cancer Treatment Centers of America-Phoenix, Phoenix, Arizona, United States|The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate, Los Angeles, California, United States|Sutter Cancer Research Consortium, San Francisco, California, United States|University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States|Cancer Treatment Centers of America - Atlanta, Atlanta, Georgia, United States|Emory University Winship Cancer Institute, Atlanta, Georgia, United States|Cancer Treatment Centers of America-Chicago, Chicago, Illinois, United States|University of Michigan, Ann Arbor, Michigan, United States|Cancer Research Consortium of West Michigan, Grand Rapids, Michigan, United States|Michigan Cancer Research Consortium, Traverse City, Michigan, United States|University of Nebraska Medical Center, Omaha, Nebraska, United States|Carolina's HealthCare System's Levine Cancer Institute, Charlotte, North Carolina, United States|Sanford Health- Bismarck, Bismarck, North Dakota, United States|Sanford Health- Fargo, Fargo, North Dakota, United States|Cancer Treatment Centers of America-Tulsa, Tulsa, Oklahoma, United States|Providence Health & Services, Portland, Oregon, United States|Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States|Cancer Treatment Centers of America-Philadelphia, Philadelphia, Pennsylvania, United States|Sanford Cancer Center Oncology Clinic and Pharmacy, Sioux Falls, South Dakota, United States|The University of Texas MD Anderson Cancer Center, Houston, Texas, United States|Intermountain Healthcare, Salt Lake City, Utah, United States|Inova Schar Cancer Institute, Fairfax, Virginia, United States|Swedish Cancer Institute, Seattle, Washington, United States		https://ClinicalTrials.gov/show/NCT02693535
221	NCT01176474	Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma		Active, not recruiting	No Results Available	Melanoma (Skin)	Biological: NY-ESO-1 157-165 (165V)|Drug: Nivolumab|Biological: gp100:280-288 (288V)|Drug: Montanide ISA 51 vegetable grade (VG)|Drug: Ipilimumab|Procedure: Apheresis Procedure	Time to Relapse|Overall Survival (OS)	H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|Medarex|Bristol-Myers Squibb	All	16 Years and older   (Child, Adult, Older Adult)	Phase 1	73	Other|NIH|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	MCC-15651|NCI-8316	July 28, 2010	October 2019	October 2020	August 6, 2010	null	July 12, 2018	H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States		https://ClinicalTrials.gov/show/NCT01176474
222	NCT03161756	Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma	CHARLI	Recruiting	No Results Available	Melanoma Stage Iv|Melanoma Stage Iii|Melanoma	Drug: Denosumab|Drug: Nivolumab|Drug: Ipilimumab	Median Progression-Free Survival|Occurrence of Grade 3 and 4 Selected Immune-related Adverse Events (irAEs) of interest|Rate of Grade 3 and 4 irAEs|Best Overall Response According to RECIST 1.1|Progression-Free Survival|Overall Survival|Toxicity Profiles of the Checkpoint-Denosumab Combinations|Occurrence of Treatment Discontinuation Due to Toxicity	Australia and New Zealand Melanoma Trials Group|Peter MacCallum Cancer Centre, Australia|Amgen|Bristol-Myers Squibb	All	18 Years and older   (Adult, Older Adult)	Phase 1|Phase 2	72	Other|Industry	Interventional	Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	ANZMTG 01.15	December 7, 2017	June 2021	June 2023	May 22, 2017	null	September 26, 2018	Royal Brisbane and Women's Hospital, Herston, Queensland, Australia|Box Hill Hospital, Box Hill, Victoria, Australia|Austin Health, Heidelberg, Victoria, Australia|Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia		https://ClinicalTrials.gov/show/NCT03161756
223	NCT03297606	Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)	CAPTUR	Recruiting	No Results Available	Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors	Drug: Olaparib|Drug: Dasatinib|Drug: Nivolumab plus Ipilimumab|Drug: Axitinib|Drug: Bosutinib|Drug: Crizotinib|Drug: Palbociclib|Drug: Sunitinib|Drug: Temsirolimus|Drug: Erlotinib|Drug: Trastuzumab plus Pertuzumab|Drug: Vemurafenib plus Cobimetinib|Drug: Vismodegib	Objective response rate defined as the number of patients with complete response or partial response|Number and severity of adverse events|Progression-free survival confirmed by disease-appropriate objective criteria	Canadian Cancer Trials Group|AstraZeneca|Bristol-Myers Squibb|Hoffmann-La Roche|Pfizer	All	18 Years and older   (Adult, Older Adult)	Phase 2	720	Other|Industry	Interventional	Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment	PM1|ESR‐17‐12831|CA209‐9DL|ML39800|WI233446	October 6, 2017	September 2021	September 2021	September 29, 2017	null	August 22, 2018	BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada|London Regional Cancer Program, London, Ontario, Canada|Ottawa Hospital Research Institute, Ottawa, Ontario, Canada|University Health Network, Toronto, Ontario, Canada|The Jewish General Hospital, Montreal, Quebec, Canada		https://ClinicalTrials.gov/show/NCT03297606
